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ABSTRACT 
Mutational and Expressional Analysis of Base Excision Repair 
(BER) Pathway Genes in Breast Cancer Patients 
Base excision repair pathway plays an indispensable role in maintaining genomic 
integrity and its ability to mediate and repair carcinogen-induced DNA lesions is a 
key determinant of susceptibility to carcinogenesis. This study was designed for 
germline mutational screening and expressional analysis of base excision repair 
(BER) pathway genes at transcriptional and translational level in breast cancer 
patients along with healthy controls and in vitro characterization of these genes using 
breast cancer cell lines. Hence, this study was divided into three parts; in first part, 
three BER pathway genes (APEX1, OGG1 & XRCC1) were screened for germline 
mutations and their possible association with breast carcinogenesis. Second part 
comprised of expression analysis of BER genes and proliferation marker Ki-67 at 
mRNA and protein level to correlate observed deregulations with risk and progression 
of breast cancer.  Third part of this study was an in-vitro analysis, to elucidate the role 
of BER pathway genes in breast carcinogenesis, using two breast cancer cell lines 
(MCF-7 and MDA-MB-MDA-231).  
Mutational analysis was carried out using PCR-SSCP followed by DNA sequencing 
in 925 individuals including 530 breast cancer patients and 395 cancer free healthy 
individuals. Sequence analysis of APEX1 revealed fourteen mutations, which included 
seven 5´UTR, one 3´UTR, two intronic and four missense mutations. Among 
identified mutations one 5´UTR (rs41561214), one 3´UTR (rs17112002) and one 
missense mutation (Ser129Arg) have already been reported while remaining elven 
mutations were novel. Six novel mutations (g.20923366T>G, g.20923435G>A, 
g.20923462G>A, g.20923516G>A, 20923539G>A, g.20923529C>T) were observed 
in 5´UTR region, two (g.20923585T>G, g.20923589T>G) in intron1 and three 
missense mutations (Glu101Lys, Ala121Pro, Ser123Trp) in exon 4. A significant 
association was observed between APEX1 mutations and increased breast cancer risk 
{(~9 fold (OR = 8.68, 95 % CI = 2.64 to 28.50) with g.20923435G>A (5’UTR) 
mutation, ~13 fold (OR= 12.63, 95 % CI = 3.01 to 53.01) with g.20923539G>A 
(5’UTR) mutation and ~5 fold increase with three missense mutations (Glu101Lys 
(OR = 4.82, 95 % CI = 1.97 to 11.80)), Ser123Trp (OR = 4.62, 95 % CI = 1.7 to 
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12.19), Ser129Arg (OR = 4.86, 95 % CI = 1.43 to 16.53) }. DNA sequencing for 
OGG1 revealed fifteen mutations, which included five intronic (g.9792260 insert_T; 
g.9793748G>A; g.9798336T>G; g.9798349T>A; g.9793680G>A, rs55846930), four 
splice site (g.9792109delT, g.9798307T>G, g.9798502T>G & g.9800972T>G), two 
3’UTR (g.9798848G>A, g.9798896T>C), three missense (Val159Gly, Gly221Arg, 
Ser326Cys) and one non-sense (Trp375STOP) mutation. Among identified mutations, 
one intronic (g.9793680G>A, rs55846930) and two missense mutations (Gly221Arg, 
TMP_ESP_3_9796483 and Ser326Cys, rs1052133) has already been reported while 
remaining twelve mutations are novel.  
Significantly increased breast cancer risk was found associated with different 
mutations in OGG1 when compared with controls. Significantly (p<0.001) increased 
(~29 fold) breast cancer risk was found associated with a splice site variant 
g.9800972T>G (OR =28.85, 95 % CI = 3.87 to 207.7) and 3´UTR variant 
g.9798848G>A (OR =29.20, 95 % CI = 33.98 to 213.74). Among intronic mutations, 
highest (~15 fold) increase in breast cancer risk was found associated with 
g.9793680G>A variation (OR =14.65, 95 % CI =1.95 to 109.9; p< 0.009). Similar 
trend was observed in all missense mutations in breast cancer patients when compared 
with controls and ~14 fold increased risk was associated with Val159Gly (OR=13.68, 
95 % CI = 1.82 to 102.9; p<0.01), ~17 fold with Gly221Arg (OR=16.85, 95 % CI 
=2.26 to 125.53; p<0.005) and ~18 fold with Ser326Cys (OR=18.45, 95 % CI 
=2.49 to 136.99; p<0.004) in breast cancer patients compared with controls. Whereas 
analysis of nonsense mutation showed that ~13 fold (OR =12.90, 95 % CI 
=1.71 to 97.28; p<0.01) increased breast cancer risk was associated with 
Trp375STOP in patients compared to controls.  
Mutational screening of XRCC1 revealed, twenty five mutations in different coding 
regions of XRCC1 including eighteen novel and seven already reported mutations. 
Among these, thirteen were missense mutations (Gly61Ala, Val72Gly, Asn183Ser, 
Arg194Trp, Arg280His, Ala283Asp, Asp356Asn, Asn510Ser, Arg559Gly, 
Arg560Gly, Tyr576Asn, Val629Gly & Val630Gly), eight synonymous mutations 
(Pro206Pro, Glu122Glu, Gln331Gln, Gln430Gln, Gln449Gln, Glu521Glu, 
Arg608Arg & Gln632Gln), three frameshift (Gly143fs*1, Ala182Argfs*29 & 
Ala587Serfs*9) and one nonsense mutation (Trp125*). Significantly higher frequency 
of one synonymous mutations Pro206Pro (p<0.003), seven missense mutations 
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Gly61Ala (p<0.001), Val72Gly (p<0.0007), Arg194Trp (p<0.0001), Arg280His 
(p<0.03), Arg559Gly (p<0.03), Arg560Gly (p<0.009), Tyr576Asn (p<0.03) and two 
frameshift mutations Ala182Argfs*29 (p<0.01), Ala587Serfs*9 (p<0.008) was 
observed in breast cancer patients when compared with controls. Some of the 
observed mutations in BER genes were found significantly correlated (p<0.03) with 
family history of cancer, menopausal age and use of tobacco. 
 For expressional analysis, BER genes (APEX1, OGG1 and XRCC1) and proliferation 
marker (Ki-67) were studied in tumor tissues and control samples of study cohort-2 
and 3 (104 and 111 samples), at mRNA level using real-time PCR. Statistically 
significant down-regulation of XRCC1 (p<0.01) and OGG1 (p<0.04) was observed in 
breast tumor samples compared to control samples. Ki-67 (p<0.03) and APEX1 
(p=0.32) were up-regulated in breast tumor samples compared with controls. 
Immunohistochemical analysis of APEX1, OGG1, XRCC1 and Ki-67 revealed that 
among 104 breast tumor samples, 81% samples showed OGG1 down-regulation, 79% 
showed APEX1 up-regulation, 73% showed XRCC1 down-regulation and 84% 
samples exhibited Ki-67 up-regulation. In mutational and expressional studies, 
APEX1, OGG1 and XRCC1 were observed as important factors responsible for onset 
and progression of breast cancer. Our data suggests that germline mutations in BER 
genes and down-regulation of BER pathway genes, such as OGG1 and XRCC1 
combined with over-expression of APEX1 and Ki-67 (proliferation marker) may 
contribute to the initiation and progression of breast cancer in Pakistani population.  
In third part of this study in-vitro experiments were performed to analyse the role of 
selected BER pathway genes (APEX1, OGG1 and XRCC1) in cancer cell behaviour 
during tumorigenesis using two breast cancer cell lines (MCF-7 & MDA-MB-MDA-
231). APEX1 knockdown cells of both cell lines showed significantly decreased 
growth (p<0.001), invasion (p<0.05) and migration (p<0.01) abilities and increased 
adhesion (p<0.05) ability. Knockdown of OGG1 and XRCC1 caused significant 
increase in cancerous characteristics of both breast cancer cell lines showing 
decreased adhesion (p<0.05) but enhanced proliferation (p<0.05), invasion (p<0.05) 
and rapid migration (p<0.05), however this significance level of difference was 
slightly variable in both cancer cell lines.  
Results from these studies suggest that APEX1, OGG1 and XRCC1 may be intriguing 
potential targets for anticancer strategies and diagnostics.  
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1. Introduction 
1.1 Breast Cancer 
Uncontrolled multiplication of cells which starts in breast tissue and becomes 
malignant is called breast cancer. Breast cancer generally initiates from the milk ducts 
or lobules. It may be ductal carcinoma or lobular carcinoma depending upon its site of 
origin (Friedman, 2005). 
1.2 Etiology of breast cancer 
Breast cancer is a multifactorial disease caused by endocrine, reproductive, 
environmental, lifestyle and genetic factors. Familial predisposition and mutations in 
high-risk genes with higher penetrance and other genes with lower-penetrance greatly 
increase the risk of breast cancer development in small proportion of patients.  
Reproductive factors associated with breast cancer risk include parity, age at 
menopause, age at first birth, breast feeding and reproductive hormones. 
Environmental factors include smoking, intake of alcoholic drinks, contraceptive use, 
hormonal replacement therapy and ionizing radiation exposure. Old age is also one of 
the important risk factor associated with breast cancer (Majeed et al., 2014, Bernard et 
al., 2014). Important primary risk factors associated with breast cancer are described 
as follows, 
1.2.1 Gender and Age 
Being a female is the basic risk factor for breast tumorigenesis. Breast cancer is 
approximately 100 folds more prevalent in females than males, possibly because of 
production of large amount of oestrogen and progesterone hormones in female, which 
may be involved in uncontrolled proliferation of breast cells. Reproductive age 
(menarche to menopause) has a positive correlation with breast cancer and breast 
cancer prevalence rises sharply after 30 years of age and rates fall slightly after 70 
years. (Leong et al., 2010; Assi et al., 2013). In Pakistan, breast cancer is reported as 
disease of younger age compared to developed western world (Bageman et al., 2007). 
Clear difference between developing and the developed countries regarding breast 
cancer has been younger age at presentation in developing countries (40 to 50 years)  
compared to developed countries (60 to 70 years) ( Leong et al., 2010). Younger age 
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at presentation in Pakistan and other developing countries may be due to lower life 
expectancy and greater environmental stress (Khokher, 2012). 
1.2.2 Nulli-parity, Breast Feeding and Endogenous Hormone Levels 
Breastfeeding and pregnancy stimulate breast cells to differentiate rapidly and these 
differentiated mature cells are supposed to be more resistant to malignancy (Russo et 
al., 2005; Britt et al., 2007). Females’ exposure to endogenous oestrogen levels may 
decrease with reduction in number of menstrual cycles due to breast feeding and 
pregnancy thus playing protective role against breast cancer. Early menarche, first 
pregnancy at later age, nulliparity and late menopause can increase the span of 
reproductive life and exposure to oestrogen thus associated with a higher risk of 
breast cancer (Colditz et al., 2006). Deregulations of endogenous estrogens has 
generally been presumed to play a role in breast carcinogenesis worldwide (Yang et 
al., 2012; Bernard et al., 2014). Estrogens are converted to certain toxic mutagenic 
metabolites that increase mitotic potential and proliferation of breast epithelial cells 
(Key et al., 2001; Colditz et al., 2006; Yager et al., 2006).  
1.2.3 Migration and International Variation 
Both breast cancer prevalence and death rates vary worldwide among different 
populations. Developed countries show higher rates compared to under developed 
countries. Increased risk has been observed in people who migrated from these low 
risk regions and settled in high risk areas (Key et al., 2001). 
1.2.4 Reproductive Factors 
Approximately 37.2% of all invasive breast tumors are attributed to reproductive risk 
factors for breast cancer (age at menarche, age at menopause, parity) (Bernard et al., 
2014). Association of late menopause with higher risk of breast cancer in women is 
most probably is due to increased exposure to estrogen and progesterone. These 
women also experience multiple anovulatory cycles which result in deficient cyclic 
progesterone. Early menarche may stimulate earlier growth of mammary gland 
through earlier action of reproductive hormones but results are contradictory in 
different populations. Effect of early menarche has been observed to increase the risk 
of breast cancer in premenopausal compared to post-menopausal women. Breast 
cancer risk decreases ~5% with each 1 year delay in menarche. Decreased risk of 
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breast cancer has been found associated with multiparity independently of the effect 
of age at first birth. Women with at least one successful pregnancy exhibit 25% more 
protection compared to nulliparous females. Nulliparous females face almost double 
risk of breast cancer compared to those having five or more than five children (Key et 
al., 2001; Tamakoshi et al., 2005; Parsa and Parsa, 2009).  
1.2.5 Oral Contraceptives 
Use of oral contraceptives has been observed well-established reproductive risk factor 
for breast carcinogenesis. Oral contraceptive users have 24% higher risk of breast 
cancer compared to those who have never used but this risk decreases significantly 
after almost 10 years cessation of these medicines. Younger age at first use of oral 
contraceptive has been observed significantly associated with higher risk. Highest risk 
of breast cancer (14% excess) was observed in age (20 –24 years) when oral 
contraceptives are maximally used and attributing approximately 12% breast cancer 
cases to hormones (Key et al., 2001; Faheem et al., 2007; Yang et al., 2012; Gierisch 
et al., 2013).  
1.2.6 Exogenous Hormones 
Exogenous hormones are consumed in the form of infertility drugs, contraceptive 
agents, as post-menopausal therapy etc. and are reported to exhibit higher risk of 
breast cancer (Key et al., 2001; Chen, 2008; Parisa and Parsa, 2009; Majeed, 2014). 
1.2.7 Diet 
Breast cancer risk has been reported 13% higher in females with highest total fat 
intake compared with lowest (Thiébaut  et al., 2007) but this may be true for only 
ER/PR positive females (Zhang et al., 2014). Inconsistent results have been observed 
for fatty diet to be a risk factor for breast cancer while high vegetable consumption 
may exert potential protective effects against breast cancer. It is also assumed that 
phyto-estrogens has the ability to counter act endogenous estrogen levels in humans 
thus providing protection against breast cancer (Vera-Ramirez et al., 2013; Zhang et 
al., 2014). 
1.2.8 Alcohol and Smoking 
Alcohol may be a risk factor for breast cancer in different ways such as via 
carcinogenic byproducts of alcohol metabolism or decreased absorption of important 
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nutrients in alcoholics. Alcohol intake by females may affect levels of estrogens and 
estrogen receptors (Pieta et al., 2012). Additionally, women have been found more 
susceptible to tobacco smoke and potentially more vulnerable to cancer development 
(Kiyohara et al., 2010). Multiple breast carcinogens are found in tobacco smoke 
which may be involved in breast carcinogenesis in both active and second hand 
smoker females, particularly in those with long-term heavy smoking or those who 
started smoking very early in life. It has been suggested in earlier studies suggest that 
breast cancer risk is likely to emerge after many years of smoking commencement, 
mainly among chronic heavy smokers (Reynolds, 2012). In Pakistani population 
chewing betel, paan, moist snuff and smoking are common strong risk factors for 
developing different types of cancers (Bhurgi et al., 2006, Faheem et al., 2007). 
1.2.9 Anthropometry 
High birth weight, adult height, obesity and elevated body mass index (BMI) in post-
menopausal females possibly due to alterations in certain hormonal levels have been 
found positively associated with breast carcinogenesis (Suzuki et al., 2012). 
1.2.10 Exercise 
Physical activity and exercise not only improves the performance of life but also has 
been observed to show a protective effect against breast cancer especially before 
menopause (McNeely et al., 2006). Obesity has been recognized a risk factor for 
postmenopausal breast cancer and physical activities are recommended for reduction 
in obesity. Endogenous estrogens, deposition of adipose tissue, insulin resistance and 
inflammation are all associated independently with increased risk of breast cancer 
while all these are affectively reduced by exercise. Physical activities have been found 
associated with 25–30% decreased risk of breast cancer in females (Bernard et al., 
2014). 
1.2.11 Radiation 
Ionizing radiations along with radiations from Sun have an increased effect on 
sensitive breast tissues especially in a younger age (Ronckers et al., 2005). 
International Agency for Research on Cancer has classified X-rays and gamma 
radiation as risk factor for breast cancer (Bernard et al., 2014) and ~1% of female 
breast cancers are associated to radiation exposure (Parkin and Darby, 2011d). 9-11% 
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higher risk of secondary breast cancer is observed in women who received 
radiotherapy for cancer, compared with those who were treated with surgery alone 
(Maddams et al., 2011; Neta et al., 2012). 
1.2.12 Carcinogens 
There are large number of chemicals and biological materials that have been 
diagnosed as carcinogens including dyes, asbestos and coal tar along with different 
other products. Endocrine disrupting chemicals and carcinogens such as ethylene 
oxides present in many occupational environments are classified as possible cause of 
breast cancer which may increase risk of breast cancer (Brophy et al., 2012; Bernard 
et al., 2014). 
1.2.13 Mutagens 
DNA repair mechanisms naturally protecting the body can be affected by different 
mutations. These mutational processes are consequence of endogenous mutagens 
usually present in the form of free radicals or due to exogenous stimuli and 
environmental exposures. Acquired mutations in oncogenes or tumor suppressor 
genes may result from mutagenic radiation or cancer-causing chemicals. Resultant 
deficient DNA repair may distress different metabolic pathways leading to 
uncontrolled cell proliferation and cancer (Ponder, 2001; Hu et al., 2013). 
Carcinogenesis is directly associated with accumulation of DNA lesion and instability 
of genome. Breast cancer is noted to be intimately associated to defects in DNA 
damage repair or cell-cycle checkpoints (De Summa et al., 2014). 
1.2.14 Familial Risk 
Familial risk can be defined as sharing of genetic material among family members or 
exposure of these members to same environment. A small percentage (5–6%) of 
breast cancer is associated to familial predisposition especially due to mutations in 
two high-risk high penetrance inherited genes. A minimum of eight genes have been 
recognized which may play contributory role in inherited breast cancer vulnerability. 
BRCA1 and BRCA2 at present are the most important and significantly increase the 
risk of breast cancer development (Lalloo and Evans et al., 2012). Almost 25% of 
breast cancer cases show inherited aspect and this risk increases two-fold with an 
incidence of breast cancer in first degree relative (McPherson et al., 2000). Risk of 
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developing breast cancer has been observed to increase almost two times in females 
having at least one first-degree relative with breast cancer as compared to females 
with no first-degree relatives suffering from cancer. Breast cancer risk may be three 
times or even higher if two or more first-degree relative are suffering from breast 
cancer (Mavaddat et al. 2010). However, it has also been observed that over 85% 
females having breast cancer in first-degree relative never developed breast cancer 
themselves and over 87% of female breast cancer patients have no first-degree 
relatives suffering from cancer (Cuzick, 2008).   
1.2.15 High-risk Mutations 
Germline mutations have a minor role (5–6%) in breast cancer and BRCA1 and 
BRCA2 have been reported as most important genes that influence the breast cancer 
incidence. Women with mutated BRCA1 or BRCA2 gene (or both) may have ~80% 
risk of having breast cancer during their lifetimes. Mutations in at least eight genes 
have commonly been identified playing role in inherited cancers (McPherson et al., 
2000; Key et al., 2001; Lalloo and Evans et al., 2012; Bernard et al., 2014). 
1.3 Types of breast cancer 
On the basis of clinical, histological and morphological conditions breast cancer is a 
diverse heterogeneous disease. It is multistep disease that progresses from low grade 
epithelial atypia to invasive ductal carcinoma (Yerushalmi et al., 2009; Edge and 
Compton, 2010). According to recent classification by WHO, there are more than 20 
different types of breast tumors. Most of these tumors initiate from epithelial cells of 
inner lining of ducts and lobules in breast and are termed as carcinomas. Breast 
carcinomas may be further grouped as non-invasive or invasive breast cancer 
(Bernard et al., 2014).   
1.3.1 Non-invasive breast cancer 
Tumor that has not yet invaded other breast tissue is termed as non-invasive tumor 
and is called carcinomas in-situ (CIS). It is a transitional phase in the evolution of 
invasive malignancy from normal breast tissue. CIS are actually pre-invasive tumors 
where outer basement membrane of ducts and lobules is still intact without any 
penetration of malignant cancer cells. CIS are further sub-grouped into ductal 
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carcinoma in-situ (DCIS) and lobular carcinoma in-situ (LCIS) (Edge and Compton, 
2010).  
1.3.1.1 Ductal Carcinoma in-situ (DCIS) 
In DCIS, cells are still restricted and bounded by the basement membrane of breast 
ducts and have not spread to proximal tissues. If DCIS is left untreated it may lead to 
more advanced and complex invasive form. DCIS have different stages and is further 
sub-divided according to nuclear grade and architectural features. Classification of 
DCIS depends upon the form of tumor that is either micro papillary, papillary or solid 
along with grading and necrotic status of cancerous cells. There is a greater risk of 
recurrence of high-grade DCIS or advancement to invasive cancer than lower grades 
of DCIS (Edge and Compton, 2010; Bane, 2013). 
1.3.1.2 Lobular Carcinoma in-situ (LCIS) 
Abnormally growing cells in milk glands of breast may develop to lobular carcinoma 
in-situ (LCIS). It is restricted to milk glands with multi-centric and multifocal origin 
and may also have risk of bilateral breast involvement. Histologically, LCIS is 
composed of high nuclear grade anaplastic cells present with in the lobules. LCIS acts 
as a precursor of other pathologically more advanced types of breast cancer. 
Classically, LCIS shows a lower and slower risk of advancement and may take 20–25 
years to become invasive type of cancer (Hajdu and Tang, 2009; Edge and Compton, 
2010). 
1.3.2 Invasive Breast Cancer 
Invasive types of breast cancer are produced if breast cancer spreads from lobules or 
milk ducts to other parts of breast.  
1.3.2.1 Invasive Ductal Carcinomas (IDC) 
Invasive carcinoma is large heterogeneous group of cancers (about 70%)  which may 
not be characterized easily by specific morphological characteristics related to special 
subtypes, also called as “no special type” or invasive ductal carcinoma. It is the most 
common subtype of invasive breast cancers present in 30-50% diagnosed patients 
(Weigelt et al., 2005; Edge and Compton, 2010). 
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1.3.2.2 Invasive Lobular Carcinoma (ILC) 
Invasive lobular carcinoma (ILC), also known as infiltrating lobular carcinoma is the 
second most prevalent epithelial type breast cancer with a frequency of 10-15% in all 
age groups. ILC is characterized by spreading of cancer from primary lobular location 
to other parts of breast tissue (Ansquer et al., 2010; Edge and Compton, 2010).  
1.3.3 Tumors with good prognosis, ER Positive Tumors 
There are other well defined, less common types of breast cancer that are grouped 
according to their prognosis and ER status and are described as follows: 
1.3.3.1 Tubular Carcinoma (TC) 
Histologically it comprises of open tubules having single layered epithelial cells with 
lower nuclear grade. Globally, 0.7 to 10.3 % of breast cancer patients are of tubular 
carcinoma mainly found in post-menopausal females with 1-6 % prevelance 
frequency. Patients with TC patients may have a high risk (13-26 %) of developing 
second primary carcinomas in contralateral breast but have normal life expectancy. 
90-100% of TC patients may have survival chances of more than 10 years (Rakha et 
al., 2010).  
1.3.3.2 Invasive Cribriform Carcinoma 
Histologically these tumors are comprised of cribriform pattern and are grouped as 
pure, classic and mix type. Mean age of patients has been observed between 53 to 58 
years with frequency of 1-6 % and 90-100 % 10 year survival rates (Edge and 
Compton, 2010). 
1.3.3.3 Pure Mucinous Carcinoma 
Presence of profuse extracellular, as well as, intracellular mucin is observed in this 
type. Different subtypes of these tumors are mucinous carcinoma, cystadeno 
carcinoma and columnar cell mucinous breast carcinoma along with signet ring cell 
cancer. It represents oldest median ages i.e. 71 years with a frequency <5% of all 
types and 80 to 100% 10 year survival rate (Tavassoli et al., 2003). 
1.3.3.4 Invasive Solid Papillary Carcinoma (SPC) 
It consists of papillae and is a rare malignant tumor having solid focal areas. It 
comprises of DCIS in more than 75% cases while 33% cases include invasions in 
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lymphatic vessels. Papillary carcinoma is a rare malignant tumor of the breast found 
in menopausal patients with an incidence of 1-2% in the general population. 
Clinically SPC is generally a slow growing tumor type, unless it becomes invasive 
(Leena et al., 2013). 
1.3.3.5 Apocrine Carcinoma (AC) 
Apocrine carcinoma is a rare type tumor (1% of invasive breast cancer). It differs from 
IDC only on the basis of cytological appearance; otherwise it has a growth pattern 
similar to IDC. Histologically, it has specific apocrine nature with large multiple 
nucleoli and excessive eosinophilic cytoplasmic granules. Its prevalence is 0.3–4% in 
general population (Wader et al., 2013). 
1.3.3.6 Neuroendocrine Tumors (NETs)  
Neuroendocrine Tumors initiate from endocrine and nerve cells and mostly behave as 
benign tumors but in some cases become malignant. This type is characterized by 
tumors comprised of thick, solid mass intercalated with flimsy fibro-vascular stroma. 
These tumors can be divided into various categories including small or large cell 
cancer (SCC or LCC), solid neuroendocrine or atypical carcinoid cancer. Its 
prevalence is 2-5% among all breast cancers. Some NETs produce their hormone in 
excess so known as functioning tumors while some others produce their hormones as 
normal so called non-functioning tumors. NETs generally grow very slowly and most 
of the patients don’t show symptoms for a long time therefore when cancer is 
diagnosed it has already mediatized to other body parts (Ramage et al., 2012).  
1.3.4 Tumors with good prognosis, ER Negative 
1.3.4.1 Medullary Carcinoma (MC) 
This carcinoma is composed of poorly differentiated cells without glandular 
structures, scanty stroma, rare node involvement, circumscribed margins and a 
prominent lympho-plasmacytic infiltrate. MCs usually have good prognosis compared 
with IDC. Preliminary tumor is identified as “atypical medullary carcinoma” (AMC). 
Observed frequency of breast cancer cases with medullary carcinoma (MC) is 1–7% 
with 50–90% of 10 year survival rates. Although, multiple studies have suggested that 
MC may be correlated with BRCA1 gene mutations but further research is still 
warranted (Huober et al., 2012).  
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1.3.4.2 Secretory Breast Carcinomas (SBC) 
This is very rare cancer type with prevalence of 0.01- 0.15% in all breast cancer cases. 
It is also termed as juvenile carcinoma due to a younger mean age of patients at 
diagnosis (Li et al., 2012).  
1.3.4.3 Adenoid Cystic Carcinomas (ACCs) 
Adenoid cystic carcinoma also known as cribriform cancer is a combination of 
proliferating glands, connective tissue cells and myoepithelium. It is slow growing 
and usually surgically treatable without any chance of reoccurrence. It is mostly found 
in post-menopausal patients and also involves pain due to neural association. Its 
frequency of occurrence is 0.1% in all breast cancer cases (Douglas et al., 2000). 
1.3.4.4 Acinic Cell Carcinoma (ACC) 
This carcinoma is different from other types due to the presence of structures that 
resemble salivary glands. Age of onset of acinic cell carcinoma varies from 35 to 80 
years. It is very rare type with limited no of patients reported so far (7 cases). ACC is 
a rare malignant epithelial cancer of breast with malignant tubular acinar structures of 
exocrine gland (Ripamonti et al., 2013). 
1.3.5 Poor Prognosis, ER Positive 
1.3.5.1 High-Grade Small-Cell NE Carcinoma 
This type of tumor is considered as an aggressive tumor type of breast and usually has 
multiple lymph node involvement, which makes it worse with respect to prognosis. 
Patients with this type of breast cancer found to have 60-70 years mean age of 
diagnosis (Ansquer et al., 2010). 
1.3.5.2 Invasive Micro Papillary Carcinoma (IMPC)  
This type is characterized with void mass of cancerous cells and lymphatic nodes 
invasions. Ages of IMPC patients range from 33 years to 78 years while, its frequency 
is <3% of all breast cancer cases (Lin et al., 2005; Ansquer et al., 2010). 
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1.3.6 Poor Prognosis, ER Negative 
1.3.6.1 Metaplastic Carcinoma 
This is a type of adenocarcinoma tumor that transforms basic epithelial or 
mesenchymal elements of tissues into a non-glandular component. This is a high 
grade pathological type mostly found in older age females. Metaplastic Carcinoma is 
most common in Hispanic or African American with a frequency of less than 5% 
among other types of breast cancers (Tavassoli et al., 2003; Ansquer et al., 2010). 
1.3.6.2 Lipid-Rich Carcinoma 
This tumor is named so as cancer cells have high cytoplasmic lipid content and less 
differentiated proliferation. Frequency of this cancer among all other types is 1 to 2% 
and usually diagnosed before 50 years (Weigelt et al., 2005; Yerushalmi et al., 2009). 
1.3.6.3 Glycogen-Rich Clear-Cell Carcinoma 
This type of carcinoma is mostly characterized by clear cytoplasm containing higher 
content of glycogen. Observed frequency is 1.4 to 3 % and mean age at diagnosis of 
patients is observed 57 years (Tavassoli et al., 2003; Weigelt et al., 2005; Yerushalmi 
et al., 2009). 
 
1.4 Hereditary/ Familial Breast Cancer 
If one or more family members are found affected by breast cancer or other related 
cancers (such as ovarian or primary peritoneal cancer), it is categorized as familial 
breast cancer. Familial or hereditary breast cancer is usually caused due to the genetic 
variations in one or both alleles of highly susceptible genes such as BRCA1, BRCA2 
and TP53. About one half of familial breast cancer cases, are hereditary cancers. 
Approximately 5% of all types of breast cancers may be due to inherited mutations in 
high risk genes. These breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2) 
are the most studied and highly penetrated genes in case of hereditary breast cancer. 
Almost 30 to 40% cases among familial types and 2 to 3 % of all breast cancer cases 
contain genetic variations in these genes. Apart from these susceptibility genes, there 
are certain other genes found to play important role in familial breast cancer cases, 
such as CHEK2, TP53 and PTEN (Chappuis et al., 2002; Wooster and Weber, 2003; 
Bogdanova and Dork 2012; Evans et al., 2013; Bernard et al., 2014).  
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Breast cancer susceptibility has been found associated with 72 loci from genome-wide 
association studies. Coding variations, mainly in DNA repair genes result in high-
penetrance predisposition loci for breast cancer. Whereas, many genome-wide 
association studies, have reported that non-coding regions of the genome involved in 
regulation of genes in various pathways are found associated with breast cancer 
susceptibility. Genes identified in susceptibility regions for breast cancer are mainly 
involved in some biological processes including mammary gland development, cell 
cycle regulation, estrogen receptor signaling and DNA repair pathways. Along with 
commonly associated variants involved in breast cancer susceptibility, rare genetic 
variations have also been observed through whole-exome and whole-genome 
sequencing strategies (Ghoussaini et al., 2013; Evans et al., 2013; Bernard et al., 
2014). Integration of emerging somatic sequence data with germ-line predisposition 
data may help in comprehensive analysis of susceptibility with reference to disease 
subtypes and in better interpretation of basic biological characteristics.  
 
Figure 1.1 Mechanisms potentially involved in breast cancer susceptibility. Genes with high 
penetrance mutations are denoted in red. Cancer candidates genes found in or near common 
breast cancer predisposition loci are denoted in blue. Status of FGFR2, MYC, CASP8, and 
CCND1genes is unclear about their association to breast cancer (adopted from Ghoussaini et 
al., 2013). 
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1.5 Sporadic Breast Cancer 
Sporadic breast cancers originate from a sequential accumulation of acquired and 
unrepaired mutations in somatic genes. Mutational activation of oncogenes, often 
coupled with non-mutational inactivation of tumor suppressor genes might be an early 
event in sporadic tumors, followed by further independent mutations in other genes of 
pre-cancerous cells. Important genes which might play a significant role in sporadic 
cancers are CCND1, ERBB2, and MYC with an occasional chance of mutational 
inactivation of BRCA1 and BRCA2. In contrast to familial cases, sporadic breast 
cancer is associated with late age at diagnosis and involvement of low penetrance 
genes (Kenemans et al., 2004).  
Sporadic breast cancer is further classified into diverse molecular subgroups that have 
distinctive characteristics usually based on hormonal receptor status (ER, PR and 
HER- 2/neu). It includes Luminal A and B subtypes, ERBB2, basal-like and normal 
breast-like subgroups. Basal-like tumors represent most undifferentiated form among 
all types of breast cancer. Up regulation of EGFR and Vascular Endothelial Growth 
Factor (VEGRF) pathways with low expressional levels of HER-2/neu is a typical 
character of basal-like subtypes. ERBB2 tumors have been observed to overexpress 
Her-2/neu and multiple genes at 17q11. Patients with ERBB2-positive breast cancer 
show comparatively poor final outcome related to ERBB2 negative cases. Luminal 
subtypes although differ in final outcome but both express estrogen receptor strongly 
and they usually show a distinguishing expression of nuclear antigen, TOPO II, as 
well as several other proteins involved in the cell cycle. DNA sequence 
polymorphisms have been linked to cancer aggressiveness and susceptibility along 
with sporadic mutations accumulating in the developing tumor as a result of genomic 
instability. Genome-wide association studies to identify SNPs connected with cancer 
susceptibility reflect the increasing credit of polymorphisms as cancer- relevant 
parameters (Melchor and Benitez, 2008; Garber, 2009; Stefansson et al., 2009). 
1.6 Categorization Basis for Breast Cancer 
Multiple criteria have been used to classify breast cancer based on TNM staging 
(Tumor Node Metastasis), different receptors status, pathology, histological grade and 
altered expression of certain genes. 
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1.6.1 Stage 
Histopathological analysis of breast cancers is performed for cancer staging which is 
greatly helpful in cancer management. Different parameters are used for TNM 
classification of breast cancer which are size of the tumor (T), number of lymph nodes 
involved (N) and tumor metastasis (M). Larger tumor size with involvement of nodal 
spread and metastasis is related to a more advanced stage and poor prognosis. Breast 
cancer is categorized from 0 to IV based on cancer spread. Stages resolve the 
treatment and outlook for recovery. Main stages used are stages 0, I, II, III, and IV. 
Stage 0 predicts an earlier pre-malignant cancer and is also called noninvasive 
carcinoma or carcinoma in-situ which can be a lobular carcinoma in-situ or ductal 
Carcinoma in situ. If cancer spreads beyond duct or lobule then it can be stageI or II 
cancer as these are the early stages of cancer. Stage I shows that tumor is not larger 
than 2 cm in diameter and cancer cells have not spread beyond the breast. In stage II 
the tumor has spread to the axillary lymph nodes and is <2 cm in diameter or the 
tumor’s diameter is 2-5 cm with or without growth to the auxiliary lymph node. 
Tumor is still stage II if it is >5 cm in size and has not spread to axillary lymph nodes. 
Stage II is also termed as “locally advanced cancer”. In this stage tumor in breast is 
large (>5cm across) and the cancer has spread to other lymph nodes or tissues near the 
breast. In stage III, tumor is more than 5cm extended to chest wall or skin, with 
involvement of axillary and internal mammary lymph node but with no distant 
metastasis. Tumors at stages I–III may be termed as 'early' tumors and are potentially 
curable. Stage IV indicates that cancer has spread to other distant organs of the body 
(e.g. bone, liver or lung etc.) along with involvement of near and distant lymph nodes 
and is defined as 'advanced metastatic' cancer (Ward et al., 2004; Hammer et al., 
2008; NCIFS, 2015). 
1.6.2 Histopathology 
Breast cancer can also be classified by its histology and according to recent WHO 
classification breast tumors have more than 20 different subtypes. Most of breast 
cancers are derived from epithelium lining (carcinoma) of the ducts/lobules, and are 
classified as mammary ductal/lobular carcinoma. These tumors are further divided 
into in-situ and invasive tumors. Carcinoma in-situ is pre-invasive proliferating cancer 
cells, still within the ductal/lobular epithelial tissue with intact basement membrane 
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and without invasion of surrounding tissue. While invasive carcinoma, invades the 
surrounding tissues and lymph nodes (Rakha et al., 2014; Bernard et al., 2014, Rakha 
et al., 2015).  
1.6.3 Tumor Grade  
While grading the tumors histologically, the resemblance is observed between tumor 
tissue and tissue of origin. Depending on the degree of differentiation, cancer can be 
characterized as low, intermediate or high grade tumor. Low grade tumors have well 
differentiated cells while high grade tumors show worse prognosis. Recent tumor 
grading system is based on assessment of three parameters  
(i) Level of architectural differentiation by tubule formation  
(ii) Nuclear grade on the basis of nuclear pleomorphism  
(iii) Change in proliferation status  
Each parameter is scored as 1, 2 or 3 and for final assessment collective score of all 3 
parameters is decisive. Tumors of grade 1 (early grade) have collective score 3–5, 
tumors of grade 2 (intermediate grade) have collective score 6 and 7 and tumors of 
grade 3 (high grade) have collective score 8 and 9.  
Usually tumors are graded by following the modified Bloom–Richardson–Elston 
grading system also known as Nottingham system. Nottingham combined histological 
grade system that is also called Nottingham Grading System is the most common and 
widely accepted grade method in breast cancer (Rakha et al., 2014; Bernard et al., 
2014; Rakha et al., 2015). 
1.6.4 Receptor status 
Histological grades of tumors are strongly associated with histological type and 
hormonal receptor expression status. Certain hormones bind to receptors present on 
cell surfaces, in cytoplasm or in nucleus and respond accordingly. Most important 
receptors present on the surface of breast cancer cells are estrogen, progesterone and 
HER-2/neu. Breast cancer cells without these receptors are classified as triple 
negative or basal-like cancers (Shabaik et al., 2011; Rakha et al., 2014; Bernard et al., 
2014; Rakha et al., 2015). 
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1.7 Epidemiology of breast cancer 
1.7.1 Global Scenario of Breast Cancer 
Breast cancer is the largest and most common group of several tumor subtypes that 
distress people of all social, racial, religious and age groups. It is the most prevalent 
cancer (25.2% of all cancers) in women and collectively in both sexes with highest 
incidence rate (43.3 per 100 000) than any other cancer worldwide. Age-standardized 
incidence rates of breast cancer are variable worldwide and are observed highest in 
Western Europe (89.9/1,00,000) and lowest in East Asia (19.3/ 1,00,0000). Nearly 
half of the global occurrence is observed in Asia with 22% in China and 7-8% in India 
and Pakistan (Bernard et al., 2014).  Globally, breast cancer accounts for about 14% 
of all cancer casualties (Jemal et al., 2011) with about five fold variation in different 
regions (Khokhar, 2012). Women of all geographic areas, races and ethnicities are 
reported to be affected from breast cancer. However, its incidence, clinical 
presentation and survival rates vary in different geographical areas and among 
different races and ethnicities within the same geographic region (Bhikoo et al., 
2011).  
Frequency of breast cancer has been observed directly proportional to levels of human 
development with more than 2-fold higher incidence in highly developed countries as 
compared to less developed countries. About 43% of the estimated new cases and 
34% of the cancer deaths occurs in Europe and North America. Highest rates of breast 
cancer occur in Australia and Europe specifically in Italy, France, and Switzerland 
have average rates of 60 to 100 per 100,000 cases. Lowest ASR (W) is observed in 
Harare, China, Thailand and India (18 to 30/100,000) (Curado, 2011). In both North 
and South American continent, USA and Canada along with Barbados, Uruguay, and 
Argentina show maximum breast cancer incidence while Mexico and Central America 
are ranked lowest in this regard (Ferlay et al., 2010). According to “Cancer Facts and 
Figures, 2014” breast cancer is the most frequently diagnosed cancer of women in 
US.  
 In Europe both highest and lowest breast cancer incidence rates in the world have 
been observed. Early stage diagnosis accompanied with postmenopausal status is a 
characteristic of European breast cancer cases (Curado, 2011). Breast cancer is 
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detected less frequently in African continent compared to other world. In Africa, 
breast cancer incidence rates are ranked lowest in Ghana and Sudan while highest in 
South Africa (Abdulrahman and Rahman, 2012). 
In Asia, breast cancer incidence is rising among all other cancers though its rate is still 
lower than western population. Asian countries with westernized life style like Japan, 
China (Hong Kong) and Singapore show highest rates while Thailand, Korea and 
India exhibit lowest rates of breast cancer in Asian countries (Curado, 2011, Bernard 
et al., 2014). In Middle East/ Arab world breast cancer is the commonest malignancy 
in females and is a comparatively younger age disease with 49 to 52 years of median 
age (El Saghir et al., 2007; El Saghir, 2008; Salim et al., 2008; Bernard et al., 2014).  
In United States breast cancer is an older age disease with median age of 61 years 
accompanied with an early stage presentation and diagnosis. Relative survival rates in 
females have also been improved with advancement in diagnosis and treatments 
(Siegel et al., 2012). Late stage presentation of biologically aggressive disease in 
relatively younger population is characteristic feature reported from developing and 
under developed countries. Genetic, economic, cultural and life style differences 
might be the main attributing factors (Khokhar 2012; Assi et al., 2013). After 
attaining a peak, incidence and mortality rates have been declining since late 1980s, in 
many of the highly developed countries as a result of improved and earlier diagnosis 
(through routine population-based screening) and broad range of highly effective 
therapies (Curado, 2011; Jemal et al., 2011; Assi et al., 2013; Bernard et al., 2014).  
1.7.2 Worldwide Breast Cancer Mortality 
Breast cancer accounts for maximum cancer related deaths in females in developed 
and less developed countries of the world. Breast cancer mortality rates differ among 
developed and under developed countries, being the lowest in low income countries. 
Worldwide breast cancer mortality rates vary ~2–5-fold (from 6-29/ 1,00,000) which 
ranks fifth cause of death from all cancers (Ferlay et al., 2010; Bernard et al., 2014). 
Variable case fatality rates are observed worldwide which is generally increasing all 
over the world reaching to peak level, but a continuous decline in death rate of 
patients under therapy has been observed over the past decade in highly developed 
countries as a result of combined effects of earlier and improved detection and more 
effective treatment regimens Elevated breast cancer incidence but lower mortality 
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rates have been observed in countries with highest levels of human development 
(Curado, 2011; Bernard et al., 2014).  
Breast cancer mortality rates in African countries have been observed approximately 
similar to European population despite the younger age of African breast cancer 
patients. Heterogeneous trends have been observed in Asian countries with lower 
mortality rates in general. Korean population exhibit lowest and Singapore highest 
breast cancer death rates in Asia with intermediary rates observed in Japan (Jemal et 
al., 2011; Assi et al., 2013; Bernard et al., 2014).  
In USA, decreased mortality rates have been observed among all races in last three 
decades with comparatively greater death rate in black women (American cancer 
society, 2014). In Europe, breast cancer death rates are highest in postmenopausal 
females and range from 7-5/1,00,000 women. Breast cancer related mortality rates are 
significantly falling in UK and Western Europe in last two decades (1991-2010), 
whereas stable or rising mortality rates are observed in Russia and Eastern Europe. 
Improved therapies and earlier diagnosis have played major role played for reduced 
breast cancer mortality rates in Western Europe (La Vecchia et al., 2010). Breast 
cancer mortality patterns in New Zealand and Australia are almost similar with 
slightly higher in New Zealand (Curado, 2011). 
1.7.3 Description of the population under study 
In this study three different cohorts have been selected, two from Pakistani and one 
from British (UK) populations. 
1.7.3.1 Scenario of breast cancer in Pakistan 
In Pakistan, breast cancer is the most commonly diagnosed cancer with an incidence 
rate of 33.1% for all cancer types and has been graded as highest in all Asian 
populations except Israeli Jews (Bhikoo et al., 2011; Jemal et al., 2011; Shaukat et al., 
2013; Majeed et al., 2014; Khalfan et al., 2014) specifically in South (Karachi) where 
incidence of breast cancer has been third highest in Asia (More et al., 2009). Breast 
cancer frequency is highest among all other cancers in Pakistan evident from data 
collected from different oncological center of country as reported by Institute of 
Nuclear Medicine and Oncology (INMOL), Lahore in year 2000 to 2009   (Khokher 
et al., 2012), Shaukat Khanum Memorial Cancer hospital (SKM-CHRC cancer 
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registry, 2013), Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN) 
(Hanif et al., 2009), Jinnah hospital Lahore from 1997 to 2001 (Aziz et al., 2003), and 
by Armed Forces Institute of Pathology, Rawalpindi Pakistan (1992-2001) (Jamal et 
al., 2006). Recently it has been reported that breast cancer is the most prevalent 
cancer in Pakistan with the highest incidence in Asia. One in eight female suffers 
from breast cancer in the course of her life. Approximately, 40,000 Pakistani females 
are dying each year due to breast cancer including younger aged females. Mortality 
rate of breast cancer patients, in developing countries, like Pakistan is increasing 
because of late stage diagnosis. Breast cancer is the second most common cause of 
death among Pakistani females. Lack of medical services, limitation of female 
oncologists and lack of awareness especially amongst people in rural areas of Pakistan 
are the major issues which must be resolved (Rasheed, 2013; Khalfan et al., 2014; 
Siddique, 2014).  
The best strategy to develop comprehensive nationwide cancer data base is to 
establish and maintain a national population related cancer registry. Effective, 
executable and monitored cancer control programs are only possible if established 
cancer registries are available at regional, national and international level. An 
incorrect assessment of the cancer burden in a specific country may result into 
negative repercussions for the cancer control program of a country. In Pakistan, 
hospital based data is the only reliable source of cancer related information of local 
patients. The Karachi Cancer Registry (KCR) is the first ever population-based 
registry of Pakistan but there is no national cancer registry in Pakistan, therefore the 
precise incidence and mortality rates of breast cancer are not known (Bhurgri, 2006; 
Moore et al., 2009; Hanif et al., 2009; Jemal et al., 2011; Khokher et al., 2012).  
Available population based cancer registry data from South Asia shows that Pakistan 
has the highest Age Standardized Rate (69 per 100,000) of breast cancer in this region 
which is comparable to European and North American rates but much higher than that 
in all other Asian countries. In fact, prevalence of breast cancer in Pakistan is highest 
than any Asian country (except Jews in Israel) and approximately 2.5 times higher 
than neighboring countries India and Iran, since annually more than 90,000 women 
suffer from breast cancer (Shaukat et al., 2013).  
Mean age of Pakistani breast cancer patients at diagnosis has been reported as 39 ± 15 
years (Fatima et al., 2010), 47±12 years (Bhikoo et al., 2011; Khokher et al., 2012; 
Baig et al., 2013), 48 years (Malik, 2002; Azizun-Nisa et al., 2008), (Siddiqui et al., 
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2000, Bhurgri et al., 2007, Sharif et al., 2009), 47.6±12, (Badar et al., 2011), <45 
years (Afsar et al., 2010). It is relatively younger age (40 to 50 years) of breast cancer 
diagnosis, compared to age at presentation (60 to 70 years) in Western countries 
(Bageman et al., 2007; Leong et al., 2010; Shaukat et al., 2013; Rasheed, 2013). 
Younger age of patients at breast cancer presentation is a feature in most developing 
countries like India (Saxena et al., 2005; Agarwal et al., 2007), Srilanka (Lokuhetty et 
al., 2009) and Cameroon (Ngowa et al., 2011). Younger age range of patients in 
Pakistan and the other developing countries may be explained by the younger age 
structure and the lower life expectancy of women in these regions (Khokher et al., 
2012). 
Multiple reproductive factors have been found to act protectively in females which 
include multiparity, late menarche and breast feeding along with early menopause. 
Longer period of breast-feeding, cause protective effect on breast cancer risk among 
both pre and post-menopausal women (Kruk, 2007). About 20% or even more 
reduced breast cancer risk has been observed in prolonged breast feeding women, or 
those who initiate breast feeding at younger ages (Newcomb, 1997). Reduced risk of 
breast cancer among premenopausal prolonged breast-feeding women may be of 
insignificant importance as breast-feeding being categorically less adaptable approach 
especially in Western societies (Lipworth et al., 2000).  Pakistani population however 
exhibits a diverse pattern of breast cancer risk factors. No or reduced breast feeding 
(less than 12 months) has been observed significantly associated with breast cancer 
risk in Pakistani population (Faheem et al., 2007). Breast cancer is even prevalent in 
multiparous, lactating females at comparatively younger age. It has been proposed 
that different genetic factors solely or in arrangement with other non-genetic factors 
may be playing a key role in this regard (Fatima et al., 2010; Khokher et al., 2012).  
Pakistani women have a higher frequency (85.3%) of Invasive Ductal Carcinoma 
(IDC) and (Azizun-Nisa et al., 2008, Majeed et al., 2014) compared to a lower 
frequency of Invasive Lobular Carcinoma (ILC), which can be attributed to low 
prevalence of the risk factors for ILC in the local population (Afsar et al., 2010; 
Khokher et al., 2012).  
Stage at presentation of breast cancer is a major determinant of patient’s survival 
during and after treatment. In a study of breast cancer cases presented at two cancer 
hospitals in Lahore, 63% and 71% patients, presented at advanced stages (TNM Stage 
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III and IV) (Gilani et al., 2003), 10 years data report of INMOL shows that 58% of 
patients presented at late stages. A similar picture has also been reported in various 
other studies from Pakistan (Malik et al., 2002; Hanif et al., 2009; Khokher et al., 
2012; Malik et al., 2010). Very few women are reported to be at stage 0 and stage I or 
at grade I at the time of registration (Afsar et al., 2010; Khokher et al., 2012). Profile 
of breast cancer patients in Pakistan follow a pattern similar to that of other 
developing countries with earlier peak age, advanced disease stage at presentation and 
poor survival rate.  
1.7.3.2 Scenario of breast cancer in UK 
United Kingdom (UK) has a well-established national level cancer registry for 
country wise cancer data of British population. In UK, breast cancer is the second 
most common cause of cancer deaths in women after lung cancer and accounts for 
~31 % of all female cancers in UK. One out of eight women in UK has chance of 
developing breast cancer at some point in their lives, with age being the strongest risk 
factor, after gender (Cancer Research UK, 2014). Incidence rates for breast cancer in 
UK have increased since 1971 while mortality rates have fallen. Presentation of breast 
cancer patients with more advanced stage and poorer survival rates compared to many 
of their European counterparts is the feature of British population. (Berrino et al., 
2007; Sant et al., 2009). Almost four out of every five new cases are diagnosed in 
women of 50 yrs and over, with more cases observed in age group 60 to 64 years that 
accounts for 14% of all new cases (Cancer Research UK, 2014).  
Higher mortality rates are observed in women above 70 years of age (Cancer 
Research UK, 2014). Approximately, 9,700 women per year die from breast cancer in 
England (24 deaths per 100,000 women). However, mortality rates have decreased by 
37 % since 1971. Earlier detection along with improved therapies for breast cancer are 
helpful in increased survival rates. Higher survival rates are observed from breast 
cancer compared to other major cancers in women such as cervical, colorectal, 
ovarian and lung cancer (Whitehead, 2012; Bernard et al., 2014).  
Although approximately 3% of breast cancer cases in the UK each year are associated 
with hormonal replacement therapy (HRT) which is now observed decreasing in 
recent years (Parkin, 2011c). Highest risk of breast cancer (14% excess) is observed 
in 20–24 years of age when oral contraceptives may be maximally used. This increase 
in breast cancer cases may be attributed to estrogens’ deregulation. Alcohol intake 
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may increase the risk of breast cancer and this risk is directly proportional to amount 
of alcohol used. Around 3,100 cases of breast cancer in the UK each year are linked to 
alcohol consumption. A more active lifestyle reduces breast cancer risk and around 
1,700 breast cancer cases in UK per year are associated to inactive life style. It is also 
estimated that about 27% of cases of female breast cancer in UK are linked to largely 
modifiable lifestyle and environmental factors (Parkin, et al., 2011e). Large 
percentage of female breast cancer in UK is observed without any positive family 
history (McPherson et al., 2000).  
Mean age of breast cancer patients in British population at the time of detection has 
been observed as 63 years (Walters et al, 2013; Cancer Research UK, 2014). Breast 
cancer incidence rates have overall increased in all age groups of British women since 
mid-1970s. The highest increases, approximately half (48%) of female breast cancer 
cases has been noted in women aged 50-64 yrs. An average of 80% breast cancer 
patients were diagnosed in the age of 50s and over while 45% of cases are diagnosed 
in women aged 65 years and over (Cancer Research UK, 2014). 
 Reproductive factors influence the risk of cancers of female genital tract (uterus and 
ovary) and breast. Breast feeding in Britain is not very common, and is generally not 
extended for more than few weeks. Certain aspects of reproductive history are 
associated differently with risks of developing breast cancer of different histological 
types. Effects of age at menarche and age at first birth on different tumor types vary 
significantly showing highest association with lobular carcinoma of breast. Age at 
menarche has a significantly greater effect on lobular cancer compared with ductal 
carcinoma (Li et al., 2008; Bernard et al., 2014, Cancer research UK, 2014). 
Multiparity is associated with reduced risk for ductal, lobular, tubular and 
substantially reduced with mucinous cancers, compared with other types of tumors 
(Reeves et al., 2009). 
  
1.8 Genetics of Breast Cancer 
Breast carcinogenesis is a resultant phenotype developed by the genetic alterations in 
certain oncogenes along with tumor suppressor genes. These alterations in genetic 
mechanism respond as unwanted cell growth, deviation from apoptosis, invasion and 
spread to neighboring cells and tissues (Ghoussaini et al., 2013; Bernard et al., 2014). 
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About 5-10% of all breast cancer cases might be as a result of mutations involved in 
genetic expression. Normally when cells are no more required in future for body after 
completion of their life cycle they undergo apoptosis. Multiple pathways and proteins 
protect the cells before they experience apoptosis which include PI3K/ AKT and 
RAS/MEK/ERK pathways. Occasionally genes related to these pathways are mutated 
and specific mutations permanently activate these pathways which result into repeated 
cell division and proliferation instead of apoptosis after accomplishment of their life 
span (Majeed et al., 2014).  
Lifetime risk for breast cancer is differentially influenced by multiple susceptibility 
genes. Many alleles with high- to intermediate penetrance have been recognized in 20 
or more genes. Out of these genes some are associated to DNA damage signalling and 
DNA repair. Genome-wide association studies have introduced more over 70 low-
penetrance loci. Copy number variation and somatic mosaicism have been considered 
as potentialy influencing processes along with classical germ-line mutation and 
single-nucleotide polymorphism. Most of the recognized loci also influence tumor 
characteristics in breast such as estrogen and progesterone receptor status (Bogdanova 
N et al., 2012; Evans et al., 2013). 
Two types of genes have been discovered to play a vital role in this scenario i.e., 
oncogenes and tumor suppressor genes. Proto-oncogenes exhibit role in controlling 
cellular proliferation and programmed natural cellular death. Certain genetic and 
expressional variations in these genes activate them to oncogenes that help cells to 
escape normal growth check points and natural death. On the other hand, tumor 
suppressor genes normally regulate cell proliferation. These genes can be classified as 
gate keepers and care takers depending on their role in controlling cell division or in 
DNA repair to maintain genomic integrity (Levitt, 2002). Somatic and germ-line 
mutations have been described in several tumor suppressor genes whereas, oncogenes 
are usually found amplified in different cancers. Genes in ATM-CHK2-TP53 cell-
cycle checkpoint pathway are mutated in relation to breast cancer, particularly TP53 
at the somatic level. BRCA1 and BRCA2 germ line variations, mainly account for 
familial breast cancer. Many other genes have been identified to increase breast 
cancer risk that includes p53, PTEN, ATM etc. However, they are responsible for a 
small number of cases as mutations in these genes are even less common than 
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mutations in BRCA1 and BRCA2 (Ingvarsson, 2004; Evans et al., 2013; Ghoussaini et 
al., 2013; Bernard et al., 2014).  
Another aspect of breast cancer that has been widely studied in past decade is the 
involvement of miRNAs in the regulation of mammary gland tumorigenesis, 
functioning either as tumor suppressors or oncogenes. There is emerging evidence 
about the involvement of other non-translated RNA markers like T-UCRs, snoRNA, 
IncRNAs and piRNAs in breast cancer diagnosis and prognosis (Behbod and Rosen, 
2012).  
1.9 DNA damaging Factors 
There are several intrinsic or extrinsic agents which may impair DNA molecule in 
each cell. These factors can be classified as endogenous and exogenous factors and 
may be helpful in designing suitable therapy for breast cancer. 
1.9.1 Endogenous factors 
Most of the DNA variations are usually due to endogenous causes which include 
spontaneous hydrolysis of N-glycosidic bond between the DNA base and deoxyribose 
sugar. Approximately 10,000 AP sites are produced in each cell per day as a result of 
hydrolytic loss of nucleobase e.g. most frequently (100–500 times per day per cell) 
uracil is formed from cytosine. Chemical alteration of DNA by reactive molecules 
during normal cellular metabolism is another endogenous reason. Among these are 
the most important are reactive oxygen species (ROS) e.g. O2−, 
•
OH and H2O2 and 
reactive nitrogen species (RNS) e.g. NO
•
. ROS and RNS produce numerous oxidative 
DNA adducts including base alteration, deoxyribose oxidation, double or single strand 
cleavage and DNA-protein cross-bridges. Additionally DNA is also damaged due to 
alkylation agents such as endogenous methyl donor e.g S-adenosyl-methionine 
(SAM) and methyl radicals synthesized during lipid per-oxidation especially at N
-
 and 
O
−
 atoms of nucleobases. Endogenous damage to DNA may also come from 
inescapable errors during routine reactions in physiological DNA processing by 
different DNA polymerases e.g. DNA mis-matches, insertions and deletions resulting 
from mis-integration of bases and chemically transformed nucleotide precursors 
(dUTP and 8-oxo-dGTP). Faulty DNA repair mechanism is most crucial in 
supplemental introduction of DNA damage. 
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1.9.2 Exogenous factors 
In addition to intrinsic factors, several environmental agents also constantly damage 
cellular DNA. Extrinsic factors include physical insults e.g. ultraviolet (UV) rays 
from sunlight and ionizing rays produced by natural (cosmic and gamma rays) and by 
artificial sources (X-rays and radiotherapy for medical managements). Ionizing 
radiations may damage indirectly by producing ROS or by stimulating multiple DNA 
damaging lesions e.g. double-strand breaks (DSB). Beside physical stress, DNA is 
also impaired by numerous alkylating agents (methyl methane sulfonate and 
temozolomide) and chemotherapeutic drugs (inhibitors of topoisomerase I or II) 
which create single- or double-strand breaks. Various chemicals commonly found in 
diet (N-nitrosoamines) and emitted in air from tobacco smoke and vehicle exhaust 
(heterocyclic amines and polycyclic aromatic hydrocarbons) are playing a key role in 
DNA-damage (Dexheimer, 2013).  
 
Figure 1.2  DNA damage, repair mechanisms and consequences  
a. Common DNA damaging agents (top); examples of DNA lesions induced by these agents 
(middle); and most relevant DNA repair mechanism responsible for the removal of the 
lesions (bottom).  
b. Acute effects of DNA damage on cell-cycle progression, leading to transient arrest in the 
G1, S, G2 and M phases (top) and on DNA metabolism (middle). Long-term consequences 
of DNA injury (bottom) include permanent changes in the DNA sequence (point mutations 
affecting single genes or chromosome aberrations which may involve multiple genes) and 
their biological effects.  
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Abbreviations: cis-Pt= cisplatin; MMC= mitomycin C (DNA-crosslinking agents); (6–4)PP= 
6–4 photoproduct;  CPD= cyclobutane pyrimidine dimer (induced by UV light); BER= 
base-excision repair; NER=nucleotide-excision repair; HR, homologous recombination; 
EJ, end joining (Adopted from Hoeijmakers , 2001). 
 
1.10 Pathways Associated with Breast carcinogenesis 
Breast carcinogenesis is associated with irregularities of different pathways including 
DNA repair, carcinogen metabolism, cell cycle control and matrix metalloproteinase 
pathways (Scully et al., 2000). Details of these pathways are given below, 
1.10.1 DNA repair Mechanisms 
Genome (huge DNA molecule with approximately three billion base pairs) is 
susceptible to damage caused by both exogenous and endogenous mutagens 
(Hoeijmakers, 2001). DNA repair mechanism acts primarily to repair these damages 
and to maintain the integrity of DNA molecules (Mahjabeen et al., 2011). Different 
DNA repair pathways work with complicated interaction to avoid breast cancer but 
multiple single-nucleotide polymorphisms in DNA repair pathways found associated 
with breast cancer risk. Effective DNA repair ability is critical in reducing the DNA 
damage buildup to avoid the stimulation of abnormal cell proliferation and 
development of tumor. It has been observed that defective DNA repair and higher 
DNA damage is frequently observed in breast cancer patients especially in female 
having family history (FH) of breast cancer which indicate the significance of DNA 
damage repair in suppression of disease. Various types of lesions caused by DNA 
damage are corrected through multiple repair mechanisms developed in each cell. 
Atleast five main DNA repair mechanisms have been found operating in mammalian 
cells for genome integrity, it includes base excision repair (BER), mismatch repair 
(MMR), nucleotide excision repair (NER) and double-strand break repair (DSBR), 
which is further subdivided into homologous recombination (HR) and non-
homologous end joining (NHEJ) pathways (Dexheimer, 2013). 
1.10.1.1 Base excision repair pathway (BER) 
BER pathway is the primary guardian against damage that results from cellular 
metabolism including reactive oxygen species, methylation, deamination and 
hydroxylation. Genetic variations in BER may result in reduced or defected repair 
capability and accumulated DNA damage consequently leading to permanent 
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mutations in the genome, which may ultimately contribute to carcinogenesis. 
Therefore, base excision repair is a universal event in cells for preventing mutagenesis 
(Zhou et al., 2011a). Generally, BER is a multiple sequential process which involves 
numerous proteins at various entry points on the basis of DNA damage encountered 
(Dexheimer, 2013).  BER first involves cleavage of damage nucleotide by DNA 
glycosylase (OGG1) generating abasic site (Lu et al., 2009). This abasic site is 
recognized by another enzyme called AP endonuclease (APEX1), which cuts the 
phosphodiester bond and creates the 3′-OH terminus adjacent to abasic site (Fortini et 
al., 2003). BER pathway is then completed by replacement of one nucleotide in short 
patch pathway and multiple nucleotides in long patch pathway by DNA polymerase 
and sealing of nick portion by ligase (Friedberg et al., 2004; Hung et al., 2005).  
1.10.1.2 Nucleotides excision repair pathway (NER) 
NER is a very useful pathway which identifies and removes diverse types of large, 
helix- disrupting lesions from DNA generated due to UV light exposure and 
interference of aromatic amines and nitrous compound (Costa et al., 2003; Shuck et 
al., 2008). NER pathway was first identified in patients with Xeroderma pigmentosum 
(XP) (Setlow et al., 1964). NER operates by sequential association of multiple repair 
proteins at the site of DNA damage. Even NER and BER are mechanistically alike but 
NER pathway is more complex and involves about thirty different types of proteins to 
perform a multi-step “cut and patch” mechanism (Nouspikel, 2008; Shuck et al., 
2008). Biologically NER is significant as defects in NER results in numerous genetic 
disorders related to extreme sun sensitivity, which include xeroderma pigmentosum, 
immunological defects, Cockayne syndrome, neurodegeneration, developmental 
delay, premature aging and cancer. NER pathway is comprised of two related sub-
pathways, global genome NER (GG-NER) and transcription coupled NER (TC-NER). 
GG-NER operates to remove DNA lesions in entire genome whereas TC-NER 
preferentially repair lesions produced on the coding strand of actively transcribing 
genes. Except initial step of damage recognition, both pathways (GG-NER and TC-
NER) proceed mechanistically similar through the common “core” NER reactions 
(Dexheimer, 2013). In first step, damage is recognized by damage recognition factors 
XPC (xeroderma pigmentosum group C) + XPA (Xerodema pigmentosum A) + RPA 
(replication protein A). In second step, transcription factor III complex unwinds the 
DNA duplex around the damage site and in third step 16-unit pre-incision complex 
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incise the damage site at dual sites 3′ and 5′ and remove the damage strand. In fourth 
and fifth step of NER pathway polymerization and ligation restore the DNA to its 
unmodified state (Farnell, 2010; Sugasawa, 2010; Dexheimer, 2013).    
1.10.1.3 Mismatch repair pathway (MMR) 
MMR pathway plays crucial role in post-replication repair of mis-incorporated 
nucleotides during DNA replication and recombination. Insertion/deletion loops 
(IDLs) produced due to polymerase slippage during replication of repetitive DNA 
sequences are also corrected by MMR proteins.  
Mutator phenotypes having frequent microsatellite instability along with higher 
mutational frequency in MMR deficient cells validate the significance of this 
pathway. Germline mutations in MMR genes are found susceptible to various 
cancers (Conde et al., 2009; Dexheimer, 2013). The MMR pathway may be divided 
into three major steps: 
i) A recognition step to recognize mis-matched bases by a hetrodimer (MutSα), 
ii) An excision step to remove erroneous strand causing in a gap by the activity of 
uvrD helicase, another mismatch protein,  
iii) Repair synthesis and ligation step to fill the gap by DNA polymerase III and 
finally completed by DNAligase I sealing the left behind nick (Fukui K (2010; 
Larrea et al., 2010; Dexheimer, 2013). 
1.10.1.4 Double strand repair pathway  
Double strands breaks (DSBs) are considered a biologically damaging lesions 
produced by some chemicals and ionizing radiations. Even single DSB, if left 
unrepaired, may cause cell death and genomic instability syndromes or may lead to 
various cancers including breast cancer through deletions, inversion and 
translocations. In conclusion, DSB repair pathways are crucial for maintenance of 
genome integrity and cell survival in mammalian cells. These pathways are non-
homologous end joining (NHEJ) and homologous recombination (HR). Both HR and 
NHEJ repair systems differ in involvement of homologous template DNA and 
reliability of DSB repair. HR is mainly an error-free repair system which utilizes 
intact sister chromatid as a template. Whereas, NHEJ is usually erroneous 
mechanism and eliminates DSBs, by simply direct ligation of the broken ends. NHEJ 
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is consistently principal pathway in mammalian cells functioning at all phases of the 
cell cycle whereas, HR is limited to late-S and G2 phases only (Li  and Heyer, 2008; 
Lieber, 2010). Basic mechanisms of HR and NHEJ pathways along with factors 
involved are as below, 
1.10.1.5 Homologous recombination (HR) 
HR may be further sub-divided into three phases: i) pre-synapsis ii) synapsis and iii) 
post-synapsis. During pre-synapsis phase, DNA ends at DSB are processed to produce 
DNA molecules containing 3´single-stranded tails by the action of hetero-trimeric 
MRN complex (Mre11-Rad50-Nbs1) and CtIP (RBBP8) (Sartori et al., 2007). Next 
step of 5´ to 3´ resection is completed by joint action of BLM helicase and Exo1 
exonuclease (Nimonkar et al., 2008). After resection, disrupting secondary structures 
are removed by binding of single-stranded DNA tails to avoid obstruction in binding 
of Rad51 recombinase. Then Rad51 replaces RPA by several mediator proteins 
(Rad52, BRCA2) and Rad51 protein group (RAD51B, RAD51C, RAD51D, XRCC2 
and XRCC3) (Forget and Kowalczykowski, 2010). In central reaction of HR, Rad51 
nucleoprotein filament completes the search for DNA sequence homology. On 
identification of homologous DNA, template DNA duplex is invaded by damaged 
DNA strand by mediation of Rad51. DNA is then synthesized from 3´end of invading 
by DNA polymerase and ligated by DNA ligase I to yield a four-way Holliday 
junction. This recombination intermediate (Holliday junction) is finally resolved  to 
complete error-free correction of the DSB in any one of three ways, 
i) Dissolution by BLM-TopIIIα complex,  
ii) Symmetrical cleavage by GEN1/Yen1,  
iii) Asymmetric cleavage by endonuclease Mus81/Eme1(Symington, 2009 
;Dexheimer, 2013). 
1.10.1.6 Non-Homologous End-Joining (NHEJ) 
NHEJ joins the two broken ends directly which leads to the deletion of small DNA 
sequence. It involves XRCC4, LIG4, DNA-PK and the catalytic subunits (Valerie and 
Povirk, 2003). NHEJ is more important than HR for repairing strand breaks induced 
by radiations. In human cells it involves RPA, XRCC2, XRCC3, Rad51 and Rad52. 
Several studies have reported that HR pathway promotes the survival when sister 
chromatides are present (Petrini and Stracker, 2003; Lieber, 2010). Cytogenetic 
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investigations have reported that hamster cells defective for XRCC2 and XRCC3 
showed elevated levels of chrosomal aberrations (Cartwright et al., 1998; Liu et al., 
1998). 
1.10.2 Xenobiotic Metabolism 
Cytochrome p450 enzymes are involved in phase 1 metabolism of drugs and 
xenobiotics (Guengerich, 2006). They are actively involved in the 
activation/inactivation of carcinogens and chemotherapic drugs (Lewis, 2003). 
Glutathione S-transferase (GST) is a group of enzymes involved in phase II 
detoxification of carcinogens (Masood et al., 2010). Role of xenobiotic metabolizing 
enzymes in carcinogenesis have been studied in various studies (Konig-Greger et al., 
2004; Skuladottir et al., 2005; Lima et al., 2008; Masood et al., 2010; Masood et al., 
2011). 
1.10.3 Cell cycle  
Cell cycle is very important pathway to repair the damaged DNA before cell 
division. Cyclin D1 (CCND1) is a major gene of cell cycle which controls the 
transition from G1 to S phase (Li et al., 2012; Yue et al., 2012). Several mutational 
studies have observed that CCND1 polymorphisms may contribute to susceptibility 
to SCCHN in different populations (Matthias et al., 1998; Holley et al., 2001; Sabir 
et al., 2012). p16 and pRb are important in regulation of cell cycle and extensively 
studied genes in different kind of cancers including HNC (Kommoss et al., 2007; 
Sabir et al., 2012). Studies of premalignant and malignant oral cavity lesions have 
shown frequent alternation of coding region of p16 gene (Shahnavaz et al., 2001; 
Kresty et al., 2002). Alterations and mutations in p16 gene result in elevated 
phosphorylation of pRb which ultimately result in carcinogenesis (Gronbaek et al. 
1998). 
1.10.4 Matrix Metalloproteinase pathway (MMP) 
MMPs are genes involved in cell adhesion, proliferation and migration (Klein et al., 
2004). In this gene family, MMP2 has been reported to be involved in lymph node 
metastasis (Monig et al., 2001; Daniele et al., 2010), MMP3 appears to be necessary 
for anchorage-independent growth (Liu et al., 2007) and MMP9 is involved in 
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infiltrative and lymph node involvement (Daniele et al., 2010). Moreover, MMP7 
gene expression is associated with risk of early HNSCC (OC et al., 2001). 
1.11 Base excision repair (BER) pathway and breast carcinogenesis 
Breast carcinogenesis is a multistep process, in which accumulated genetic changes 
lead to cell dysregulation which contribute to the proliferative advantage of cancer 
cell (Grandis et al., 2004). To prevent cell dysregulation and maintain the integrity of 
genome, a set of complex DNA repairing system hs evolved in mammals. Base 
excision repair pathway (BER) is the primary defense system against damage 
produced from deamination, reactive oxygen species and hydroxylation. Therefore, 
BER is a universal event in cells and is relevant for preventing mutagenesis (Hung et 
al., 2005). BERstarts with the recognition and hydrolytically cleaving of damaged 
base from the base-deoxyribose glycosyl bond of the defective nucleotide by a DNA 
glycosylase and apurinic/apyrimidinic (AP) site is generated. Another enzyme AP 
endonuclease (APEX1) recognizes and cuts the sugar-phosphate back bone at 5´ end 
of the abasic site and recruits another enzyme polymerase β (Polβ) (Karahalil et al., 
2012). Polβ then inserts one nucleotide at 3´ end of the nick in sugar-phosphate back 
bone. In case of main pathway (Short patch BER), the 5´-teminal deoxyribose-
phosphate residue is removed by Polβ due to its lyase activity. Polβ also work 
together with x-ray repair cross-complementing group 1 (XRCC1) protein and DNA 
ligase III in the form of XRCC1-ligase III heterodimer. XRCC1 performs as a scaffold 
protein to bring the Polβ and the ligase together at repair site to complete the repair 
process and single nucleotide repair patch is generated. Occasionally if terminal 
sugar-phosphate residue, due to its more non-compatible structure, is not easily 
cleaved by AP-lyase activity of Polβ then a patch of nucleotides is added to the 3’ end 
by poly-δ/ε generating a flap containing the 5’ sugar phosphate to initiate alternative 
minor sub-pathway (long-patch BER). In long-patch BER a flap of few nucleotide is 
excised by an enzyme flap endonuclease-1 (FEN1) under the stimulating and scaffold 
action of a protein, “proliferating cell nuclear antigen (PCNA)” just similar to XRCC1 
action in main pathway (Short patch BER). DNA ligase-I finally seals this newly 
constructed longer-patch to complete the repair (Hung et al., 2005; Hung et al., 2008). 
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Figure 1.3 Mechanism for base-excision repair pathway (short and long patches) 
(Adapted from Hoeijmakers, 2001) 
Several functional studies have shown that impaired BER pathway may be a risk 
factor for development of lung (Speina et al., 2003; Paz-Elizur et al., 2006) and other 
cancers (Tudek, 2007). Molecular mechanism responsible for this pathway damage 
may include BER pathway gene polymorphisms and expressional deregulation of 
proteins involved in repair pathways (Tudek, 2007). SNPs search studies have 
revealed that risk of cancer increases due to the presence of multiple polymorphisms 
instead of only one polymorphism (Tudek, 2007). For example, APEX1 
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polymorphism (Asp148Glu) and XRCC1 polymorphism (Arg194Trp) may have 
combined effect on increased risk of pancreatic cancer, while each of these variants 
separately have no effect (Jiao et al., 2006). The main genes operating in BER 
pathway are OGG1, APEX1 and XRCC1. Detailed description of these genes is given 
below, 
1.11.1 Apurinic/apyrimidinic endonuclease 1 (APEX1)  
APEX1 is important rate limiting enzyme in BER pathway (Fortini et al., 2003). It 
resides on 14q11.2 – 14q12 and has five exons (Parsons et al., 2004). APEX1 
hydrolyzes 5′ backbone of DNA molecule generated after the removal of 8-oxoG by 
OGG1, producing a 3′ hydroxyl group and 5′ deoxyribose phosphate group. AP site is 
cytotoxic and mutagenic, so a decrease in APEX1 activity results in mutagenesis and 
carcinogenesis (Wiederhold et al., 2004). APEX1 has two domain, DNA repairing 
domain and Redox domain. The carboxy terminus of APEX1 contains the 
endonuclease activity required for DNA repair and spans residues 61-318, whereas 
residues 1-127 comprise the redox domain (Figure 1.4) (Hsieh et al., 2001). 
 
Figure 1.4 APEX1 protein and gene structure. The coding exons, the protein domains 
and the regions of interaction with other BER proteins are indicated (Adopted from 
Simonelli et al., 2012). 
APEX1 has been characterized in numerous functional studies. The E. coli and yeast 
demonstrated hypersensitivity to hydrogen peroxide and UV light when AP activity 
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was eliminated (Demple et al., 1983; Sammartano and Tuveson, 1983; Ramotar et al., 
1991).
 
Human cells exposed to sub-lethal doses of oxidizing agents showed an 
increase in both the amount of APEX1 as well as APEX1 activity (Ramana et al., 
1998). 
The limited epidemiologic data examining the relationship between APEX1 
polymorphisms and cancers related traits has suggested a weak to null effect (Misra et 
al., 2003; Ito et al., 2004; Popanda et al., 2004). Many investigators have focused on 
the Asp148Glu variant, as it resides in the carboxy terminus. However, variants 
outside the APEX1 DNA repair domain, such as residues 61-318 or promoter regions, 
could be markers for disease causing SNP and may be informative (Avery, 2007). 
Variants in different regions of APEX1 gene have been identified and found to 
influence the susceptibility and progression of different cancers including lung cancer 
(Lo et al., 2009; Lu et al., 2009), bladder cancer (Wang et al., 2010), glioblastoma 
(Zhou et al., 2011b); cervical cancer (Wang et al., 2013) and breast cancer (Zang et 
al., 2006; Kang et al., 2013a)   
1.11.2  8-oxoguanine DNA glycosylase-1(OGG1) 
OGG1 gene is located on human chromosome 3p26.2 (Park et al., 2007). It has eight 
exons and produces two transcripts by alternative splicing, α-OGG1 (alternatively 
OGG1 type 1a) and β-OGG1 (type 2a) (Lu et al., 1997). α-OGG1 and β-OGG1 
mRNA is transcribed from 1-7 exons and 1-6 plus eight exons respectively (Nishioka 
et al., 1999). α-isoform is 345 amino acids long protein and localized in nucleus 
whereas β-isoform is 424 amino acids long and localized in mitochondria ( Shinmura 
et al., 2000). OGG1 enzyme is characterized by HhH-GDP motif composed of a 
helix-hairpin-helix (HhH) element followed by a Gly/Pro-rich loop, terminating in an 
invariant aspartic acid (Figure 1.3) (Labahn et al., 1996; Bruner et al., 2000). OGG1 
does not require any additional co-factor to recognize the 8-oxoG DNA and to initiate 
BER pathway. It recognizes 8-oxoG and releases this modified base by cleaving the 
N-glycosyl oxidized-G- deoxyribose backbone bond and produces AP site.  
OGG1 gene is highly polymorphic among humans and is also mutated in cancer cells. 
Mutations of OGG1 have been implicated in the development of certain human 
diseases including cancer (Rossneret al., 2006). Gene knockout mice defective in 
OGG1 accumulate higher levels of 8-oxoG lesions compared with wild-type controls 
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and exhibit elevated spontaneous mutations, especially when exposed to higher levels 
of oxidative stress (Arai et al., 2003). These observations suggest that OGG1 acts as a 
major gene responsible for 8-oxoG removal (Xu et al., 2008). 
 
Figure 1.5 Structure of the two major isoforms of human OGG1 gene. Schematics of 
α- (345 amino acids) and β-OGG1 (424 amino acids) proteins are shown. The first 
316 amino acids are common for both isoforms, while the C-termini vary 
considerably. The mitochondrial localization signal (MLS, position 9–26), nuclear 
localization signal (NLS, 335–342) and HhH-GPD motif are indicated (Adopted from 
Hashiguchi et al., 2004). 
Several studies have reported the role of OGG1 in DNA repair. Impaired OGG1 
activity in Eukaryotes results in G:C to T:A transversion and mutator phenotype 
development (Michaels and Miller, 1992; Grollman and Moriya, 1993; Thomas et al., 
1997). Inactivation of OGG1, results in increased 8-oxoG in lung cancer (Nishimura, 
2002). OGG1 functional reduction appears to be associated with increased risk of 
cancer (Paz-Elizur et al., 2006).  Many SNPs have been reported in literature for 
OGG1 gene. Among these SNPs C/G polymorphism at position 1235 (Ser326Cys) in 
exon seven is the most studied OGG1 variant. Cys/Cys carriers are postulated to have 
a decreased capability in repairing oxidative DNA damage compared to Ser/Ser or 
Ser/Cys carriers (Kohno et al., 1998). Two more reported SNPs of OGG1 are Asp-
268-Asn and Lys-249-Gln (Nash et al., 1997). Mutation of Asp-268 and Lys-249 to 
Asn and Gln, respectively, generate variant forms that lack base excision repair 
activity (Norman et al., 2003). 
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1.11.3  X-ray cross complementing group 1 (XRCC1)  
XRCC1 is a key factor in BER and DNA single stand break (SSB) repair pathway 
(Fan et al., 2004). XRCC1 gene contains 17 exons and human gene maps to 
chromosome 19q13.2 (Cappelli et al., 1997). It is first mammalian gene implicated in 
cellular sensitivity to ionizing radiations. XRCC1 protein serves as a scaffolding 
protein for other repair factors (Campalans et al., 2005) and physically interact with 
several enzymes involved in SSBR and BER (Fan et al., 2004) such as DNA ligase 
IIIα, DNA polymerase β, APEX1 and OGG1 (Marintchev et al., 1999). 
XRCC1 has two BRCT1 domains and one NTD domain. BRCT1 is a binding site for 
PARP whereas BRCT2 is a binding site for ligase 3 (Lig3). The linker area between 
BRCT1 and NTD has been suggested to be the area for binding other proteins 
including APEX1, OGG1 and PCNA (Figure 1.5) (Lee et al., 2001).  
Figure 1.6 XRCC1, protein and gene structure. The protein domains and the regions 
of interaction with other BER proteins are indicated (Adopted from Simonelli et al., 
2012). 
Five polymorphisms have been identified in XRCC1 gene. Three polymorphisms 
(Arg399Gln, Arg194Trp and Arg280His) lead to amino acid change in evolutionary 
conserved region of XRCC1 and two polymorphisms (Pro206Pro, Gln632Gln) are 
silent (Qu et al., 2005; Mahjabeen et al., 2012a). Arg194Trp polymorphism has been 
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identified at codon 194 and position 26304 (exon 6) (Sturgis et al., 1999). This 
polymorphism is located in region separating the polymerase β and polyADP ribose 
polymerase interacting domains (Demokan et al., 2005). Arg399Gln polymorphism 
has been identified at codon 399 and position 26304 (exon 10) (Shall and de Murcia, 
2000). This polymorphism is located within BRCT-1 domain resulting in impaired 
BER activity (Ramachandran et al., 2005). Patients carrying this polymorphism have 
elevated risk of DNA adduct formation, IR sensitivity and tobacco related DNA 
impairment (Lunn et al., 1999; Hu et al., 2001). Arg280His polymorphism has been 
identified at codon 280 and exon 9. Two silent polymorphisms, (Pro206Pro on exon 7 
and Gln632Gln on exon 17) also have been located in highly conserved regions of 
human genome (Lamerdin et al., 1995). Several studies have reported the association 
of  these XRCC1 polymorphisms with different types of cancers such as lung (Hung et 
al., 2005; Yin et al., 2007), breast (Campalans et al., 2005; Schreiber et al., 2007), 
gastric (Berquist et al., 2010), colon
 
(Holmila et al., 2010), HNC
 
(Vidal et al., 2001), 
esophageal (Holmila et al., 2010) and bladder cancer
 
(Talamini et al., 2002; Yin et al., 
2007).  
 
1.12 Plan of Study  
Although, BER pathway gene (OGG1, APEX1 and XRCC1) polymorphic system and 
cancer susceptibility have been investigated in different populations; neither of these 
genes has been studied in relation to breast cancer patients in Pakistani population. So 
a preliminary screening of these genes is planned to bridge the gap. This study is 
designed to evaluate the contribution of OGG1 (ID 4968), APEX1 (ID 328) and 
XRCC1 (ID 7515) germline mutational spectrum with respect to breast cancer from 
different ethnic groups of Pakistani population. Apart from screening these genes on 
genome scale, expressional analysis of BER pathway genes (OGG1, APEX1 and 
XRCC1) along with proliferation marker Ki-67, is designed in tumor tissues. 
Expressional alterations will be correlated with clinical parameters like TNM staging. 
Protein profiling of these genes in breast cancer in somatic tissues will also be 
included in this study so that the complete picture of BER pathway can be presented 
in an elaborative manner. Next part of this study is designed to explore the association 
of expression profile of these genes with breast carcinogenesis using breast tumor 
tissues to evaluate their altered expression and its effect on patient outcome and 
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survival along with cellular functions such as growth, adhesion, invasion and cellular 
migration in two breast cancer cell lines (MCF-7 and MDA-MB-231). 
A concise format presentation of the study plan is as follows; 
 A population based case-control study for screening of genetic variations in BER 
pathway genes (OGG1, APEX1 and XRCC1) at germline level in breast cancer 
patients and analysis of these variations in etiology of breast carcinogenesis with 
reference to different risk factor involved. 
 Expression analysis at transcriptional and translational levels of BER pathway 
genes in breast cancer patients and correlation of these genes with breast cancer 
risk and disease progression (TNM staging) in Pakistani and British cohort. 
 Investigation of the role and behavior of BER genes on cellular functions such as 
growth, adhesion, invasion and cellular migration in breast cancer cell lines, using 
a series of in-vitro experiments. 
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2.1 Materials 
2.1.1 Chemicals  
A list of chemicals/reagents used in this study is given below along with manufacturer 
name 
Reagents Manufacturer  
Acrylamide Merck, USA 
Agarose Invitrogen, USA 
Ammonium Persulfate Merck, USA 
Antibodies Calbiochem &Millipore, USA 
APEX1, OGG1, XRCC1, Ki-67 Antibodies Novus Biological, USA 
Bisacrylamide Invitrogen, USA 
Boric acid Serva, USA 
Chloroform Merck, USA 
Chromatography paper Whatman International Ltd., UK 
Culture plate inserts containing 8µm pores BD Biosciences, UK 
DAB Chromogen Biogenics Corp, USA 
DEPC-treated water Merck, USA 
Dimethyl Sulphide (DMSO) Fisher scientific, USA 
GeneRuler (1kb and 100bp) plus DNA ladder Thermo Scientific, USA  
Dounce tissue grinder  WHEATON, USA 
EDTA Invitrogen, USA 
Electric Cell-Substrate Impedance Sensing 
(ECIS) system 
Applied Biophysics Inc, USA 
Eppendorfs  Alpha Laboratories, UK 
Ethanol Sigma, USA 
Ethidium bromide Sigma, USA 
Falcon tubes Fisher Scientific, UK 
FAST SYBR Green master mix Applied Biosystem, USA 
GREENTaq® ReadyMix™ PCR Reaction Mix  Sigma, USA 
HistoGrip Invitrogen, USA 
Hybond nitrocellulose membrane Amersham Biosciences, UK 
Isoamyl alcohol Merck, USA 
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Isopropanol Merck, USA 
Magnesium Chloride Thermo Scientific, USA 
Methanol Fisher Scientific, UK 
Nuclease free water Invitrogen, USA 
Optimium MEM Gibco, USA 
PCR Master Mix Thermo scientific, USA 
PCR Primers (APEX1, OGG1, XRCC1, Ki-67) Alpha DNA, Canada 
PCR Primers (GAPDH) Sigma, USA 
Phenol Merck, USA 
Plate reading spectrophotometer (ELx 800) Bio-Tek, Wolf Laboratories, UK 
Proteinase K Sigma, USA 
Quantitative PCR primers (APEX1, OGG1, 
XRCC1, Ki-67) 
Sigma, USA 
RNA isolation kit Qiagen, USA 
RNA Later Ambion, USA 
Roller mixer Wolf laboratories, UK 
SD10 Semi Dry Maxi System blotting unit Wolf Laboratories, UK 
SDS Sigma, USA 
Secondary antibody Cell Signalling Tech, USA 
Sodium Acetate Sigma, USA 
Sodium Chloride Invitrogen, USA 
Sucrose Invitrogen, USA 
Super script III First-Strand kit Invitrogen, USA 
Supersignal West Dura system reagents Pierce Biotechnology, USA 
TEMED Invitrogen, USA 
Tris Sigma, USA 
Tris EDTA (T.E buffer) USB, USA 
Trizol Invitrogen, UK 
UVITech imager UVITech, Inc., UK 
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2.1.2 Solutions 
Solutions used in present study are as follows, 
2.1.2.1 Solutions for DNA extraction 
Solution A 
Add 27.36g (0.32M) sucrose, 0.254g (5mM) MgCl2 and 0.302g (10mM) Tris in 
distilled water to make final volume up to 250ml and dissolve thoroughly. Autoclave 
the solution and on cooling add 1% vol/vol Triton X100. 
Sloution B 
Add 3.51g (100mM) NaCl2, 0.182g (10mM) Tris and 0.11g (2mM) EDTA in distilled 
water to make up a final volume of 150ml. 
Solution C 
Mix Isoamyl alcohol and chloroform in a ratio of 1:24.  
20% Sodium dodecyl sulphate (SDS) 
Dissolve 20g of sodium dodecyl sulphate in 100ml of distilled water.  
Proteinase K (PK) 
Add 0.015g PK in 7.5ml of Glycerol (50%) to make stock solution. For working 
solution (20mg/ml) dilute stock solution in sterile water and store at 4ºC for further 
use.  
Sodium Acetate 
Dissolve 24.6gm sodium acetate in 100ml distilled water to prepare 3M sodium 
acetate. 
2.1.2.2 Solutions for electrophoresis 
10x TBE buffer (Tris, Boric acid, EDTA) 
Dissolve 109g Tris, 55g boric acid and 9.3g disodium EDTA in distilled water to 
make final volume up to 1 litre, adjust the pH at 7.4 and autoclave. For agarose gel 
electrophoresis dilute the solution to 1× concentration prior to use. 
Ethidium bromide (EtBr) 
Dissolve 0.1g of ethidium bromide in 10ml of distilled water. Wrap container in an 
aluminium foil to protect solution from exposure to sunlight and store at 4
o
C before 
use. 
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Loading dye 
Dissolve 0.025g bromophenol blue and 4g sucrose in 10ml double distilled water and 
mix well. 
10% Ammonium persulfate (APS) 
Dissolve 10g of ammonium persulfate in 100ml distilled water to make 10% APS 
solution and store at 4°C. 
Monomers: Acrylamide/ Bisacrylamide (30% sol.) 
Mix 29.0g acrylamide and 1g bisacrylamide in100ml distilled water to make 30% 
working monomers solution and stored at 4ºC. 
2.1.2.3 Solutions for protein isolation and western blotting  
Lysis buffer 
To make 1l of RIPA buffer, mix 10g deoxylcholate, 8.76g NaCl, 10ml Tris (1M, pH 
7.2), 10ml of 10% SDS, 10ml of 0.5M EDTA and 1ml of Triton X-100 in distilled 
water. Filter the buffer before use in experiments. 
Blocking buffer 
Dissolve 5g of non-fat milk (NFM), 10ml of 1×TBS and 200µl of Tween20 in 170ml 
of distilled water 
Tris buffer saline Tween20 (TBST) 
Add 100ml of 10× TBS and 1ml of Tween20 in 1l of distilled water to make 1× 
TBST. 
SDS 10× running buffer 
Dissolve 1.44kg glycine, 303g Tris and 100g SDS in distilled water to make a final 
volume up to 1l.  
Transfer buffer  
Add 15.15g Tris, 72g Glycine and 1l of Methanol in distilled water to make a final 
volume up to 5l. 
Washing buffer 
Add 0.5μl of Tween 20 in 500ml of 1% TBS to prepare washing buffer.
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2.1.2.4 General solutions 
Sodium Hydroxide NaOH 
Add 0.8 g NaOH in 20 ml distilled water to prepare 1M NaOH stock solution. To 
make 10mM working solution, add 250μl from stock solution in 24.75ml distilled 
water. 
 DEPC water 
To prepare 5ml DEPC water, add 250μl of diethyl pyron carbonate (DEPC) in 4.75ml 
distilled water thoroughly mix to solution and autoclave before use. 
2.1.2.5 Solutions for cell culturing 
Trypsin (25mg/ml) 
Dissolve 500mg Trypsin in 20ml EDTA (0.05M) and filter through a 0.2μm Minisart 
filter (Sartorius, Epsom, UK). Aliquot dissolved Trypsin to 250μl sample tubes and 
keep at -20°C until further use. For working solution, dilute the 250μl aliquot in 10ml 
of EDTA (0.05M) solution to use for cell detachment. 
Penicillin (120mg/ml) 
Dissolve 600mg of Crystapen Injection Benzyl penicillin Sodium (Britannia 
Pharmaceuticals limited, UK) thoroughly in 5ml sterile injection water (B.Braun, 
Germany) to make working solution. 
Streptomycin Sulphate (250mg/ml) 
Dissolve 5g of Streptomycin Sulphate thoroughly in 20ml sterile injection water, filter 
the solution using 0.2μm Minisart filter and store at -20°C until use. 
Bovine Saline solution (BSS) 
Dissolve 79.5g NaCl, 2.2g KCl, 2.1g KH2PO4 and 1.1g Na2HPO4 in distilled water to 
make a final volume of 10l and adjust pH at 7.2. 
LB agar 
Dissolve 15g of agar, 10g of Tryptone, 10g of NaCl and 5g Yeast extract in distilled 
water to make a final volume of 1litre and adjust pH at 7.0. Autoclave the solution, 
cool slightly and then add selective antibiotics (as required) and pour into 10cm
3
 petri 
dish plates (Bibby Sterilin Ltd., UK). Allow the solution to cool and harden, invert 
these petri dishes and store at -4°C till further use. 
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LB broth 
Dissolve 10g of Tryptone (Duchefa Biochemie, The Netherlands), 10g NaCl and 5g 
Yeast extract (Duchefa Biochemie, The Netherlands) in distilled water up to a final 
volume of 1liter. Adjust pH of the solution at 7.0, and autoclave. Allow to cool, add 
specific antibiotic as required and store at room temperature. 
2.1.2.6 Solutions for immunohistochemistry 
DAB Chromagen 
Firstly, add 2 drops of wash buffer in 5ml of distilled water and shake. Then add 4 
drops of DAB solution (Vector Laboratories Inc., Burlingame, USA) in the same 
container and shake again. Finally, add 2 drops of H2O2 to the above solution mixture 
and shake well. 
Avidin-Biotin Complex (ABC) 
Add 4 drops of reagent A to 20ml of wash buffer then add 4 drops of reagent B. Mix 
this solution thoroughly and leave to stand for approximately 30 minutes before use. 
Phosphate buffer saline (PBS) 
Dissolve one tablet of PBS (SIGMA-ALDRICH) in 200ml of deionized water to 
make 0.01M PBS. 
2.2 Methods 
2.2.1 Patient recruitment 
Present case-control study comprised of clinically and histopathologically 
diagnosed female breast cancer patients and healthy cancer free females. Patients 
were identified and registered for study from oncological centres and surgical 
departments of different hospitals of Pakistan.  Formal approval for study design and 
sampling was obtained from ethical and research committees of COMSATS institute 
of Information Technology, Islamabad and collaborating oncological and surgical 
hospitals. Involvement of patients and controls to study group was purely on 
volunteer basis with pre-informed consent. Inclusion criterion for patients included in 
the study was as follows. 
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 Females, having clinically and histopathologically confirmed breast cancer. 
 Free from any other familial disease such as blood pressure, diabetes and 
cardiovascular diseases. 
 No restriction for age, ethnicity, locality, stage of cancer and type of therapy 
undergoing for breast cancer patients. 
Selection of individuals for control group in the study was under following criterion: 
 Females without any clinical symptoms of any type of cancer or pre-cancerous 
lesion. 
 Free from any other familial disease such as blood pressure, diabetes and 
cardiovascular diseases. 
 Age and ethnicity matched and preferably close relatives of patients donating 
blood samples. 
Two different groups of patients and controls were recruited in present study. Cohort-
1 and 2 involved Pakistani populations recruited from Nuclear medicine Oncology 
and Radiotherapy Institute (NORI) Islamabad, Federal Govt. Services Hospital 
Islamabad, Pakistan Institute of Medical Sciences (PIMS) Islamabad and Military 
hospital (MH) Rawalpindi and Allied Hospital Faisalabad. Cohort-3 comprised of 
breast cancer patients from UK and tumor samples were obtained from tissue bank of 
Cardiff University-Peeking University Cancer Institute (CUPUCI) Cardiff, UK.  
Cohort-1 was used to screen germ line mutations using blood samples (5ml/subject) 
from 530 breast cancer cases and 395 healthy control individuals. Blood samples were 
collected in 5ml vacutainer containing EDTA as anticoagulant. Cohort-2 was used to 
assess altered transcriptional (mRNA) expression of BER genes. It comprised of 104 
tumor tissues along with equal number of non-cancerous tumor matched adjacent 
tissues as control. This mRNA expression analysis was also performed in British 
population (study cohort-3) which comprised of 111 tumor tissues along with non-
cancerous tumor matched adjacent tissues as control. This enabled the comparison of 
mRNA expression in two different populations. All patients and control subjects were 
personally interviewed at the time of sample collection on the specifically drafted 
questionnaire performa (annexure-1). Detailed information regarding disease status, 
on-going therapies and patient’s personal and family history were documented either 
directly from patients, their attendant or with the help of concerned oncologist/ 
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surgeon. Data about tumor type, tumor grade, HER-2/neu and hormonal receptor 
status was also recorded from available biopsy, histopthalogical and 
immunohistochemical reports. 
2.2.2 Sample collection and storage 
After detailed history and consent signing by patients, freshly excised tumor and 
control tissues were collected from surgical centres, immediately after surgery, in 
containers with RNA later® solution (Qiagene®/ Ambion®, USA) and were stored at 
-80°C till further use. RNA later® solution was used to stabilize and protect cellular 
RNA in tissues from denaturation. RNA later® solution is compatible with most of 
the RNA isolation methods and is helpful to isolate purified RNA from stored tissue 
samples. RNA later® inhibits disruption of tissue structure, thus tissues equilibrated 
in RNA later® were safely used to keep tissues intact during repeated 
thawing/freezing cycles and sectioning for Immunohistochemistry.   
2.3 Isolation and Quantification of Genomic DNA 
2.3.1 DNA Extraction 
Genomic DNA was isolated from leucocytes by phenol chloroform method described 
by Masood et al., 2011 with minor alterations.  
500µl of already aliquoted blood was gently mixed with 800µl of Tris (20mM) in 
1.5ml centrifuge tube by tilting the tube and was left at room temperature for 10 
minutes. Uniformly mixed sample was centrifuged for 1min at 14,000rpm and 
supernatant (about 1200µl) was poured gently and carefully into a separate tube. 
Remaining small pallet (100-150µl) was re-suspended in 1ml of Tris (20mM) and 
above cited steps were repeated twice to make three washings in total. After 
satisfactory washing, pallet was re-suspended in 375µl sodium acetate (0.2M, 5.2pH), 
50µl SDS (10%) and 10µl proteinase-K (40mg/ml). The tube containing re-suspended 
pallet was placed overnight in water bath at 65°C for incubation. 
After an overnight digestion, any remaining pallet in cell suspension was uniformly 
disrupted or agitated by gentle tapping and 120µl of buffered phenol (8.0pH) was 
added. The tube was centrifuged at 14000rpm for 5min; upper aqueous phase 
(supernatant) was aspirated very carefully without disturbing lower organic phase 
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with the help of wide mouth tip and transferred to new centrifuged tube. 120µl of 
mixture of phenol: Chloroform: isoamyl alcohol (25:24:1) was added to supernatant 
and mixed gently for 30sec. This mixture was centrifuged for 5min at 14000rpm. 
Upper aqueous phase (supernatant) was again transferred to new centrifuge tube and 
1000µl of ice chilled ethanol solution (95%) was added to it. The contents were mixed 
by gentle tilting for 10min and the tube was again centrifuged for 10min at 14000rpm. 
After centrifugation, supernatant was carefully discarded without disturbing the pallet 
and 500µl of ethanol solution (70%) was added. Contents were tilt, mixed and 
centrifuged for 1min at 14000rpm. Supernatant was again discarded very carefully 
without disturbing the pellet. Rim of the centrifuge tube was blot dried and then 
placed for air drying for 2-3min. 100µl of distilled water or in Tris EDTA buffer 
(8.0pH) was added to semidried pellet and was placed at 65°C until DNA pellet was 
completely dissolved. 
2.3.2 DNA Quantification 
Before further processing, freshly extracted DNA was quantified by 
spectrophotometry and yield gel electrophoresis. Methodology for these techniques is 
described below; 
2.3.2.1 Spectrophotometry 
For quantification of DNA, Nanodrop spectrophotometer (ND-1000, USA) was used. 
Extracted stock DNA solution was diluted in nuclease free double distilled water at 
1:4 ratio, vortex mixed and short spinned. Sensor of cuvette was wiped with kimwipe 
and 2-4µl of nuclease free double distilled water was pipetted on the sensor of 
Nanodrop cuvette read as blank (reference). Sensor of cuvette was wiped again with 
kimwipe and 2µl DNA sample was dispensed on the sensor for spectrophotometric 
quantification. UV absorbance of DNA sample was measured at 260nm and 280nm. 
DNA peak noted at 260nm with A260/A280 ratio between 1.8 and 2.0. 
2.3.2.2 Yield Gel electrophoresis 
For DNA estimation, 1% agarose gel was used, prepared by adding 1.0g of agarose 
powder to 100ml of 1xTBE buffer (Tris-Borate electrophoretic buffer). Solution was 
mixed thoroughly and heated to boil till completely dissolved. On cooling up to 55°C, 
5µl (5mg/mL) of ethidium bromide (EtBr) was added to gel solution and was mixed. 
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Prepared agarose/ethidium solution was poured into dual comb 16 teeth caster (Hofer 
scientific Inc. USA) and waited till it was solidified. DNA samples were diluted to 1:4 
ratio by adding nuclease free double distilled water, mixed and short spinned. 2µl of 
diluted DNA mixed by pipetting with 2µl of loading dye (10x) was loaded into wells 
of solidified gel. Equal volume of DNA with known concentration was also loaded in 
at least one well of each row as control.  Gel was run for 50-60min at 120volts and 
47mA. For estimation of DNA concentration, gel pictures were recorded using CCD 
video camera fitted BioDoc Analyze (Biometra GmbH, Germany). 
2.4 Polymerase Chain Reaction (PCR) 
2.4.1 Primer Designing 
PCR primers for complete coding region and intron/exon boundaries of APEX1 (ID 
328), OGG1 (ID 4968) and XRCC1 (ID 7515) were designed using PRIMER 3 input 
software (version 0.4.0) and their specificity was verified by primer BLAST (NCBI). 
Primer sequences for coding region of each of three genes along with their optimized 
annealing temperature and product sizes in base pairs are mentioned in Table 2.1. 
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Table 2.1 Primers designed for APEX1 gene with product size and annealing 
temperature 
APEX1 
Exons 
Primer Sequences(5′-3′) 
Product 
Size (bp) 
Annealing 
temperature 
Exon 1F GAGGGAGGCGAGGCTAAG 
342 63° C 
1R CCCTCACCCACGAAACTAGA 
Exon 2F GCTGGTTTCATGATTTCTTTGC 
191 63°C 
2R GCTTCTAGGAAGAAGGGCTGA 
Exon 3F TTGGAAACCACCAGCTTTTT 
299 62°C  
3R GGGGTGACTAAACCCTAAGACC 
Exon 4F AATACGTTTTCCACCTTTCTTTT 
258 58°C 
4R GAGTTCAGGCATTAGGCATCA 
Exon 5AF TCTTGATTGCTTTCCCTTTTC 
363 58°C 
5AR GGCACAGCCTGCAGTAATTC 
Exon 5BF GGGGAACAAAAAGAATGCTG 
339 60°C 
5BR AATGGTAGTTGAGGGGGCTTA 
Exon 5CF ATCACTTTGAGCCTGGGAAA 
292 63°C 
5CR GAATGTGTAGCCCCACGAAG 
    F= forward primer R= reverse primer 
Table 2.2 Primers designed for OGG1 gene with product size and annealing 
temperature 
OGG1 
Exons 
Primer Sequences (5′-3′) 
Product Size 
(bp) 
Annealing 
temperature 
Exon 1F GTGTGG GCGAGG CCTTAAG 
408 61°C 
1R CATATTAAAGGTAAC AGG TTGG 
Exon 2F CATGGAGCTATTGTAGGATAG 
387 60°C 
2R GAGAAGTGACTTATGTCCAAG 
Exon 3F TACCTAGGATCTGACCTGTG 
405 61°C 
3R GAGTTGATCAGACCAGGCAG 
Exon 4F CAGGCTTGGCTCATTTCCTG 
376 61°C 
4R GAGGTAGAGAGCTCACTTAC 
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Exon 5F GCTATAAGCAAGATGCTGGC 
438 60°C 
5R AGGGAGGACACCTAGGTAC 
Exon 6F TCCCAACACTGTCACTAGTC 
326 61°C 
6R CTTGTTGTGCAAACTGACTGC 
Exon 7F TCCGCTATGCCTCACTAATTC 
416 62°C 
7R CCCAACACCTTCTCTATTCCA 
Exon 8F TTGTGCAGGACAGCAATCTC 
312 61°C 
8R CCTGGGTCATGTGACCATCT 
F= forward primer R= reverse primer 
Table 2.3 Primers designed for XRCC1 gene with product size and annealing 
temperature 
Exons Primer Sequences (5′-3′) 
Product 
Size (bp) 
Annealing 
Temperature  
Exon 1F AGGAAACGCTCGTTGCTAAG 
370 60°C 
1R TTCCAAGAGAACCCCAAAAG 
Exon 2F GGGAGGACTCAAAGGAATCA 
249 60°C 
2R GCTCAGGAGCAGAATCTGGA 
Exon 3F TCCAAAGGAGATTCATCCTGA 
300 58°C 
3R ACTCACATCTGCCCCATGTC 
Exon 4F CCAGCCCCTAGAAGCTCTCA 
300 52°C 
4R TCAATATTGGCCCTTATTTCC 
Exon 5F TTCCCTGAGTGAAAAGGGTCT 
247 60°C 
5R AGGTCCCGCAAGGTCAGTAT 
Exon 6F ACTCCCCATGGCCTTCTC 
290 58°C 
6R TCAGACCCAGGAATCTGAG 
Exon 7F CTGGATCACTGGTGGGTTTT 
288 60°C 
7R AGGGGATGGGGATGGATT 
Exon 8F CAGCACCTCCAAGGTGAAAT 
293 62°C 
8R CCTCCCTCAGATTCAGGACA 
Exon 9F CTGGACTGCTGGGTCTGAG 416 64°C 
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9R AAAGCACAAGGTGGAGGAGA 
Exon 10F TCTGTCTCCCCTGTCTCGTT 
268 62°C 
10R CAGTCTGACTCCCCTCCAGA 
Exon 11F GCTGTTGCCTCCTGAACG 
250 60°C 
11R GGCAAGAGTGGGAAGTTTGG 
Exon 12F CTTCCCACTCTTGCCTCTTG 
359 64°C 
12R AGGTCCCCAGGCTCTCTTC 
Exon 13F GTGCCATACTGGGAGAGCTG 
202 64°C 
13R GAGAGTGAGCATGCAGAGCA 
Exon 14F GATTCTGGGGACACAGAGGA 
397 59°C 
14R GAGTGGGTTGAGGAAGGAGA 
Exon 15F CCTCGTCACTCCTGTTTGGT 
233 59°C 
15R TCCCAGCAGGTCCCTGAG 
Exon 16F TGAGAGTGGCTGGGGAGTAG 
244 60°C 
16R GGAGTCCATACGGGAATGTG 
Exon 17F CCAGCTTTGAGGAGGTGAGT 
392 64°C 
17R CCAGATCTCTGACGGAGGTG 
    F= forward primer R= reverse primer 
2.4.2 Optimization of PCR conditions  
PCR conditions were optimized for specific primer binding and amplification of 
coding regions/exons using different reagents concentrations. A wide range of 
annealing temperatures and extension time durations were also tried to maximally 
minimize the nonspecific primer binding and amplification. Verification of optimized 
amplification was carried out by electrophoresis of PCR products. A list of reagents 
used for amplification of PCR products is given in Table 2.4. 
Separate PCR reaction was carried out for each exon in a 10μl reaction mixture 
containing 1μl of genomic DNA (approximately 50ng) templates, 1μl (10mM) of each 
primer, 1μl nuclease free water and 5μl PCR master mix (Thermo Scientific) 
containing 0.05U/μl Taq DNA polymerase, reaction buffer, 4mM MgCl2, 0.4mM of 
each dNTP. Amplification conditions were initial denaturation step for 5min at 94°C 
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followed by 35 cycles each of which comprised of 45sec at 94°C, exon specific 
annealing temperature for 1min and extension for 1min at 72°C, final extension step 
for 10min at 72°C and hold at 4°C. 
Table 2.4 PCR reaction mixture composition 
Reagents Volume/reaction 
Genomic DNA templates (40-50ng) 2.00 µl 
Primer forward (10mM) 1.00 µl 
Primer reverse (10mM) 1.00µl 
PCR master mix (Thermo Scientific) 5.00 µl 
Nuclease free Water 1.00 µl 
 
2.4.3 Amplification of breast cancer patients and controls samples 
Amplification of 530 breast cancer patients and 395 control samples was carried out 
under above mentioned optimized conditions and a total of 10µl PCR reaction 
mixture containing gene specific primers and reagent concentrations as mentioned in 
tables 2.2, 2.3 and 2.4 was used for amplification. 
 
2.5 Horizontal gel electrophoresis of PCR products 
Amplified PCR products of each exon were visualized on 2% agarose gel, pre-stained 
with ethidium bromide. Along with PCR products, 100bp DNA ladder (Thermo 
Scientific GeneRuler) was also run as standard for quantification of amount and 
confirmation of PCR product size. 2% agarose maxi gel was prepared by heating 2g 
of agarose powder in 100 ml of 1x Tris-Borate electrophoresis buffer (TBE) for about 
1-2min. When agarose was completely dissolved in buffer as clear solution it was 
cooled to 55°C and 5µl of 5mg/ml of ethidium bromide (EtBr) was uniformly mixed 
in gel solution. Agarose solution was then poured into 16 teethed caster with dual 
comb (Hoefer scientific, Inc. USA) and allowed to solidify. 2µl of each PCR product 
mixed with 3-4µl of loading dye was also loaded along with 100bp DNA ladder 
(Invitrogen, USA) as standard. Agarose gel was electrophoresed at 100V and 47mA 
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for 1hr. For confirmation of PCR product size gel pictures were captured and saved 
using CCD video camera fitted BioDoc Analyze (Biometra, Germany). 
2.6 Single-strand conformational polymorphism (SSCP) 
SSCP was performed for the detection of mutations/polymorphisms in coding regions 
of specific genes under study. SSCP is an inexpensive and sensitive method for 
detection of genetic variants. 
2.6.1 Preparation of Polyacrylamide gel  
8% non-denaturing gel was prepared using acrylamide bisacrylamide for SSCP 
analysis. Properly washed and ethanol cleaned glass plates were assembled with 0.4 
mm spacers and clamped together for gel preparation and electrophoresis. To prepare 
one gel following reagents were used. 
 30% acrylamide bisacrylamide solution     13.5ml 
 10x TBE (Tris base + boric acid + EDTA)    5.0ml 
 10% APS (Ammonium per sulphate)     350µl 
 TEMED       20µl 
 Distilled water   to make a final volume of 50ml 
Above listed mixture solution was poured between the glass plates, shark toothed 
comb was placed for well formation. Gel was allowed to polymerize and solidify for 
about 45min. 
2.6.2 Sample preparation and denaturation to single strand 
5µl of amplified PCR product was transferred to fresh microcentrifuge tube and equal 
amount (5µl) of denaturant NaOH/formamide was vortex mixed. Samples were 
heated to 95°C for 8min to denature and then immediately transferred to ice for rapid 
cooling for 5min. Denaturation of double stranded DNA molecule due to intense 
heating (heat shock) was followed by rapid cooling to retain the single stranded 
configuration of DNA. 
2.6.3 Vertical gel electrophoresis   
Polymerized acrylamide gel plates were adjusted on vertical gel apparatus (Whatman 
Inc, USA). Shark tooth comb was removed gently and single stranded DNA samples 
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were loaded carefully in the wells after mixing with loading dye. Pre-cooled 1xTBE 
buffer was used for electrophoresis for more than 90min depending upon product size 
at 120volts and 300mA. Fresh running buffer was used for each run and apparatus 
was kept in cool environment to maintain the sensitivity of apparatus. 
2.6.4 Gel staining and visualization 
On completion of electrophoresis, gels were separated from glass plates with the help 
of gel separator and stained it by placing for 5min in a tank containing ethidium 
bromide solution. Stained gel was gel visualized and saved using CCD video camera 
fitted BioDoc Analyze (Biometra, Germany).  
2.7 Variant identification and DNA sequencing 
The mobility pattern of the samples during SSCP-PAGE was compared with that of 
healthy controls and samples showing the alteration in mobility pattern with reference 
to controls were considered as variants. Amplified samples identified as variants were 
prepared for DNA sequencing as per instruction of MCLab (USA). Protocol followed 
by MCLab for sequencing is as follow,  
2.7.1 Purification of amplified PCR products 
A number of unused reagents (such as dNTPs and primers) in amplified PCR products 
may hinder in the sequencing reaction. For this reason DNA sequencing, samples 
were purified from excessive unused reagents through ethanol precipitation method 
before placing for sequencing.  
2.7.2 Sequencing protocol reaction conditions 
Sequencing of the samples was carried out using the kit reagents BigDye
TM 
Terminator Cycle sequencing ready reaction kit (Perkin Emler/Applied Biosystems, 
USA). For sequencing 25-30ng of purified PCR product, 1µl of 5X Reaction Buffer 
(400 mM Tris pH=8.7, 10 mM MgCl2), 1µl of primer, 1µl of BigDye
TM 
and up to 
10µl of dH2O were required as reagents. Initial denaturation for 20sec at 96˚C was 
followed by 35 cycles, each comprised of three steps; first step of 15sec at 96˚C, 
second step of 15min at 50˚C, third step of 4min at 60˚C. Final extension was done at 
60˚C for 4min. For short term storage, samples were placed at room temperature. 
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2.7.3 Precipitation of the sequencing products 
For ultimate purification of the sequencing products, 40µl of 70% ethanol was added 
to 100µl sequencing reaction tubes and left at room temperature for 20min. The tubes 
were centrifuged for 20min at 14000rpm and supernatant was discarded. Pellet was 
washed by adding 80µl of 75% ethanol and was air dried at room temperature.  
2.7.4 Preparation and loading of sequencing sample 
Pellet of the sequencing sample was re-suspended in 15µl of highly deionized 
formamide (Perkin Elmer, USA). A brief heat shock was given at 95˚C for 5min. The 
samples were placed on ice, short spinned and run on ABI 3100 Genetic Analyzer. A 
modern CE instrument comprises five basic elements such as capillary, data system, 
high voltage supply, vial transporting system, and on-line detector. 
2.7.5 Sequencer and sequencing analysis 
A modern CE instrument comprises of five core elements including high voltage 
supply, data system, vial transporting system, capillary and on-line detector. Sequence 
data retrieved from the sequencer is compared with normal sequence given in 
Genebank. 
2.8 Mutational analysis of sequenced samples 
After sequencing results were analysed through softwares BioEdit (version 7.0.5), 
DNA Dragon (version 1.5.6 [Build 1]) and BLAST available on NCBI website. 
Alamut biosoftware (version 2.2-5) was also used for confirmation of mutations, 
conservation level of mutation nucleotide and amino acid as well as its possible 
effects at genomic, cDNA and protein level. Mutations were also analyzed using 
Align GVGD, SIFT (Sorting in Tolerant from Tolerant) and Mutation Taster software 
(Baig et al., 2013). Grantham Variation (GV) and Grantham Deviation (GD) scores, 
in combination referred as Align-GVGD which predicts the transactivation activity of 
each missense substitution (Mathe et al., 2006; Tavtigian et al., 2008). SIFT classifies 
substitutions as tolerated or deleterious using sequence homology to predict the 
effects of amino acid substitutions on protein function (Kumar et al., 2009). Mutation 
Taster evaluates disease causing potential of any alteration in sequence (Schwarz et 
al., 2010). A p-value close to 1.0 indicates a high security of prediction. 
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2.9 mRNA Expressional Analysis of BER pathway genes (APEX1, 
OGG1 and XRCC1) in breast cancer patients (study cohort 2 and 3) 
Effects of genetic variations are tissue-specific, so expressional analysis of proteins 
involved in these processes is another valuable approach to understand mechanisms 
involved in carcinogenesis. In this part of study expressional analysis of APEX1 (ID 
328), OGG1 (ID 4968) and XRCC1 (ID 7515) along with clinical parameters were 
explored in breast cancer patients of cohort-2 and cohort-3. 
2.9.1 RNA Isolation from tumor samples 
Breast tumor and control samples stored at -80ºC were taken out and allowed to thaw. 
Tissues samples were retrieved from RNA later and small piece of sample (about 
100mg) was removed by sterile razor blade. Excessive RNA later was quickly blotted 
away with lab wipe or paper towel and tissue piece was transferred to 1.5ml 
centrifuge tube. RNA isolation was carried out by Trizol reagent method with minor 
modifications as described earlier (Mahjabeen et al., 2012). Detailed method used in 
this study is described as follow, 
1ml Trizol reagent was added to the centrifuge tube containing piece of tumor or 
control tissue sample and was further cut or scratched into even smaller pieces. 
Sample along with trizol reagent was shifted to glass-Teflon (Dounce tissue grinder 
WHEATON, USA) and were mechanically homogenized. Glass-Teflon was placed in 
ice box and whole set up in hood to protect skin or eyes from the effects of trizol. 
Sample was then kept for 5min at 37°C to complete the homogenization. 200µl 
chloroform (Sigma- Aldrich, Dorset, UK) was added in the tube and shaken 
vigorously for 15sec. Homogenous mixture was incubated again at 37°C for 12-
15min. Resultant mixture was centrifuged at 13,000rpm for 15min at 4ºC. Three 
separate phases appeared after centrifugation; a red organic phase (containing 
protein), an interphase (containing DNA) and an upper colourless aqueous phase 
(containing RNA). The upper aqueous phase was carefully picked up and transferred 
to new centrifuge tube without disturbing the interphase. 500μl of isopropanol per ml 
of trizol reagent was added in aqueous phase and kept at room temperature for 10min.  
Tube was centrifuged at 13000rpm for 10min at 4ºC to precipitate the RNA at the 
bottom of the tube. Supernatant was discarded and RNA pellet was washed in 1ml of 
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ethanol (75%) per ml of trizol reagent used. Sample was vortex mixed and centrifuged 
at 7,500rpm for 5min at 4ºC and left over ethanol was removed. RNA pellet was air 
dried for 10-15min (over-drying may decrease solubility of pellet). RNA pellet was 
dissolved in appropriate volume of DEPEC water and stored at -80ºC. 
2.9.2 Quantification of RNA samples 
Isolated RNA was quantified for estimation of yield quality using Nanodrop 
spectrophotometer (ND-1000 Thermo scientific, USA). Sensor of cuvette was wiped 
with kimwipe and 2-4µl of nuclease free double distilled water was pipetted on the 
sensor of Nanodrop cuvette read as blank (reference). Sensor of cuvette was wiped 
again with kimwipe and RNA sample (1μl) was dispensed on sensor and UV 
absorbance by RNA was measured at both 260 and 280nm wavelengths. RNA purity 
was measured by finding OD A260/A280 ratio between 1.7-1.9. Any higher or lower 
ratio is indicator of impurities in RNA and was not used further in experiments. 
Amount of RNA used for cDNA synthesis was 250ng per sample. 
2.9.3 Synthesis of cDNA  
Amount of RNA used for cDNA synthesis was 250-300ng per sample.  SuperScript 
First-Strand Synthesis System (Invitrogen, USA) and oligo primers were used to 
reverse transcribe RNA which produces higher cDNA yields with optimum purity and 
specificity. cDNA synthesis was divided into two steps; 
a) Annealing phase 
RNA sample (250-300ng/sample), pretreated with DNase was added in a sterile 0.5ml 
centrifuge tube. Volume (μl) of RNA samples might vary in each tube depending 
upon its concentration to make it up to 250-300ng/sample. Hence variable samples 
volume has been narrated as “x” instead of exact volume but the final volume did not 
exceeded more than 10μl. 
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      Component             Reaction Volume  
                RNA     = xµl 
           10mM dNTP mix   = 1µl 
Random hexamers (50ng/ µl)  = 1µl 
DEPC-treated water   = 6µl 
Total     =10µl 
Sample mixture was incubated for 5min at 65ºC and then placed on ice for 1min.  
b) Extension phase 
2x Master mix containing followings reagents for each reaction was prepared in fresh 
tubes, 
           Component             Volume/reaction 
10X RT buffer   =2µl 
25 mM MgCl2    = 4µl    
0.1M DTT    =2µl    
RNase Out    =1µl 
Total     =9µl 
Master mix (9µl) was added to each sample mixture and heated at 42ºC for 2min. 
Superscript III RT (1μl) was added to each tube, mixed and again heated at 42ºC for 
50min. This prolonged step helps in fine full-length cDNA synthesis with higher 
yields of first-strand cDNA. Reaction was then carried out at 70°C for 15minutes and 
then shifted on ice. 1μl of RNase 1H was mixed in each tube and placed at 37ºC for 
20min to remove traces of RNA template, from final cDNA.  Freshly synthesized 
cDNA was immediately used for PCR or stored at -20ºC. 
2.9.4 Quantitative PCR reaction 
Quantitative PCR (qPCR) reaction was carried out to find the relative expression of 
BER pathway genes (APEX1, OGG1, XRCC1) along with tumor marker Ki-67 and 
GAPDH (as internal control). Gene specific primer and reagents used in master mix 
preparation are given in Table 2.5 and 2.6. 
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Table 2.5 Primers for qPCR analysis 
Primer Forward Primer Reverse Primer 
APEX1 
 
CAGAGGCCAAGAAGAGTAAG 
ACTGAACCTGACCGTACACT
GGGTGAGGTTTTCTGAT 
OGG1 
 
GTTCTGCCTTCTGGACAAT 
ACTGAACCTGACCGTACATC
CATACTTGATCCGCTAGT 
XRCC1 
 
TCAGCTTTCGTGGAGGTG 
ACTGAACCTGACCGTACAAT
GAAAGATGAGGTGACCAG 
GAPDH CTGAGTACGTCGTGGAGTC 
ACTGAACCTGACCGTACACA
GAGATGATGACCCTTTTG 
F =forward primer       R= reverse primer   underlined= Z-sequence 
 
Table 2.6 PCR reaction mixture composition for quantitative PCR reaction 
Components volume per 10µl reaction mixture 
qPCR Master Mix 5.0µl 
cDNA 2.0µl 
Primer Forward 0.3µl 
Primer Reverse 0.3µl 
Probe 0.3μl 
Nuclease free water 2.1 µl 
Total 10.0µl 
 
Each reaction was carried out using gene specific primer pairs (Table 2.5) specifically 
designed for qPCR. Reverse primer in each pair have a Z-sequence 
(ACTGAACCTGACCGTACA) and concentration of this primer was 100pM 
compared to that of forward primer which have 10pM (Table 2.5). During reaction 
shedding of Z-sequence from reverse primer and its detected fluorescent compared to 
that of standard qPCR reactions with a known gene copy number (GAPDH) formed 
the basis behind the quantification of gene copy number of a specific sample under 
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analysis. Each qPCR reaction was repeated three times and data were saved for 
interpretation and correlation. Results of each reaction were given as number of 
transcripts/μl compared to that of internal standard. Results were further normalized 
using the expression of GAPDH in these samples.  
qPCR reaction mixture (10µl) for each sample was transferred to separate well of 96-
well plate. Plate was then sealed with transparent thermo seal and was centrifuged by 
using mini plate spinner (Labnet, USA). qPCR reaction was performed using Veriti 
96 well thermal cycler (Applied Biosynthesis, USA). Conditions used for qPCR are 
presented in Figure 2.1. 
 
Figure 2.1 Reaction conditions for qPCR. 
 
2.10 Immunohistochemistry (IHC) of BER pathway genes (APEX1, 
OGG1 and XRCC1) and proliferation marker (Ki-67) in breast cancer 
patients  
Expression of BER pathway genes (APEX1, OGG1 and XRCC1) and proliferation 
marker (Ki-67) was analysed by immunohistochemical staining at translational level. 
104 breast tumor samples along with equal number of non-cancerous tumor matched 
adjacent tissues as control samples were used in present study, detailed process of 
tissue sampling and storage conditions are cited in methodology section. 
Immunohistochemistry was carried out by established protocol (Ye et al., 2008) with 
minor modifications. Detail of IHC protocol is as follows; 
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2.10.1 Tissue Processing 
Freshly excised tumor and control tissues samples of breast tumor samples (study 
cohort 2) were fixed in sera for 4-5hrs for further processing. Lung carcinoma was 
used as positive control for OGG1 and XRCC1 protein while thyroid tissue and brain 
tumor was used as positive control for Ki-67 and APEX1 protein respectively. The 
composition of sera is as under: 
Absolute Alcohol       60ml 
Glacial Acetic acid                  10ml 
Formaldehyde        30ml 
The tissues were desiccated in a series of ascending grades of alcohol (70%, 80%, 
90% and finally into 100%) and were shifted to cedar wood oil until they became 
transparent. Tissues were embedded in boats containing melted paraffin wax to fix for 
microtomy. 
2.10.2 Microtomy  
Embedded tissues were serially sectioned (5-7µm) using Reichert Microtome (USA) 
and sections were mounted on pre-cleaned glass slides coated with adhesive solution 
(HistoGrip, Invitrogen, USA). Mounted tissue sections were stretched by placing the 
slides on Fisher slide warmer (Thermo scientific, UK) at 60˚C and the slides were 
completely de-paraffinized by placing overnight in tilted position in paraffin oven. 
Prepared slides were then preserved in dark boxes until use. 
2.10.3 Fixation  
Slides were immersed in 1% iodine xylene followed by ascending grades of ethanol 
(70%, 80%, 90% and 100%). Slides were then washed three times in phosphate buffer 
saline (PBS) and boiled in citrate buffer for 4min using pressure cooker. Slides were 
washed again for three times in PBS. Two drops of blocking solution, reagent 1A 
(Vectastain Elite ABC kit, Vector laboratories) were then added on to slides for 
10min and slides were then washed off with PBS. 
2.10.4 Immunohistochemical Staining  
Antibodies used for immunostaining of tissues are given below Table 2.7 
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Table 2.7 Antibodies used for immunohistochemical staining 
Antibodies 
Host 
Species 
Conc. used Company 
APEX1 Mouse 1:500 
Santa Cruz Biotechnology, 
Inc. UK 
OGG1 Mouse 1:500 
Santa Cruz Biotechnology, 
Inc. UK 
XRCC1 Rabbit 1:500 
Santa Cruz Biotechnology, 
Inc. UK 
Ki-67 Mouse 1:1000 Novus Biologicals, Inc. USA 
Single stain boost 
IHC detection 
Mouse 40-120µl 
Cell signaling technology, 
Inc. USA 
Single stain boost 
IHC detection 
Rabbit 40-120µl 
Cell signaling technology, 
Inc. USA 
 
2.10.4.1 Application of antibody 
Stock antibodies were diluted in suitable diluents up to specific concentrations and 
placed in refrigerator for 10 min. Primary antibody was added onto slides which were 
placed for 1hr at room temperature. Phosphate buffer saline (PBS) was applied to a 
duplicate slide instead of primary antibody as negative control. Slides were washed 
three times with PBS. Three drops of secondary antibody (reagent 1B) were then 
added on to slides which were then placed at room temperature for 30min. Slides 
were washed again for three times in PBS and 2 drops of Reagent 2 conjugate were 
applied for 30min. The slides were then rinsed in PBS solution three times. Avidin 
Biotin Complex (ABC) mixture was prepared by adding one drop of reagent A, two 
drops of reagent B and 1 drop of reagent C (Vectastain Elite ABC kit, Vector 
laboratories) in 1ml of distilled water and was left at room temperature for 1hr. For 
detection of biotinylated target, 100µl of ABC mixture was added onto the slides 
which were kept for 30min at room temperature. In the end, two drops of DAB (3, 3′ 
Diaminobenzidine tetrahydrochloride) chromogen (Vector Laboratories) were added 
to slides and kept in dark for 10-15min to detect the binding of antibody.  
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2.10.4.2 Haematoxylin counterstaining 
The slides were washed in distilled water and counter stained with haematoxylin for 
10min. The slides were then washed in acid alcohol and in running tap water for 
30min. After rinsing in distilled water, slides were air dried, mounted with coverslip 
using canada balsam and left for air drying. 
2.10.4.3 Microphotography and Immuno-reactive scoring 
Immunochemically stained slides were observed under photographic microscope 
(Olympus BX41TF, Japan) at different magnifications. Immunohistochemical 
findings of OGG1, XRCC1, APEX1 and Ki-67 were independently evaluated by two 
pathologists, who were blinded about the clinical outcome and other clinico-
pathological data of subjects under study. Disagreement, if any, between both 
histopathologists was resolved by consensus. Tumor cells were counted in ten high 
power random fields to evaluate the immunoreactivity and following formula was 
used for the evaluation, 
                 Immunoreactive score = intensity score x proportion score 
Where total immunoreactivity (from 0 to 12 score) was divided into low 
immunoreactivity (0-4 score) and high immunoreactivity (>4 score). Intensity was 
graded from 0-3 with negative to strong staining. Intensity score was specified; 0 for 
negative intensity, 1 for weak intensity, 2 for moderate intensity and 3 for strong 
staining intensity. The proportion score was considered 0 if no positive cell, 1 if ≤10% 
positive cells, 2 if 11-50% positive cells, 3 if 51-80% positive cells and 4 if > 80% 
positive cells distribution was observed. 
2.11 Breast cancer cell lines 
In-vitro analyses, two breast cancer cell lines MDA-MB-231 (from ATCC, 
Rockvillie, Maryland, USA) and MCF-7 (from ECACC, Salibury, England) were 
used. Breast cancer cell lines were stored and cultured according to the recommended 
protocol provided with these cell lines. 
2.11.1 MCF-7 
MCF-7 cell line was named so as this was developed first time in 1973 by Michigan 
Cancer Foundation and seven efforts were made for the establishment of self-
  Material and Methods 
66 
 
prevailing stock of this cell line. MCF-7 cell line was originally isolated in 1970 from 
the body of a Caucasian female patient, Frances Mallon. Cancer cells were isolated 
from the pleural effusion of chest wall nodules of the patient. Karyotype of MCF-7 
comprises of 69 chromosomes which were reduced from originally possessed 85 
chromosomes after 220 passages. These cells express estrogen receptors, progesterone 
receptors and WNT7b protein and their growth can be inhibited by tumor necrosis 
factor alpha (TNFα) (Burdall et al., 2003; Lacroix & Leclercq, 2004; Charafe-Jauffret 
et al., 2006; Lacroix et al., 2006). MCF-7 cells usually proliferate up to double in 
approximately 29 hours.   
2.11.2 MDA-MB-231 
MDA-MB-231 cells were initially derived from nodular epithelial cells in pleural 
effusion of Caucasian patients. These cells have receptors for transforming necrosis 
growth factor (TGFα) and epidermal growth factor (EGF). These cells have been 
found negative for estrogen receptors, progesterone receptor, HER-2/neu expression 
and their growth is not largely influenced by hormones. In these cells, aneuploidy 
with chromosome counts in near-triploid range (range = 52 to 68, model number = 
64) has also been observed. In addition to normal chromosomes eleven marker 
chromosomes having stable rearrangement along with some un-assignable 
chromosomes have been observed while N8 and N15 chromosomes have been found 
missing in these cells (Lacroix and Leclercq, 2004; Grigoriadis et al., 2012). 
 
2.12 Media preparation and Cancer Cell Lines Storage Conditions 
Breast cancer cell lines were routinely cultured in DMEM/ Ham’s F12 with L-
Glutamine medium (PAA Laboratories, Somerset, UK) with added antibiotics 
(penicillin and streptomycin) and 10% FCS. L-Glutamine (2mM) was used as an 
essential amino acid for primary nitrogen reservoir for the synthesis of proteins, 
nucleic acids and other nitrogenous compounds. Streptomycin (200μl) and penicillin 
(25U)/500ml medium were used to avoid bacterial contamination in the specific cell 
lines. Growth of other eukaryotic cells was controlled by adding blasticidin S that 
inhibits peptide bond formation in the ribosomal machinery of the cells. Only 
transformed cells retaining blasticidin S resistant genes could possibly survive and 
proliferate in the supplemented culture. Different concentrations of blasticidin S were 
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used for specific requirement; for preparation of selection medium 50μg/ml to 
75μg/ml and for maintenance medium and routine culturing 0.5μg/ml of blasticidin S 
were added. 
2.13 Revival of Cells from Liquid Nitrogen Tanks 
Breast cancer cell lines containing small cryogenic centrifuge tubes were stored in 
liquid nitrogen (-196°C) tanks. These tubes were removed from liquid nitrogen for 
revival when required. After removal from liquid nitrogen tubes were thawed by 
placing in a water bath at 37°C until liquefaction. Outer surface of the tube was 
cleaned thoroughly with a sterile swab to avoid contamination. Contents of 
cryocentrifuge tube (cells along with the DMSO containing medium) were shifted to a 
universal container containing 10ml of pre-warmed medium to immediately dilute the 
DMSO present in tube. The universal container was then centrifuged at 3,000rpm for 
5minutes and medium was aspirated to remove any traces of DMSO. Pellet of the 
revived cells was then re-suspended in 5ml of pre-warmed medium and transferred to 
a fresh 25cm
3
 tissue culture flask. Culture flask was then kept in an incubator at 37°C 
with 5% CO2 to retain a normal growth pattern. After incubation, the flask was 
examined under the microscope to estimate the percentage of healthy adherent cells. 
The medium was routinely replaced to remove any dead non- surviving cells after 
freezing/resuscitation process. When confluent, the cells were sub-cultured using 
standard sub-culturing techniques. 
 
2.14 Replenishment of Medium for Breast Cancer Cell Lines 
To maintain the normal physiology of breast cancer cells, earlier described 
supplemented DMEM medium was used. Cells were grown and maintained in either 
25cm
2
 or 75cm
2
 tissue culture flasks (Greiner Bio-One Ltd, UK) in an incubator set at 
37°C, 95% humidity and 5% CO2. Upon reaching 80–90% confluency, cells were sub 
cultured in fresh sterile flasks. All tissue culture techniques were performed following 
aseptic techniques inside class II laminar flow cabinet. Breast cancer cells were 
usually observed for confluency and physiological status at 40x resolution using 
inverted microscope (Olympus, Hamburg, Germany). 
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2.15 Detachment of Adherent Cells and Cell Counting 
When cells became confluent enough, medium was aspired out of the flask and cells 
were rinsed briefly with EDTA. To detach the adherent cells, 1ml trypsin/EDTA 
solution was added to the tissue culture flask and incubated for few minutes at 37˚C. 
Detached cell suspension was poured in 20ml universal container (Greiner Bio-One 
Ltd, UK) and centrifuged at 3,000rpm for 5min to pellet the cells. Medium was 
replaced without disturbing the pellet in container. Cell suspension solution was then 
used for counting cells/millimeters for use in cellular assays or splitted into new tissue 
culture flasks in small quantities. Neubauer haemocytometer counting chamber was 
used to calculate the cell numbers in cell suspension fluid using an inverted 
microscope (Reichet, Austria) at 10x magnification. Following formula was used to 
count the cells present in these squares; 
Cell number / ml = (number of cells counted in 16 squares ÷ 2) x (1 x 10
4
) 
 
2.16 Storage of cell stocks in liquid nitrogen 
To store in liquid nitrogen, stocks of low passage cells were ideally preferred. To 
obtain maximum number of cells, 75cm
3
 flasks were trypsinized and medium was 
centrifuged to pellet the cells. Cells pellet was re-suspended in the required volume of 
a protective medium (10% DMSO in normal growth medium) depending on the 
number of cryogenic tubes to be frozen. 1ml of re-suspended cells was aliquoted into 
already labeled 1.8ml cryotubes (Nunc, Fisher Scientific, UK). Filled cryotubes were 
loosely wrapped in tissue paper and placed at -81°C for an overnight freezing. Cells 
were then shifted to liquid nitrogen tanks for long term storage. Purpose for gradually 
slow freezing was to increase resuscitation rate compared to fast freezing as reported 
in previously published reports (Coombes and Crawford, 1998). 
 
2.17 Maintenance of cancer cell lines  
Breast cancer cell lines used in this study (MDA-MB-231 and MCF-7) were cultured 
in DMEM containing 2mM L-glutamine, 4.5mM NaHCO3 and 15mM HEPES. 10% 
FCS, 50units/ml benzylpenicillin (Britannia, UK) and 50μg/ml streptomycin (Sigma) 
were also supplemented into medium. Cell lines were seeded at cell densities of 
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1x10
5
cells/ml for routine sub-culture or 5x105cells/ml for experimental work in 25cm
2
 
or 75cm
2
 culture flasks (Nuclon). All seeded culture flasks were loosely capped and 
placed horizontally in an incubator (Flow Laboratories) set at 37°C. 
2.18 In-vitro expressional analysis of APEX1, OGG1 and XRCC1 
molecule in breast cancer cell lines 
2.18.1 Initial screening of breast cancer cell lines 
Both cell lines (MDA-MB-231 and MCF-7) were screened first for APEX1, OGG1 
and XRCC1 molecule expression at transcript level. Expression of APEX1, OGG1 and 
XRCC1 was checked by using gene specific forward and reverse conventional primer 
pair given in Table 2.8 
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Table 2.8 Primer sequences used in present study for in-vitro analysis (synthesis of 
ribozymes) 
Primer  Forward primer Reverse primer 
GAPDH 
conventional 
GGCTGCTTTTAACTCTG
GTA 
GACTGTGGTCATGAGTCCTT 
APEX1 
conventional 
ATGCCGAAGCGTGGGA
A 
TCACAGTGCTAGGTATAGG 
APEX1 
Ribozyme 1 
CTGCAGGTTTGCCACTG
GGTGAGGTTTTCTCTGA
TGAGTCCGTGAGGA 
ACTAGTGTATGAGGACCCCCCAG
ATTTCGTCCTCACGGACT 
APEX1 
Ribozyme 2 
CTGCAGAAGGAGCTGAC
CAGTATTCTGATGAGTC
CGTGAGGA 
ACTAGTCAGGAGCTGCCTGGACT
CTCTCATTTCGTCCTCACGGACT 
OGG1 
conventional 
ATGCCTGCCCGCGCGCT
TCTGCCC 
CTAGCCTTCCGGCCCTTT 
OGG 1 
Ribozyme 1 
CTGCAGTCTGAGTCAGT
GTCCATACTTCTGATGA
GTCCGTGAGGA 
ACTAGTGGAGTGGTGTACTAGCG
GATTTCGTCCTCACGGACT 
OGG 1 
Ribozyme 2 
CTGCAGCTCCACCATGC
CAGTGATGCGGGCCTGA
TGAGTCCGTGAGGA 
ACTAGTATCTGTTCCTCCAACAAC
AACATTTCGTCCTCACGGACT 
OGG 1 
Ribozyme 3 
CTGCAGCCACCTTGGTG
CCCACTCCAGGCAGCTG
ATGAGTCCGTGAGGA 
ACTAGTGAGGAGGCCCACAAGG
CCCTCTGCATTTCGTCCTCACGG
ACT 
XRCC1 
conventional 
ATGCCGGAGATCCGCCT
CCGCCAT 
TTATTAAATGCATCGTGTGT 
XRCC 1 
Ribozyme 1 
CTGCAGGTAAGTGTCTG
CCTTGAGTTCTGATGAG
TCCGTGAGGA 
ACTAGTCGACTCACTGTGCAGAA
AATTTCGTCCTCACGGACT 
XRCC 1 
Ribozyme 2 
CTGCAGGTCCTGCCGGG
TCGCTGGCTGTGACTGG
GCTGATGAGTCCGTGAG
GA 
ACTAGTCAGCCGGATCAACAAGA
CATTTCGTCCTCACGGACT 
XRCC 1 
Ribozyme 3 
CTGCAGGTGCTGCCTAT
GGCCCTGGACTGATGAG
TCCGTGAGGA 
ACTAGTGCTGCCTCCTCAGCCTC
TCCAGTTTCGTCCTCACGGACT 
T7F TAATACGACTCACTATA
GGG 
 
RbBMR TTCGTCCTCACGGACTC
ATCAG 
 
RbToPF CTGATGAGTCCGTGAGG
ACGAA 
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Expression of APEX1, OGG1 and XRCC1 in both cell lines (MCF-7 and MDA-
MB231) was estimated by conventional PCR with reaction conditions shown in 
Figure 2.2.  
 
 
Figure 2.2 Reaction conditions for conventional PCR. 
 
2.18.2 Designing and generation of APEX1, OGG1 and XRCC1 ribozymes 
Hammerhead ribozyme transgenes were constructed on the basis of secondary 
structure of specific mRNAs specifically targeted to APEX1, OGG1 and XRCC1 
transcripts (Figure 2.3, 2.4 and 2.5). 
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Figure 2.3 Secondary structure of human APEX1 mRNA used to design anti-APEX1 
transgenes. 
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Figure 2.4 Secondary structure of human OGG1 mRNA used to design anti-OGG1 
transgenes. 
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Figure 2.5 Secondary structure of human XRCC1 mRNA used to design anti-XRCC1 
transgenes. 
 
Initial prediction of mRNA secondary structures for each of APEX1, OGG1 and 
XRCC1 genes were made using Zuker’s RNA mFold software (Zuker, 2003). Within 
each predicted secondary structures suitable GUC codon was selected and short 
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hammer head transgenes primers were designed against particular region. So that the 
hammerhead catalytic region of the ribozyme interacted and precisely cleaved a 
specific GUC sequence within the target mRNA transcript leading to the loss of 
specific molecule (APEX1, OGG1, XRCC1) at transcript level. Two ribozyme primer 
sets for APEX1 (APEX1rib1F-APEX1rib1R and APEX1rib2F-APEX1rib2R), three 
ribozyme primer sets for OGG1 (OGGrib1F-OGG1rib1R, OGG1rib2F-OGG1rib2R 
and OGG1rib3F-OGG1rib3R) and three ribozyme primer sets for XRCC1 
(XRCC1rib1F-XRCC1rib1R, XRCC1rib2F-XRCC1rib2R and XRCC1rib3F-
XRCC1rib3R) were used in touch down PCR procedure as mentioned in Table 2.9. 
PCR conditions used for synthesis of these ribozymes generation are as follows;  
Table 2.9 PCR conditions for synthesis of transgenic ribozymes generations 
Initial 
denaturation 
Annealing cycles for synthesis of ribozymes generations (48 holds) Final 
extension 
(1 hold) 
 
Cooling 
(1 hold) 
Stages in 
each cycle ↓ 
8 
cycles 
8 
cycles 
8 
cycles 
8 
cycles 
8 
cycles 
8 
cycles 
       94°C 
(5min) 
Denaturation 
(10sec) → 
94°C 94°C 94°C 94°C 94°C 94°C 
    72°C 
(7min) 
    4°C 
(∞) 
Annealing 
(15sec) → 
70°C 65°C 60°C 57°C 54°C 50°C 
Extension 
(20sec) → 
72°C 72°C 72°C 72°C 72°C 72°C 
 
Presence and correct size of synthesized transgenic ribozyme generations were 
electrophoretically confirmed using 2% agarose gel before inserting into the pEF6 
plasmid by TOPO cloning reaction. 
2.18.3 Transformation of transgenic ribozymes into the competent cells 
Coding regions of genes under study (APEX1, OGG1, and XRCC1) were amplified 
using gene specific primer pairs (APEX1F1-APEX1R1, OGG1F1-OGG1R1, 
XRCC1F1-XRCC1R1) through normal PCR (Table 2.10). Size, specificity and 
amplified product yield (for specific gene expression and all related ribozymes) were 
estimated and confirmed by running the products on 2% agarose gel along with 1kb 
ladder. Cloning of amplified transgene products of genes under study (APEX1, 
OGG1, and XRCC1) was completed by following the protocol recommended in 
pEF6/V5-HisTOPO® TA Expression Kit manual (Invitrogen Corporation, Canada).  
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Figure 2.6 Schematic presentation of the pEF6/V5-His TOPO (5840bp) vector 
(produced form pEF6/V5-His TOPO TA Expression Kit protocol) 
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Table 2.10 PCR primers used for amplification of BER pathway genes  
Primer Forward primer Reverse primer 
APEX1 normal 
CAGAGGCCAAGAAGAGTAAG AGGTCAATTTCTTCATGTGC 
OGG1 normal 
GTTCTGCCTTCTGGACAAT TCATATGAGGACTCTCGTAGC 
XRCC1 normal 
TCAGCTTTCGTGGAGGTG CTTGGTTCAAATCCAACTTC 
 
Reaction conditions used are as follows 
Ribozyme PCR Product   0.5 to 4µl   
Diluted Salt solution    1µl 
Sterile distilled Water   up to final volume 5µl 
TOPO
® 
Vector (pEF-6/V5)  1µl 
Above cited reaction mixture was gently agitated and kept at room temperature for 
5minutes and stored in ice until proceeding to One Shot
®
 chemical transformation. 
25µl of One Shot TOP10
®
 (chemically competent E. coli) was then added to reaction 
mixture and gently mixed by stirring the whole mixture with pipette tip. Vials were 
then placed on ice for 30min. After a brief heat shock (for 30sec) in water bath at 
42°C, Vials were immediately shifted back on ice for 2-5min. After adding 250µl of 
SOC medium to each vial, they were capped and kept at 37°C for 1hr at 230rpm on a 
horizontal orbital shaker (Bibby Stuart Scientific, UK). After shaking, cell mixture in 
the vials was spread onto two pre-warmed selective LB-agar plates (containing 
100µg/ml ampicillin) at varying contents seeding density (high and low). Since the 
vector (pEF-6/V5) contains ampicillin resistant gene, so only those competent cells 
survived after overnight incubation at 37°C which retained plasmid (pEF-6/V5).  
2.18.4 Selection and orientation analysis of positive colonies 
After an overnight incubation at 37°C, growth of surviving cell colonies on agar 
plates was examined. After proper labelling on the plates, 10 colonies were randomly 
selected for each ribozyme to analyse the orientation of insertings. The analysis of 
colonies was important to identify grown colonies containing vector plus insert in 
correct direction before amplification. Colonies were tested for correct insertion and 
orientation of insert in the plasmid by PCR using two sets of plasmid specific primers 
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(T7F vs RbToP and T7F vs RbBMR). Product size obtained using the plasmid 
specific primers, T7F and RbBMR, indicated about the size of inserted sequence and 
confirmed that full sequence had been inserted without degradation. There were 
approximately 90bp between the T7F promoter and the beginning of the insert, thus 
correct orientation size was more than 500bp. Similarly a band of approximately 
140bp by using the same set of primers indicate the reverse orientation of the 
amplified product. Two separate PCR reactions (Table 2.11 and 2.12) were carried 
out for each selected colony as follows, by using two different sets of primers (Table 
2.7)  
Table 2.11 Ribozyme orientation reaction mixture-I 
Contents in reaction mixture volume 
2xRED Taq Ready mix PCR Reaction mix 10µl 
T7F plasmid specific forward primer 2µl 
Ribozyme specific forward primer (RbToP) 2µl 
Nuclease free PCR water 6µl 
DNA from picked colonies Enough for reaction 
 
Table 2.12 Ribozyme orientation reaction mixture-II 
Contents in reaction mixture volume 
2XRED Taq Ready mix PCR Reaction mix 10µl 
T7F plasmid specific forward primer 2µl 
Ribozyme specific forward primer (RbBMR) 2µl 
Nuclease free PCR water 6µl 
DNA from picked colonies Enough for reaction 
 
For confirmation of correctly oriented DNA (vector plus insert) present in the 
colonies, a sample (1/3
rd
 portion of colonies for specific ribozyme) was picked from 
the LB-agar plate with the help of a sterile pipette tip and inoculated into both  of the 
above mentioned reaction mixtures before the addition of the specific primers. Both 
reaction mixtures were then amplified using PCR conditions for conventional PCR 
presented in Figure 2.2, Amplified products were run on 2% agarose gel for 
electrophoresis and results were visualized under UV light. Remaining 1/3
rd
 portion of 
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colonies displaying correct orientation of the insert were picked off the LB-agar plates  
and  were  added to universal container (UC) for inoculation  to 10ml of ampicillin 
selective LB medium at the ratio of 1000:1 (10 ml LB+ 10 µl ampicillin). Mixture 
was horizontally shaken at 225rpm while being incubated overnight at 37°C 
2.18.5 Plasmid isolation and quantification 
After confirmation, selected colonies with correctly orientated inserts were used for 
plasmid isolation. Plasmids were extracted using Sigma GenElute Plasmid MiniPrep 
Kit according to the recommended protocol. 10ml of overnight culture of LB broth 
(10 ml LB + 10 µl ampicillin) inoculated with the right colony was centrifuged at 
12,000 g for 1 min (or at 3000 g for 10 min) to obtain bacterial pellet. Pellet was then 
completely re-suspended in 200µl of re-suspension solution (containing RNase A) 
and mixed thoroughly by pipetting up and down until homogenized. 200µl of lysis 
solution was then added to the mixture and the container inverted 6-8 times (should 
not exceed than 5min). 350µl of the neutralisation binding solution was added and the 
tube was gently inverted 4–6 times (to precipitate the cell debris). Finally, the tube 
was spun at 12,000g for 10min in a microcentrifuge tube to pellet the debris and 
supernatant (clear lysate) would be further used.  Mini prep column was inserted into 
a 1.5ml collection tube and 500µl of column preparation solution was passed through 
it by spinning at 12000g for 1min. Flow through liquid from the collection tube was 
discarded and clear lysate (from the previous step) was transferred to the freshly 
prepared column. Mini spin column along with collection tube was centrifuged at 
12000g for 1 min to bind the plasmid DNA to the column and flow through liquid was 
discarded. 
Column was spun at 12,000g for 30sec to 1min after adding 750µl of diluted wash 
solution (containing ethanol) and flow-through liquid was discarded. An additional 
spin for 1-2min at maximum speed was given to remove excess ethanol and the 
column was finally transferred to a fresh collection tube. 100µl of elution solution 
was added to the column and centrifuged at 12,000g for 1min to elute the plasmid. 
Flow-through liquid (elute) contains plasmid DNA which was then run on 1% agarose 
gel along with plasmid DNA ladder (101R) to confirm the presence and correct size 
of the plasmid DNA. 
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2.18.6 Sequencing of the insert for screening mutants 
In order to verify the desired insert with correct orientation and for any chances of 
probable mutants in the inserts, the respective plasmid DNA was sequenced using T7 
primer. Sequencing was carried out from GeneBio Company (UK) and BioEdit 
software was used to analyse sequence products. 
2.18.7 Transfection of mammalian cells using electroporation 
7µl of purified and quantified transgenic plasmid DNA (of each ribozyme for APEX1, 
OGG1 and XRCC1) are introduced in MDA-MB-231 and MCF-7 breast cells 
separately.  Confluent wild type cells of both cell lines were trypsinized, pelleted, re-
suspended and counted using hemocytometer. Five million cells were uniformly 
suspended by gentle pipetting in 5ml normal medium in a large universal container. 
800 µl of the cell suspension along with the purified plasmid DNA was added into 
electroporation cuvettes (Eurgenetech, Southampton, UK) and mixed briefly. Each 
cuvette was exposed to an electrical pulse of 310V and 1500 unit capacitance by an 
electroporator (Easyjet, UK). Immediately after exposure to electrical pulse, cells and 
the plasmid suspension was transferred into 10ml of pre warmed normal medium and 
placed in an incubator at 37°C to let any surviving cells to fully recover from 
electroporation stress. Normal pEF6 vector plasmid was also introduced, by 
electroporation in both breast cancer cell lines as internal control (MCF-7
Ct
 and 
MDA-MB-231
Ct
). Summarized process is given in Figure 2.7. 
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Figure 2.7 Process of TOPO cloning and cancer cell transfection 
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2.18.8 Establishment of stable MDA-MB-231 and MCF-7 cancer cell lines  
Transfected cells were incubated overnight in normal medium and then shifted to 
selection medium (normal medium + 5µg/ml blasticidin S) for at least 5 days. Only 
those cells which were transfected with plasmid survived, since inserted plasmid had 
blasticidin resistant gene. Wild type cells (not transfected with plasmid but passed 
through electroporation stress) of both breast cancer cell lines used as an internal 
control and transfected with normal plasmid used as positive control, were also kept 
in selection medium for equal duration.  After 5-7 days, internal control breast cancer 
cells died completely while cells having positive transformation of specific types of 
plasmid remained alive and healthy.  Transformed cancer cells were then shifted to 
maintenance medium (Normal medium + 0.5µg/ml blasticidin S) to place a selection 
pressure on the cells in maintaining the plasmid and resulted in perfect long term 
transformation of the cells. 
2.18.9 Confirmation of transformation of cell lines  
Both breast cancer cell lines were verified for transformation in the start and after 
long periods of use through RT-PCR and western blot analysis. Confirmation of 
transfection was done to evaluate the efficiency and stability of both transformation 
and expression sequence. 
2.19 RNA isolation and expressional analysis 
Both breast cancer cell lines transfected with gene specific ribozymes, (MDA-MB-
231
APEX1rib1, rib2
, MDA-MB-231
OGG1rib1, rib2 & rib3
, MDA-MB-231
XRCC1rib1, rib2 & rib3 
, MB-
231
Wt
, MDA-MB-231
Ct
 MCF-7
APEX1rib1, rib2
, MCF-7
OGG1rib1, rib2 & rib3 
MCF-
 XRCC1rib1, rib2 
& rib3
,
 
MCF-7
Wt
, MCF-7
Ct
) were grown to almost 80-90% confluency by incubating at 
37˚C with 5% CO2 and humidity. Medium was aspirated from the 75cm
2
 flask and 
cells were washed once with 2x balanced saline solution (BSS). Monolayer cells 
washed with BSS were lysed directly in the flask by adding 1ml TRI REAGENT
TM 
and scraping the cell layer with sterile scraper. Cell lysate was mixed several times by 
pipetting up and down to produce homogenous lysate. Cell lysate was either stored at 
-20°C or used to extract total RNA after keeping it at room temperature for 5min. 
RNA was extracted using total RNA isolation reagents by recommended protocol 
provided with TRI reagent (Sigma , Dorset, UK) and described in materials and 
methods (section 2.9.1). Freshly extracted RNA sample was quantified by Biotech 
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Photometer spectrophotometer (WPA UV 1101, UK) which was standardized to a 
concentration of 500 ng/µl. RNA was  then used as template to reverse transcribe into  
cDNA using High-Capacity cDNA Reverse transcription Kit (Applied Biosystems
®, 
USA). Reverse transcription polymerase chain reaction (RT-PCR) was performed in 
Thermocycler (Applied Biosystems
®, 
USA) using a total of 20µl reaction mixture 
containing 10µl of 2x master mix from kit and 10µl of RNA sample (500ng RNA in 
10µl of RNas free water). The composition of reaction mixture (Table 2.13) and PCR 
reaction conditions (Figure 2.8) were as follows. 
Table 2.13 Composition of reaction mixture for reverse transcription PCR (RT-PCR)  
RT reaction mixture components Volume used 
10✕ RT Buffer 
2
X
 M
as
te
r 
M
ix
 f
ro
m
 k
it
 2 µl 
10✕ RT Random Primers 2 µl 
25✕ dNTP Mix (100 mM) 0.8 µl 
MultiScribe™ Reverse Transcriptase (50 U/µl) 1 µl 
RNase Inhibitor 1 µl 
Nuclease free distilled water 3.2 µl 
RNA sample (500ng RNA in 10µl of RNas free water) 10 µl 
TOTAL 20 µl 
 
 
Figure 2.8 Reaction conditions for reverse transcription PCR (RT-PCR)  
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After cDNA synthesis, expressional variations were quantified with the aid of real 
time quantitative polymerase chain reaction (qPCR). cDNA samples were probed by 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers together with 
those specific for APEX1, OGG1 and XRCC1 transcripts (Table 2.14) to check and 
confirm the quality and uniformity of cDNA levels in samples. qPCR reaction was 
performed in Veriti 96 well thermal cycler (ABI, USA) using GREENTaq® 
ReadyMix™ PCR Reaction Mix (Sigma).  Reaction conditions for qPCR are given in 
Figure 2.1, 
2.20 SDS-PAGE and Western blotting   
2.20.1 Cell lysis and protein extraction 
Breast cancer cell lines wild types, controls, and transgenes generated were grown and 
maintained in separate large flasks (75cm
3
). Once the cells were 60-70% confluent 
but still in log phase of growth, the medium was aspirated and monolayer was washed 
with 2x sterile balanced saline solution (BSS). After aspiration of BSS, 300µl of lysis 
buffer (composition given in materials section) was added in 75cm
3
 flask and cell 
monolayer was scrapped with the help of sterile cell scrapper while placing the flask 
on ice. Scraped cells along with lysis buffer were then transferred to 1.8ml eppendorf 
(Alpha Laboratories, Hampshire, UK) using a sterile transfer pipette. The tubes were 
then placed on ice or preferably on Labinco rotating wheel (Wolf laboratories, UK) at 
4°C for 30 min.  Tubes with completely lysed cells were centrifuged at 13,000 rpm at 
4°C° for 15 minutes to remove any insoluble debris materials. Supernatant was then 
shifted to fresh micro centrifuge tube and protein was quantified. 
2.20.2 Protein quantification 
Protein concentration was determined using a DC Protein Assay kit (Bio-Rad 
laboratories, UK) through microplate method. Initially, a range of samples with 
known concentrations were set up by preparing a serial dilution of a 10µg/ml Bovine 
Serum Albumin (BSA) as standards (Sigma, UK). Standards were prepared by serial 
dilution from 10µg/ml to 0.005µg/ml in the same lysis buffer solution which was used 
in protein isolation method. 5µl of the given protein samples along with the standards 
were loaded into separate wells of 96 well plate after labelling. Reagent A and reagent 
S were mixed at 50:1 ratio (each millilitre of reagent A with 20µl of reagent S) to 
prepare working reagent A. 25µl of working reagent A and 200µl of reagent B were 
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simultaneously added into each well containing standards.  Samples were mixed 
briefly with the pippete tip and waited for 45 min to allow the colorimetric reaction to 
occur effectively.  Absorbance of protein samples and standards was read at 620nm 
with the help of an ELx800 plate reading spectrophotometer (Bio-Tek, UK). 
Concentrations of samples were determined by comparing them with a standard curve 
constructed on the basis of absorbance of the BSA standards. All protein samples 
were then normalised by diluting in a suitable amount of lysis buffer to get preferred 
final concentration of 1.0–1.5mg/ml.  Normalised protein samples were further 
diluted in a 1:1 ratio in 2x Lamelli sample buffer.  Samples were then boiled and 
stored at -20
o
C until further use. 
2.20.3 SDS-PAGE Electrophoresis 
Presence or absence and concentrations of specific proteins extracted from 
transfected, internal control and external control cells were detected through SDS-
PAGE carried out by using an OmniPAGE VS10 vertical electrophoresis system 
(OminPAGE, UK). Both stacking and resolving gels mixtures were prepared in 
separate universal containers and poured in space in between the glass plates fixed in 
a loading cassette. Composition of 10% resolving gel (15ml) and 5% stacking gel 
(5ml) is given in table 2.14 
Table 2.14 Composition of gels for SDS-PAGE  
Component 10% Resolving Gel (15ml) 5% Stacking gel (5ml) 
Distilled water 
30% acrylamide mix 
1.5M Tris (pH 8.8) 
10% SDS 
10% APS 
TEMED 
5.9ml 
5.0ml 
3.8ml 
  0.15ml 
  0.15ml 
     0.006ml 
3.4ml 
  0.83ml 
  0.63ml 
  0.05ml 
  0.05ml 
    0.005ml 
Once the resolving gel had solidified, the mixture of stacking gel was prepared and 
poured onto the top of resolving gel. A plastic Teflon comb was placed immediately 
in the stacking gel for well formation and waited for its hardening to form a gel. 
When both resolving and stacking gels had solidified in the loading cassette, the 
whole assembly was placed into an electrophoresis tank and immersed in 1x running 
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buffer. Combs were carefully removed and 18µl of each protein sample was loaded 
into separate wells along with 8-10µl of molecular weight protein marker in at least 
one well of each gel.  Molecular weights of each sample protein were determined by 
comparing with protein ladder after electrophoresis at 125V, 40mA and 50W for a 
variable length of time (depending upon the protein size and gel percentage). 10% 
polyacrylamide (Santa Cruz Biotechnology, UK) gel was used in present study, as 
expected BER pathway protein (APEX1, OGG1 and XRCC1) size was between 20 – 
90kDa. 
2.20.4 Western Blotting 
After PAGE, loading cassette was removed from the electrophoresis tank and 
unclipped to remove the gels. Protein samples were transferred from polyacrylamide 
gel to a nitrocellulose membrane by Western blotting. The stacking gel was discarded 
while resolving gel was placed on the top of a Hybond nitrocellulose membrane (0.2 
pore size) (Sigma-Aldrich, UK) in a SD10 SemiDry Maxi System blotting unit. 
Nitrocellulose membrane and resolving gel together were sandwiched between 3 
pieces of 3mm blotting paper pre-soaked in 1x transfer buffer on both sides in a 
specific arrangement (Anode : sponge : paper : membrane : gel : paper : sponge : 
cathode) as shown in Figure 2.9. 
 
Figure 2.9 Arrangement of western blotting components 
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Electroblotting of proteins onto nitrocellulose membrane was carried out at 100V, 
250mA, 8W for about 60min.  After electroblotting, nitrocellulose membrane was 
removed and stored at 4
o
C in 10% skimmed milk, 0.1% polyoxyethylene (20) sorbitan 
monolaurate (Tween 20) in TBS until required for specific antibody probing. Proteins 
blotted onto nitrocellulose membrane were probed for specific proteins.  
2.20.5 Staining of proteins 
a) Nitrocellulose membrane staining 
Membranes were stained with specific antibodies prior for probing to confirmation of 
successful transfer and for cutting of membrane into horizontal strips. Membrane was 
stained briefly with Ponceau S solution (Sigma-Aldrich, UK) for several minutes to 
allow visualisation of protein bands on the membrane and was washed with TBS 
Tween several times to remove the excessive stain. On visualization membrane was 
cut into required number of pieces which were marked for specific protein. 
Membranes were also stained in Amido black stain after completion of antibody 
probing and kept as record. The membranes were then allowed to dry completely 
overnight and were stored as a record. 
b) Polyacrylamide gel staining 
After electroblotting, resolving gel was stained for several minutes in Coomassie blue 
protein stain (Thermo Scientific, USA) and viewed exclusively for confirmation of 
effective protein transfer from the gel.  
2.20.6 Detection of specific proteins  
Membranes were transferred to 50ml falcon tubes containing TBS Tween and 5% 
fresh milk (Marvel) blocking solution and placed on a roller mixer for 1hr at room 
temperature. After this initial blocking, membranes were incubated in 10ml of 
primary antibodies for specific proteins (APEX1, OGG1, XRCC1 and GAPDH) 
dissolved in milk solution (1% Marvel, 0.1% Tween 20 in TBS, 0.05% azide) in 
respective falcon tube. APEX1, OGG1 and GAPDH (internal control) antibodies of 
mouse origin and XRCC1 of rabbit origin were used in this study. Probing 
concentrations were 1:500 for APEX1, 1:100 for OGG1, 1:200 for XRCC1 and 1:500 
for GAPDH. After 1hr of incubation at room temperature in primary antibody 
solution, membranes were washed three times in TBS Tween (each wash of 15 min) 
to ensure complete removal of the primary antibody. After washing, the membrane 
  Material and Methods 
88 
 
was subjected to secondary antibody of the same species as that of primary mixed in 
3% milk solution at a concentration of 1:1000 and left for 1hr. Secondary antibody 
was discarded and nitrocellulose membranes were washed 3-5 times in TBS 1% 
Tween (each wash of 5min) followed by two washes of 10min with TBS to ensure 
complete removal of the secondary antibody After washing, antigen-antibody 
complex was detected by chemiluminescent detection technique. Antibodies and their 
concentrations used for detection of APEX1, OGG1 and XRCC1 protein are given in 
table 2.15 
Table 2.15 Antibodies for Western blot and ICC staining   
Antibody Host species 
product 
size 
(kDa) 
Conc. used Supplier /Company 
APEX1 Mouse 37 1:500 
Santa Cruz 
Biotechnology, Inc. UK 
OGG1 Mouse 38 1:100 
Santa Cruz 
Biotechnology, Inc. UK 
XRCC1 Rabbit 70 1:200 
Santa Cruz 
Biotechnology, Inc. UK 
GAPDH Goat 37 
1:100 for ICC 
1:500 for W. blot 
Santa Cruz 
Biotechnology, Inc. UK 
 
2.21 Chemiluminescent detection of antigen-antibody complex 
After binding of protein specific antibodies, the membranes were separated in a 
weighing boat and immersed in Supersignal West Dura system reagents. The two 
reagents were added in a 1:1 ratio and membranes were kept immersed for five 
minutes. Excessive reagents were removed and the membrane was placed inside 
UVITech imager and images were saved. Saved images were then further analysed 
using UVIband software package (UVITEC, UK) which quantifies the protein bands 
detected on screen. Expression of GAPDH was used as an internal control and it 
helped in further normalisation of the samples (following initial quantification and 
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standardisation). Western blotting was repeated two times and resultant bands from 
both repeats were quantified and standardised separately.  
2.21.1 Staining breast cancer cell lines with APEX1, OGG1 and XRCC1 
antibodies 
30000 transfected breast cancer cells along with control pEF transfected cells of both 
cell lines (MDA-MB-231 and MCF-7) were seeded in 16 well chamber slides and 
grown in normal DMEM medium at 37˚C overnight. Following protocol for 
immunucytochemistry (ICC) was followed; 
A) Fixation  
Culture medium was gently aspirated and cell layer was washed two times with 200µl 
BSS buffer to remove any proteins from culture medium. 200µl of buffered formaline 
(4%) was added into each chamber and placed at room temperature for 10min for 
fixation. 
B) Permeabilization 
Fixative was aspirated and cells were washed three times with TBS buffer. 100µl of 
permeabilization buffer (0.1% Triton in TBS buffer) was added into each well of the 
chamber slide and placed at room temperature for 10 min. 
C) Staining  
Permeabilization buffer was decanted and cells were washed two times carefully with 
washing buffer. For blocking the cells, serum diluted in washing buffer (1drop in 5ml 
washing buffer) was added in wells for 20min. After aspiration of serum, cells were 
washed for four times in washing buffer and immersed in diluted primary antibodies 
(APEX1, OGG1 and XRCC1) for antibody specific optimum time and optimum 
temperature. For this purpose primary antibodies were diluted in blocking solution 
(1:100-150 ratio) before use and were kept at room temperature. To remove surplus 
primary antibody cells were washed four times in buffer. 100µl each of specific 
antibodies was then added to respective well of chamber slide and were placed at 
room temperature for 30min. To remove any surplus and non-specific binding of 
protein, slides were washed four times with washing buffer and freshly made ABC 
complex was added on slides and placed at room temperature for 30minutes. Chamber 
slides were washed four times with washing buffer and slides were kept in dark area 
for 5min after adding freshly prepared chromogen solution (DAB) onto the slides. 
Each well of the chamber slide was washed in water and cells were counter stained 
  Material and Methods 
90 
 
with Mayer Htx for 1min. Chamber slides were again washed in water for 5min. 
Respective wells of the chamber slide were observed under microscope after fixation 
with formalin and images were saved. 
 
2.22 In-vitro characterization of study genes (APEX1, OGG1, XRCC1) 
in breast cancer cell lines 
Confluent flasks of MCF-7 (MCF-7
Wt
, empty pEF6, MCF-7
Ct
, MCF-7
APEX1
, MCF-
7
OGG1
, MCF-7
XRCC1
) and MDA-MB-231 (MDA-MB-231
Wt
, MDA-MB-231
Ct
, MDA-
MB-231
APEX1
, MDA-MB-231
OGG1
, MDA-MB-231
XRCC1
) cell lines grown in 
maintenance media at 37˚C with 5% CO2 were used for various functional assays.  
2.22.1 Breast cancer cell growth assay  
Set of three 96 well plates (Nunc, Fisher Scientific, UK) were used for growth assay. 
After trypsinization, cells were re-suspended in normal medium and were counted by 
using haemocytometer. Equal number of  knockdown and control breast cancer cells 
(3000) were suspended in 200µl normal medium were seeded in each well and at least 
five replicates for each cell line (MCF-7 & MDA-MB-231)  in the rows of 96 well 
plates. Seeded plates were labelled ( as day1, day3 and day5) and placed in incubator 
at 37˚C, 5% CO2
 
and humidity to attain
 
optimal growth for 1, 3 and 5 days. Cells were 
placed in normal maintenance DMEM medium for growth. After the applicable 
growth period of each plate, medium was aspirated and cells were washed with BSS 
buffer and fixed in formaldehyde (4%) for 4-5 mins. Formaldehyde was discarded, 
cells were stained with crystal violet solution (0.5% w/v) for 4-5 min and then rinsed 
in distilled water. Plates were placed inverted for air drying or in oven at 37˚C. 200µl 
of acetic acid (10%) was added to wells and plates were kept for some time and then 
tapped gently for uniform mixing of stains with acetic acid. In next step, cell density 
was determined by measuring the absorbance at 540nm by placing the plate in plate 
reading spectrophotometer (ELX800, Bio-Tek, UK). Cell growth was calculated as 
percentage increase of absorbance and calculated by comparing the absorbance 
obtained for specific incubation period by using following equation;    
Percentage increase = (day 3 or 5 absorbance) - day1 absorbance/day1 absorbance 
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Percentage increased growth in knockdown and  controls cells was also calculated to 
get clear idea of growth difference in all cell types from day-1 to 3 and day 1 to 5.  
At least four duplicate wells were analysed within each experiment and the entire 
experiment procedure was repeated four times. 
2.22.2 In-vitro tumour cell matrigel adhesion assay 
Adhesion assay was performed to observe the ability of tumour cells to adhere to an 
artificial Matrigel basement membrane. It was modified from the technique described 
previously by Malik et al (1995). 5µg of Matrigel mixed in 100µl of serum free 
medium was dispensed to each well of a 96 well plate and was dried in an oven to 
create an artificial basement membrane. 100µl of serum free medium was added into 
each well and placed for 40min to optimally rehydrate the Matrigel membrane. 45,000 
cells were seeded onto the Matrigel basement membrane into each well containing 
200µl of normal medium and incubated at 37°C for 40min. After incubation, the 
medium was aspirated carefully and Matrigel basement membrane was washed five 
times with BSS solution to remove any loosely adhered cells. Adherent cells were 
then fixed in formaldehyde in BSS (4% v/v) for 5min and then stained in crystal 
violet solution in distilled water (0.5% w/v). After air drying, adherent cells were 
observed and counted under the microscope in at least 10 random fields per well. 
Entire experimental procedure was repeated three times.  
2.22.3 In-vitro tumour cell matrigel invasion assay 
The invasive ability of the control and transfected cells through 8µm pores in an 
artificial basement membrane was assessed using an In-vitro matrigel invasion assay. 
Experimental procedure used is modified from that described by Albini et al (2000). 
Culture plate inserts containing 8µm pores (BD Biosciences, UK) was used in this 
assay. The working matrigel solution prepared in serum free medium to a 
concentration of 50µg per 100µl was added to the inserts and allowed to dry in an 
oven. After drying, inserts were placed into sterile 24 well plates and the artificial 
membrane was rehydrated by adding 100µl of serum free medium, for 40min. Serum 
free medium was aspirated and 1ml of normal medium was added to each well 
containing insert for sustenance of any cells invading through the insert. 20,000 cells 
in 200µl of normal medium were then poured in the insert.  Plate was then placed in 
incubator at 37˚C, 5% CO2 and 95% humidity for 72hrs. Inserts were removed from 
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plates, cleaned from inside and cells were counted under microscope after formalin 
fixation and crystal violet staining. 
2.22.4 Electric Cell-Substrate Impedance Sensing (ECIS) Analysis for 
Breast Cancer Cell Attachment and migration  
The electric cell-substrate impedance sensing (ECIS) system (Applied Biophysics Inc, 
USA) was used to detect and track MCF-7 and MDA-MB-231 cell migration as 
described previously (Jiang et al., 2008). 200,000 cells per well were seeded in 300μl 
of medium containing HEPES buffer onto ECIS 96W1E arrays and placed in an 
incubator at 37˚C, 5% CO2 and 95% humidity. The cells were incubated till a 
confluent monolayer was formed over the array electrodes. This monolayer was then 
wounded electrically to create a simultaneous physical break of equal dimensions in 
the cell monolayer. After electrical wound, alteration in resistance (ohms) narrates the 
migration ability of breast cancer cells and resistance is directly proportional to 
migration rate. Changes in the tendency for migration after electrical wounding in 
knock down cell lines compared to controls were calculated using ECIS system. 
Migration of breast cancer cells was observed up to eight hours following electrical 
wounding but migration rate of knockdown breast cancer cells was compared with the 
migration rate of control cells up to initial four hours following each electrical wound 
because after four hours, cellular migration was affected due to re-confluency of cells 
in wound area. At least two wounds were given in each ECIS plate and ECIS 
experiment was repeated thrice and average mean of the resistance (ohms) obtained 
from all three experiments was used for analysis and comparison of cancer cell 
migration. Rate of change in impedance was measured using the software provided 
with ECIS system. 
2.23 Statistical Analysis 
Data for statistical analysis was arranged according to SPSS 17.0 software and 
analyzed using different appropriate statistical tests. For each gene (OGG1, APEX1 
and XRCC1) mutations, allele and genotype frequencies were calculated and 
compared with controls according to Hardy-Weinberg equilibrium. Odd ratios (ORs) 
and 95% confidence intervals (CIs) were calculated using Medcal software. p-values 
were calculated by χ2-test, Fisher’s exact test and one sample t-test. Mutations were 
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correlated with clinico-pathological parameter of patients using Pearson correlation 
and t-test. 
χ2 –test, one way ANOVA and Mann-Whitney test were utilized for expressional 
profiling of BER pathway genes and Ki-67 with clinical and histopathological 
parameter (e.g. tumor grades and TNM staging). Correlations between gene-gene 
expression and genes expression to histopathological parameters were evaluated by 
Spearman’s Correlations. Statistical significance was established at value of p<0.05. 
Asterisks (*), (**), (***) indicate p<0.05, p<0.01, p<0.001 respectively. 
In all in-vitro assays the transfected breast cancer cell lines containing APEX1, OGG1 
and XRCC1 ribozyme transgenes, were compared with respective pEF6 plasmid 
controls (cells containing closed pEF6 plasmid only) using a two-sample, two tailed t-
test. All experiments were repeated at least thrice and all data was normalized to reach 
solid conclusion. 
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3. Results 
3.1 Germline mutational analysis of APEX1, OGG1 and XRCC1 
In first part of this study, germline mutation analysis of BER pathway genes (APEX1, 
OGG1 and XRCC1) in breast cancer patients and controls was performed by 
polymerase chain reaction (PCR) followed by single strand conformational 
polymorphism (SSCP) and DNA sequencing. 
3.1.1 Demographic characteristics of study cohort-1 
Cohort-1 of the present study comprised 530 breast cancer female patients and 395 
healthy female individuals used as controls. Mean age of patients and healthy controls 
was observed as 46.4 ±11.6 and 42.80 ±13.0 years, respectively.  Non- significant 
difference was observed between patients and controls with reference to age (p=0.8), 
age at menarche (p=0.9), menopausal status (p=0.5), parity (p=0.36) and age at first 
birth (p=0.1).  However, significant difference was observed between patients and 
controls with reference to family history (p<0.04), age at menopause (p<0.043) and 
smoking history (p<0.024). Demographic characteristics of study cohort-1 are 
summarized in Table 3.1. 
3.1.2 Histopathological characteristics of cancer patients study cohort-1 
Histopathological characteristics of patients were recorded from their biopsy and 
immunohistochemical reports provided by concerned oncological centres (Table 3.2). 
At the time of diagnosis majority of patients (51.5%) had unilateral breast tumor 
involving left breast. On the basis of histopathological tumor typing and grading 
majority of patients were presented for treatment with invasive ductal carcinoma 
(64.86%) and at histological grade II (47.43%). In case of ER, PR and HER-2/neu 
status, majority of patients were negative for ER (64.9%), PR (62.88%) and HER-
2/neu (57.54%) receptors. Detailed information regarding histopathological 
characteristics of study cohort-1 are summarized in Table 3.2. 
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Table 3.1 Demographic characteristics of patients and controls of in cohot-1 of 
present case-control study 
Variables 
Cancer cases 
(n= 530) 
Control 
(n=395) 
Odds ratio 
(95%CI) 
p-value 
1. Age (years) 
Mean (±S.D) 46.4 (±11.59) 42.8 (±12.96)  0.8 
≤40 188 (35.47%) 163 (41.30%) 
0.78 (0.6 to 1.0) 0.07 
>40 342 (64.53%) 232 (58.70%) 
2. Family History of  Cancer 
Yes 44 (8.3%) 19 (4.81%) 
1.8 (1.0 to 3.12) <0.04
*
 
No 486 (91.7%) 376 (95.19%) 
3. Age at menarche (years) 
<13  133 (25.09%) 98 (24.81%) 
1.0 (0.8 to 1.37) 0.9 
≥13  397 (74.91%) 297 (75.19%) 
4. Menopausal Status 
Pre-menopausal 288 (54.34%) 222 (56.20%) 
0.92 (0.7 to 1.2) 0.5 
Post-menopausal 242 (45.66%) 173 (43.80%) 
5. Age at Menopause 
≤48 years 146 (61.33%) 87 (50.29%) 
1.5 (1.0 to 2.23)  0.043
*
 
>48 years 96 (39.67%) 86 (49.71%) 
6. Parity             (Married Patients 487)  (Married Controls 326) 
Nulliparity (P0) 63 (13%) 49 (15%)  
0.36 Uni/bi-parity (P1-2) 129 (26%) 81 (25%) 
Multiparity (P3-n) 295 (61%) 196 (60%) 
7. Age at First Birth       (N=424)            (N=277) 
< 25 years 299 (70.52%) 179 (64.62%) 
1.3 (0.9 to 1.8) 0.1 
≥ 25 years 125 (29.48%) 98 (35.38%) 
8. Smoking History (cigarette, paan, betel quid, moist sniff ) 
Non-Smokers 443 (84%) 351(88.86%) 
0.6 (0.4 to 0.9) 0.024
*
 
Smokers 87(16%) 44 (11.14%) 
 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test 
* p<0.05   
n= total number of samples  CI= confidence interval  
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 Table 3.2 Histopathological characteristics of cancer patients of in cohot-1 of present 
case-control study 
1. Site of breast tumor (n= 530) 
Variables Bilateral Unilateral Right Unilateral Left 
No (%age) 26 (4.9%) 231(43.6%) 273(51.5%) 
2. Tumor Type (n=333) 
Variables DCI IDC ILC and others 
No (%age) 78 (23.42%) 216 (64.86%) 39 (11.71%) 
3. Tumor Grade (n= 447) 
Variables Grade I Grade II Grade III Grade IV 
No (%age) 110 (24.61%) 212 (47.43%) 112 (25.05%) 13 (2.90%) 
4. ER Status (n=322) 
Variables ER-ve ER+ve 
No (%age) 209 (64.9%) 113 (35.1%) 
5. PR Status (n=326) 
Variables PR-ve PR+ve 
No (%age) 205 (62.88%) 121(37.12%) 
6. HER-2/neu status (n=285) 
Variables HER-2/neu -ve HER-2/neu +ve 
No (%age) 164 (57.54%) 121 (42.46%) 
DCI, Ductal Carcinoma in Situ   IDC, Invasive Ductal Carcinoma 
ILC, Invasive Lobular Carcinoma ER,   Estrogen Receptor   
PR,   Progesterone Receptor   HER-2/neu, Human Epidermal growth factor Receptor 2 
 
3.1.3 DNA extraction and quantification  
Genomic DNA was extracted from both control and patient blood samples and 
quantified according to protocol described in sections 2.3.1 and 2.3.2. DNA samples 
were electrophoresed on 1% agarose gel and stained with Ethidium bromide (EtBr). 
Electropherograms of controls and patients DNA samples are given in Figure 3.1  
  Results 
98 
 
 
Figure 3.1: Electropherogram of ethidium bromide stained (EtBr) 1% agarose gel (A) 
showing extracted DNA from control blood samples (C47 to C58) where ″C″ refers to control 
sample number. (B) Showing extracted DNA from blood samples of breast cancer patients 
(P76 to P89) where ″P″ refers to patient sample number. 
3.1.4 DNA amplification  
For mutation/polymorphism detection, genomic DNA (approx.50 ng/µl) extracted 
from control and patients’ blood samples was amplified using PCR for whole coding 
region along with exon/intron boundaries of APEX1, OGG1 and XRCC1. Amplified 
products were electrophoresed on 2% agarose gel along with 100 bp DNA ladder. 
Negative control samples were also run in each PCR along with that of patient 
samples to avoid the chances of non-specific amplification. Electrophoresed gel was 
stained in EtBr solution and visualized in UV trans-illuminator (Bio Rad, UK). 
Electropherogram immages of amplifide products are shown in Figure 3.2A, 3.2B, 3.2C, 
3.2D, 3.2E and 3.2F. 
 
Figure 3.2A: Electropherogram of APEX1 amplified products (exon 5B, Product size: 
339 bp) in patient (P) and control (C) samples. 
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Figure 3.2B: Electropherogram of APEX1 amplified products (exon 5C, Product size: 
292 bp) in patient (P) and control (C) samples. 
 
Figure 3.2C: Electropherogram of OGG1 amplified products (exon 1, Product size: 
408bp) in patient (P) and control (C) samples. 
 
Figure 3.2D: Electropherogram of OGG1 amplified products (exon 6, Product size: 
326bp) in patient (P) and control (C) samples. 
 
Figure 3.2E: Electropherogram of XRCC1 amplified products (exon 4, Product size: 
300bp) in patient (P) and control (C) samples. 
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Figure 3.2F: Electropherogram of XRCC1 amplified products (exon 7, Product size: 
288bp) in patient (P) and control (C) samples. 
 
3.2 Germline mutation detection and sequence analysis of APEX, 
OGG1 and XRCC1  
Mutation screening of all exons of respective genes (APEX1, OGG1 and XRCC1) was 
carried out through single strand conformational polymorphism (SSCP). For this 
purpose, all amplified PCR products were prepared for SSCP using polyacrylamide 
gel electrophoresis (PAGE) as described in materials and methods (section 2.6) 
Mutations were detected by poly acrylamide gel electrophoresis (PAGE) on the basis 
of conformational changes and mobility shift induced in single stranded molecule as a 
result of any change. For further confirmation of SSCP findings, direct genome 
sequencing of selected amplified PCR products were performed. 
3.2.1 SSCP and sequence analysis of APEX1  
All five exons of APEX1 were examined in breast cancer patient and control samples 
using SSCP. Samples with electrophoretic mobility shifts were selected as mutants in 
APEX1 and were further confirmed by sequencing. Sequencing results helped in 
characterization of type and specific location of mutation in APEX1. Altered mobility 
patterns were observed in exons 1, 3, 4 and 5 of APEX1 gene as shown in Figure 3.3. 
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Figure 3.3: Electropherogram observed on EtBr stained 8% non-denaturing poly 
acrylamide gel after electrophoresis of samples followed by PCR-SSCP. Arrows 
indicate the mobility shifts and allelic pattern as a result of germline mutations in 
exon 1, 2, 3, 4, 5b and 5c of APEX1 in breast cancer samples compared with control 
samples. ‘P’ refers to breast cancer patients samples and ‘C’ refers to control samples. 
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3.2.2 Sequence analysis of APEX1 
Sequence analysis of samples showing altered mobility pattern after PCR-SSCP 
analysis revealed a total of fourteen different types of germline mutations in APEX1 
(Figure 3.4 and 3.5). All five exons of APEX1 including exon-intron boundaries were 
screened extensively for germline mutations in 530 patients and 395 control 
individuals.  Observed mutations include seven 5’UTR, one 3’UTR, two intronic and 
four missense mutations as listed in Table 3.3. All APEX1 mutations observed in this 
study were heterozygous. Among identified mutations one 5’UTR (g.20923416C>T, 
rs41561214), one 3’UTR (20925669A>T, rs17112002) and one missense mutation 
(Ser129Arg, Mahjabeen et al., 2013) has already been reported while remaining elven 
mutations are novel.  Six novel mutations (g.20923366T>G, g.20923435G>A, 
g.20923462G>A, g.20923516G>A, 20923539G>A, g.20923529C>T) were observed 
in 5’UTR region, two (g.20923585T>G, g.20923589T>G) in intron 1 and three 
(g.20924881G>A, Glu101Lys; g.20924941G>C, Ala121Pro; g.20924948C>G, 
Ser123Trp) were observed in exon 4 (Figure 3.10). First missense mutation 
(g.20924881G>A, Glu101Lys) resulted in change of codon from GAG to AAG 
encoding amino acid Glutamic acid instead of Lysine. Second missense mutation 
(g.20924941G>C, Ala121Pro) resulted in change of codon from GCT to CCT 
encoding amino acid Proline instead of Alanine. Third missense mutation 
(g.20924948C>G, Ser123Trp) resulted in change of codon from TCG to TGG 
encoding amino acid Serine instead of Tryptophan and fourth missense mutation 
(g.20924967 T>G, Ser129Arg) resulted in change of codon from AGT to AGG 
encoding amino acid Serine instead of Arginine. No SNP and splice site mutation was 
observed in exon 1, 2, 3 and coding region of exon 5. Out of all fourteen mutations, 
six were also observed in control samples but with significantly lower frequency. 
Changes observed due to these mutations, at genomic DNA and resultantly at cDNA 
and protein levels are mentioned in Table 3.3.  
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Figure 3.4: Sequencing electropherogram of mutations in APEX1 in breast cancer. A 
to N are 5´UTR mutations while O and P are 3´UTR mutations.  
(A) Showing control g.20923366 with wild type sequence (B) showing mutant 
g.20923366 with T>G substitution. (C) Showing control g.20923435 with wild type 
sequence (D) showing mutant g.20923435 with G>A substitution. (E) Showing 
control g.20923462 with wild type sequence (F) showing mutant g.20923462 with 
G>A substitution. (G) Showing control g.20923516 with wild type sequence (H) 
showing mutant g.20923516 with G>A substitution. (I) Showing control g.20923539 
with wild type sequence (J) showing mutant g.20923539 with G>A substitution. (K) 
Showing control g.20923529 with wild type sequence (L) showing mutant 
g.20923529 with C>T substitution. (M) Showing control g.20923416 with wild type 
sequence (N) showing mutant g.20923416 (rs41561214) with C>T substitution. (O) 
Showing control g.20925669 with wild type sequence (P) showing mutant 
g.20925669 (rs17112002) with A>T substitution.  
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Figure 3.5: Sequencing electropherogram of APEX1 mutations 
(Q) Showing control g.20923585 and g.20923589 with wild type sequences (R) showing 
substitution mutants g.20923585 and g.20923589 both with T>G substitution. S to X are 
missense substitutions in Exon 4 (S) Showing control g.20924881 with wild type sequence 
(T) showing mutant g.20924881 with G>A substitution resulting in change of codon from 
GAG to AAG causing missense mutation Glu101Lys. (U) Showing controls g.20924941 and 
g.20924948 with wild type sequences (V) showing first mutant g.20924941 with G>C 
substitution resulting in change of codon from GCT to CCT causing missense mutation 
Ala121Pro and second mutant g.20924948 with C>G substitution resulting in change of 
codon from TCG to TGG resulting missense mutation Ser123Trp. (W) Showing control 
g.20924967 with wild type sequence (X) showing mutant g.20924967 with T>G substitution 
resulting in change of codon from AGT to AGG causing missense mutation Ser129Arg. 
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Table: 3.3 Mutations observed in APEX1 in breast cancer patients   
Exon 
Change in Genomic DNA 
(Change of codon ) 
Chr14(GRCh37 
Change at 
cDNA Level 
NM_001641.2 
Change at 
Protein 
Level 
5’UTR * g.20923366T>G c.-256T>G  
5’UTR* g.20923435G>A c.-187G>A  
5’UTR* g.20923462G>A c.-160G>A  
5’UTR* g.20923516G>A c.-106G>A  
5’UTR* g.20923539G>A c.-83G>A  
5’UTR* g.20923529C>T c.-93C>T  
5’UTR 
(rs41561214) 
g.20923416C>T c.-206C>T  
3’UTR 
(rs17112002) 
g.20925669A>T c.*2A>T  
Intron 1* g.20923585T>G c.-69+32T>G  
Intron 1* g.20923589T>G c.-69+36T>G  
Exon 4* 
g.20924881G>A 
(GAG to AAG) 
c.301G>A p.Glu101Lys 
Exon 4* 
rs371585266G>T 
g.20924941G>C 
(GCT to CCT) 
c.361G>C p.Ala121Pro 
Exon 4* 
g.20924948C>G 
(TCG to TGG) 
c.368C>G p.Ser123Trp 
Exon 4* 
g.20924967T>G 
(AGT to AGG) 
c.387T>G p.Ser129Arg 
 
rs = reference single nucleotide polymorphism (SNP) identifier;  Nomenclature of 
sequence variants follows the recommendations by the Human Genome Variation 
Society (HGVS, http://www.hgvs.org/mutnomen/) Classification of novel sequence 
variants is as suggested by Plon et al., 2008. * = novel mutation 
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3.2.3 Frequency of mutations in APEX1  
Frequency of APEX1 mutations was significantly different in breast cancer patients 
and controls. Increased breast cancer risk was found associated with different 
mutations when compared with controls (Table 3.4). In case of 5´UTR mutations, ~4-
fold increase in  breast cancer risk was associated with g.20923366T>G (OR = 4.08, 
95 % CI = 1.97 to 8.43), g.20923516G>A (OR= 3.86, 95 % CI = 1.46 to 10.18), 
g.20923529C>T (OR= 4.26, 95 % CI = 1.41 to 12.88) mutations in breast cancer 
patients compared to controls, whereas ~5 fold increased  breast cancer risk was 
associated with g.20923416C>T (OR= 5.07, 95 % CI = 2.27 to 11.32), ~6 fold 
increase  with  g.20923462G>A (OR= 5.66, 95 % CI = 1.97 to 16.23), ~9 fold 
increase with g.20923435G>A (OR = 8.68, 95 % CI = 2.64 to 28.50) and ~13 fold 
increase with g.20923539G>A (OR= 12.63, 95 % CI = 3.01 to 53.01)  mutations in 
breast cancer patients compared to controls . Similarly, ~5 fold increase in breast 
cancer risk was found to be associated with 3’UTR mutations g.20925669A>T (OR= 
5.42, 95 % CI = 2.74 to 10.73) and both intronic mutations g.20923585T>G (OR= 
5.11, 95% CI= 2.32 to 11.25) and g.20923589T>G (OR= 5.19, 95% CI= 2.43 to 
11.10) in breast cancer patients compared to controls. While analyzing missense 
mutations, ~5 fold increased breast cancer risk was found associated with missense 
mutations Glu101Lys (OR = 4.82, 95 % CI = 1.97 to 11.80),  Ser123Trp (OR = 4.62, 
95 % CI = 1.7 to 12.19) and Ser129Arg (OR = 4.86, 95 % CI = 1.43 to 16.53) in 
breast cancer patients compared to controls. Moreover ~4 fold increase in breast 
cancer risk was found associated with missense mutation Ala121Pro (OR = 3.68, 95 
% CI = 0.98 to 13.86) in breast cancer patients compared to controls. These risks 
persisted even when data was adjusted for χ2 analysis and found statistically 
significant. 
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Table: 3.4   Mutations and their Allele frequencies observed in the APEX1 in breast cancer patients 
 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test; * p<0.05;   
CI confidence interval
MUTATION/ 
EXON 
Chr14(GRCh37) 
PATIENTS CONTROL 
ODD RATIO 
(95% CI) 
P Value 
Number 
Allele frequency 
Minor/ Major 
Number 
Allele frequency 
Minor/ Major 
g.20923366T>G  
5’UTR 
46 G 0.13 / T 0.87 09 G 0.35 / T 0.65 4.0 (2.0 to 8.4) <0.0001
*
 
g.20923435G>A 
 5’UTR 
33 A 0.1 / G 0.9 03 A 0.12 / G 0.88 8.7 (2.6 to 28.5) <0.0001
*
 
g.20923462G>A  
5’UTR 
29 A 0.08 / G 0.92 04 A 0.15 / G 0.85 5.7 (2.0 to 16.2) <0.0002
*
 
g.20923516G>A  
5’UTR 
25 A 0.07 / G 0.93 05 A 0.19 / G 0.81 3.9 (1.5 to 10.2) <0.004
*
 
g.20923539G>A  
5’UTR 
32 A 0.09 / G 0.91 02 A 0.09 / G 0.91 12.6 (3 to 53.0) <0.0001
*
 
g.20923529C>T  
5’UTR 
12 T 0.03 / C 0.97 00 T 00 / C 1.0 4.3 (1.4 to 12.8) <0.009
*
 
g.20923416C>T 
 5’UTR(rs41561214) 
24 T 0.07/ C 0.93 00 T 00 / C 1.0 5.1 (2.3 to 11.3) <0.0001
*
 
g.20925669A>T 
 3’UTR (rs17112002) 
34 T 0.1 / A 0.9 00 T 00 / A 1.0 5.4 (2.7 to 10.7) <0.0001
*
 
g.20923585T>G  
Intron 1 
25 G 0.07 / T 0.93 00 G 00 / T 1.0 5.1 (2.3 to 11.5) <0.0001
*
 
g.20923589T>G  
Intron 1 
27 G 0.08 / T 0.92 00 G 00 / T 1.0 5.2 (2.4 to 11.1) <0.0001
*
 
g.20924881G>A 
 Exon 4 Glu101Lys 
19 A 0.05/ G 0.95 00 A 00 / G 1.0 4.8 (2.0 to 11.8) <0.0003
*
 
g.20924941G>C 
Exon 4, Ala121Pro 
(rs371585266G>T) 
8 C 0.02 / G 0.98 00 C 00 / G 1.0 3.7 (0.9 to 13.9) 0.08 
g.20924948C>G 
Exon 4,Ser123Trp 
16 G 0.05 / C 0.95 00 G 00 / C 1.0 4.6 (1.7 to 12.2) <0.001
*
 
g.20924967T>G 
Exon 4 Ser129Arg 
19 G 0.05 / T 0.95 03 G 0.12 / T 0.88 4.9 (1.4 to 16.5) <0.004
*
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3.2.4 In-silico predictions of missense mutations in APEX1  
Missense mutations were analysed with Alamut biosoftware (version 2.4-5) which 
further involves PhyloP scoring, SIFT scoring,  Align GVGD scoring and Mutation 
Taster for multiple calculations and In-silico predictions.  PhyloP score provides 
information about conservation levels of mutated nucleotides and altered amino acids. 
PhyloP score was used in rating the nucleotides from ″not conserved″ (Phylo P score 
−14.1) to ″highly conserved″ (Phylo P score 6.4). In case of missense mutation 
Glu101Lys (g.20924881G>A), highly conserved nucleotide ″G″was replaced by 
nucleotide ″A″ (phyloP: 4.32) replacing highly conserved amino acid Glutamic acid by 
Lysine.  Alamut software was also used for In-silico predictions of overall effects of 
mutations, physico-chemical alteration between normal and replaced amino acids and 
role in disease causing through Align GVGD score, Grantham distance, SIFT score and 
Mutation Taster. Mutation taster predicted three missense mutations (Glu101Lys, 
Ser123Trp, and Ser129Arg) as potentially disease causing (p-1.0). Missense mutation 
Ser123Trp (g.20924948C>G) was found to be deleterious (SIFT score = 0.01). Greater 
physico-chemical difference was predicted between Serine and Tryptophan amino acids 
(Ser123Trp; Grantham distance = 177) and Serine and Arginine amino acids 
(Ser129Arg; Grantham distance = 110). In-silico predictions about APEX1 missense 
mutations are presented in Table 3.5. 
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Table: 3.5 Missense mutations in APEX1 in breast cancer patients with conservation score, SIFT score, Align GVGD score, Grantham distance 
and Mutation Taster prediction  
Change in Nucleotide  
with its conservation level  
PhyloP score [−14.1;6.4] 
Amino acid change  
with its conservation 
level (considering 13 species) 
SIFT score 
(median) 
Align GVGD score 
(C0-C65) 
Grantham 
distance 
(0-215) 
Mutation Taster 
(p- value) 
g.20924881G>A  
Highly conserved nucleotide  
phyloP: 4.32 
Glu101Lys 
Highly conserved amino 
acid, up to Baker's yeast 
Tolerated  0.18 
(2.95) 
C0 
(GV:95.14-GD:0.0) 
56 
Disease causing 
(p-1.0) 
g.20924941G>C  
Weakly conserved nucleotide 
phyloP: 1.66  
Ala121Pro 
Moderately conserved 
amino acid 
Tolerated  0.22 
(2.95) 
C0 
(GV:22.66-GD:0.0) 
27 
Polymorphism 
(p-1.0) 
g.20924948C>G 
Moderately conserved 
nucleotide phyloP: 2.55 
Ser123Trp 
Moderately conserved 
amino acid 
Deleterious  
0.01 (2.95) 
C15 
(GV:120.14-GD: 97.5) 
177 
Disease causing 
(p-1.0) 
g.20924967T>G  
Weakly conserved nucleotide 
phyloP: 0.12  
Ser129Arg 
Moderately conserved 
amino acid 
Tolerated 0.16 
(2.95) 
C0 
(GV: 141.06 - GD: 0.0) 
 
110 
Disease causing 
(p-1.0) 
PhyloP was used as a conservation score rating the nucleotides from ″not conserved″(−14.1) to ″highly conserved″(6.4) [Pollard et al., 2010). Align GVGD score: 
most likely deleterious (C65) to least likely deleterious (C0) GV (Grantham variation) and GD (Grantham deviation). The Grantham distance was used to evaluate 
physico-chemical changes in amino acids (0 = no physico-chemical changes; 215 = large changes)[Grantham et al., 1974]. In-silico predictions were performed 
using PolyPhen-2 [Adzhubei et al.,2010], SIFT score: <0.05 deleterious, >0.05 tolerated [Kumar et al., 2009] an Mutation Taster: disease causing variants (p-value 
1.0), might not be disease causing (p value <0.99) [Schwarz et al., 2010].  
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3.2.5: Association of APEX1 mutations in breast cancer patients with related 
hormonal receptors 
Majority of the breast cancer patients (Table 3.1) were histopathologically confirmed cases 
of invasive ductal carcinoma (64.86%), at grade-II (40.00%), with ER –ve (64.9%), PR –ve 
(62.88%) and HER-2/nue –ve (57.54%).  Frequency of APEX1 mutations was observed 
significantly higher in patients with invasive ductal carcinoma (IDC), negative PR status 
(p<0.004), negative ER (p<0.002) and negative HER-2/neu Status (p<0.001). Observed 
APEX1 mutations were found significantly correlated with IDC tumor type (r = 0.710**; 
p<0.004) ER status (r = 0.756**; p<0.002), PR status (r = 0.720**; p<0.004) and HER-
2/neu Status (r = 0.782**, p<0.001) of breast cancer patients. Correlation of APEX1 
mutations with type of tumor and hormonal receptor status (ER/PR and HER-2/neu) of 
breast cancer patients is given in Table 3.6 
 
3.2.6 Association of APEX1 mutations with family history and menopausal age 
of breast cancer patients 
In present study, observed mutations were also correlated with family history and 
menopausal age of breast cancer patients. Demographically frequency of patients with 
family history was observed significantly higher (p<0.0001) compared to frequency of 
control individuals (Table 3.1). One 3´UTR mutation, g.20925669A>T (p<0.009) and two 
missense mutations Glu101Lys (p<0.009) and Ser129Arg (p<0.05) were found 
significantly higher in breast cancer patients with family history of cancer when compared 
with patients without family history and control individuals. Furthermore, correlations 
between frequencies of APEX1 mutations and menopausal age of breast cancer patients 
revealed that the frequency of 5´UTR, 3´UTR and intronic mutations were present 
significantly higher in patients with early menopause (menopause ≤50 years) when 
compared with patients with late menopausal status and controls. Association of APEX1 
mutations with family history and menopausal age of breast cancer patients is presented in 
Table 3.7. 
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Table: 3.6 Correlation between APEX1 mutations and tumor types, ER/PR status and HER-2/neu status of breast cancer patients 
 
Mutations 
Type of Tumor ER Status PR Status HER-2/neu Status 
DCIS 
No (%) 
IDC 
No (%) 
ILC 
No (%) 
-ve 
No (%) 
+ve 
No (%) 
-ve 
No (%) 
+ve 
No (%) 
-ve 
No (%) 
+ve 
No (%) 
g.20923366T>G 5’UTR 8 (10.25) 32(14.81) 4(10.25) 29(13.87) 13(11.50) 28(13.66) 14(11.57) 24(14.46) 16(13.22) 
g.20923435G>A 5’UTR 7(8.97) 24(11.11) 2(5.13) 19(9.09) 13(11.50) 16(7.8) 16(13.22) 16(9.76) 12(9.91) 
g.20923462G>A 5’UTR 8(10.25) 16(7.4) 5(12.82) 16(76.55) 12(10.62) 16(7.8) 12(9.91) 15(9.14) 11(9.09) 
g.20923516G>A 5’UTR 4(5.13) 17(7.87) 2(5.13) 18(8.61) 6(5.30) 18(8.78) 6(4.96) 17(10.36) 6(4.96) 
g.20923539G>A 5’UTR 9(11.54) 21(9.72) 2(5.13) 20(9.57) 10(10.62) 21(10.24) 9(7.44) 16(9.76) 12(9.91) 
g.20923529C>T 5’UTR 5(6.41) 6(2.77) 1(2.56) 6(2.87) 4(3.35) 8(3.9) 2(1.65) 5(3.04) 4(3.3) 
g.20923416C>T5’UTR 
(rs41561214) 
6(7.69) 11(5.09) 6(15.38) 15(7.18) 8(7.08) 14(6.83) 9(7.44) 8(4.87) 9(7.44) 
g.20925669A>T 3’UTR 
 (rs17112002) 
8(10.25) 23(10.65) 2(5.13) 19(9.09) 13(11.50) 19(9.27) 13(10.74) 12(7.32) 13(10.74) 
g.20923585T>G Intron 1 6(7.69) 14(6.48) 3(7.69) 17(8.13) 5(4.42) 14(6.82) 8(6.61) 13(7.93) 7(5.78) 
g.20923589T>G Intron 1 6(7.69) 15(6.94) 3(7.69) 16(76.55) 9(7.96) 16(7.8) 13(10.74) 15(9.14) 8(6.61) 
g.20924881G>A Exon 4  
 p.Glu101Lys 
2(2.56) 14(6.48) 1(2.56) 10(4.78) 7(6.19) 11(5.36) 6(4.96) 7(4.27) 6(4.96) 
g.20924941G>C Exon 4 
 p.Ala121Pro 
2(2.56) 5(2.31) 1(2.56) 5(2.39) 2(2.21) 5(2.43) 2(1.65) 3(1.83) 4(3.3) 
g.20924948C>G Exon 4 
 p.Ser123Trp 
4(5.13) 10(4.63) 2(5.13) 10(4.78) 3(2.65) 10(4.87) 3(2.48) 7(4.27) 6(4.96) 
g.20924967T>G Exon 4 
 p.Ser129Arg 
3(3.85) 8(3.70) 5(12.82) 9(4.30) 8(7.08) 9(4.39) 8(6.61) 6(3.66) 7(5.78) 
Correlation
a
 0.710** 0.756** 0.720** 0.782** 
p-value
b
 0.004 0.002 0.004 0.001 
a = Pearson correlation coefficient                  b = p value for χ2 test                            *p<0.05; **p<0.05;  ***p<0.05  
IDC = invasive ductal carcinoma                    DCI = Ductal Carcinoma in situ              LCI = Lobular Carcinoma in situ 
ER =Estrogen Receptor,                                PR = Progesterone Receptor,                   HER-2/nue = Human Epidermal Growth Factor Receptor 2 
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Table: 3.7 Association of APEX1 mutations with family history and menopausal age in breast cancer patients and controls 
 
Mutations 
Family history of cancer Menopause at ≤50 years Menopause at  >50 years 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
g.20923366T>G 5´UTR 9 (9.6) 02 (40) 3.4 (0.7 to 15.8), 0.12 19 (12.26) 4 (36.36) 3.6 (1.2 to 10.8), 0.01* 5 (11.1) 2 (25) 1.9 (0.4 to 9.7), 0.7 
g.20923435G>A 5´UTR 7 (7.45) 01(20) 5.3 (0.7 to 43.0), 0.14 16 (10.32) 01 (9.9) 12.3 (1.6 to 92.9), 0.001* 4 (8.8) 1(12.5) 3.0 (0.3 to 26.9), 0.4 
g.20923462G>A 5´UTR 5 (5.33) 0 2.9(0.6  to 14.8), 0.24 14 (9.03) 2 (18.18) 5.3(1.2 to 23.6), 0.01* 4(8.8) 01 (12.5) 3.0 (0.3 to 26.9), 0.4 
g.20923516G>A 5´UTR 6 (6.38) 01(20) 4.5 (0.5 to 37.6), 0.24 13 (8.39) 2 (18.18) 4.9 (1.1 to 22.0), 0.03* 2 (4.4) 02 (25) 0.7 (0.1 to 5.3), 1.00 
g.20923539G>A 5´’UTR 6 (6.38) 0 3.2 (0.7 to 14.5), 0.24 17 (10.97) 01(9.9) 13.1 (1.7 to 98.5), 0.001* 4(8.8) 0  (12.5 2.5 (0.4 to 15.0), 0.4 
g.20923529C>T 5´UTR 2 (2.23) 0 1.5 (0.1 to 14.5), 1.00 06 (10.32) 0 3.2 (0.7 to 14.5), 0.24 1(2.2) 0 0.7 (0.04 to 12.2), 1.00 
g.20923416C>T 5´UTR 
(rs41561214) 
4 (4.46) 0 2.5 (0.4 to 15.0), 0.39 10(6.45) 0 4.0 (1.2 to 13.3), 0.02* 3(6.6) 0 2.1 (0.3 to 15.0),  0.64 
g.20925669A>T 3´UTR 
(rs17112002) 
12 (12.8) 0 4.2 (1.4 to 13.0), 0.009* 16 (10.32) 0 4.6 (1.8 to 12.2), 0.001* 6 (13.2) 0 3.2 (0.7 to 14.5), 0.24 
g.20923585T>G Intron 1 5 (5.33) 0 2.9 (0.6 to 14.8), 0.24 13 (8.39) 0 4.4 (1.5  to 12.7), 0.005* 3 (6.6) 0 2.01 (0.3 to 15.0), 0.64 
g.20923589T>G Intron 1 5(5.33) 0 2.9(0.6  to 8), 0.24 11 (7.1) 0 4.1 (1.5 to 12.7), 0.01* 3 (6.6) 0 2.1 (0.3 to 15.0), 0.64 
g.20924881G>A Exon 4 
p.Glu101Lys 
12 (12.8) 0 4.3 (1.4 to 12.9), 0.009* 08 (5.16) 0 3.7 (1.0 to 13.9), 0.08 4(8.8) 0 2.5 (0.4 to 15.0), 0.4 
g.20924941G>C Exon 4 
p.Ala121Pro 
4 (4.46) 0 2.5 (0.4 to 15.0), 0.39 02 (1.3) 0 1.5 (0.1 to 15.0), 1.00 1 (2.2) 0 0.7 (0.04 to 12.2), 1.00 
g.20924948C>G Exon 4 
p.Ser123Trp 
8 (8.92) 0 3.7 (1.0 to 13.9), 0.08 04 (2.6) 0 2.5 (0.4 to 15.0), 0.4 2(4.4) 0 1.5 (0.1 to 14.5), 1.00 
g.20924967T>G Exon 4 
p.Ser129Arg 
09 (9.6) 01(20) 6.8 (0.9 to 53.9), 0.05* 06(5.2) 01(9.9) 4.5 (0.5 to 37.6), 0.2 3 (6.6) 01 (12.5) 2.2 (0.2 to 21.6), 0.64 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test;  * p<0.05; OR= Odds Ratios; CI = confidence interval 
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3.2.7 Association of APEX1 mutations with smoking status  
Association of different types of APEX1 mutations with smoking status of breast 
cancer patients and control was found significant. ~5 fold increase in breast cancer 
risk was associated with 3´UTR mutation g.20925669A>T (OR= 5.0, 95 % CI = 
2.35 to 10.15; p < 0.0001) and ~10 fold increase with missense mutation Ser129Arg 
(OR= 10.4, 95 % CI = 3.6 to 29.95; p< 0.0001) in smoker patients when compared 
with nonsmokers. In case of 5´UTR mutations, ~2 fold increase in breast cancer risk 
was associated with g.20923366 T>G mutation in breast cancer patients compared to 
controls. Furthermore, statistically significant difference in mutation frequency (p< 
0.05) was observed in smoker and non-smoker patients having 5´UTR mutations 
(g.20923366T>G, g.20923416C>T, g.20923435G>A and g.20923462G>A) as shown 
in Table 3.8.  
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Table: 3.8 Association of APEX1 mutations with smoking status of breast cancer 
patients 
* p<0.05; p-values were computed from two-tailed student’s t-test and χ2 with Fisher 
exact test; OR= Odds Ratios; CI = confidence interval 
  
 
MUTATION/ EXON 
Chr14(GRCh37) 
Breast cancer patients 
Smokers 
(%) 
Non smokers 
(%) 
OR
 
(95%CI), p value 
g.20923366T>G 5’UTR 17 (20.5) 29 (10.9) 2.2 (1.11 to 4.2), 0.02* 
g.20923435G>A 5’UTR 02 (2.4) 31 (11.8) 0.2 (0.04 to 0.7), 0.02* 
g.20923462G>A 5’UTR 02 (2.4) 27 (10.3) 0.2 (0.05 to 0.9), 0.04* 
g.20923516G>A 5’UTR 03 (3.6) 22 (8.4) 0.4 (0.12 to 1.4), 0.16 
g.20923539G>A 5’UTR 04 (4.8) 24 (9.2) 0.5 (0.17 to 1.5), 0.2 
g.20923529C>T 5’UTR 04 (4.8) 08 (3.1) 1.6 (0.47 to 5.5), 0.4 
g.20923416C>T 5’UTR 
 (rs41561214) 
00 22 (8.4) 0.1 (0.01 to 1.0), 0.05
*
 
g.20925669A>T 3’UTR 
 (rs17112002) 
19 (22.9) 15 (5.7) 5.0 (2.35 to 10.2), <0.0001
*
 
g.20923585T>G Intron 1 03 (3.6) 22 (8.4) 0.4 (0.11 to 1.4), 0.1 
g.20923589T>G Intron 1 03 (3.6) 28 (10.6) 0.3 (0.09 to 1.07), 0.06 
g.20924881G>A Exon 4 
 Glu101Lys 
08 (9.6) 11 (4.2) 2.4 (0.94 to 6.27), 0.06 
g.20924941G>C Exon 4 
 Ala121Pro, rs371585266G>T 
02 (2.4) 06 (2.3) 1.05 (0.20 to 5.32), 0.9 
g.20924948C>G Exon 4 
 Ser123Trp 
02 (2.4) 12 (4.6) 0.5 (0.11 to 2.34), 0.4 
g.20924967T>G Exon 4 
 Ser129Arg 
14 (16.9) 05 (1.9) 10.4 (3.6 to 30.0), <0.0001
*
 
  Results 
115 
 
3.3 SSCP and sequencing of OGG1  
SSCP analysis of all eight exons of OGG1 in 530 breast cancer patient and 395 
control samples was performed to screen for germline mutation. Analysis revealed an 
altered mobility pattern in almost all exons of OGG1 in breast cancer patients and 
some control samples. Samples with an electrophoretic mobility shift were selected as 
positive for OGG1 mutations. To confirm the findings of SSCP, DNA sequencing of 
samples with altered mobility patterns was carried out to categorize the mutations, 
characterize their genotype and location in gene. Figure 3.6 shows the altered mobility 
patterns for different exons of OGG1 by SSCP analysis. 
 
Figure 3.6: Electropherogram observed on EtBr stained 8% non-denaturing poly acrylamide 
gel after electrophoresis of samples followed by PCR-SSCP. Arrows indicate the mobility 
shifts and allelic pattern as a result of germline mutations in exon 1, 2, 4, 5 and 6 of OGG1 in 
breast cancer samples compared with control samples. ‘P’ refers to breast cancer patients 
samples and ‘C’ refers to control samples. 
  Results 
116 
 
3.3.1 Germline mutations in Splice site, intronic and 3´UTR regions of 
OGG1  
In present study, using sequence analysis, a total of fifteen mutations were observed 
in OGG1. Among these, five mutations were observed in intronic regions including 
one insertion (g.9792260 insert_T) and four substitution mutations (g.9793680G>A; 
g.9793748G>A; g.9798336T>G; g.9798349T>A). In addition to these, four mutations 
were observed in splice site regions including one deletion (g.9792109delT) and three 
substitution mutations (g.9798307T>G, g.9798502T>G and g.9800972T>G). 
Moreover, two substitution mutations (g.9798848G>A; g.9798896T>C) were also 
observed in 3´UTR region of OGG1 (Figure 3.7). Among these, one intronic 
mutation (g.9793680G>A, rs55846930) has already been known while other 
mutations are novel. Splice site mutations were observed at 2 bps upstream in donor 
splice site region of gene. Changes observed due to these mutations, at genomic DNA 
and resultantly at cDNA levels and possible consequences predicted by Alamut bio 
software (version 2.4-5) are mentioned in Table 3.9. 
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Figure 3.7: Sequencing electropherogram of polymorphisms of OGG1. A, B, C, D 
and E are Intronic Mutations {(A) g.9792260 insertion of T in Intron 1 (B) g.9793680 
G>A (rs55846930) substitution in Intron 3 (C) g.9793748 G>A substitution in Intron 
3 (D) g.9798336 T>G substitution in Intron 5 (E) g.9798349 T>A substitution in 
Intron 5}. F, G, H and I are Splice site Mutations {(F) g.9792109 deletion of T at 
Splice site region of Intron 1 (G) g.9798307 T>G substitution in Splice site region of 
Intron 5 (H) g.9798502 T>G substitution in Splice site region of Intron 6 (I) 
g.9800972 T>G substitution in Splice site region of Intron 7a}. J and K are 
substitutions in 3' UTR {(J) g.9798848 G>A substitution in 3' UTR (K) g.9798896 
T>C substitution in 3' UTR}.  
 
 
  Results 
118 
 
Table: 3.9 Mutations observed in splice site, intronic and 3´UTR regions of 
OGG1 in breast cancer patients   
mutation type/ 
 Intron# 
Change in 
Genomic DNA 
Chr3(GRCh37) 
Change at 
cDNA Level 
NM_002542.5 
Possible consequence predicted 
by Alamut bio software (version 
2.4-5) 
Insertion /  
Intron 1 
g.9792260ins_T c.137+153dupT  
Substitution / 
 Intron 3 
 (rs55846930) 
g.9793680G>A c.565+47G>A  
Substitution / 
 Intron 3 
g.9793748G>A c.565+115G>A  
Substitution / 
 Intron 5 
g.9798336T>G c.898+31T>G  
Substitution / 
 Intron 5 
g.9798349T>A c.898+44T>A  
Splice site 
 deletion / 
 Intron 1 
g.9792109del T c.137+2delT 
Alteration is in donor splice site 2 
bps upstream and skip of exon 1 
is very likely 
Splice site 
 Substitution / 
 Intron 5 
g.9798307T>G c.898+2T>G 
Alteration is in donor splice site 2 
bps upstream and skip of exon 5 
is very likely 
Splice site 
 substitution /  
Intron 6 
g.9798502T>G c.948+2T>G 
Alteration is in donor splice site 2 
bps upstream and skip of exon 6 
is very likely 
Splice site 
 substitution / 
 Intron 7a 
g.9800972T>G c.1048+2T>G 
(NM_016828.2) 
Alteration is in donor splice site 2 
bps upstream and skip of exon 7 
is very likely 
Substitution/  
3' UTR 
g.9798848G>A c.*14G>A  
Substitution/3' 
UTR 
g.9798896T>C c.*62T>C  
 
rs = reference single nucleotide polymorphism (SNP) identifier;  Nomenclature of 
sequence variants follows the recommendations by the  Human Genome Variation 
Society (HGVS, http://www.hgvs.org/mutnomen/)  Novel sequence variants  are 
classified as suggested by Plon et al (2008). 
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3.3.2 Missense and nonsense mutations observed in OGG1 in breast cancer 
patients and controls 
Sequence analysis of OGG1 also revealed three missense and a nonsense mutation in 
breast cancer patients and some of the controls (Figure 3.8). Among these, one 
missense (Val159Gly) and one nonsense (Trp375STOP) mutation is novel while two 
missense mutations are already reported (Gly221Arg; TMP_ESP_3_9796483 and 
Ser326Cys; rs1052133). Two missense mutations (g.9793544T>G, Val159Gly; 
g.9796483G>A, Gly221Arg) were observed in exon 3 and 4 respectively while third 
missense mutation (g.9798773C>G, Ser326Cys) was observed in exon 6d whereas 
nonsense mutation (g.9807669G>A, Trp375STOP) was observed in exon 8. Genotype 
analysis of these mutations revealed that one missense (Val159Gly) and one nonsense 
(Trp375STOP) mutation was heterozygous while other two missense mutations 
(Gly221Arg and Ser326Cys) were observed homozygous. Missense mutations 
(Val159Gly and Gly221Arg) are detected in protein domains, HhH-GPD and 8-
oxoguanine DNA-glycosylase and nonsense mutation (Trp375STOP) in protein 
domain, 8-oxoguanine DNA-glycosylase. Changes observed due to these mutations, 
at genomic DNA and resultantly at cDNA levels and possible consequences predicted 
by Alamut biosoftware are mentioned in Table 3.10. 
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Figure 3.8: Sequencing electropherogram of mutations of OGG1. L, M, N and O are 
Missense mutations {(L) Missense mutation Val159Gly showing g.9793544 T>G 
substitution in exon 3 resulting in change of codon from GTG to GGG encoding 
amino acid Valine instead of Glycine (M) Missense mutation Gly221Arg 
(TMP_ESP_3_9796483 ) showing g.9796483 G>A substitution in exon 4 resulting in 
change codon from GGG to AGG encoding amino acid Glycine instead of Arginine 
(N) Missense mutation Ser326Cys (rs1052133) (CM993185) showing g.9798773C>G 
substitution  in exon 6d resulting in change of codon from TCC to TGC encoding the 
amino acid Serine instead of Cysteine and (O) Nonsense mutation Trp375STOP* 
showing g.9807669 G>A substitutions in exon 8 resulting in change of codon from 
TGG to TGA terminating the  protein instead of encoding Tryptophan amino acid. 
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Table: 3.10 Missense and nonsense mutations observed in OGG1 in breast cancer 
patients   
Mutation type/ 
Exon 
Change in 
Genomic DNA 
Chr3(GRCh37) 
Change in 
cDNA 
NM_016821.2 
Change in Protein/ 
possible consequence 
Missense mutation/ 
Exon 3 
g.9793544T>G c.476T>G 
p.Val159Gly 
variant in protein domains 
HhH-GPD and 8-
oxoguanine DNA-
glycosylase 
Missense mutation/ 
Exon 4 
(TMP_ESP_3_9796483) 
g.9796483G>A c.661G>A 
p.Gly221Arg 
variant in protein domains 
HhH-GPD and 8-
oxoguanine DNA-
glycosylase 
Missense mutation/ 
Exon6d (rs1052133) 
(CM993185) 
g.9798773C>G c.977C>G 
p.Ser326Cys 
variant in protein domain:  
8-oxoguanine DNA-
glycosylase 
Termination/  
Exon 8 
g.9807669G>A c.1125G>A 
NM_016821.2 
p.Trp375STOP 
Premature termination 
resulted in truncated 
protein 
 
rs = reference single nucleotide polymorphism (SNP) identifier;  Nomenclature of 
sequence variants follows the recommendations by the Human Genome Variation 
Society (HGVS, http://www.hgvs.org/mutnomen/) Novel sequence variants  are 
classified as suggested by Plon et al., 2008. HhH-GPD= hallmark helix-hairpin-helix 
and Gly/Pro rich loop domain. 
3.3.3 In-silico predictions about missense mutations in OGG1  
Missense and nonsense mutations in OGG1 were analysed with Alamut biosoftware 
(version 2.4-5) which involves PhyloP scoring, SIFT scoring, Align GVGD scoring 
and Mutation Taster for multiple calculations and in-silico predictions.  PhyloP score 
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provided information about conservation levels of mutated nucleotides and altered 
amino acids. PhyloP score was used in rating the nucleotides from (Phylo P score 
−14.1) to ″highly conserved″ (Phylo P score 6.4). In case of first missense mutation 
(g.9793544T>G; Val159Gly), highly conserved nucleotide ″T″ was replaced by ″G″ 
(phyloP: 4.97) and codon GTG was changed to GGG replacing the moderately 
conserved amino acid Valine to Glycine. In case of second missense mutation 
(g.9796483G>A; Gly221Arg) a moderately conserved nucleotide ″G″ was replaced 
by ″A″ (phyloP: 2.38) and codon GGG was changed to GGA replacing amino acid 
Glycine to Arginine. In third missense mutation (g.9798773C>G; Ser326Cys) non 
conserved nucleotide ″C″ was replaced by ″G″ (phyloP: 0.28) and codon TCC was 
changed to TGC replacing amino acid Serine to Cysteine. Whereas, in case of 
nonsense mutation (g.9807669G>A; Trp375STOP), a weekly conserved nucleotide 
″G″ was replaced to ″A″ (phyloP: 0.12) and codon TGG was changed to stop codon 
TGA that caused truncation of protein.  
Alamut software was also used for in-silico predictions of overall effects of 
mutations, physico-chemical alteration between normal and replaced amino acids and 
role in disease causing through Align GVGD score, Grantham distance; SIFT score 
and Mutation Taster. Mutation taster predicted two missense mutations (Val159Gly 
and Gly221Arg) and a nonsense mutation (Trp375STOP) as potentially disease 
causing (p-1.0). All three missense mutations caused moderate difference in physico-
chemical structure of normal and replaced amino acids but nonsense mutation resulted 
into higher physico-chemical difference (Grantham dist. = 170) in overall protein 
structure and truncated protein was predicted to be produced. Missense mutation 
Val159Gly and nonsense mutation (Trp375STOP) was found to be deleterious (SIFT 
score = 0.01). In-silico predictions about OGG1 missense mutations are given in 
Table 3.11. No major difference in protein structure was observed when changes in 
protein structure as a result of missense mutations (Val159Gly and Gly221Arg) were 
predicted using automated Swiss model and was compared with wild-type protein 
model obtained from protein data bank. Superimposed protein structures (wild type 
and mutated OGG1) are shown in Figure 3.9. 
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Table: 3.11 Mutations in OGG1 in breast cancer patients with conservation score, SIFT score, Align GVGD score, Grantham distance 
and Mutation Taster prediction  
Change in nucleotide with 
its conservation level 
PhyloP score [−14.1;6.4] 
Change 
in 
codon 
Change in amino acid 
with its conservation level 
(considering 13 species) 
SIFT score 
(median) 
Align GVGD score 
(C0-C65) 
Grantham distance 
(physico-chemical difference 
b/w amino acids) 
(0-215) 
Mutation Taster 
(p- value) 
g.9793544T>G 
Highly conserved 
nucleotide phylo P: 4.97 
GTG 
to 
GGG 
Val159Gly 
Moderately conserved 
amino acid 
Deleterious 
0.01 (2.95) 
C0 
(GV: 197.52 - GD: 72.75) 
109 
(Moderate) 
disease causing 
(p- 1.0) 
g.9796483G>A 
Moderately conserved 
nucleotide phylo P: 2.38 
GGG 
to 
AGG 
Gly221Arg 
Moderately conserved 
amino acid 
Tolerated 
0.28 (2.95) 
C0 
(GV: 161.50 - GD: 19.25 
 
125 
(Moderate) 
disease causing 
(p- 0.999) 
g.9798773C>G 
Not conserved 
nucleotide phylo P: 0.28 
TCC 
to 
TGC 
Ser326Cys 
Weakly conserved 
amino acid 
Tolerated 
0.19 (2.95) 
C0 
(GV: 353.86 - GD: 0.00) 
112 
(Moderate) 
polymorphism 
(p- 1.0) 
g.9807669G>A 
Not conserved 
nucleotide phylo P: 0.12 
TGG 
to 
TGA 
Trp375STOP 
Moderately conserved 
amino acid 
Deleterious 
0.01 (2.95) 
C0 
(GV: 197.52 - GD: 72.75) 
170 (large) 
Protein truncation 
disease causing 
(p-1.0) 
PhyloP was used as a conservation score rating nucleotides from ″not conserved″ (−14.1) to ″highly conserved″ (6.4) [Pollard et al., 2010). 
Align GVGD score: most likely deleterious (C65) to least likely deleterious (C0) GV (Grantham variation) and GD (Grantham deviation). The 
Grantham distance was used to evaluate physico-chemical changes in amino acids (0 = no physico-chemical changes; 215 = large changes) 
[Grantham et al., 1974]. In-silico predictions were performed using PolyPhen-2 (Polymorphism Phenotyping-2) [Adzhubei et al., 2010], SIFT 
(Sorting Intolerant From Tolerant) score: <0.05 deleterious, >0.05 tolerated [Kumar et al., 2009] and Mutation Taster: disease causing variants 
(p-value 1.0), might not be disease causing (p value <0.99) [Schwarz et al., 2010] 
  Results 
124 
 
 
 
 
Figure 3.9: Superimposed protein structure of mutated OGG1 with its wild type. 
Wild-type OGG1 protein (grey) and mutated OGG1 protein (blue). Superimposed 
structure of normal wild type and mutated OGG1 protein showing the location of two 
observed mutations, Val159Gly and Gly221Arg. Wild-type protein model was 
obtained from protein data bank. Structure was predicted using automated Swiss 
model. Two structures, wild and mutated, were aligned using UCSF chimera software 
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3.3.4 Frequency of mutations in OGG1  
Frequency of OGG1 mutations was significantly different in breast cancer patients 
compared to control individuals. Increased breast cancer risk was found associated 
with different mutations when compared with controls (Table 3.12). In case of 
intronic  mutations, ~4-fold increase in  breast cancer risk was associated with 
insertion mutation g.9792260 insert_ T (OR = 3.80, 95 % CI = 1.67 to 8.7; p<0.001), 
~15 fold increase with mutation g.9793680G>A (OR= 14.7, 95 % CI = 1.95 to 109.9; 
p<0.009), ~11 fold increase with mutation g.9793748G>A (OR= 10.7, 95 % CI = 
1.40 to 81.6; p<0.02) and ~13 fold increase with mutation g.9798349T>A (OR= 13.3, 
95 % CI = 3.18 to 55.7; p<0.0004 ) in breast cancer patients compared to controls. In 
case of splice site mutations, ~20 fold increase in breast cancer risk was associated 
with splice site deletion  g.9792109delT (OR= 20.1, 95 % CI = 2.71 to 148.5; p<0.003 
), ~12 fold increase with g.9798307T>G (OR= 12.1, 95 % CI = 1.60 to 91.7; p<0.01) 
mutation, ~14 fold increase with g.9798502T>G (OR= 13.7, 95 % CI = 1.82 to 102.9; 
p<0.01) mutation and ~29 fold increase with g.9800972T>G (OR= 28.9, 95 % CI = 
3.87 to 207.7; p<0.001) mutation in breast cancer patients compared to controls. In 
similar fashion increased breast cancer risk was found associated with 3´UTR 
mutations where ~29 fold increase was observed associated with g.9798848G>A 
(OR= 29.2, 95 % CI = 3.98 to 213.7; p<0.001) mutation and ~13 fold increase with 
g.9798896T>C (OR= 12.9, 95% CI= 3.97 to 41.6; p<0.0001) mutation in breast 
cancer patients compared to controls.  While analyzing missense mutations, a 
significantly increased breast cancer risk was also found associated with missense 
mutations when compared with controls showing ~14 fold increase with Val159Gly 
mutation  (OR = 13.68, 95 % CI = 1.82 to 102.9; p<0.01), ~17 fold increase with 
Gly221Arg mutation (OR = 16.85, 95 % CI = 2.26 to 125.5; p<0.005), ~19 fold 
increase with Ser326Cys mutation(OR = 18.5, 95 % CI = (2.5 to 137.0; p<0.004 ) and 
~13 fold increase with nonsense mutation  Trp375STOP (OR = 12.9, 95 % CI = 
(1.1 to 97.3; p<0.01). These risks persisted and found statistically significant even 
when data was adjusted for χ2 analysis. 
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Table: 3.12     Mutations and their Allele frequencies observed in the OGG1 in breast cancer patients and 
controls 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test  
* p<0.05;   
CI = confidence interval 
MUTATION/ EXON 
Chr3(GRCh37) 
PATIENTS CONTROL 
ODDs RATIO 
(95% CI) 
p Value 
Number 
Allele frequency 
Minor/ Major 
Number 
Allele frequency 
Minor/ Major 
g.9792260 insert_ T 
Intron 1 
34 T 0.09 /  0.91 07 T 0.35 /  0.65 3.80 (1.67 to 8.7) 0.001
*
 
g.9793680G>A 
(rs55846930) Intron 3 
19 A 0.05 / G 0.95 00 A 00 / G 0.1 14.7 (1.95 to 109.9) 0.009
*
 
g.9793748G>A 
Intron 3 
14 A 0.04 / G 0.96 00 A 00 / G 0.1 10.7 (1.40 to 81.6) 0.02
*
 
g.9798336T>G 
Intron 5 
10 G 0.03 / T 0.97 06 G 0.40 / T 0.60 1.3 (0.45 to 3.5) 0.67 
g.9798349T>A 
Intron 5 
34 A 0.09 / T 0.91 02 A 0.10 /  T0.90 13.3 (3.18 to 55.7) 0.0004
*
 
g.9792109delT 
Splice site Intron 1 
26 0.07 / T 0.93 00 00 / T 1.0 20.1 (2.71 to 148.5) 0.003
*
 
g.9798307T>G 
Splice site Intron 5 
16 G 0.04 / T 0.96 00 G 00 / T 1.0 12.1 (1.60 to 91.7) 0.01
*
 
g.9798502T>G 
Splice site Intron 6 
18 G 0.05 / T 0.95 00 G 00 / T 1.0 13.7 (1.82 to 102.9) 0.01
*
 
g.9800972T>G 
Splice site intron 7a 
36 G 0.10 / T 0.90 00 G 00 / T 1.0 28.9 (3.87 to 207.7) 0.001
*
 
g.9798848G>A 
3' UTR 
37 A 0.10 / G 0.90 00 A 00 / G 0.1 29.2 (3.98 to 213.7) 0.001
*
 
g.9798896T>C 
3' UTR 
48 C 0.13 / T 0.87 03 C 0.15 / T 0.85 12.9 (3.97 to 41.6) 0.0001
*
 
g.9793544T>G 
Exon 3, Val159Gly 
18 G 0.05 / T 0.95 00 G 00 / T 1.0 13.68 (1.82 to 102.9) 0.01
*
 
g.9796483G>A 
(TMP_ESP_3_9796483) 
Exon 4, Gly221Arg 
22 A 0.06 / G 0.94 00 A 00 / G 0.1 16.85 (2.26 to 125.5) 0.005
*
 
g.9798773C>G 
(rs1052133) (CM993185) 
Exon 6d Ser326Cys 
24 G 0.06 / C 0.94 00 G 00 / C 1.0 18.5 (2.5 to 137.0) 0.004
*
 
g.9807669G>A 
Exon 8, Trp375STOP 
17 A 0.05 / G 0.95 00 A 00 / G 0.1 12.9 (1.1 to 97.3) 0.01
*
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3.3.5 Association of OGG1 mutations in female breast cancer patients with 
related hormonal receptors 
Frequency of OGG1 mutations was observed significantly higher in patients with 
invasive ductal carcinoma (p<0.0001), negative ER (p<0.001) and negative PR status 
(p<0.01). All observed OGG1 mutations were observed significantly correlated with 
tumor types (r = -0.333***; p<0.0001), ER status (r = 0.739**; p<0.001) and PR 
status (r = -0.155*; p<0.01) of breast cancer patients but a non-significant correlation 
was observed between all observed mutations and HER-2/neu Status (r = 0.318, 
p=0.12) of breast cancer patients. Correlation of OGG1 mutations with type of tumor 
and hormonal receptor status (ER/PR and HER-2/neu) of breast cancer patients is 
given in Table 3.13. 
3.3.6 Association of OGG1 mutations with family history and menopausal 
age in breast cancer patients 
OGG1 mutations observed in this study were also correlated with family history and 
menopausal age of breast cancer patients and control individuals. Frequency of 
patients with family history was observed significantly higher (p=0.04) compared to 
frequency of controls with family history (Table 3.1). Significantly higher frequency 
of one intronic mutation, g.9793680G>A (p<0.03), one splice site mutation 
g.9798502T>G (p<0.03) and one missense mutations Ser326Cys (p<0.009) was 
observed in patients with family history when compared with controls. Correlations 
between frequencies of OGG1 mutations and menopausal age of breast cancer 
patients (Table 3.14) revealed that the frequency of three intronic mutations 
(g.9792260 ins_T, p<0.04; g.9793680G>A, p<0.05 and g.9798349T>A, p<0.009) two 
splice site mutations (g.9800972T>G, p<0.03; g.9800972T>G, p<0.02), both 3´UTR 
mutations (g.9798848G>A and g.9798896T>C, p<0.02 ) and one missense mutation 
(Ser326Cys, p<0.03 ) were significantly higher in patients with early menopause 
(menopause at ≤50 years) when compared to controls and  patients with late 
menopausal  patients (menopause at >50 Years). Association of OGG1 mutations with 
family history and menopausal age in breast cancer patients is presented in Table 
3.14. 
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Table: 3.13 Correlation between OGG1 mutations and tumor types, ER/PR status and HER-2/neu status of breast cancer patients 
 
Mutations 
Type of Tumor ER Status PR Status HER-2/neu Status 
DCIS 
No. (%) 
IDC 
No. (%) 
ILC & 
others 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
g.9792260 insert_ T Intron 1 6(7.69) 24(11.11) 4(10.25) 20(9.57) 12(10.62) 28(13.66) 6(4.96)) 24(14.46) 9(7.44) 
g.9793680G>A Intron 3 (rs55846930) 9(11.54) 8(3.70) 2(5.13) 10(4.78) 9(7.96) 16(7.8) 2(1.65) 15(9.14) 4(3.3) 
g.9793748G>A Intron 3 8(10.25) 5(2.31) 1(2.56) 10(4.78) 4(3.35)) 5(2.43) 9(7.44) 7(4.27) 7(5.78) 
g.9798336T>G Intron 5 00 6(2.77) 4(10.25) 6(2.87) 3(2.65) 8(3.9) 2(1.65) 5(3.04) 4(3.3) 
g.9798349T>A Intron 5 8 (10.3) 21(9.72) 5(12.82) 18(8.61) 13(11.50) 21(10.24) 13(10.74) 16(9.76) 13(10.74) 
g.9792109delT Splice site Intron 1  4(5.13) 16(7.4) 6(15.38) 16(76.55) 10(10.62) 18(8.78) 8(6.61) 17(10.36) 12(9.91) 
g.9798307T>G Splice site Intron 5 6(7.69) 10(4.63) 00 9(4.30) 7(6.19) 09(4.39) 6(4.96) 8(4.87) 6(4.96) 
g.9798502T>G Splice site Intron 6 4(5.13) 11(5.09) 3(7.69) 16(76.55) 2(2.21)) 9(4.39) 9(7.44) 12(7.32) 6(4.96) 
g.9800972T>G Splice site intron 7a   3(3.85) 28(12.96) 1(2.56) 19(9.09) 13(11.50) 14(6.82) 16(13.22) 13(7.93) 16(13.22) 
g.9798848G>A 3' UTR 00 30(13.89) 3(7.69) 24(11.48) 13(11.50) 16(7.8) 13(10.74) 16(9.76) 8(6.61) 
g.9798896T>C 3' UTR 8(10.25) 17(4.63) 5(12.82) 29(13.87) 14(12.38) 11(5.36) 12(9.91) 15(9.14) 11(9.09) 
g.9793544T>G Exon 3, Val159Gly 4(5.13) 14(6.48) 00 12(5.65) 6(5.30) 16(7.8) 2(1.65) 3(1.83) 12(9.91) 
g.9796483G>A Exon 4, Gly221Arg 
(TMP_ESP_3_9796483 ) 
5(6.41) 14(6.48) 2(5.13) 15(7.18) 5(4.42) 10(4.87) 8(6.61) 7(4.27) 6(4.96) 
g.9798773C>G Exon 6d Ser326Cys 
(rs1052133) (CM993185) 
6(7.69) 15(6.94) 1(2.56) 12(5.65) 8(7.08) 19(9.27) 3(2.48) 6(3.66) 7(5.78) 
g.9807669G>A Exon 8 Trp375STOP 7(8.97) 4(1.85) 2(5.13) 9(4.30) 7(6.19) 5(2.28) 14(11.57) 7(4.27) 6(4.96) 
Correlation
a
         -0.333*** 0.739** -0.155* 0.318 
p-value
b
         0.0001               0.001 0.01 0.12 
aPearson correlation coefficient                                    bp value for χ2 test;                                              p<0.05 is considered statistically significant  
IDC invasive ductal carcinoma                                     DCI Ductal Carcinoma in Situ                             ILC  Invasive Lobular Carcinoma 
ER Estrogen Receptor,                                                 PR Progesterone Receptor,                                   HER-2/nue Human Epidermal Growth Factor Receptor 2 
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Table: 3.14 Association of OGG1 mutations with family history and menopausal age of breast cancer patients in present study 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test   * p<0.05;  OR= Odds Ratios;  CI = confidence interval
 
Mutations 
Family history of cancer Menopause at ≤50 years Menopause at  >50 years 
Patient 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
g.9792260 ins_T  Intron 1 8 (8.2) 02 (40) 3.0 (0.6 to 14.3), 0.1 17 (10.4) 4 (50.0) 3.2 (1.1 to 9.6), 0.04* 5 (10.9) 2 (25) 1.8 (0.3 to 9.4), 0.4 
g.9793680G>A  Intron 3   
(rs55846930) 
12 
(12.2) 
0 9.1 (1.2 to 70.5), 0.03* 11 (6.7) 0 8.2 (1.0 to 64.0), 0.05* 4 (8.7) 0 2.9 (0.3 to 26.1), 0.3 
g.9793748G>A Intron 3 5 (5.1) 0 3.7 (0.4 to 32.2),  0.2 10 (6.1) 0 7.4 (0.9 to 58.5), 0.06 4(8.7) 0 2.9 (0.3 to 26.1), 0.3 
g.9798336T>G Intron 5 6 (6.1) 01(20) 4.5 (0.5 to 37.6), 0.1 08 (4.9) 2 (25.0) 2.9 (0.6 to 13.9), 0.2 2 (4.3) 2 (25) 0.7 (0.1 to 5.1), 0.7 
g.9798349T>A Intron 5 6 (6.1) 01(20) 4.5 (0.5 to 37.6), 0.1 19 (11.7) 01(12.5) 14.6 (2 to 110.5), 0.009* 4(8.7) 1(12.5) 2.9 (0.3 to 26.1), 0.3 
g.9792109delT Splice site 
Intron 1  
4 (4.1) 0 3.0 (0.3 to 26.9), 0.3 13 (8.0) 0 9.8 (1.3 to 75.3), 0.03* 1(2.2) 0 0.7 (0.04 to 11.5), 0.8 
g.9798307T>G Splice site 
Intron 5 
2 (2.0) 0 1.5 (0.1 to 16.5), 0.7 06 (3.7) 0 4.4 (0.5 to 36.6), 0.2 4(8.7) 0 2.9 (0.3 to 26.1), 0.3 
g.9798502T>G Splice site 
Intron 6 
12 
(12.2) 
0 9.1 (1.2 to 70.5), 0.03* 06 (3.7) 0 4.4 (0.5 to 36.6), 0.2 3 (6.5) 0 2.2 (0.2 to 20.9), 0.5 
g.9800972T>G Splice site 
intron 7a   
0 0 00 16 (9.8) 0 12.2 (1.6 to 92.7), 0.02* 6 (13.0) 0 4.4 (0.5 to 36.6), 0.2 
g.9798848G>A 3' UTR 5(5.1) 0 3.7 (0.4 to 32.2),  0.2 14 (8.6) 0 10.6 (1.4 to 81.1), 0.02* 3 (6.5) 0 2.2 (0.2 to 20.9), 0.5 
g.9798896T>C 3' UTR 9 (9.2) 01(20) 6.8 (0.8 to 54.0), 0.07 16 (9.8) 01(12.5) 12.2 (1.6 to 92.7), 0.02* 3(6.5) 1(12.5) 2.2 (0.2 to 20.9), 0.5 
g.9793544T>G Exon 3, 
Val159Gly 
4 (4.1) 0 3.0 (0.3 to 26.9), 0.3 02 (1.2) 0 1.4 (0.1 to 15.9), 0.8 1 (2.2) 0 0.7 (0.04 to 11.5), 0.8 
g.9796483G>A Exon 4, 
Gly221Arg MP_ESP_3_9796483 
2 (2.0) 0 1.5 (0.1 to 16.5), 0.7 04 (2.5) 0 2.9 (0.3 to 26.1), 0.3 2(4.3) 0 1.4 (0.1 to 15.9), 0.8 
g.9798773C>G Exon 6d, 
Ser326Cys  
(rs1052133) (CM993185) 
19 
(19.4) 
0 14.6 (2.0 to 110), 0.009* 13 (8.0) 0 9.8 (1.3 to 75.3), 0.03* 3 (6.5) 0 2.2 (0.2 to 20.9), 0.5 
g.9807669G>A Exon 8 
Trp375STOP 
4 (4.1) 0 3.0 (0.3 to 26.9), 0.3 08 (4.9) 0 5.9 (0.7 to 47.5), 0.1 1 (2.2) 0 0.7 (0.04 to 11.5), 0.8 
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3.3.7 Distribution and association of OGG1 mutations with smoking status  
Observed OGG1 mutations were correlated with smoking status of patients and 
controls. A significant interaction was observed between smoking and OGG1 
mutations in breast cancer patients. Statistically significant difference was noted in 
smoker and non-smoker patients with splice site mutations (g.9792109delT, p<0.002 
and g.9800972T>G, p<0.03) and one missense mutation Ser326Cys (p<0.0001). when 
analysed, ~4 fold increased breast cancer risk was associated with splice site deletion 
g.9792109delT (OR= 3.67, 95 % CI = 1.6 to 8.3; p<0.002), ~2 fold increase with 
splice site substitution g.9800972T>G (OR= 2.19, 95 % CI = 1.07 to 4.48; p<0.03) 
and ~8 fold increased breast cancer risk was associated with missense mutation 
Ser326Cys (OR= 8.1, 95 % CI = 3.2 to 20.4; p<0.0001) in smoker patients when 
compared with nonsmokers. Similarly significant difference in mutation frequency 
and association of breast cancer risk was also observed in smoker and non-smoker 
patients having 3´UTR mutation g.9798848G>A (OR=0.3, 95 % CI = 0.1 to 0.88; p < 
0.03) and one intronic mutation g.9792260 ins_T (OR=0.34, 95 % CI = 0.12 to 1.0; p 
< 0.05). Association of OGG1 mutations with smoking status of breast cancer patients 
is presented in Table 3.15. 
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Table: 3. 15 Distribution and association of OGG1 mutations with smoking status  
in breast cancer patients 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test   
* p<0.05;  CI = confidence interval; OR= Odds Ratios 
MUTATION/ EXON 
Chr3(GRCh37) 
Patients 
Smokers 
(%) 
Non smokers 
(%) 
OR (95%CI), p
 
value 
g.9792260 ins_T  Intron 1 4 (4.6) 30 (12.4) 0.34 (0.12 to 1.0), 0.05* 
g.9793680G>A Intron 3   
(rs55846930) 
5 (5.7) 14 (5.8) 1.0 (0.35 to 2.84), 1.0 
g.9793748G>A Intron 3 1(1.1) 13 (5.4) 0.2 (0.03 to 1.59), 0.13 
g.9798336T>G Intron 5 2(2.3) 08 (3.3) 0.7 (0.14 to 3.31), 0.64 
g.9798349T>A Intron 5 5 (5.7) 29 (12.0) 0.45 (0.17 to 1.19), 0.1 
g.9792109delT Splice site 
 Intron 1  
14(16.1) 12 (5.0) 3.67 (1.6 to 8.3), 0.002* 
g.9798307T>G Splice site 
 Intron 5 
0 16 (6.6) 0.16 (0.1 to 1.26), 0.08 
g.9798502T>G Splice site 
 Intron 6 
2(2.3) 16 (6.6) 0.33 (0.07 to 1.48), 0.1 
g.9800972T>G Splice site 
 intron 7a   
15 (17.2) 21 (8.7) 2.19 (1.1 to 4.48), 0.03* 
g.9798848G>A 3' UTR 4 (4.6) 33 (7.8) 0.3 (0.1 to 0.88), 0.03* 
g.9798896T>C 3' UTR 09(10.3) 39 (16.1) 0.6 (0.28 to 1.3), 0.2 
g.9793544T>G Exon 3, 
 Val159Gly 
2(2.3) 16 (6.6) 0.3 (0.07 to 1.47), 0.15 
g.9796483G>A Exon 4, 
Gly221Arg (TMP_ESP_3_9796483) 
4 (4.6) 18 (7.4) 0.6 (0.2 to 1.8), 0.3 
g.9798773C>G Exon 6d 
, Ser326Cys (rs1052133)  
17(19.5) 07 (2.9) 8.1 (3.2 to 20.4),   0.0001* 
g.9807669G>A Exon 8 
 Trp375STOP 
3(3.4) 14(5.8) 0.6 (0.16 to 2.1), 0.4 
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3.4 SSCP and sequence analysis of XRCC1  
SSCP analysis of all seventeen exons of XRCC1 in 530 breast cancer patient and 395 
control samples was performed to screen for germline mutation. Analysis revealed an 
altered mobility pattern in almost all exons of XRCC1 in breast cancer patients and 
some of the control samples. Samples with an electrophoretic mobility shift by SSCP 
were selected as positive for XRCC1 mutations. Figure 3.10 shows the altered 
mobility patterns of XRCC1 of exons by SSCP. To confirm the findings of SSCP, 
direct DNA sequencing of samples showing altered mobility patterns was carried out 
to categorize the mutations, characterize the genotype and for specific location in the 
gene.  
3.4.1 Germline mutations in XRCC1  
Sequence analysis of all seventeen exons of XRCC1 along with exon-intron margins 
revealed a total of twenty five mutations in coding region and sixteen mutations in 
noncoding region of XRCC1. XRCC1 mutations in coding region include one non-
sense, thirteen missense, eight synonymous and three frameshift mutations, while 
mutations in noncoding region of XRCC1 include two 5´UTR, one 3´UTR, seven 
intronic and six splice site mutations. Among these, eleven mutations are known 
while thirty mutations are novel. Detailed description of observed XRCC1 mutations 
regarding their number, types and location in gene are presented in Table 3.16. 
Table 3.16: Mutations and their types detected in XRCC1  
Type of mutation Number of mutation Exon/Intron 
5´UTR substitution 2 5´UTR 
3´UTR substitution 1 3´UTR 
Intronic substitution/deletion 7 Intron 3, 5, 6, 7, 13, 15 
Splice site substitution 6 Intron 3, 5, 12, 15, 16 
Frameshift 3 Exon 5, 6, 16 
Missense 13 Exon 3, 6, 9, 14, 15, 16, 17 
Nonsense 1 Exon 4 
Synonymous 8 Exon 4, 7, 9, 11, 12, 14, 17 
 
  Results 
133 
 
 
 Figure 3.10: Electropherogram observed on EtBr stained 8% non-denaturing poly 
acrylamide gel after electrophoresis of samples followed by PCR-SSCP. Arrow indicate the 
mobility shifts and allelic pattern as a result of germline mutations in exon 2, 3, 6, 9, 14, 15 
and 17 of XRCC1 in breast cancer samples compared with control samples. ‘P’ refers to 
breast cancer patients samples and ‘C’ refers to control samples. 
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3.4.2 Mutations observed in non-coding regions of XRCC1 in breast cancer 
patients 
As presented in Table 3.16, sixteen different types of mutations were observed in non-
coding regions of XRCC1 (Figure 3.11 and 3.12). Among these, two mutations were 
observed in 5´UTR, one in 3´UTR, seven in intronic and six mutations in splice 
regions of different introns. Both mutations observed in 5´UTR region have already 
been reported (g.44079611G>A, rs2307187; g.44079687G>A, rs3213245).  Among 
these one mutation g.44079611G>A (rs2307187) was observed in promoter region of 
XRCC1. Similarly, only mutation observed in 3´UTR region (g.44047516G>T) has 
already been reported (rs2307172).  Seven mutations were observed in intronic 
sequence of XRCC1 (g.44065030C>G, g.44057715T>G, g.44057512C>T, 
g.44057108A>C, g.44050178delT, g.44048274A>C and g.44048270C>T). Among 
intronic mutations, one mutation is deletion mutation (g.44050178delT) in intron 13 
while remaining intronic mutations are all substitutions in intron 3, 5, 6, 7 and 15. All 
mutations detected in intronic regions are novel. Sequence analysis also revealed six 
mutations (g.44065060A>T, g.44057759A>T, g.44057667A>T, g.44050742C>T, 
g.44048294A>C and g.44047762delT) in splice site regions of XRCC1. One splice 
site mutation has already been reported while five mutations are novel. One of the 
splice site mutations is deletion mutation (g.44047762delT) observed 2 bps upstream 
in the donor splice site  causing destruction of expression of exon 16 whereas 
remaining five splice site mutations were substitution mutations. All splice site 
mutations were observed at 2-5 bp upstream or downstream in donor or acceptor 
splice sites (c.255+2T>A, c.489+2T>A, c.490-3T>A, c.1426+5G>A, c.1712+2T>G 
and c.1712+2T>G). Alamut bio software (version 2.4-5) predicted that skip of exon 3, 
5, 12, 15 and 16 is very likely due to these splice mutations Table 3.16. Changes 
observed as a result of mutations in non-coding region of XRCC1, at genomic DNA 
and resultantly at cDNA levels along with their possible consequences predicted by 
Alamut bio software (version 2.4-5) are mentioned in Table 3.17. 
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Table: 3.17 Mutations observed in 5´UTR, 3´UTR, intronic and splice site regions of 
XRCC1 in breast cancer patients and controls 
mutation type / 
Intron# 
Change in 
Genomic DNA 
reverse strand 
Chr19(GRCh37) 
Change in 
cDNA 
NM_006297.2 
Possible consequence predicted by 
Alamut bio software (version 2.4-5) 
Substitution / 
5' UTR (rs2307187) 
g.44079611G>A c.-1C>T 
The promoter region might be 
affected 
Substitution /  
5' UTR (rs3213245) 
g.44079687G>A c.-77C>T  
Substitution/ 3' UTR 
(rs2307172) 
g.44047516G>T c.1902+28C>A 3 prime UTR variant 
Splice site substitution/ 
Intron 3  
g.44065060A>T c.255+2T>A 
Alteration is in donor splice site 2bps 
upstream, skip of exon 3 is very likely 
Splice site 
substitution/Intron 5 
g.44057759A>T c.489+2T>A 
Alteration is in donor splice site 2bps 
upstream, skip of exon 5 is very likely 
Splice site substitution / 
Intron 5 (rs370495012) 
g.44057667A>T  c.490-3T>A 
Alteration is in acceptor splice site 
3bps downstream of exon 5  
Splice site substitution 
Intron 12 
g.44050742C>T c.1426+5G>A 
Alteration is in donor splice site 5bps 
upstream of exon 12 
Splice site substitution 
/Intron 15 
g.44048294A>C c.1712+2T>G 
Alteration is in donor splice site 2 bps 
upstream, skip of exon 15 is very likely 
Splice site substitution / 
Intron 16 
g.44047762delT c.1788+2delA 
Alteration is in donor splice site 2 bps 
upstream, skip of exon 16 is very likely 
Substitution/ intron 3 g.44065030C>G c.255+32G>C  
Substitution/ intron 5 g.44057715T>G c.489+46A>C  
Substitution/ intron 6 g.44057512C>T c.601+41G>A  
Substitution/ intron 7 g.44057108A>C c.711+26T>G  
Deletion/ intron 13 g.44050178delT c.1481+26delA  
Substitution/ intron 15 g.44048274A>C c.1712+22T>G  
Substitution/ intron 15 g.44048270C>T c.1712+26G>A  
 
rs = reference single nucleotide polymorphism (SNP) identifier;  Nomenclature of sequence variants 
follows the recommendations by the  Human Genome Variation Society (HGVS, 
http://www.hgvs.org/mutnomen/).  Novel sequence variants are classified as suggested by Plon et al 
(2008). 
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Figure 3.11: Sequencing electropherogram of germline polymorphisms in 5'UTR, 3'UTR and 
splice site regions of XRCC1 (changes are shown at genomic DNA level using reverse strand 
sequence Chr19 (GRCh37) as taken from Ensemble genome browser). A and B are 
substitutions in 5' UTR {(A) g.44079611G>A (rs2307187) substitution in 5' UTR (B) 
g.44079687G>A (rs3213245) substitution in 5' UTR}. (C)  g.44047516G>T (rs2307172) 
substitutions in 3' UTR. D, E, F, G, H and I are mutations in splice site region {(D) 
g.44065060A>T substitution  in splice site region of intron 3 (E) g.44057759A>T 
substitution in splice site region of intron 5 (F) g.44057667A>T (rs370495012) substitution 
in splice site region of intron 5 (G) g.44050742C>T substitution in splice site region of intron 
12 (H) g.44048294A>C substitution in splice site region of intron 15 and (I) g.44047762delT  
is deletion of T at splice site region of intron 16} 
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Figure 3.12: Sequencing electropherogram of germline mutations in intronic regions of 
XRCC1 (Changes are shown at Genomic DNA level using reverse strand sequence Chr19 
(GRCh37) as taken from Ensemble genome browser). J, K, L, M, N and O are mutations in 
intronic regions {(J) g.44065030C>G substitution in intron 3 (K) g.44057715T>G substitution 
in intron 5 (L) g.44057512C>T substitution in intron 6 (M) g.44050178delT is deletion of T in 
intron 13 (N) g.9798349 T>A substitution in Intron 5 (O) g.44048274A>C and g.44048270C>T 
are substitution in intron 15} 
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3.4.3 Frequency of mutations observed in non-coding regions of XRCC1 in 
breast cancer patients 
Frequency of XRCC1 mutations observed in noncoding regions of gene was found 
significantly higher in breast cancer patients compared to control individuals. 
Increased breast cancer risk was found associated with different mutations when 
compared with controls.  Frequency of one of the 5' UTR substitutions, 
g.44079611G>A (rs2307187) was found to be significantly high in breast cancer 
patients when compared with controls.  In case of intronic mutations, frequency of 
four mutations g.44065030C>G, g.44057512C>T,  g.44057108A>C, g.44050178delT  
was observed significantly higher in patients compared to control individuals, where 
~24-fold increase in  breast cancer risk was associated with intronic substitution g. 
44065030C>G (OR =24.47, 95 % CI = 3.33 to 180.1; p<0.002), ~21 fold increase 
with mutation g.44057512C>T (OR= 21.15, 95 % CI = 2.86 to 156.3; p<0.003), ~10 
fold increase with mutation g. g.44057108A>C (OR= 9.91, 95 % CI = 1.3 to 76.1; 
p<0.03) and ~11 fold increase with deletion mutation g.44050178delT (OR= 11., 95 
% CI = 47, 1.51 to 87.25; p-=0.02). In case of mutations in splice site regions, ~17 
fold increase in breast cancer risk was associated with splice site substitution  
g.44065060A>T (OR= 17.06, 95 % CI = 2.3 to 127.14; p<0.006 ), ~14 fold increase 
with g.44057759A>T (OR= 13.85, 95 % CI = 1.84 to 104.2; p<0.001) mutation, ~9 
fold increase with g.44057667A>T (OR= 9.13, 95 % CI = 1.18 to 70.5; p=0.03) 
mutation and ~6 fold increase with splice site deletion g.44047762delT G (OR= 6.19, 
95 % CI = 1.85 to 20.73; 0.003). These risks persisted even when data was adjusted 
for χ2 analysis and found statistically significant. XRCC1 mutations in non-coding 
regions and their allele frequencies in breast cancer patients are presented in Table 3.18. 
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Table: 3.18 Mutations and their allele frequencies observed in the non-coding regions of XRCC1 in 
breast cancer patients 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test   
* p<0.05;  CI = confidence interval 
MUTATION/ 
INTRON 
Chr3(GRCh37) 
reverse strand 
PATIENTS CONTROL 
 
ODDs RATIO 
(95% CI) 
 
P Value Number 
Allele frequency 
Minor/ Major 
Number 
Allele frequency 
Minor/ Major 
g.44079611G>A 
 5' UTR (rs2307187) 
16 G0.03/ A0.97 03 G0.008/ A0.992 4.1 (1.18 to 14.1) 0.03
*
 
g.44079687G>A  
5' UTR (rs3213245) 
19 G0.036/ A0.964 06 G0.015/ A0.985 2.41 (0.95 to 6.1) 0.06 
g.44047516G>T 
3' UTR (rs2307172) 
10 G0.02/ T0.98 13 G0.033/ T0.967 0.57 (0.25 to 1.3) 0.2 
g.44065060A>T 
Splice site intron 3 
22 A0.042/ T0.958 00 00 17.06 (2.3 to 127.1) 0.006
*
 
g.44057759A>T 
Splice site intron 5 
18 A0.034/ T0.967 00 00 13.85 (1.84 to 104.2) 0.001
*
 
g.44057667A>T 
(rs370495012) 
Splice site intron 5  
12 A0.023/ T0.977 00 00 9.13 (1.18 to 70.5) 0.03
*
 
g.44050742C>T 
Splice site intron 12 
06 C0.01/ T0.99 06 C0.015/ T0.985 0.74 (0.24 to 2.3) 0.6 
g.44048294A>C 
Splice site intron 15 
08 A0.015/ C0.985 06 A0.015/ C0.985 0.99 (0.34 to 2.9) 1.0 
g.44047762delT 
Splice site intron 16 
24 T0.045/ -0.955 03 T0.008/ -0.992 6.19 (1.85 to 20.7) 0.003
*
 
g.44065030C>G 
intron 3 
31 C0.058/ G0.942 00 00 24.47 (3.33 to 180.1) 0.002
*
 
g.44057715T>G 
intron 5 
11 T0.021/ G0.979 08 T0.02/ G0.98 1.02(0.41 to 2.6) 1.0 
g.44057512C>T 
intron 6 
27 C0.051/ T0.949 00 00 21.15 (2.86 to 156.3) 0.003
*
 
g.44057108A>C 
intron 7 
13 A0.025/ C0.975 00 00 9.91 (1.3 to 76.1) 0.03
*
 
g.44050178delT 
intron 13 
15 T0.028/ -0.972 00 00 11.47 (1.51 to 87.3) 0.02
*
 
g.44048274A>C 
intron 15 
18 A0.034/ C0.967 10 A0.025/ C0.975 1.35 (0.62 to 2.96) 0.45 
g.44048270C>T 
intron 15 
18 C0.034/ T0.967 10 C0.025/ T0.975 1.35 (0.62 to 2.96) 0.45 
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3.4.4 Synonymous mutations observed in XRCC1 in breast cancer patients and 
controls individuals 
Mutational screening of all seventeen exons of XRCC1 revealed eight synonymous mutations 
in different exons of gene (Figure 3.13). Among these, three mutations (g.44057227T>C, 
Pro206Pro, rs915927; g.44050028C>T, Glu521Glu, rs377436010 and g.44047550T>C, 
Gln632Gln, rs3547) has already been reported while remaining five mutations are novel 
(g.44058846C>T, Glu122Glu; g.44056258C>T, Gln331Gln; g.44051039C>T, Gln430Gln; 
g.44050826C>T, Gln449Gln and g.44047622A>G, Arg608Arg). Synonymous mutations 
were observed in exon 4, 7, 9, 11, 12, 14 (one in each exon) and exon 17 (two mutations).  
Change in codon sequence, position of amino acid and frequencies of altering codon in 
human genome are presented in Table 3.19. 
Table: 3.19 Synonymous mutations observed in XRCC1 in breast cancer patients  
Exon 
# 
Change at 
Genomic DNA 
(reverse strand) 
Chr19(GRCh37) 
Change at cDNA 
Level 
NM_006297.2 
Change of 
codon 
Amino acid/ Frequencies of 
altering codons in the human 
genome as reported by Alamut bio 
software (version 2.4-5) 
4 g.44058846C>T c.381G>A GAG to GAA 
p.Glu122Glu 
GAG (0.583) / GAA (0.417) 
7 
g.44057227T>C 
rs915927 
c.618A>G 
CCA to CCG p.Pro206Pro 
CCA (0.274) / CCG (0.115) 
9 g.44056258C>T c.993G>A 
CAG to CAA p.Gln331Gln 
CAG (0.744) / CAA (0.256) 
11 g.44051039C>T c.1290G>A 
CAG to CAA p.Gln430Gln 
CAG (0.744) / CAA (0.256) 
12 g.44050826C>T c.1347G>A 
CAG to CAA p.Gln449Gln 
CAG (0.744) / CAA (0.256) 
14 
g.44050028C>T 
rs377436010 
c.1563G>A 
GAG to GAA p.Glu521Glu 
GAG (0.583) / GAA (0.417) 
17 g.44047622A>G c.1824T>C 
CGT to CGC p.Arg608Arg 
CGT (0.082) / CGC (0.19) 
17 
g.44047550T>C 
rs3547 
c.1896A>G 
CAA to CAG p.Gln632Gln 
CAA (0.256) / CAG (0.744) 
rs = reference single nucleotide polymorphism (SNP) identifier;  Nomenclature of sequence variants follows the 
recommendations by the  Human Genome Variation Society (HGVS, http://www.hgvs.org/mutnomen/).  Novel 
sequence variants  are classified as suggested by Plon et al (2008). 
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Figure 3.13: Sequencing electropherogram of germline synonymous mutations in XRCC1 
(Changes are shown at Genomic DNA level using reverse strand sequence Chr19 (GRCh37) 
as taken from Ensemble genome browser). A, B, C, D, E, F, G and H are synonymous 
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mutations {(A) Synonymous mutation Glu122Glu showing g.44058846C>T substitution in 
exon 4 resulting in change of codon from GAG to GAA but again encoding amino acid 
Glutamic acid (B) Synonymous mutation Pro206Pro showing g.44057227T>C (rs915927) 
substitution in exon 7 resulting in change of codon from CCA to CCG but again encoding 
amino acid Proline (C) Synonymous mutation Gln331Gln showing g.44056258C>T 
substitution in exon 9 resulting in change of codon from CAG to CAA but again encoding 
amino acid Glutamine (D) Synonymous mutation Gln430Gln showing g.44051039C>T 
substitution in exon 11 resulting in change of codon from CAG to CAA but again encoding 
amino acid Glutamine (E) Synonymous mutation Gln449Gln showing g.44050826C>T 
substitution in exon 12 resulting in change of codon from CAG to CAA but again encoding 
amino acid Glutamine (F) Synonymous mutation Glu521Glu showing g.44050028C>T 
(rs377436010) substitution in exon 14 resulting in change of codon from GAG to GAA but 
again encoding amino acid Glutamic acid (G) Synonymous mutation Arg608Arg showing 
g.44047622A>G substitution in exon 17 resulting in change of codon from GAG to GAA but 
again encoding amino acid Arginine (H) Synonymous mutation Gln632Gln showing 
g.44047550T>C (rs3547) substitution in exon 17 resulting in change of codon from CAA to 
CAG but again encoding amino acid Glutamine} 
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3.4.5 Allele frequencies of synonymous mutations observed in XRCC1 in breast 
cancer patients 
Frequencies of synonymous mutations observed in XRCC1 were calculated in both breast 
cancer patients and control subjects. Increased breast cancer risk was found associated with 
different mutations when compared with controls (Table 3.17).  Frequency of the 
synonymous mutation, g.44057227T>C (rs915927) was found to be significantly high 
(0.003) in breast cancer patients when compared with controls and~20-fold increased breast 
cancer risk was associated with this mutation. Whereas other synonymous mutations were 
also found with higher frequencies in breast cancer patients compared with control 
individuals but differences were statistically non-significant.   
  
 
 
 
 
.   
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Table: 3.20 Allele frequencies of synonymous mutations observed in XRCC1 in breast 
cancer patients 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test   
*p<0.05; **p<0.01;  CI = confidence interval  No. =Nnumber
MUTATION/ 
EXON 
Chr3 (GRCh37) 
reverse strand 
PATIENTS CONTROL  
ODDs RATIO 
(95% CI) 
 
p value 
No. 
Allele frequency 
Minor/ Major 
No. 
Allele frequency 
Minor/ Major 
g.44058846C>T, 
Exon4 
19 C0.036/ T0.964 12 C0.03/ T0.97 1.2 (0.6 to 2.5) 0.6 
g.44057227T>C  
Exon7 (rs915927)   
26 T0.05/ C0.95 00 00 20.3 (2.74 to 150.4) 0.003
**
 
g.44056258C>T  
Exon9 
10 C0.019/ T0.981 06 C0.015/ T0.985 1.3 (0.45 to 3.5) 0.7 
g.44051039C>T  
Exon11 
14 C0.026/ T0.974 10 C0.025/ T0.975 1.0 (0.46 to 2.4) 0.9 
g.44050826C>T 
Exon 12 
09 C0.017/T0.983 13 C0.033/T0.967 0.5 (0.21 to 1.2) 0.1 
g.44050028C>T  
Exon 14 
(rs377436010) 
10 C0.019/ T0.981 02 C0.005/ T0.995 3.8 (0.82 to 17.3) 0.09 
g.44047622A>G 
Exon17 
32 A0.06/ G0.94 14 A0.035/G0.965 1.78 (0.9 to 3.32) 0.09 
g.44047550T>C 
Exon17  (rs3547) 
26 T0.05/ C0.95 12 T0.03/ C0.97 1.6 (0.82 to 3.3) 0.16 
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3.4.6 Missense, frameshift and non-sense mutations observed in XRCC1 in breast 
cancer patients 
Sequence analysis revealed seventeen different types of mutations in different coding regions 
of XRCC1 which alter the transcript and amino acid sequence including thirteen missense, 
three frameshift and one non-sense mutation (Figure 3.14). Among missense mutations, nine 
are novel (Gly61Ala, Val72Gly, Ala283Asp, Asp356Asn, Asn510Ser, Arg559Gly, 
Arg560Gly, Val629Gly, Val630Gly) and four mutations have already been reported 
(Asn183Ser, rs56357789; Arg194Trp, rs1799782; Arg280His, rs25489 and Tyr576Asn, 
rs2682557). Missense mutations were observed in different functionally important domains 
of XRCC1 protein. Three missense mutations (Gly61Ala, Val72Gly and Asn183Ser) were 
detected in N-terminal domain (NTD), three missense mutations (Arg194Trp, Arg280His and 
Ala283Asp), in nuclear localization signal (NLS) domain, two missense mutations 
(Asp356Asn and Asn510Ser) in BRCA1 carboxy terminal-I (BRCT-I) domain and five 
missense mutations (Arg559Gly, Arg560Gly, Tyr576Asn, Val629Gly and Val630Gly) in 
BRCA1 carboxy- terminal-II (BRCT-II) domain. 
 While screening the XRCC1 for mutations, three frameshift mutations (g.44057821delC, 
Gly143fs*1; g.44057611dupC, Ala182Argfs*29 and g.44047794dupA, Ala587Serfs*9) were 
also observed in different functionally important domains of XRCC1 protein. All of the 
observed frameshift mutations were novel. Two frameshift mutations (Gly143fs*1 and 
Ala182Argfs*29) were detected in nuclear localization signal (NLS) domain and one 
frameshift mutation (Ala587Serfs*9) in BRCA1 carboxy- terminal-II (BRCT-II) domain.  All 
frameshift mutations (Gly143fs*1, Ala182Argfs*29 and Ala587Serfs*9) severely affect the 
downstream reading frame which ends in STOP codon at 1, 28 and 8 position downstream 
respectively.  One non-sense mutation (g.44058837C>T, Trp125*) was also observed in 
mutational screening of XRCC1. Nonsense mutation was novel and is detected in nuclear 
localization signal (NLS) domain of XRCC1 protein. This nonsense mutation severely 
interrupts the downstream reading frame and results in truncation of protein prematurely at 
amino acid 125. Alamut bio software (version 2.4-5) predicted that mRNA produced as a 
result of frameshift and nonsense mutations might be targeted for nonsense mediated decay 
(NMD). Localization of mutations in different domains of coding region of XRCC1, changes 
observed at genomic DNA level, resultantly at cDNA levels and protein level along with their 
possible consequences predicted by Alamut bio software (version 2.4-5) are mentioned in 
Table 3.21. 
  Results 
146 
 
Table: 3.21 Missense, frameshift and nonsense mutations observed in XRCC1 in breast cancer patients   
Mutation type/ 
 Exon# 
Change in 
genomic DNA 
Chr19(GRCh37) 
(reverse strand) 
Change in 
cDNA  
NM_006297.2 
Codon change 
Change in Protein / Possible consequence 
predicted by Alamut bio software (version 2.4-5) 
Missense/Exon 3 g.44065135C>G 
c.182G>C 
GGG to GCG 
p.Gly61Ala 
Variation is in N-terminal domain (NTD)  
Missense/Exon 3 g.44065102A>C 
c.215T>G 
GTG to GGG 
p.Val72Gly 
Variation is in N-terminal domain (NTD) 
Missense/Exon 6 
 (rs56357789)  
g.44057606T>C c.548A>G 
AAC to AGC 
p.Asn183Ser 
Variation is in N-terminal domain (NTD)  
Missense/Exon 6 
 (rs1799782)  
g.44057574G>A 
c.580C>T 
CGG to TGG 
p.Arg194Trp, Variation is in nuclear localization 
signal (NLS) domain. 
Missense/Exon 9 
 (rs25489) 
g.44056412C>T c.839G>A 
CGT to CAT 
p.Arg280His, Variation is in nuclear localization 
signal (NLS) domain. 
Missense/Exon9 g.44056403G>T c.848C>A 
GCC to GAC 
p.Ala283Asp, Variation is in nuclear localization 
signal (NLS) domain.  
Missense/Exon 9 g.44056185C>T c.1066G>A 
GAC to AAC 
p.Asp356Asn, Variation is in BRCA1 carboxy 
terminal-I (BRCT-I) domain. 
Missense/Exon 14 g.44050062T>C c.1529A>G 
AAT to AGT 
p.Asn510Ser 
Missense/Exon 15 g.44048333G>C c.1675C>G 
CGG to GGG 
p.Arg559Gly, Variation is in BRCA1 carboxy- 
terminal-II (BRCT-II) domain. 
Missense/Exon 15 g.44048330G>C c.1678C>G 
CGG to GGG 
p.Arg560Gly, Variation is in BRCA1 carboxy- 
terminal-II (BRCT-II) domain  
Missense/Exon 16 
(rs2682557) 
g.44047826A>T c.1726T>A 
AAT to TAT 
p.Tyr576Asn, Variation is in BRCA1 carboxy- 
terminal-II (BRCT-II) domain  
Missense/Exon 17 g.44047560A>C c.1886T>G 
GTG to GGG 
p.Val629Gly, Variation is in BRCA1 carboxy - 
terminal-II (BRCT-II) domain  
Missense/Exon 17 g.44047557A>C c.1889T>G 
GTG to GGG 
p.Val630Gly, Variation is in BRCA1 carboxy - 
terminal-II (BRCT-II) domain  
Frameshift/  
Exon 5 
g.44057821delC c.429delG 
GGC fs..TGA 
p.Gly143fs*1, Reading frame ends in STOP 
codon one position downstream.  
Frameshift/ 
 Exon 6 
g.44057611dupC c.543dupG 
p.Ala182Argfs*29, Reading frame ends in STOP 
codon 28 positions downstream.  
Frameshift/  
 Exon 16 
g.44047794dupA c.1758dupT 
GCA to fs 
p.Ala587Serfs*9, Reading frame ends in STOP 
codon 8 positions downstream.  
Nonsense/ Exon4 g.44058837C>T c.375G>A  
TGG to TGA 
p.Trp125* Reading frame interrupted prematurely.  
Alamut bio software (version 2.4-5) predicted that mRNA produced as a result of frameshift and nonsense 
mutations might be a target for nonsense mediated decay (NMD); rs = reference single nucleotide 
polymorphism (SNP) identifier; Nomenclature of sequence variants follows the recommendations by the Human 
Genome Variation Society (HGVS, http://www.hgvs.org/mutnomen/). Novel sequence variants are classified as 
suggested by Plon et al (2008). HhH-GPD= hallmark helix-hairpin-helix and Gly/Pro rich loop domain 
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Figure 3.14 Sequencing electropherogram of germline missense mutations in XRCC1 
(changes are shown at genomic DNA level using reverse strand sequence Chr19 (GRCh37) 
as taken from Ensemble genome browser). A to K are missense mutations { (A) missense 
mutation Gly61Ala showing g.44065135C>G substitution in exon 3 resulting in change of 
codon from GGG to GCG encoding amino acid Alanine instead of Glycine (B) missense 
mutation Val72Gly showing g.44065102A>C substitution in exon 4 resulting in change 
codon from GTG to GGG encoding the amino acid Glycine instead of Valine (C) missense 
mutation Asn183Ser (rs56357789) showing g.44057606T>C substitution  in exon 6 resulting 
in change of codon from AAC to AGC encoding the amino acid Serine instead of Asparagine 
(D) missense mutation Arg194Trp (rs1799782) showing g.44057574G>A substitution  in 
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exon 6 resulting in change of codon from CGG to TGG encoding the amino acid Tryptophan 
instead of Arginine. (E) Missense mutation Arg280His (rs25489) showing g.44056412C>T 
substitution in exon 9 resulting in change of codon from CGT to CAT encoding the amino 
acid Histidine instead of Arginine. (F) Missense mutation Ala283Asp showing 
g.44056403G>T substitution in exon 9 resulting in change of codon from GCC to GAC 
encoding the amino acid Aspartic acid instead of Alanine. (G) Missense mutation Asp356Asn 
showing g.44056185C>T substitution in exon 9 resulting in change of codon from GAC to 
AAC encoding the amino acid Asparagine instead of Aspartic acid. (H) Missense mutation 
Asn510Ser showing g.44050062T>C substitution in exon 14 resulting in change of codon 
from AAT to AGT encoding the amino acid Serine instead of Asparagine. (I) Missense 
mutation Arg559Gly showing g.44048333G>C substitution in exon 15 resulting in change of 
codon from CGG to GGG encoding the amino acid Glycine instead of Arginine (J) Missense 
mutation Arg560Gly showing g.44048330G>C substitution in exon 15 resulting in change of 
codon from CGG to GGG encoding the amino acid Glycine instead of Arginine (K) Missense 
mutation Tyr576Asn (rs2682557) showing g.44047826A>T substitution in exon 16 resulting 
in change of codon from AAT to TAT encoding the amino acid Asparagine instead of 
Tyrosine (K) Missense mutations Val629Gly and Val630Gly showing g.44047560A>C  
g.44047557A>C substitutions respectively in exon 17 resulting in change of codon in both 
cases from GTG to GGG  encoding the amino acid Asparagine instead of Tyrosine in both 
cases. 
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Figure 3.15 Sequencing electropherogram of germline frameshift and non-sense 
mutations in XRCC1 (Changes are shown at Genomic DNA level using reverse strand 
sequence Chr19 (GRCh37) as taken from Ensemble genome browser). A, B and C are 
frameshift mutations {(A) Frameshift mutation Gly143fs*1 showing deletion of ″C″ 
nucleotide at position g.44057821delC in exon 5 resulting in frameshift and reading frame 
terminated in STOP codon TGA one position downstream of mutated codon GGC, hence 
truncation of protein instead of encoding amino acid Glycine. (B) Frameshift mutation 
Ala182Argfs*29 showing duplication of ″C″ nucleotide at position g.44057611dupC in exon 
6
th
 resulting in frameshift and reading frame terminated in a STOP codon at 28 position 
downstream of mutated codon, hence truncation of protein instead of encoding amino acid 
Alanine. (C) Frameshift mutation Ala587Serfs*9 showing duplication of ″A″ nucleotide at 
position g.44047794dupA in exon 16 resulting in frameshift and reading frame terminated in 
STOP codon at 8
th
 position downstream of mutated codon GCA, hence truncation of protein 
instead of encoding amino acid Glycine}. (D) Nonsense mutation Trp125* showing 
g.44058837C>T substitutions in exon 4 resulting in change of codon from TGG to TGA, 
hence reading frame is interrupted prematurely causing the truncation of protein instead of 
encoding the Tryptophan  amino acid at 125
th
 position. 
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3.4.7 Allele frequencies of missense, frameshift and nonsense mutations observed 
in XRCC1 in breast cancer patients and controls 
Frequencies of missense, frameshift and nonsense mutations in XRCC1 were found 
significantly different in breast cancer patients and control subjects. Increased breast cancer 
risk was found associated with different mutations when compared with controls (Table 
3.22). Analysis of  missense  mutations showing significant difference in frequency revealed 
that ~5-fold increase in  breast cancer risk was associated with Gly61Ala mutation (OR = 
4.86, 95 % CI = 1.43 to 16.53; p<0.001), ~31 fold increase with mutation Val72Gly (OR= 
31.29, 95 % CI =  4.28 to 228.8; p<0.0007),~5 fold increase with mutation Arg194Trp (OR= 
4.76, 95 % CI =  2.32 to 9.78; p<0.0001), ~10 fold increase with mutation Arg280His (OR= 
9.9, 95 % CI = 1.29 to 76.0; p<0.03), ~3 fold increase with mutation Arg559Gly (OR= 2.9, 
95 % CI = 1.0 to 7.83; p<0.03), ~15 fold increase with mutation Arg560Gly (OR= 14.65, 95 
% CI =(1.95 to 109.9; p<0.009)  and ~9 fold increase with mutation Tyr576Asn (OR= 9.13, 
95 % CI = 1.2 to 70.5; p<0.03 ). While analyzing frameshift mutations, a significantly 
increased breast cancer risk was also found associated with  two frameshift mutations when 
compared with controls showing ~12 fold increase with Ala182Argfs*29 mutation  (OR = 
12.26, 95 % CI = 1.6 to 92.8; p<0.01) and ~15 fold increase with  Ala587Serfs*9 mutation 
(OR = 15.45, 95 % CI = 2.0 to 115.63). These risks persisted even when data was adjusted 
for χ2 analysis and found statistically significant. 
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Table: 3.22     Allele frequencies of missense, frameshift and nonsense mutations observed in non-coding regions of 
XRCC1 in breast cancer patients and controls 
 p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test   
*
p<0.05;
 **
p<0.01;
 **
p<0.001;  CI = confidence interval;  No.= Number 
MUTATION 
Chr3(GRCh37) 
reverse strand 
PATIENTS CONTROL  
ODDs RATIO 
(95% CI) 
 
P Value No. 
Allele frequency 
Minor/ Major 
No. 
Allele frequency 
Minor/ Major 
g.44065135C>G,  
Gly61Ala 
19 C0.036/ G0.964 03 C0.008/ G0.992 4.86 (1.43 to 16.53) 0.001
***
 
g.44065102A>C   
Val72Gly 
39 A0.074/ C0.926 00 00 31.29 (4.28 to 228.8) 0.0007
***
 
g.44057606T>C   
Asn183Ser (rs56357789) 
08 T0.015/ C 0.985 00 00 6.04 (0.75 to 48.48) 0.09 
g.44057574G>A   
Arg194Trp  (rs1799782)  
53 G0.1/ A0.9 09 G0.023/ A0.978 4.76 (2.32 to 9.78) <0.0001
***
 
g.44056412C>T   
Arg280His  (rs25489)  
13 C0.025/ T0.975 00 00 9.9 (1.29 to 76.0) 0.03
*
 
g.44056403G>T   
Ala283Asp 
08 G0.015/ T0.985 00 00 6.04 (0.75 to 48.48) 0.09 
g.44056185C>T  
Asp356Asn 
10 C0.019/ T0.981 08 C0.02/ T0.98 0.93(0.36 to 2.38) 0.9 
g.44050062T>C  
Asn510Ser 
09 T0.017/ C0.983 06 T0.015/ C0.985 1.12 (0.39 to 3.17) 0.8 
g.44048333G>C  
Arg559Gly 
19 G0.036/ C0.964 05 G0.013/ C0.987 2.9 (1.0 to 7.83) 0.03
*
 
g.44048330G>C  
Arg560Gly 
19 G0.036/ C0.964 00 00 14.65(1.95 to 109.9) 0.009
**
 
g.44047826A>T  
Tyr576Asn (rs2682557) 
12 A0.023/ T0.977 00 00 9.13 (1.2 to 70.5) 0.03
*
 
g.44047560A>C  
Val629Gly 
17 A0.032/ C0.968 10 A0.025/ C0.975 1.3 (0.6 to 2.8) 0.5 
g.44047557A>C  
Val630Gly 
22 A0.042/ C0.958 08 A0.02/ C0.98 2.1 (0.9 to 4.75) 0.08 
g.44057821delC   
Gly143fs*1 
09 C0.017/ -0.983 00 00 6.8 (0.85 to 53.9) 0.07 
g.44057611dupC   
Ala182Argfs*29 
16 CC0.03/ C0.97 00 00 12.26 (1.6 to 92.8) 0.015
*
 
g.44047794dupA  
Ala587Serfs*9 
20 AA0.038/A0.962 00 00 15.45 (2.0 to 115.63) 0.008
**
 
g.44058837C>T 
Trp125* 
08 C0.015/ T0.985 00 00 6.04 (0.75 to 48.48) 0.09 
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3.4.8 In-silico predictions about missense mutations in XRCC1  
Missense, frameshift and nonsense mutations in XRCC1 were also analysed via 
Alamut biosoftware (version 2.4-5) which involves PhyloP scoring, SIFT scoring,  
Align GVGD scoring and Mutation Taster for multiple calculations and in-silico 
predictions.  PhyloP score provided information about conservation levels of mutated 
nucleotides and altered amino acids. PhyloP score was used in rating the nucleotides 
from ″not conserved″ (Phylo P score −14.1) to ″highly conserved″ (Phylo P score 
6.4).  
In case of first missense mutation (g.44065135C>G, Gly61Ala), moderately 
conserved nucleotide ″G″ was replaced by ″C″ (phyloP: 3.76) and codon GGG was 
changed to GCG replacing highly conserved amino acid Glycine to Alanine. In case 
of second missense mutation (g.44065102A>C, Val72Gly) a weekly conserved 
nucleotide ″T″ was replaced by ″G″ (phyloP: 1.66) and codon GTG was changed to 
GGG replacing amino acid Valine to Glycine. In third missense mutation 
(g.44057606T>C, Asn183Ser) non conserved nucleotide ″A″ was replaced by ″G″ 
(phyloP: -1.89) and codon AAC was changed to TGC replacing moderately conserved 
amino acid Asparagine to Serine. In fourth missense mutation (g.44057574G>A, 
Arg194Trp) weekly conserved nucleotide ″C″ was replaced by ″T″ (phyloP: -0.29) 
and codon CGG was changed to TGG replacing highly conserved amino acid 
Arginine to Tryptophan. In fifth missense mutation (g.44056412C>T, Arg280His) 
weekly conserved nucleotide ″G″ was replaced by ″A″ (phyloP: 0.04) and codon CGT 
was changed to CAT replacing moderately conserved amino acid Arginine to 
Histidine. In sixth missense mutation (g.44056403G>T, Ala283Asp) weekly 
conserved nucleotide ″C″ was replaced by ″A″ (phyloP: 1.98) and codon GCC was 
changed to GAC replacing moderately conserved amino acid Alanine to Aspartic 
acid. In seventh missense mutation (g.44056185C>T, Asp356Asn), moderately 
conserved nucleotide ″G″ was replaced by ″A″ (phyloP: 3.51) and codon GAC was 
changed to AAC replacing highly conserved amino acid Aspartic acid to Asparagine. 
In eighth missense mutation (g.44050062T>C, Asn510Ser), moderately conserved 
nucleotide ″A″ was replaced by ″G″ (phyloP: 3.84) and codon AAT was changed to 
AGT replacing moderately conserved amino acid Aspartic acid to Serine. In ninth 
(g.44048333G>C, Arg559Gly) and tenth (g.44048330G>C Arg560Gly) missense 
mutations weekly conserved nucleotide ″C″ was replaced by ″G″ (phyloP: 0.37) and 
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codon CGG was changed to GGG replacing moderately conserved amino acid 
Arginine to Glycine. In eleventh missense mutation (g.44047826A>T, Tyr576Asn) 
moderately conserved nucleotide ″A″ was replaced by ″T″ (phyloP: 2.22) and codon 
AAT was changed to TAT replacing moderately conserved amino acid Tyrosine to 
Aspartic acid. In twelveth (g.44047560A>C, Val629Gly) and thirteenth 
(g.44047557A>C, Val630Gly) missense mutations moderately conserved nucleotide 
″T″ was replaced by ″G″ (phyloP: 3.60) and codon GTG was changed to GGG 
replacing moderately conserved amino acid Valine to Glycine.  
Alamut software was also used for in-silico predictions of overall effects of 
mutations, physico-chemical alteration between normal and replaced amino acids and 
role in disease causing through Align GVGD score, Grantham distance; SIFT score 
and Mutation Taster. On the basis of SIFT score nine missense mutations (Gly61Ala, 
Val72Gly, Arg194Trp, Arg280His, Ala283Asp, Arg559Gly, Arg560Gly, Val629Gly, 
Val630Gly) were categorized as deleterious as presented in Table 3.22. Mutation 
taster predicted eight missense mutations (Gly61Ala, Val72Gly, Asp356Asn, 
Asn510Ser, Arg559Gly, Arg560Gly, Val629Gly and Val630Gly) as potentially 
disease causing (p-1.0). Grantham distance was used to determine the differences in 
physico-chemical structure of normal and replaced amino acids due to mutation and 
hence affecting overall protein structure. Physico-chemical differences between 
normal and mutated amino acids and other in-silico predictions about XRCC1 
missense mutations observed in this study are presented in Table 3.23.   
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Table: 3.23 Missense mutations observed in XRCC1 in breast cancer patients with conservation score, SIFT score, Align GVGD score, 
Grantham distance and Mutation Taster prediction  
Change in Nucleotide with its 
conservation level  (reverse strand) 
PhyloP score [−14.1;6.4] 
Change in 
Codon 
Amino acid change 
with its conservation 
level (considering 11 sp.) 
SIFT score 
(median) 
Align GVGD score 
(C0-C65) 
Grantham dist. 
[0-215] (physico-
chemical difference 
b/w amino acids)  
Mutation 
Taster 
(p- value) 
g.44065135C>G  
Moderately conserved; phyloP: 3.76  
GGG to GCG 
p.Gly61Ala 
Highly conserved a.a. 
Deleterious 
0.00 (3.52) 
C55 (GV: 0.00 - GD: 60.00) 60 (small) 
disease causing 
(p- 1.0) 
g.44065102A>C (rs25496) 
Weekly conserved; phyloP: 1.66 
GTG to GGG 
p.Val72Gly 
Highly conserved a.a. 
Deleterious 
0.00 (3.52) 
C0 (GV: 223.30 - GD: 50.17) 109 (Moderate) 
disease causing 
(p- 1.0) 
g.44057606T>C  (rs563577789) 
Not conserved; phyloP: -1.89 
AAC to AGC 
p.Asn183Ser 
Moderately conserved a.a. 
Tolerated 
0.59 (3.52) 
C0 (GV: 128.12 - GD: 0.00) 46 (small) 
polymorphism 
(p- 1.0) 
g.44057574G>A  (rs1799782) 
Weekly conserved; phyloP: 0.29 
CGG to TGG 
p.Arg194Trp 
Highly conserved a.a. 
Deleterious 
0.00 (3.52) 
C65 (GV: 0.00 - GD: 101.29) 101 (moderate) 
polymorphism 
(p- 0.0) 
g.44056412C>T (rs25489) 
Weakly conserved; phyloP: 0.04 
CGT to CAT 
p.Arg280His 
Moderately conserved a.a. 
Deleterious 
0.02 (3.53) 
C0 (GV: 243.69 - GD: 0.00) 29 (small) 
polymorphism 
(p- 1.0) 
g.44056403G>T 
Weakly conserved; phyloP: 1.98 
GCC to GAC 
p.Ala283Asp 
Moderately conserved a.a. 
Deleterious 
0.02 (3.53) 
C0 (GV: 221.66 - GD: 61.50) 126 (Moderate) 
polymorphism 
(p- 0.964) 
g.44056185C>T 
Moderately conserved; phyloP: 3.51 
GAC to AAC 
p.Asp356Asn 
Highly conserved a.a. 
Tolerated 
0.24 (3.53) 
C0 (GV: 222.77 - GD: 2.03) 23 (small) 
disease causing 
(p- 1.0) 
g.44050062T>C 
Moderately conserved; phyloP: 3.84 
AAT to AGT 
p.Asn510Ser 
Moderately conserved a.a. 
Tolerated 
0.25 (3.53) 
C0 (GV: 239.25 - GD: 33.99) 46 (small) 
disease causing 
(p- 0.608) 
g.44048333G>C 
Weakly conserved; phyloP: 0.37 
CGG to GGG 
p.Arg559Gly 
Moderately conserved a.a. 
Deleterious 
0.00 (4.32) 
C0 (GV: 353.86 - GD: 0.00) 125 (Moderate) 
disease causing 
(p- 0.998) 
g.44048330G>C 
Not conserved; phyloP: -0.04 
CGG to GGG 
p.Arg560Gly 
Moderately conserved a.a. 
Deleterious 
0.00 (4.32) 
C0 (GV: 353.86 - GD: 0.00) 125 (Moderate) 
disease causing 
(p- 0.998) 
g.44047826A>T (rs2682557) 
Moderately conserved; phyloP: 2.22 
AAT to TAT 
p.Tyr576Asn 
Moderately conserved a.a. 
Tolerated 
0.15 (4.32) 
C0 (GV: 353.86 - GD: 0.00) 143 (Large) 
polymorphism 
(p- 0.964) 
g.44047560A>C 
Moderately conserved; phyloP: 3.60 
GTG to GGG 
p.Val629Gly 
Moderately conserved a.a. 
Deleterious 
0.00 (4.32) 
C0 (GV: 353.86 - GD: 0.00) 109 (Moderate) 
disease causing 
(p- 1.0) 
g.44047557A>C  
Moderately conserved; phyloP: 3.60 
GTG to GGG 
p.Val630Gly 
Moderately conserved a.a. 
Deleterious 
0.00 (4.32) 
C0 (GV: 353.86 - GD: 0.00) 109 (Moderate) 
disease causing 
(p- 1.0) 
a.a= amino acid; PhyloP used for conservation score of nucleotides from ″not conserved″ (−14.1) to ″highly conserved″ (6.4) [Pollard et al., 2010). Align GVGD score: most 
likely deleterious (C65) to least likely deleterious (C0) GV (Grantham variation) and GD (Grantham deviation). The Grantham distance was used to evaluate physico-
chemical changes in amino acids (0= no physico-chemical changes; 215= large changes) [Grantham et al., 1974]. In-silico predictions were performed using PolyPhen-2 
(Polymorphism Phenotyping-2) [Adzhubei et al., 2010], SIFT (Sorting Intolerant From Tolerant) score: <0.05 deleterious, >0.05 tolerated [Kumar et al., 2009] and Mutation 
Taster: disease causing variants (p-value 1.0), might not be disease causing (p value <0.99) [Schwarz et al., 2010]  
  Results 
155 
 
3.4.9 Association of XRCC1 mutations in breast cancer patients with related 
hormonal receptors 
Frequency of XRCC1 mutations was observed significantly higher in patients with invasive 
ductal carcinoma (IDC) (p<0.00001), negative PR status (p<0.009) and negative ER 
(p<0.01). Frequency of XRCC1 mutations was also observed higher in patients with 
negative HER-2/neu status as compared to patients with positive HER-2/neu status but 
differences were non-significant (p=0.17). Observed XRCC1 mutations were found 
significantly correlated with IDC tumor type (r = 0.372***; p<0.00001), ER status (r = 
0.581*; p<0.01) and PR status (r = 0.171*; p<0.009) of breast cancer patients.  Correlation 
between HER-2/neu Status of breast cancer patients was observed non-significant (r = 
0.368, p=0.17). Correlation of XRCC1 mutations with type of tumor and hormonal receptor 
status (ER/PR and HER-2/neu) of breast cancer patients is presented in Table 3.24.   
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Table: 3.24 Correlation between XRCC1 mutations and tumor types, ER/PR status and HER-2/neu status in breast cancer patients 
Mutations 
Type of Tumor ER Status PR Status HER-2/neu Status 
DCIS 
No. (%) 
IDC 
No. (%) 
ILC 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
-ve 
No. (%) 
+ve 
No. (%) 
g.44079611G>A 5' UTR rs2307187 3 (4.23) 6 (2.94) 2 (5.56) 7 (3.83) 5 (4.55) 10 (5.24) 0 9 (5.96) 4 (3.48) 
g.44065060A>T Splice site intron 3 3 (4.23) 10 (4.9) 2 (5.56) 9 (4.92) 6 (5.45) 8 (4.19) 9 (7.56) 10 (6.62) 6 (5.22) 
g.44057759A>T Splice site intron 5 2 (2.82) 12 (5.88) 1 (2.78) 7 (3.83) 4 (3.64) 7 (3.66) 7 (5.88) 6 (3.97) 7 (6.09) 
g.44057667A>T Splice site intron 5 (rs370495012) 0 6 (2.94) 2 (5.56) 5 (2.73) 3 (2.73) 4 (2.09) 6 (5.04) 4 (2.65) 4 (3.48) 
g.44047762delT Splice site intron 16 2 (2.82) 10 (4.9) 4 (11.11) 11 (6.01) 4 (3.64) 10 (5.24) 9 (7.56) 9 (5.96) 6 (5.22) 
g.44065030C>G intron 3 4 (5.63) 15 (7.35) 3 (8.33) 14 (7.65) 8 (7.27) 12 (6.28) 9 (7.56) 11 (7.28) 10 (8.7) 
g.44057512C>T intron 6 4 (5.63) 12 (5.88) 2 (5.56) 10 (5.46) 10 (9.09) 6 (3.14) 10 (8.4) 16 (10.6) 3 (2.61) 
g.44057108A>C intron 7 1 (1.41) 8 (3.92) 0 6 (3.28) 5 (4.55) 5 (2.62) 6 (5.04) 5 (3.31) 3 (2.61) 
g.44050178delT intron 13 5 (7.04) 6 (2.94) 2 (5.56) 5 (2.73) 4 (3.64) 10 (5.24) 3 (2.52) 6 (3.97) 5 (4.35) 
g.44057227T>C  p.Pro206Pro rs915927 11 (15.49) 9 (4.41) 0 12 (6.56) 5 (4.55) 9 (4.71) 4 (3.36) 4 (2.65) 12 (10.43) 
g.44065135C>G  p.Gly61Ala 0 10 (4.9) 2 (5.56) 6 (3.28) 5 (4.55) 8 (4.19) 9 (7.56) 5 (3.31) 7 (6.09) 
g.44065102A>C  p.Val72Gly 8 (11.27) 19 (9.31) 2 (5.56) 10 (5.46) 13 (11.82) 22 (11.52) 12 (10.08) 12 (7.95) 7 (6.09) 
g.44057606T>C  p.Asn183Ser rs56357789/ 2 (2.82) 3 (1.47) 1 (2.78) 2 (1.09) 3 (2.73) 3 (1.57) 4 (3.36) 3 (1.99) 3 (2.61) 
g.44057574G>A p.Arg194Trp rs1799782 6 (8.45) 29(14.22) 2 (5.56) 26 (14.21) 14 (12.73) 13 (6.81) 11 (9.24) 23 (15.23) 10 (8.7) 
g.44056412C>T p.Arg280His rs25489  6 (8.45) 15 (7.35) 1 (2.78) 4 (2.19) 4 (3.64) 19 (9.95) 3 (2.52) 4 (2.65) 2 (1.74) 
g.44048333G>C  p.Arg559Gly 4 (5.63) 4 (1.96) 2 (5.56) 8 (4.37) 6 (5.45) 5 (2.62) 6 (5.04) 4 (2.65) 6 (5.22) 
g.44048330G>C   p.Arg560Gly 2 (2.82) 9 (4.41) 2 (5.56) 8 (4.37) 6 (5.45) 7 (3.66) 3 (2.52) 4 (2.65) 3 (2.61) 
g.44047826A>T p.Tyr576Asn rs2682557 0 9 (4.41) 2 (5.56) 10 (5.46) 0 10 (5.24) 0 3 (1.99) 2 (1.74) 
g.44057611dupC  p.Ala182Argfs*29 4 (5.63) 8 (3.92) 2 (5.56) 9 (4.92) 2 (1.82) 9 (4.71) 4 (3.36) 5 (3.31) 6 (5.22) 
g.44047794dupA  p.Ala587Serfs*9 4 (5.63) 4 (1.96) 2 (5.56) 14 (7.65) 3 (2.73) 14 (7.33) 4 (3.36) 8 (5.3) 9 (7.83) 
a
Pearson correlation coefficient                0.372*** 0.581* 0.171* 0.368 
bp value for χ2 test                0.00001                  0.01 0.009 0.17 
p<0.05 is considered statistically significant     IDC = invasive ductal carcinoma                   DCI = Ductal Carcinoma in Situ                           ILC = Invasive Lobular Carcinoma 
ER = Estrogen Receptor,                                   PR = Progesterone Receptor,                          HER-2/nue = Human Epidermal Growth Factor Receptor 2 
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3.4.10 Association of XRCC1 mutations with family history and 
menopausal age in breast cancer patients 
Association of observed XRCC1 mutations with family history and menopausal age of 
breast cancer patients and control were analysed as shown in Table 3.25. Analysis 
revealed a relatively higher frequency of XRCC1 mutations in patients with family 
history of cancer when compared with controls with family history of cancer but 
differences were found statistically non-significant. 
 Association of menopausal age of patients and controls with breast cancer risk was 
analysed (Table 3.26). Frequency of one intronic mutation (g.44065030C>G, p= 0.03) 
and one missense mutation (Val72Gly, p= 0.025) was significantly higher in patients 
with early menopause (menopause at ≤50 years) when compared to controls and 
patient with late menopause (menopause at >50 years). Whereas frequency of one 
synonymous mutation (Pro206Pro, p= 0.004) and one missense mutation (Arg194Trp, 
p= 0.01) was significantly higher in patients with late menopause (menopause at >50 
years) when compared to controls and patients with early menopause patients 
(menopause at ≤50 years).  
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Table: 3.25 XRCC1 mutations associated with family history of breast cancer 
patients in present study 
  p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test  
 
*
p<0.05;  CI = confidence interval;  OR= Odds Ratios  
Mutations 
Family history of cancer 
Patients 
(%) 
Control 
(%) 
OR (95%CI),  p-value 
g.44079611G>A 5' UTR  
rs2307187 
10 (10.2) 3 (15.8) 0.6 (0.15 to 2.45), 0.48 
g.44057667A>T Splice 
site intron 5 rs370495012 
10 (10.2) 0 2.0 (0.25 to 16.99), 0.51 
g.44047762delT 
Splice site intron 16 
08 (8.1) 3 (15.8) 0.47 (0.11 to 1.98), 0.31 
g.44057227T>C  
p.Pro206Pro rs915927 
13 (13.2) 0 3.0 (0.37 to 24.30), 0.30 
g.44065135C>G  
p.Gly61Ala 
2 (2) 2 (10.5) 0.17 (0.02 to 1.34), 0.09 
g.44057574G>A 
p.Arg194Trp rs1799782 
25 (25.4) 8 (42.1) 0.52 (0.19 to 1.44), 0.21 
g.44056412C>T 
p.Arg280His  rs25489  
07 (7.1) 0 1.38 (0.16 to 11.95), 0.77 
g.44048333G>C  
p.Arg559Gly 
3 (3.1) 2 (10.5) 0.27 (0.04 to 1.73), 0.17 
g.44047826A>T 
p.Tyr576Asn  rs2682557 
07 (7.1) 1 (5.3) 1.38 (0.16 to 11.95), 0.77 
g.44057611dupC  
p.Ala182Argfs*29 
08 (8.2) 0 1.6 (0.19 to 13.59), 0.67 
g.44047794dupA  
p.Ala587Serfs*9 
05 (5.1) 0 0.97 (0.11 to 8.78), 0.98 
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Table: 3.26 Association of XRCC1 mutations with menopausal age in breast cancer 
patients in present study 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test  
 
*
p<0.05; CI = confidence interval; OR= Odds Ratios  
Mutations 
Menopause at ≤50 years Menopause at  >50 years 
OR (95%CI), 
p-value 
Patients +  Control 
= Total 
%age 
Patients +  Control 
= Total 
%age 
g.44079611G>A  
5' UTR rs2307187 
6 +1= 7 7.9 2 +3= 5 6.3 
1.3 (0.39 to 4.21), 
0.68 
g.44057667A>T  
Splice site intron 5 
rs370495012 
4 +0 = 4 4.5 0 0 
3.7 (0.4 to 33.98), 
0.24 
 
g.44047762delT  
Splice site intron 16 
4 +0 = 4 4.5 5 + 3 = 8 10 
0.4 (0.12 to 1.46), 
0.17 
g.44065030C>G  
intron 3  
11 + 0 = 11 12.4 2 + 0 = 2 2.5 
5.5 (1.18 to 25.6), 
0.03* 
g.44057227T>C  
p.Pro206Pro 
rs915927 
2 +0 = 2 2.2 12 +2 = 14 17.5 
0.1 (0.02 to 0.5), 
0.004** 
g.44065135C>G  
p.Gly61Ala 
7+1 = 8 9.0 2 +1 = 3 3.8 
2.5 (0.65 to 9.9), 
0.18 
g.44065102A>C  
p.Val72Gly 
13 + 0 = 13 14.6 2 +1 = 3 3.8 
4.4 (1.2 to 16.0), 
0.025* 
g.44057574G>A 
p.Arg194Trp 
rs1799782 
8 + 3 = 11 12.4 16 + 7 = 23 28.8 
0.4 (0.16 to 0.8), 
0.01** 
g.44056412C>T 
p.Arg280His rs25489  
3 + 0 = 3 3.4 2 + 2 = 4 5.0 
0.7 (0.14 to 3.1), 
0.6 
g.44048333G>C  
p.Arg559Gly 
8 + 2 = 10 11.2 2 + 3 = 5 6.3 
1.9 (0.62 to 5.8), 
0.26 
g.44048330G>C   
p.Arg560Gly 
10 + 0 = 10 11.2 2 +1 = 3 3.8 
3.3 (0.86 to 12.3), 
0.08 
g.44057611dupC  
p.Ala182Argfs*29 
6 + 0 = 6 6.7 10 + 0 = 10 12.5 
0.5 (0.18 to 1.46), 
0.2 
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3.4.11 Distribution and association of XRCC1 mutations with smoking status  
Association of observed XRCC1 mutations with smoking status of patients and controls were 
also analysed and a significant interaction was observed between smoking status and 
missense mutations observed in XRCC1 in breast cancer patients. Asn183Ser, Arg194Trp and 
Tyr576Asn were with significantly higher frequency in smoker patients when compared with 
non-smoker patients. ~20 fold increased breast cancer risk was associated with missense 
substitution Asn183Ser (OR= 19.54, 95 % CI = 2.4 to 158.8; p =0.005), ~6 fold increase with 
missense substitution Arg194Trp (OR= 5.9, 95 % CI = 2.35 to 14.79; p=0.0002) and ~6 fold 
increased breast cancer risk with missense mutation Tyr576Asn (OR= 6.45, 95 % CI = 
1.67 to 24.93; p= 0.007) in patients with smoking history when compared with nonsmoker 
patients.  However, in case of other XRCC1 mutations, statistically non-significant (p<0.05) 
difference in mutation frequency and association with breast cancer risk was observed among 
smoker and non-smoker patients. Distribution and association of XRCC1 mutations with 
smoking status in breast cancer patients is presented in Table 3.27. 
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Table: 3.27 Distribution and association of XRCC1 mutations with smoking status in 
breast cancer patients 
p-values were computed from two-tailed student’s t-test and χ2 with Fisher exact test  
 
*
p<0.05; 
**
p<0.01; 
***
p<0.001;   CI = confidence interval;  OR= Odds Ratios  
MUTATION/ EXON 
Chr3(GRCh37) 
Patients (%) 
OR
 
 (95%CI), p
 
value 
Smokers Non-smokers 
g.44079611G>A  
5' UTR rs2307187 
2(2.3) 08 (4.1) 0.55 (0.11 to 2.63), 0.45 
g.44065060A>T  
Splice site intron 3 
5 (5.7) 10 (5.2) 1.12 (0.37 to 3.39), 0.20 
g.44057759A>T  
Splice site intron 5 
1(1.1) 07 (3.6) 0.31 (0.04 to 2.56), 0.28 
g.44057667A>T  
Splice site intron 5 (rs370495012) 
2(2.3) 6 (3.1) 0.74 (0.15 to 3.73), 0.71 
g.44047762delT  
Splice site intron 16 
4 (4.6) 12 (6.2) 0.73 (0.23 to 2.33), 0.6 
g.44065030C>G intron 3 4 (4.6) 16 (8.2) 0.54 (0.17 to 1.65), 0.28 
g.44057512C>T intron 6 2(2.3) 16 (8.2) 0.26 (0.06 to 1.16), 0.08 
g.44057108A>C  intron 7 0 4 (2.1) 0.55 (0.06 to 5.02), 0.6 
g.44050178delT intron 13 0 15 (7.7) 0.14 (0.02 to 1.07), 0.06 
p.Pro206Pro rs915927 4 (4.6) 9 (4.6) 0.99 (0.30 to 3.31), 0.99 
p.Gly61Ala 1 (1.1) 9 (4.6) 0.25 (0.03 to 1.96), 0.18 
p.Val72Gly 9 (10.3) 12 (6.2) 1.75 (0.71 to 4.32), 0.23 
p.Asn183Ser rs56357789 8 (9.2) 0 19.54(2.4 to 158.8), 0.005** 
p.Arg194Trp  rs1799782 17(19.5) 07 (3.6) 5.9 (2.35 to 14.79), 0.0002*** 
p.Arg280His rs25489  4 (4.6) 16 (8.2) 0.54 (0.17 to 1.65), 0.28 
p.Arg559Gly 4 (4.6) 15 (7.7) 0.57 (0.18 to 1.78), 0.34 
p.Arg560Gly 4 (4.6) 08 (4.1) 1.12 (0.33 to 3.82), 0.85 
p.Tyr576Asn  rs2682557 8(9.2) 3 (1.5) 6.45 (1.67 to 24.93), 0.007** 
p.Ala182Argfs*29 5 (5.7) 07 (3.6) 1.63 (0.5 to 5.28), 0.42 
p.Ala587Serfs*9 3(3.4) 14(7.2) 0.46 (0.13 to 1.64), 0.23 
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3.5 mRNA expression analyses of BER pathway genes  
3.5.1 Demographic and clinico-pathological characteristics of breast 
cancer patients from Pakistani population (cohort-2) 
Tumor samples were collected from different hospitals of Pakistan and were used for 
mRNA expression profiling of BER pathway genes and proliferation marker Ki-67. 
Quantitative real-time PCR was used for mRNA expressional analysis of selected 
BER pathway genes (APEX1, OGG1 and XRCC1). Observed mRNA expressional 
levels in breast tumor and control samples were also compared with clinico-
pathological parameters of patients. Mean age of patients was 47.64 years with a 
higher incidence of breast cancer (60.58 %) in patients aged above 40 years. Majority 
of patients were with invasive ductal carcinoma (53%), at stages III and IV (64%) and 
at histological grade 2 (38.46%). Patients were classified into different categories on 
the basis of the clinical outcome (prognosis and survival). Most of the patients were 
predicted with NPI-1 (50%) and were found free of relapse of cancer (58.65%). 
Demographic and clinico-histopathological characteristics of breast cancer patients in 
cohort-2 are presented in Table 3.28 and clinical outcome (prognosis and survival) of 
breast cancer patients after surgery and other therapies are presented in Table 3.29. 
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Table 3.28 Demographic and clinico-histopathological characteristics of breast cancer 
patients of study cohort-2 
Clinico-pathological information Patients (n=104) %age 
Mean Age in years (range)                             47.64 (18 - 80)  
≤40 years 41 38.2 
>40 years 63 60.58 
Age at menarche 
≤12 years 58 55.77 
>12 years 46 44.23 
Family History of cancer 
Yes 10 9.62 
No 94 90.38 
Site of breast tumor 
Unilateral Left 65 62.5 
Unilateral Right 36 34.6 
Bilateral 03 02.9 
Histological tumor type 
Ductal carcinoma in-situ (DCI) 24 23.08 
Invasive ductal carcinoma (IDC) 55 52.88 
Invasive lobular carcinoma (ILC) & others 25 24.04 
Histological grade 
Grade 1 (well differentiated) 27 25.96 
Grade 2 (moderately differentiated) 40 38.46 
Grade 3 (poorly differentiated) 37 35.58 
Clinical stage (C-stage) 
Stage I and II   12 + 25 = 37 35.58 
Stage III and IV  52 + 15 = 67 64.42 
Hormonal receptor status  
ER                    (+ve, -ve, ND) 33, 45, 26 32, 43, 25 
PR                    (+ve, -ve, ND) 38, 42, 24 37, 40, 23 
HER-2/neu       (+ve, -ve, ND)  41, 49, 14 39, 47, 14 
n=Total number of samples; ER= Estrogen Receptor; PR=Progesterone Receptor; 
HER-2/neu =Human Epidermal growth factor Receptor 2; ND= not determined 
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Table 3.29 Clinical outcome (prognosis and survival) after surgery of breast cancer 
patients of study cohort-2 
Clinical outcome Patients (n=104) %age 
Nottingham Prognostic Index (NPI) 
 NPI-1    (score < 3.4) 52 50.0 
 NPI-2    (score 3.4-5.4) 32 30.77 
 NPI-3    (score > 5.4) 20 19.23 
Clinical outcome (survival) 
Free of relapse (Surv-1) 61 58.65 
With metastasis (Surv-2) 06 5.77 
With local recurrence (Surv-3) 10 9.62 
Died (Surv-4)  
Died of breast cancer  13 12.5 
Died of related disease 09 8.65 
Unknown 05 4.81 
NPI-1 = good prognosis; NPI-2 = moderate prognosis; NPI-3= poor prognosis 
3.5.2 APEX1 mRNA levels in breast cancer patients (study cohort-2) 
APEX1 transcripts levels were quantified in breast tumor tissues and normal 
background (control) tissues and then normalized by GAPDH and β-Actin. Mean 
APEX1 transcript level in tumor tissues was observed higher when compared with 
normal control tissues, but the difference was statistically non-significant (p=0.32) 
(Figure 3.16A).  
3.5.2.1 Association of APEX1 transcript levels with tumor type and histological 
grade 
Significant differences were observed (p=0.002) when APEX1 transcripts levels were 
further assessed in different tumor types of breast cancer. Significantly higher APEX1 
transcript levels (p=0.013) were observed only in ductal carcinoma in situ (DCI) 
compared to control tissues whereas decreased APEX1 transcript levels were found in 
invasive lobular carcinoma (ILC) and others tumor types when compared to both 
control and invasive ductal carcinoma (IDC) but the difference was non-significant 
(p=0.69) (Figure 3.16B). Association of APEX1 transcript levels with different 
histological grades of breast tumor was also analysed and an increased APEXI 
transcript levels were observed in advanced tumor grades. Significantly higher 
  Results 
165 
 
APEX1 transcript levels (p<0.05) were found in grade-3 when compared with initial 
grades (Figure 3.16C).  
3.5.2.2 Association of APEX1 transcript levels with clinical stage of tumor and 
hormonal receptors of patients 
Significantly higher APEXI transcript levels were observed in advanced clinical 
stages of tumor (p=0.01). Significantly increased APEX1 transcript levels (p= 0.052) 
were observed in advanced stages (stage III and IV together) when compared with 
earlier stages (stage I and II together) (Figure 3.16D). When APEX1 mRNA 
expression was analysed in breast tumor samples with reference to different hormonal 
receptors (ER, PR and HER-2/neu), deregulation in APEX1 transcript levels was 
noted and a significantly higher APEX1 transcript levels (p= 0.048) were observed in 
patients with ER–ve status when compared with  patients having ER+ve status. 
Increased APEX1 mRNA expression was observed in PR+ve and HER-2/neu+ve 
patients when compared with PR-ve and HER-2/neu-ve patients, respectively, but the 
differences were statistically non-significant (Figure 3.16E). 
3.5.2.3 Association of APEX1 transcript levels with NPI and Survival status 
Values of Nottingham prognostic index (NPI) were calculated to determine prognosis 
of patients after surgery and other breast cancer therapies. Patients with NPI value 
<3.4 were classified as NPI-1(good prognosis), with NPI value 3.4-5.4 were classified 
as NPI-2 (moderate prognosis) and with NPI value >5.4 were classified as NPI-3 
(poor prognosis). Down regulation in APEX1 mRNA expression was observed in 
patients with higher NPI values, showing lowest levels of APEX1 transcript in 
patients with poor prognosis (NPI-3) amongst all three groups (p=0.27) (Figure 
3.16F). As per clinical outcome recorded at final follow up, patients were divided into 
four categories i.e. Surv-1 (free of relapse), Surv-2 (with metastasis), Surv-3 (with 
local recurrence) and Surv-4 (died of breast cancer or related diseases). Overall 
significant differences (p=0.0003) were observed in transcript levels of APEX1 among 
different groups (control, Surv-1 to 4). However, partially significant differences were 
observed when APEX1 transcript levels of each group were independently compared 
with each other. APEX1 mRNA expression was observed significantly higher 
(p=0.0002) in free of relapse patients (Surv-1) compared to controls but observed 
significantly lower (p=0.043) in died patients (Surv-4) when compared with free of 
relapse patients (Surv-1). Decreased APEX1 transcript levels were also observed in 
  Results 
166 
 
patients with metastasis and local recurrence (Surv-2 and 3) compared to controls and 
free of relapse patients (Surv-1) but the differences were statistically non-significant 
(Figure 3.16G). p-values were computed using student’s t-test and one-way ANOVA. 
 
Figure 3.16A Quantitative analysis of APEX1 transcript levels in control and tumor 
tissues 
 
 
Figure 3.16B Quantitative analysis of APEX1 transcript levels in breast cancer tissues 
according to different histological tumor types 
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
1.00E+12
Control Tumor
R
el
at
iv
e 
A
P
E
X
1
 e
x
p
re
ss
io
n
 
log.  scale base 10 
1.00E+00
1.00E+01
1.00E+02
1.00E+03
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
1.00E+12
1.00E+13
Control DCI IDC ILC and Others
R
el
at
iv
e 
A
P
E
X
1
 e
x
p
re
ss
io
n
 
  Results 
167 
 
 
Figure 3.16C Quantitative analysis of APEX1 transcript levels in breast cancer tissues 
with reference to different histological grades 
 
 
 
Figure 3.16D Quantitative analysis of APEX1 transcript levels in case of different 
clinical stages tumor 
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Figure 3.16E Quantitative analysis of APEX1 transcript levels with reference to 
different hormonal receptors (ER, PR and HER-2/neu) showing 
deregulation in APEX1 transcript levels 
 
 
 
Figure 3.16F Quantitative analysis of APEX1 transcript levels on the basis of NPI 
values  
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Figure 3.16G Quantitative analysis of APEX1 transcript levels with reference to 
clinical outcome of patients 
3.5.3 OGG1 mRNA levels in breast cancer patients (cohort-2) 
OGG1 transcripts levels were quantified in breast tumor tissues and background 
(normal) control tissues and normalized by GAPDH and β-Actin. Mean OGG1 
transcript level in breast tumor tissues was observed significantly lower (p=0.037) 
when compared with background normal tissues (Figure 3.17A). 
3.5.3.1 Association of OGG1 transcript level with tumor type and tumor grade 
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grade-2 tumors (p=0.01) and grade-3 tumors (p=0.015) independently. OGG1 
transcript levels were observed lower in tumors of all grades when compared with 
control but differences were not significant (grade-1, p=0.56; grade-2, p=0.13 and 
grade-3, p=0.15) (Figure3.17C). Similarly significantly decreased OGGI transcript 
levels were observed in advanced clinical stages showing lowest value in stage-IV 
tumors when compared with tumors of other stages and control samples (p <0.0001). 
Decrease in OGG1 transcript levels was observed significantly lower in tumors of 
stage-II (p=0.01), stage-III (p<0.0001) and stage-IV (p=0.004) when compared 
independently with stage-I as shown in Figure 3.17C. 
3.5.3.2 Association of OGG1 transcript levels with clinical stage and hormonal 
status of breast cancer patients  
Decrease in OGG1 transcript levels were found significantly lower (p=0.007) in 
advanced stages (III and IV together) when compared with initial stages (I and II 
together) and with control samples (p= 0.05) (Figure 3.17D). When OGG1 mRNA 
expression in breast tumor samples was analysed with reference to different hormonal 
receptors (ER, PR and HER-2/neu), deregulation in OGG1 transcript levels was 
observed but the differences were non-significant. OGG1 transcript levels were 
observed higher in ER+ve patients (p=0.07), PR-ve patients (p=0.6) and HER-2/neu-
ve patients (p=0.23) compared with ER–ve patients, PR+ve patients and HER-
2/neu+ve patients, respectively (Figure 3.17E). 
3.5.3.3 Association of OGG1 transcript level with NPI and survival status 
Nottingham prognostic index (NPI) values were calculated to determine prognosis of 
patients after surgery and other breast cancer therapies. Down regulation in OGG1 
mRNA expression was observed in patients with higher NPI values showing greater 
decrease in OGG1 transcript levels in patients with NPI-3 (poor prognosis) amongst 
all three groups (p=0.14). Significantly lower OGG1 transcript levels were observed 
in patients with poor prognosis (NPI-3) (p=0.043) compared to patients with moderate 
prognosis (NPI-2). Significant decrease in OGG1 transcript levels (p=0.048) were 
observed significant when patients with moderate and poor prognosis (NPI-2 + NPI-3 
together) were compared to patients with good prognosis (NPI-1) (Figure 3.17F).  
As per clinical outcome recorded at final follow up, patients were divided into four 
categories i.e. Surv-1, Surv-2, Surv-3 and Surv-4. Significant differences were 
observed in transcript levels of OGG1 among different patient groups (Surv-1 to 4) 
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and control samples. When analysed, significant decrease in OGG1 transcript levels 
were observed in patients with poor survival (Surv-2 to 4) (p= 0.001). OGG1 
transcript levels were also observed significantly lower in patients, who died due to 
breast cancer (Surv-4) as compared to patients with metastasis (Surv-2) (p=0.0002) 
and patient with local recurrence (Surv-3) (p=0.04)  as shown in Figure 3. 17G.  
  
Figure 3.17A Quantitative analysis of OGG1 transcript levels in control and tumor 
tissues 
 
Figure 3.17B Quantitative analysis of OGG1 transcript levels in breast cancer tissues 
according to different histological tumor types  
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Figure 3.17C Quantitative analysis of OGG1 transcript levels in breast cancer tissues 
with reference to different histological grades  
 
 
Figure 3.17D Quantitative analysis of OGG1 transcript levels in case of different 
clinical stage tumors 
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Figure 3.17E Quantitative analysis of OGG1 transcript levels in tumors with 
reference to different hormonal receptors (ER, PR and HER-2/neu) 
 
 
Figure 3.17F Quantitative analysis of OGG1 transcript levels on the basis of NPI 
value of each patient divided in good, moderate and poor prognosis  
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Figure 3.17G Quantitative analysis of OGG1 transcript levels according to clinical 
outcome after final follow up of patients 
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down regulation of XRCC1 mRNA expression was observed in advanced grade 
tumors (2+3 together) when compared to initial tumors of grade-1. Difference was not 
significant when grade-1 was independently compared with grade-2 (p=0.06) and 
grade-3 (p=0.20), similarly non-significant differences were observed when grade-2 
was compared with grade-3 (p=0.28) and grade-1+2 (together) were compared with 
advanced grade-3 (p=0.27). XRCC1 transcript levels were lower in all tumors of all 
grades when compared with controls but the differences were statistically non-
significant (Figure 3.18C).  
3.5.4.2 Association of XRCC1 transcript level with clinical stage and hormonal 
status of breast cancer patients 
While analyzing XRCC1 mRNA expression with reference to clinical stages of tumors 
trend of gradual decrease in XRCCI transcript levels was observed in successive 
advanced clinical stages when compared among each other (p=0.0005) and with 
control samples. Significantly decreased XRCC1 transcript levels were observed in 
advanced stages (III +IV together) when compared with initial stages (I + II together) 
(p=0.05). Similarly significantly decreased XRCC1 transcript levels were observed in 
stage-IV (P=0.02) compared to control samples. Significantly decreased in XRCC1 
transcript level was observed in stage-II (p=0.001) and stage-III (p=0.007) when 
compared independently with initial stage-I (Figure 3.18D). When XRCC1 mRNA 
expression in breast tumor samples was analysed with reference to different hormonal 
receptors (ER, PR and HER-2/neu), deregulation in XRCC1 transcript levels was 
observed but differences were statistically non-significant. Decrease in XRCC1 
transcript levels were observed in patients with ER+ve, PR+ve and HER-2/neu+ve 
status when compared with the patients with ER–ve (p=0.21), PR-ve (p=0.31) and 
HER-2/neu-ve (p=0.35) patients respectively (Figure 3.18E).  
3.5.4.3 Association of XRCC1 transcript level with NPI and Survival status 
Nottingham prognostic index (NPI) values were calculated to determine prognosis of 
patients after surgery and other breast cancer therapies. Patients with NPI value <3.4 
were classified as NPI-1(good prognosis), with NPI value 3.4-5.4 were classified as 
NPI-2 (moderate prognosis) and with NPI value >5.4 were classified as NPI-3 (poor 
prognosis). Down regulation in XRCC1 mRNA expression was observed in patients 
with successive higher NPI values showing higher decrease in XRCC1 transcript 
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levels in patients with NPI-3 (poor prognosis) amongst all three groups (p=0.3). 
Significantly decreased XRCC1 transcript level (p=0.028) was observed in patients 
with poor prognosis (NPI-3) when compared with patients with moderate prognosis 
(NPI-2). Decreased XRCC1 transcript levels were observed in patients with moderate 
prognosis and poor prognosis when compared with the XRCC1 transcript levels of 
patients with good prognosis (NPI-1) and control samples but differences were 
statistically non-significant (Figure 3.18F). 
On the basis of clinical outcome recorded at final follow up, patients were divided 
into four categories i.e. Surv-1 (free of relapse), Surv-2 (with metastasis), Surv-3 
(with local recurrence) and Surv-4 (died of breast cancer or related diseases). 
Significant differences were observed in transcript levels of XRCC1 among different 
patient groups (Surv-1 to 4) and control samples. There was decrease in XRCC1 
transcript levels in patient groups with poor survival (Surv-2 to 4) (p=0.001) as 
compared to those patients who were free of relapse (Surv-1). Significantly decreased 
XRCC1 transcript levels were observed in patients who were died due to breast cancer 
or other related diseases (Surv-4) as compared to patients with metastasis (Surv-2) 
(p=0.002) and patient with local recurrence (Surv-3) (p=0.002). Decrease in XRCC1 
transcript level was also significant (p=0.04) in patients with local recurrence (Surv-3) 
compared to those with metastasis (Surv-2) as shown in Figure 3.18G.  
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Figure 3.18B Quantitative analysis of XRCC1 transcript levels in breast 
 tissues of different histological tumor types  
 
 
Figure 3.18C Quantitative analysis of XRCC1 transcript levels in breast cancer 
tissues of different histological grades 
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Figure 3.18D Quantitative analysis of XRCC1 transcript levels different clinical stage 
tumors 
 
Figure 3.18E Quantitative analysis of XRCC1 transcript levels in tumors with 
different hormonal receptors (ER, PR and HER-2/neu) showing 
deregulation in OGG1 transcript levels 
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Figure 3.18F Quantitative analysis of XRCC1 transcript on the basis NPI values 
  
 
Figure 3.18G Quantitative analysis of XRCC1 transcript levels according to clinical 
outcome after final follow up of patients 
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3.5.5 Ki-67 mRNA levels in breast cancer patients  
When analysed, Ki-67 expression was significantly (p<0.05) higher in breast tumor 
tissues compared to non-cancerous tissues used as controls (Figure 3.19A). The 
expression level of Ki-67 was significantly (p<0.05) higher in late-stage tumors (III-
IV) compared to early-stage tumors (I–II) as shown in Figure 3.19B. Similar trend in 
Ki-67 expression was also observed in larger (T3-T4, p<0.04) tumor tissues as 
compared to smaller (T1–T2) tumors as shown in Figure 3.19D. Statistically 
significant (p<0.01) increase in Ki-67 mRNA level was observed in the tissues with 
positive lymph node status (N3) as compared to those with N0-N2 lymph node status 
as shown in Figure 3.19E. Difference in Ki-67 mRNA expression of poorly and well 
developed tumors was non-significant as shown in Figure 3.19C. Similarly, difference 
in Ki-67 transcript levels in breast cancer patients with different metastatic stages was 
also non-significant (Figure 3.19F). 
 
 
Figure 3.19A Quantitative analysis of Ki-67 transcript levels in control and breast 
tumor tissues  
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Figure 3.19B Quantitative analysis of Ki-67 transcript levels in breast cancer patients 
with reference to different clinical stages 
*P<0.05 
 
 
Figure 3.19C Quantitative analysis of Ki-67 transcript levels in different tumor 
grades of breast cancer  
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Figure 3.19D Quantitative analysis of Ki-67 transcript levels in breast cancer patients 
with different tumor stages 
**P<0.01 
 
 
Figure 3.19E Quantitative analysis of Ki-67 transcript levels in breast cancer patients 
with reference to lymph node metastasis  
**P<0.01 
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Figure 3.19F Quantitative analysis of Ki-67 transcript levels in breast cancer patients 
with different metastatic stages 
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3.6 Demographic and clinico-pathological characteristics of breast cancer 
patients from British population (cohort-3) 
Breast tumor tissues samples (n = 111) along with normal back ground (control) 
tissues were collected immediately after surgery from patients of British population 
(Study Cohort-3). Tumors were stored in RNA later at −80°C till they were used for 
mRNA expressional profiling of selected BER pathway genes. Demographic 
characteristics of study cohort showed that female patients recruited in this cohort-3 
belonged to a wide range of age group (22 – 84 years) with a mean age of 49.33 years. 
Incidence of breast cancer was observed higher (63.11 %) in patients aged >40 years. 
For the presence of tumor cells, histological grading and staging of collected tissues 
was performed and verified by a consultant pathologist by examination of frozen 
sections stained following H and E staining.  
 
Clinico-histopathological findings of study cohort-3 revealed that 76.58% of the 
patient samples were diagnosed with ductal tumor types (DCI and IDC), 10% of 
patients was with lobular carcinoma, 3% of patients were with muscin type of tumors, 
1.8% of patients were with medullary tumors and 7.21% of patients were with tubular 
and other carcinomas as shown in Table 3.30. In case of TNM staging, majority of 
tumors (88.29%) were at initial TNM stages (TNM1 and TNM2) while only 11.71% 
1of tumors were at advanced TNM stages (TNM3 and TNM4). On the basis of 
histological grading, most of the breast cancer patients had advanced grade tumors, 
comprising of 49.55% with grade-3, 33.33% with grade 2 and only 17.12% with early 
grade-1 tumors.  Majority of patients were diagnosed negative for different hormonal 
receptors including ER –ve (59 %) and HER-2/neu –ve (73%), compared to those 
which were positive for respective hormonal receptors ER +ve (31%) and HER-2/neu 
+ve (20%).  Demographic and Clinico-histopathological characteristics of breast 
cancer patients in study cohort-3 from British population are presented in Table 3.30.  
3.6.1 Clinical outcome (prognosis and survival) of breast cancer 
patients from British population (study cohort-3) 
After surgery and different therapies, patients were classified into different categories 
on the basis of the clinical outcome (prognosis and survival). Patients were classified 
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in three groups on the basis of their predicted prognosis i.e. NPI-1 (good prognosis), 
NPI-2 (moderate prognosis) and NPI-3 (poor prognosis) by calculating Nottingham 
Prognostic Index (NPI) values.  Most of the patients (52.25%) belonged to NPI-1 
whereas 34.24% were categorised as NPI-2 and 13.51% as NPI-3. To get information 
regarding survival after surgery, patients were routinely followed where median 
follow-up period was 120 months. As per clinical outcome recorded at final follow 
up, patients were divided into four categories i.e. Surv-1 (free of relapse), Surv-2 
(with metastasis), Surv-3 (with local recurrence) and Surv-4 (died of breast cancer or 
related diseases). 70.27% patients of this study cohort were free of relapse, 6.31% 
were with metastatic cancer and 4.5% were with local recurrence of cancer. Whereas 
17.12% of patients had died, of which 12.62% died of breast cancer and 4.5% expired 
due to other non-cancerous disease. Clinical outcome (prognosis and survival) after 
surgery of breast cancer patients in cohort-3 from British population are presented in 
Table 3.31. 
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Table 3.30 Demographic and clinico-histopathological characteristics of breast  
cancer patients from British population (Study cohort-3) 
Clinico-pathological information Patients (n=111) %age 
Histological tumor type 
Ductal 85 76.58 
Lobular 12 10.81 
Muscin 04 3.60 
Medullary 02 1.80 
Tubular 01 0.90 
Others 07 6.31 
Histological grade 
Grade 1 (well differentiated) 19 17.12 
Grade 2 (moderately differentiated) 37 33.33 
Grade 3 (poorly differentiated) 55 49.55 
TNM staging 
TNM 1 62 55.86 
TNM2 36 32.43 
TNM3 9 8.11 
TNM4 4 3.6 
Hormonal receptor status 
ER                     (+ve, -ve, ND) 35, 65, 11 31, 59, 10 
HER-2/neu        (+ve, -ve, ND) 22, 81, 08 20, 73, 07 
n=Total number of samples; ER= Estrogen Receptor; PR=Progesterone Receptor; 
HER-2/neu =Human Epidermal growth factor Receptor 2; ND= not determined 
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Table: 3.31 Clinical outcomes (prognosis and survival) after surgery of breast cancer 
patients from British population (Study cohort-3) 
Clinical outcome (prognosis and survival) Patients (n=111) %age 
Nottingham Prognostic Index (NPI) 
 NPI1    (score < 3.4) 58 52.25 
 NPI2    (score 3.4-5.4) 38 34.24 
 NPI3    (score > 5.4) 15 13.51 
Clinical outcome (survival) 
Free of relapse (Surv-1) 78 70.27 
With metastasis (Surv-2) 7 6.31 
With local recurrence (Surv-3) 5 4.5 
Died (Surv-4) 
Died of breast cancer  14 12.62 
Died of related disease 05 4.5 
Unknown 02 1.8 
NPI-1 = good prognosis; NPI-2 = moderate prognosis; NPI-3= poor prognosis 
3.6.2 APEX1 mRNA Levels in Breast Cancer Patients (Cohort-3) 
Quantitative real-time PCR was used for mRNA expressional analysis of selected 
BER pathway genes (APEX1, OGG1 and XRCC1). Observed mRNA expression in 
breast tumor and control samples was also compared with clinico-pathological 
parameters and clinical outcome (prognosis and survival) of patients (Table 3.32 and 
Table 3.33). Quantified transcript levels of APEX1 gene in breast tumor and 
background control tissues (BGCT) were normalized by GAPDH and Ck-19. APEX1 
transcript levels were observed higher in breast tumor samples when compared with 
APEX1 transcript levels in background control tissue (BGCT) but the difference was 
not statistically significant (p> 0.05) (Figure 3.20A).  
3.6.2.1 Association of APEX1 transcript level with tumor type and histological 
grades 
 Analysis of APEX1 transcript levels with respect to different histological tumor types 
revealed that APEX1 transcript levels were significantly decreased in lobular 
(p=0.008) and Medullary (p<0.0001) tumors as compared to ductal tumors (Figure 
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3.20B). When analysed with respect to histological grades, APEX1 transcript levels 
were observed significantly lower in grade-1 (well differentiated) tumors compared to 
controls (p=0.045) and grade-2 (moderately differentiated) (p=0.022) tumors. 
Whereas, APEX1 transcript levels were observed higher in grade-3 (poorly 
differentiated) tumors when compared to control and grade-2 tumors, but the 
differences were not significant (p > 0.05) (Figure 3.20C).  
3.6.2.2 Association of APEX1 transcript level with TNM stage and hormonal 
receptors 
When analysed according to TNM stages, decreased APEX1 transcript levels were 
observed in initial stage (TNM1) tumors compared to control (p=0.02) and tumors of 
TNM3 (p=0.001) stage. A gradual increase in APEX1 transcript levels were observed 
in advanced TNM stages with highest level observed in TNM4 tumors but this 
difference was statistically non-significant (p>0.05) as shown in Figure 3.20D. While 
analysing APEX1 mRNA expression in breast tumor samples with reference to 
different hormonal receptors (ER and HER-2/neu) deregulation in APEX1 transcript 
levels was observed and a significantly higher APEX1 transcript levels (p=0.0008) 
were observed in patients with ER–ve status when compared with  patients having 
ER+ve status. Increased APEX1 mRNA expression observed in HER-2/neu+ve 
patients compared to HER-2/neu-ve patients but the difference was statistically non-
significant (p>0.05) as shown in Figure 3.20E.  
3.6.2.3 Association of APEX1 transcript level with NPI and Survival status 
Values of Nottingham prognostic index (NPI) were calculated to determine prognosis 
of patients after surgery and other breast cancer therapies. Patients with NPI value 
<3.4 were classified as NPI-1(good prognosis), with NPI value 3.4-5.4 were classified 
as NPI-2 (moderate prognosis) and with NPI value >5.4 were classified as NPI-3 
(poor prognosis). Down regulation in APEX1 mRNA expression was observed in 
patients with higher NPI values showing lowest levels of APEX1 transcript in patients 
with poor prognosis (NPI-3) amongst all three groups. However, the difference 
between patients with poor (NPI-3), moderate (NPI-2) and good (NPI-1) prognosis 
was statistically non-significant (p>0.05) as shown in Figure 3.20F.  
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As per clinical outcome recorded at final follow up, patients were divided into four 
categories i.e. Surv-1 (free of relapse), Surv-2 (with metastasis), Surv-3 (with local 
recurrence) and Surv-4 (died of breast cancer or related diseases). Significantly higher 
APEX1 mRNA expression was observed in patients who were free of relapse (Surv-1) 
when compared  with  those patients who had local recurrence (Surv3) (p=0.009) and 
those who were died due to breast cancer or  any related diseases (Surv 4) (p=0.04). 
APEX1 transcript levels were also found to be higher in patients with metastasis 
(Surv2) compared to patients with local recurrence (Surv3) and those who died due to 
breast cancer or other diseases (Surv 4) but differences were statistically non-
significant (p>0.05). Deregulation in APEX1 transcript levels were also observed 
when different patient groups (Surv-1 to 4) were compared with controls but the 
differences were observed non-significant (p>0.05) (Figure 3.20G). Hence lower 
levels of APEX1 transcript were found to be related with an overall poor survival of 
patients and local recurrence of breast tumors. p-values were computed using 
student’s t-test  and Mann-Whitney U test. 
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Table 3.32 Summary of APEX1 transcript levels in study cohort-3 
Group 
Tumor transcript 
Mean  (SE Mean) 
BGCT transcript 
Mean  (SE Mean) 
p-value 
(Mann-Whitney U test) 
APEX1 transcript  in tumor tissue and control tissue 
APEX1 vs BGCT 8728 (1576) 6175 (1581) p=0.1 
APEX1 transcript  in different tumor types 
Ductal Lobular Muscin Medullary Tubular Others 
9853 (2237) 2070 (1358) 9095 (3045) 234.1(28.7) 1442.9 (0) 5470 (5130) 
Ductal vs Lobular ***p=0.008 
Ductal vs Medullary 
***
p<0.0001 
{Ductal vs Muscin}, {Ductal vs others}, {Lobular vs Muscin}, 
{Lobular vs medullary}, {Lobular vs others}, {Muscin vs 
medullary} 
p>0.05 
Histological grade
 
 
Grad 1 1409 (693) 
6175 (1581) 
*
p=0.045 
Grade 2 9812 (3460) p=0.63 
Grade 3 22072 (12992) p=0.23 
Grade 1 vs grade 2 
*
p=0.022 
{Grade 1 vs grade 3}, { Grade 2 vs grade 3} p>0.05 
TNM staging 
TNM1 805 (141) 
6175 (1581) 
*
p=0.020 
TNM2 2423 (1395) p=0.32 
TNM3 3804 (852) p=0.27 
TNM4 22072 (12992) p= 0.16 
TNM1+2 vs TNM3+4 **p=0.001 
{TNM1 vs TNM2}, {TNM1 vs TNM4}, {TNM2 vs TNM3}, 
{TNM2 vs TNM4}, {TNM2 vs TNM4}, {TNM3 vs TNM4} 
p>0.05 
Hormonal receptor status 
ER-ve {13249 (2999)}     vs     ER+ve {2412 (746)} 
***
p=0.0008 
HER-2/neu –ve {7083 (1893)}     vs 
HER-2/neu +ve {17634 (3823)} 
p>0.05 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001  
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Table 3.33 APEX1 transcript levels in relation to clinical outcome (prognosis and 
survival) in study cohort-3 
Group 
Tumor transcript 
Mean  (SE Mean) 
BGCT transcript 
Mean  (SE Mean) 
p-value (Mann-
Whitney U test) 
Nottingham Prognostic Index (NPI) 
1 (<3.4) 10560 (2985) 
6175 (1581) 
p=0.24 
2 (3.4-5.4) 9543 (2755) p=0.86 
3 (>5.4) 6808 (2697) p=0.40 
{NPI-1 vs NPI-2}, {NPI-1 vs NPI-3}, {NPI-2 vs NPI-3} p>0.05 
Survival 
Free of relapse (Surv-1) 10598 (2421) 
6175 (1581) 
p=0.18 
With metastasis (Surv-2) 11990 (9076) p=0.56 
Local  recurrence (Surv-3) 2926 (1389) p=0.22 
Died (Srv-4) 3290 (2551) p=0.40 
{Surv234 vs BGCT},{Surv1 vs surv2},{Surv1 vs surv234} p>0.05 
{Surv1 vs surv3},  
{Surv1 vs surv4} 
{
*
p=0.009}, 
{
*
p=0.04} 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group;  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001 
 
 
Figure 3.20A Quantitative analysis of APEX1 transcript levels in tumor and control 
tissues 
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Figure 3.20B Quantitative analysis of APEX1 transcript levels in breast cancer tissues 
according to different histological tumor types 
 
 
 
Figure 3.20C Quantitative analysis of APEX1 transcript levels in breast cancer tissues 
with reference to different histological grades  
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Figure 3.20D Quantitative analysis of APEX1 transcript levels with reference to TNM 
stages of tumor 
 
 
 
Figure 3.20E Quantitative analysis of APEX1 transcript levels with reference to 
different hormonal receptors (ER and HER-2/neu) showing 
deregulation in APEX1 mRNA expression  
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Figure 3.20F Quantitative analysis of APEX1 transcript levels on the basis of NPI 
value of each patient divided in good, moderate and poor prognosis 
 
 
Figure 3.20G Quantitative analysis of APEX1 transcript levels according to clinical 
outcome after final follow up of patients 
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3.6.3 OGG1 mRNA Levels in Breast Cancer Patients (Study cohort-3)  
OGG1 transcripts levels in breast tumor tissues and background control tissues were 
quantified and then normalized by GAPDH and β-Actin. OGG1 transcript levels in 
study cohort-3 are summarized in Table 3.34 and 3.35. Mean OGG1 transcript levels 
in breast tumor tissues were observed lower compared to background control tissues 
but the difference was statistically non-significant (p=0.54)  as shown in Figure 
3.21A.  
3.6.3.1 Association of OGG1 transcript level with tumor type and histological 
grades 
OGG1 transcript levels were further assessed in different tumor types of breast 
cancer. Overall down regulation in OGG1 mRNA expression was observed in 
different tumor types compared to background control tissue. Relative decrease in 
OGG1 transcript levels were observed in all tumor types compared to control tissues 
but the differences were statistically non-significant (p>0.05) as shown in Figure 
3.21B. OGG1 transcript levels were also analysed in association with different 
histological grades of breast tumors. Decreased OGG1 transcript levels were observed 
in tumors of all grades compared to control tissues but the differences were observed 
statistically non-significant (p>0.05) as shown in Figure 3.21C.  
3.6.3.2 Association of OGG1 transcript level with TNM stage and hormonal 
receptors 
When OGG1 mRNA expression was analysed in association with TNM stages of 
breast tumors, mean OGG1 transcript levels were observed lower in tumors of all 
TNM stages as compared to control tissues but the differences were non-significant 
(p>0.05). Significantly decreased (p=0.043) OGG1 mRNA expression was observed 
in advanced TNM stage tumors (TNM3 + TNM4 together) when compared with 
initial TNM stage tumors (TNM1 + TNM2 together) as shown in Figure 3.21D. When 
OGG1 mRNA expression was analysed in different breast tumor samples with 
reference to hormonal receptors (ER and HER-2/neu), deregulation in OGG1 
transcript levels was observed but differences were statistically non-significant 
(p>0.05). Increased OGG1 transcript level was observed in ER+ve patients when 
compared with ER–ve patients (p=0.51) whereas decrease in OGG1 transcript levels 
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were observed in HER-2/neu+ve patients when compared with HER-2/neu-ve patients 
(p=0.22) as shown in Figure 3.21E. 
3.6.3.3 Association of OGG1 transcript level with NPI and Survival status 
Nottingham prognostic index (NPI) values were calculated to determine prognosis of 
patients after surgery and other breast cancer therapies. Down regulation in OGG1 
mRNA expression was observed in patients with higher NPI values showing greater 
decrease in OGG1 transcript levels in patients with NPI-3 (poor prognosis) amongst 
all three groups. OGG1 transcript levels were observed lower in patients belonging to 
all prognostic groups i.e. NPI-1 (good prognosis), NPI-2 (moderate prognosis) and 
NPI-3 (poor prognosis) when compared with controls but the differences were 
statistically non-significant (p>0.05)  as shown in Figure 3.21F. As per clinical 
outcome recorded at final follow up, patients were divided into four categories i.e. 
Surv-1 (free of relapse), Surv-2 (with metastasis), Surv-3 (with local recurrence) and 
Surv-4 (died of breast cancer or related diseases). Partially significant differences 
were observed in transcript levels of OGG1 among different patient groups (Surv-1 to 
4) and control samples. Decreased OGG1 transcript levels were observed in patients 
with poor survival (Surv-3 to 4) and lowest OGG1 mRNA expression was observed in 
those patients who were died due to breast cancer or other diseases. OGG1 transcript 
levels were observed significantly lower in patients who were died due to breast 
cancer or any other related disease (Surv-4) when compared with patients who were 
free of cancer relapse (Surv-1; p=0.03) and who were with metastasis (Surv-2; 
p=0.042). Similarly reduced OGG1 transcript levels were observed in all patients 
groups (Surv-1 to 4) compared to control samples but this decrease was non-
significant (Surv-1 p=0.75, Surv-2 p=0.76, Surv-3 p=0.54, Surv-4 p=0.31) as shown 
in Figure 3.21G. 
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Table 3.34 Summary of OGG1 transcript levels in study cohort-3 
Group 
Tumor transcript 
Mean  (SE Mean) 
BGCT transcript 
Mean  (SE Mean) 
p-value (Mann-
Whitney U test) 
OGG1 transcript  in tumor tissue and control tissue 
OGG1 vs BGCT 50 (12) 110 (54) p=0.54 
OGG1 transcript  in different tumor types 
Ductal Lobular Muscin Medullary Tubular others 
54.4 (13.7) 72.1 (57.2) 0.25 (0.25) 0.00005 (0) 9.143 (0) 1.45 (1.29) 
{Ductal vs Muscin}, {Ductal vs others} *P<0.0002 
Ductal vs Medullary *P<0.0001 
{Ductal vs Lobular}, {Lobular vs Muscin}, {Lobular vs medullary}, 
{Lobular vs others}, {Muscin vs medullary}, {Muscin vs others } 
p>0.05 
Histological grade
  
 
Grad 1 51.1 (33) 
110 (94) 
p=0.49 
Grade 2 41 (21) p=0.31 
Grade 3 14.9 (13) p=0.14 
Grade 1 vs grade 2, {Grade 1 vs grade 3},{ Grade 2 vs grade 3} p>0.05 
TNM staging 
TNM1 51.1 (33) 
110 (94) 
p=0.56 
TNM2 33.3 (15) p=0.43 
TNM3 19.7 (9) p=0.36 
TNM4 11.4 (7.1) p=0.31 
{TNM1 vs TNM2}, {TNM1 vs TNM3}, {TNM1 vs TNM4}, {TNM2 
vs TNM3}, {TNM2 vs TNM4}, {TNM2 vs TNM4}, {TNM3 vs 
TNM4} 
p>0.05 
TNM1+TNM2 vs TNM3+TNM4 *P=0.043 
Hormonal receptor status 
ER-ve {33 (13) }     vs     ER+ve { 47.2 (7)} p=0.51 
HER-2/neu –ve {42 (13)}    vs     HER-2/neu +ve {22.5 (9.1)} p=0.22 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001 
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Table 3.35 OGG1 transcript levels in relation to clinical outcome (prognosis and 
survival) in study cohort-3 
Group 
OGG1 transcript 
Mean  (SE Mean) 
BGCT transcript 
Mean  (SE Mean) 
p-value  
(Mann-Whitney U test) 
NPI Index 
1 (<3.4) 62 (24) 
110 (94) 
p=0.63 
2 (3.4-5.4) 57 (33.2) p=0.62 
3 (>5.4) 43 (16) p=0.49 
{NPI-1 vs NPI-2}, {NPI-1 vs NPI-3}, {NPI-2 vs NPI-3} p>0.05 
Survival 
Free of relapse 
(Surv-1) 
79 (38) 
110 (94) 
p=0.75 
With metastasis 
(Surv-2) 
75(31) p=0.76 
Local  recurrence 
(Surv-3) 
50 (15) p=0.54 
Died (Srv-4) 11.2 (8.5) p=0.31 
{Surv234 vs BGCT},{Surv1 vs surv2}, 
{Surv1 vs surv234},{Surv1 vs surv3} 
p>0.05 
{Surv1 vs surv4},   
{Surv2 vs surv4} 
{
*
p=0.031} 
{
*
p=0.042} 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001 
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Figure 3.21A Quantitative analysis of OGG1 transcript levels in control and tumor 
tissues  
 
 
Figure 3.21B Quantitative analysis of OGG1 transcript levels in breast cancer tissues 
according to different histological tumor types 
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Figure 3.21C Quantitative analysis of OGG1 transcript levels in breast cancer tissues 
with reference to different histological grades 
. 
 
Figure 3.21D Quantitative analysis of OGG1 transcript levels with reference to TNM 
stages of tumor 
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Figure 3.21E Quantitative analysis of OGG1 transcript levels in patients with 
different hormonal receptors (ER and HER-2/neu) showing 
deregulation in OGG1 transcript levels 
 
 
Figure 3.21F Quantitative analysis of OGG1 transcript levels in good, moderate and 
poor prognostic categories of breast cancer patients 
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Figure 3.21G Quantitative analysis of OGG1 transcript levels according to clinical 
outcome after final follow up of patients  
3.6.4 XRCC1 mRNA levels in breast cancer patients  
XRCC1 transcripts levels in breast tumor tissues and background control tissues were 
quantified and then normalized by GAPDH and β-Actin in patients of study cohort-3. 
XRCC1 transcript levels in study cohort-3 are summarized in Table 3.36 and 3.37. 
Down regulation in XRCC1 mRNA expression was observed in breast tumor tissues 
when compared with background control tissues (BGCT), but the difference was 
statistically non-significant (p>0.05) as show in Figure 3.22A.  
3.6.4.1 Association of XRCC1 transcript level with tumor type and histological 
grades  
XRCC1 transcript levels were further assessed in different tumor types of breast 
cancer and significantly lower (p<0.05) XRCC1 transcript levels were observed in 
muscin, medullary and other tumor types when compared with lobular tumours 
(Figure 3.22B). XRCC1 transcript levels were also analysed in association with 
different histological grades of breast tumors. Down regulation in XRCC1 mRNA 
expression was observed in tumors of all grades compared to control samples but 
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levels was observed in advanced grade tumors with the lowest levels in grade-3 
tumors as shown in Figure 3.22C.  
3.6.4.2 Association of XRCC1 transcript levels with TNM stages and hormonal 
receptors 
While analysing XRCC1 mRNA expression with reference to TNM stages of tumors, 
decrease in XRCCI transcript levels was observed in advanced stages when compared 
with controls but differences were statistically non-significant (Figure 3.22D). When 
XRCC1 mRNA expression in breast tumor samples was analysed with reference to 
different hormonal receptors (ER and HER-2/neu), down regulation in XRCC1 
transcript levels was observed in ER+ve and HER-2/neu+ve patients when compared 
with ER–ve and HER-2/neu-ve patients respectively but differences were statistically 
non-significant as shown in Figure 3.22E.  
3.6.4.3 Association of XRCC1 transcript levels with NPI and Survival status 
Nottingham prognostic index (NPI) values were calculated to determine prognosis of 
patients after surgery and other breast cancer therapies. Down regulation in XRCC1 
mRNA expression was observed in patients with successive higher NPI values 
showing lowest XRCC1 transcript levels in patients with NPI-3 (poor prognosis) 
amongst all three groups but the differences were statistically non-significant 
(p>0.05). When compared, XRCC1 mRNA expression was significantly down 
regulated (p=0.045) in patients with poor prognosis (NPI-3) when compared with that 
of healthy individuals as shown in figure Figure 3.22F. On the basis of clinical 
outcome recorded at final follow up, patients were divided into four categories i.e. 
Surv-1 (free of relapse), Surv-2 (with metastasis), Surv-3 (with local recurrence) and 
Surv-4 (died of breast cancer or related diseases). Significant difference was observed 
in transcript levels of XRCC1 among different patient groups (Surv-1 to 4) and control 
samples. Reduced XRCC1 transcript levels were observed in patients of different 
survival groups (Surv-1 to 4) showing lowest XRCC1 mRNA expression in Surv-4 
patients compared to the Surv-1 patients (p=0.041) and controls (p=0.051). Non-
significant decrease (p>0.05)  in XRCC1 transcript levels was observed among 
patients with metastasis, patients with cancer free survival and patients with local 
recurrence (surv-1 to 3) as shown in Figure 3.22G. p-values were computed using 
student’s t-test and Mann-Whitney U test. 
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Table 3.36 Summary of XRCC1 transcript levels in study cohort-3
 
Group 
Tumor transcript  Mean  
(SE Mean) 
BGCT transcript 
Mean  (SE Mean) 
p-value (Mann-
Whitney U test) 
XRCC1 transcript  in tumor tissue and control tissue 
XRCC1 vs BGCT 13.8 (6.0) 29 (12.5) p=0.57 
XRCC1 transcript  in different tumor types 
Ductal Lobular Muscin Medullary Tubular Others 
20.4 (12.8) 10.5 (6.4) 2.5 (1.5) 3 (0) 6.43 (0) 1.45 (0.29) 
{Lobular vs Muscin}, {Lobular vs medullary}, {Lobular vs others} *p<0.05 
{Ductal vs Lobular}, { Ductal vs Medullary}, {Ductal vs Muscin}, 
{Ductal vs others}, {Muscin vs medullary}, {Muscin vs others } 
p>0.05 
Histological grade
  
 
Grad 1 15.4 (4.7) 
29 (12.5) 
p=0.49 
Grade 2 13.2 (2.9) p=0.31 
Grade 3 10.2 (3.8) p=0.24 
Grade 1 vs grade 2, {Grade 1 vs grade 3},{ Grade 2 vs grade 3} p>0.05 
TNM staging  
TNM1 22.01 (8.2) 
29 (12.5) 
p=0.36 
TNM2 18.2 (6.8) p=0.43 
TNM3 16.3 (5.5) p=0.56 
TNM4 11.4 (5.1) p=0.31 
{TNM1 vs TNM2}, {TNM1 vs TNM3}, {TNM1 vs TNM4},  
{TNM2 vs TNM3}, {TNM2 vs TNM4}, {TNM2 vs TNM4},  
{TNM3 vs TNM4} 
p>0.05 
Hormonal receptor status 
ER-ve {13.4 (5.4)}     vs     ER+ve { 3.6 (1.6)} p=0.48 
HER-2/neu –ve {12.4 (4.2)} vs  HER-2/neu +ve {7.2 (3.1)} p=0.21 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001 
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Table 3.37 XRCC1 transcript levels in relation to clinical outcome (prognosis and 
survival) in study cohort-3 
Group 
Tumor 
transcript 
Mean  (SE Mean) 
BGCT 
transcript Mean  
(SE Mean) 
p-value 
 (Mann-Whitney 
U test) 
Nottingham prognostic Index (NPI) 
1 (<3.4) 25.0 (11.0) 
29 (12.5) 
p=0.26 
2 (3.4-5.4) 13.6 (6.8) p=0.13 
3 (>5.4) 8.6 (5.3) *p<0.045 
{NPI-1 vs NPI-2}, {NPI-1 vs NPI-3}, {NPI-2 vs NPI-3} p>0.05 
Survival 
Free of relapse (Surv-1) 21.9 (11.8) 
29 (12.5) 
p=0.57 
With metastasis (Surv-2) 16.9 (12.7) p=0.29 
Local  recurrence (Surv-
3) 12.4 (6.9) p=0.21 
Died (Srv-4) 3.5 (2.8) *p=0.04 
{Surv234 vs BGCT},{Surv1 vs surv2}, 
{Surv1 vs surv234}, {Surv1 vs surv3} 
p>0.05 
{Surv1 vs surv4}  *p=0.051 
Median levels and interquartile range (IQR) of APEX1/GAPDH ratio in the respective group  
BGCT= Background control tissue; 
*
p<0.05; 
**
p<0.01; 
***
p<0.001 
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Figure 3.22A Quantitative analysis of XRCC1 transcript levels in control and tumor 
tissues 
 
 
  
Figure 3.22B Quantitative analysis of XRCC1 transcript levels in different 
histological tumor types of breast 
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Figure 3.22C Quantitative analysis of XRCC1 transcript levels in breast tumors of 
different histological grades 
 
 
Figure 3.22D Quantitative analysis of XRCC1 transcript levels in different clinical 
stage tumors 
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Figure 3.22E Quantitative analysis of XRCC1 transcript levels in different hormonal 
receptors (ER and HER-2/neu) in breast cancer patients 
 
 
Figure 3.22F Quantitative analysis of XRCC1 transcript levels on the basis of NPI 
values of breast cancer patients  
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Figure 3.22G Quantitative analysis of XRCC1 transcript levels in different survival 
categories of breast cancer patients 
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3.7 Correlations between BER pathway genes, proliferation marker Ki-67 
and clinico-pathological parameters of breast cancer patients at 
transcriptional level 
The expression levels of BER pathway genes (APEX1, OGG1 and XRCC1) and 
proliferation marker Ki-67 at mRNA level were correlated by Spearman correlation. 
To explore gene versus gene relationship, we observed a positive Spearmen 
correlation between XRCC1 versus OGG1 (r = 0.966**, p<0.001) and a negative 
correlation between XRCC1 versus APEX1 (r = -0.199*, p<0.05) in tumor tissues. (* 
indicates the level of significance of Spearmen correlations as calculated by SPSS). 
No significant correlation was found between XRCC1 and Ki-67. In addition to this, a 
negative Spearman correlation was observed between OGG1 versus APEX1 (r= -
0.211*, p<0.03) and OGG1 versus Ki-67 (r= -0.195*, p<0.05). However, a positive 
correlation was observed between APEX1 versus Ki-67 (r= 0.332*, p<0.02) in breast 
cancer patients as shown in Table 3.38. 
In case of clinico-pathological versus clinico-pathological parameters and gene versus 
clinicopathological characteristic relationship, a positive correlation was observed 
between ER versus Her (r= 0.213*, p<), ER versus N-stage (r= 0.209*, p<0.05), C-
stage versus grade (r = 0.598**, p<0.001), C-stage versus T-stage (r = 0.219*, 
p<0.04), C-stage versus N-stage (r = 0.451**, p<0.004), C-stage versus M-stage (r = 
0.521**, p<0.002), grade versus T-stage (r = 0.368**, p<0.005), grade versus N-stage 
(r=0.373**, p<0.005), and grade versus M-stage (r=0.686**, p<0.001). Furthermore, 
positive correlation was also observed between T-stage versus M-stage (r=0.375**, 
p<0.005), N-stage versus M-stage (r=0.337**, p<0.005) and N-stage versus APEX1 
(r=0.223*, p<) in breast cancer patients as presented in Table 3.38. 
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Table 3.38 Correlations between BER pathway genes (OGG1, APEX1 and XRCC1), proliferation marker (Ki-67) mRNA expression and clinico-
pathological characteristics of breast cancer patients
†
 
Type     ER       PR    HER-2/neu     C-stage     Grade     T-stage    N-stage     M-stage      XRCC1    OGG1      APEX1       Ki-67                         
Type      0.01   0.03       0.06            -0.104       0.05          0.118        0.107        0.025           0.08           -0.057        0.057        -0.082 
ER                   -0.09      0.213*        -0.009       -0.007      -0.101       0.209*      -0.062         -0.062        0.129          -0.125       -0.095 
PR                                 -0.006         0.184        0.034        0.172        0.063        0.07             0.049         -0.12           0.035        0.05 
HER-2/neu                                      0.082        0.112        0.03          -0.001       0.168           -0.094        0.126          -0.070      0.041 
C-stage                                                              0.598*      0.219*      0.451**   0.521**       0.045          0.084          0.001        -0.028 
Grade                                                                                 0.368**    0.373**   0.686**       0.022          0.105          0.092        0.145 
T-stage                                                                                                0.109        0.375**       -0.135        -0.092        0.066        0.028 
 N-stage                                                                                                                0.337**       -0.074        -0.080        0.223*      0.076  
 M-stage                                                                                                                                   -0.062        -0.063        0.100        0.094                                     
 XRCC1                                                                                                                                                      0.966**      -0.199*     -0.032 
OGG1                                                                                                                                                                            -0.211*     -0.195* 
APEX1                                                                                                                                                                                           0.332*                                                                                                                                                                        
Ki-67                                                                                                                                                                                                  
† Spearman Correlation Coefficients. Expression levels of OGG1, APEX1, XRCC1 and Ki-67 for Patient Cohort were based on the relative mRNA level 
p values were computed using one way ANOVA and χ2-test; * p <0.05; ** p <0.01; *** p <0.001 
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3.8 Expressional profiling of BER pathway genes at translational level by 
immunohistochemistry 
Immunohistochemical analysis was used for expression profiling of selected BER 
pathway genes (APEX1, OGG1 and XRCC1) at protein level. Expression profiling of 
these selected genes was further correlated with proliferation marker, Ki-67. 104 
breast cancer tissues were used for this analysis. The demographic and clinico-
pathological parameters of this study cohort have been mentioned in section 3.5.1 and 
Table 3.28. 
The immunohistochemical analysis revealed several significant differences in the 
expression of investigated markers between our patients. The immunostaining for 
each protein was determined as positive or negative by a cut-off value determined as 
follows; 
OGG1, APEX1 and XRCC1 staining was interpreted as positive when >10% of the 
tumor cells showed distinct staining. In case of Ki-67, staining was interpreted as 
positive when >25% showed distinct nuclear staining. 
 
3.9 Immunohistochemistry of APEX1 genes 
APEX1 expression at translation was observed in 104 breast cancer tumor samples 
using Immunohistochemistry. APEX1 expression was up-regulated in breast tumor 
samples compared to positive control tissues. APEX1 expression was observed up-
regulated in undifferentiated breast tumors compared with moderately differentiated 
breast tumors as shown in Figure 3.23 
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Figure 3.23 Expression profiling of APEX1 gene in breast tumor samples at 
translation level by immunohistochemistry. APEX1 expression in (A) negative 
control, (B) positive control, (C) moderately differentiated primary tumors, (D) poorly 
differentiated or undifferentiated breast tumors. 
The APEX1 immunoreactive intensity was measured in 104 breast tumor samples and 
observed that 13% cases showed weak immunoreactive intensity, 19% cases showed 
moderate and 68% cases showed strong immunoreactive intensity. The strong 
immunoreactive intensity was observed in significantly higher (p<0.05) number of 
breast tumors when compared to weak and moderate immunoreactive intensities as 
shown in Figure3.24A. Among these 104 breast tumor samples observed in present 
study, 79% patients showed up-regulation, 19% showed down-regulation and 2% 
showed no change as shown in Figure 3.24B. 
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Figure 3.24 (A) Immunoreactive intensity of APEX1 gene in breast tumor samples 
(B) 79% patients showed up-regulation and 19% cases showed down-
regulation 
3.9.1 Correlation between APEX1 expression and clinico-pathological 
characteristics 
Expression deregulations of APEX1 gene at protein level were measured using IHC in 
association with different clinico-pathological categories (Age, age at menarche, 
family history, histological tumor type, tumor grade, C-stage and survival status) of 
breast cancer patients are shown in Table 3.39. The impact of these clinical factors on 
APEX1 expression level was evaluated using Spearman correlation as explained in 
Table 3.43. 
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Table 3.39 Protein expression of APEX1 gene in breast cancer patients 
Clinico-pathological 
Information 
Patients 
(n=104) 
 
APEX1 protein expression 
n (%) 
Down regulation                 Up-regulation 
(n=20)                             (n=82) 
n (%)                              n (%) 
Age  
≤40 41  (39)            13 (65)                              28(34) 
>40 63  (61)            07 (35)                              54(66) 
Age at menarche 
≤12 58 (56)            02(10)                             56 (68) 
>12 46 (44)            18 (90)                             26 (32) 
Family History of cancer 
Yes 10 (10)            06 (30)                             04 (05) 
No 94 (90)            14 (70)                             78 (95) 
Site of breast tumor 
Unilateral Left 65 (62)             09 (45)                            54 (65) 
Unilateral Right 36 (35)             08 (40)                            28 (34) 
Bilateral 03 (03)             03 (15)                            01 (01) 
Histological tumor type 
Ductal carcinoma in-situ  24 (23)             08 (40)                            16 (20) 
Invasive ductal carcinoma  55 (53)             06 (30)                            48 (58) 
Invasive lobular carcinoma  25 (24)             06 (30)                            18 (22) 
Histological grade 
Grade 1  27 (26)             08 (40)                            19 (23) 
Grade 2 40 (38)             07 (35)                            33 (40) 
Grade 3  37 (36)             05 (25)                            30 (37) 
Clinical stage (C-stage) 
Stage I and II   37 (36)             09 (45)                             28 (34) 
Stage III and IV  67 (64)             11 (55)                             54 (66) 
Hormonal receptor status  
ER                
Positive 
Negative 
 
33 (32) 
45 (43) 
 
           16 (80)                              17 (21) 
           04 (20)                              41 (50) 
PR                
Positive 
Negative 
 
38 (37) 
42 (40) 
 
            13 (65)                             25 (30) 
            07 (35)                             35 (43) 
HER-2/neu 
Positive 
Negative  
 
41 (39) 
49 (47) 
 
            14 (70)                             27 (33) 
            06 (30)                             43 (52) 
Clinical outcome (survival) 
Free of relapse 61 (60)             07 (35)                             53 (66) 
With local recurrence 06 (06)             04 (20)                             02 (03) 
With metastasis 10 (09)             02 (10)                             08 (11) 
Died Died of breast cancer 13 (12)             01 (05)                             11 (14) 
Died of related disease 09 (09)             05 (25)                             04 (05) 
Unknown 05 (04)             01 (05)                             01 (01) 
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3.10 Immunohistochemistry of OGG1 genes 
Expression level of OGG1 was evaluated in 104 breast tumor samples by 
immunohistochemistry. The OGG1 expression was down-regulated in breast tumor 
samples when compared with positive control tissues. OGG1 protein was further 
down-regulated in undifferentiated breast tumors compared to moderately 
differentiated samples as shown in Figure 3.25. 
 
 
Figure 3.25 Expression profiling of OGG1 gene in breast tumor samples at 
translation level by immunohistochemistry. OGG1 expression in (A) negative control, 
(B) positive control, (C) moderately differentiated primary tumors, (D) poorly 
differentiated or undifferentiated breast tumors. 
The OGG1 immunoreactive intensity was measured in 104 breast tumor samples. It 
was observed that 72% cases showed weak immunoreactive intensity, 24% cases 
showed moderate and 4% cases showed strong immunoreactive intensity. The weak 
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immunoreactive intensity was observed in significantly higher (p<0.03) number of 
breast tumor tissues when compared to moderate and strong immunoreactive 
intensities as shown in Figure 3.26A. Among these, 104 breast tumor samples 
observed in this study, 81% patients showed down-regulation, 18% showed up-
regulation and 1% showed no change as shown in Figure 3.26B. 
 
Figure 3.26 (A) Immunoreactive intensity of OGG1 gene in breast cancer tumor 
samples (B) 81% patients showed down-regulation and 18% cases showed up-
regulation 
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3.10.1 Correlation between OGG1 expression and clinico-pathological 
characteristics 
Expression deregulations of OGG1 gene at protein level were measured by IHC in 
association with different clinico-pathological categories (Age, age at menarche, 
family history, histological tumor type, tumor grade, C-stage and survival status) of 
breast cancer patients are shown in Table 3.40. The impact of these clinical factors 
and other genes under study (APEX1, XRCC1 and Ki-67) on OGG1 expression level 
was evaluated using Spearman correlation as explained in Table 3.43. 
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Table 3.40 Protein expression of OGG1 gene in breast cancer patients 
Clinico-pathological 
Information 
Total patients 
n=104 
OGG1 Expression 
 
n (%) 
Down regulation       Up-regulation 
(n=84)                           (n=19) 
 n (%)                           n (%) 
Age  
≤40 41  (39) 28 (33)                         12 (63) 
>40 63  (61) 56 (67)                         07 (37) 
Age at menarche 
≤12 58 (56) 48 (57)                         10 (53) 
>12 46 (44) 36  (43)                        09 (47) 
Family History of cancer 
Yes 10 (10) 07 (08)                         03 (16) 
No 94 (90) 77 (92)                         16 (84) 
Site of breast tumor 
Unilateral Left 65 (62) 54(64)                          11 (58) 
Unilateral Right 36 (35) 29 (35)                         06 (32) 
Bilateral 03  (03) 01 (01)                         02 (10) 
Histological tumor type 
Ductal carcinoma in-situ 24 (23) 18 (21)                         06 (32) 
Invasive ductal carcinoma 55 (53) 49 (59)                         05 (26) 
Invasive lobular carcinoma  25 (24) 17 (20)                         08 (42) 
Histological grade 
Grade 1  27 (26) 21 (25)                         05 (26) 
Grade 2 40 (38) 36  (43)                        04 (21) 
Grade 3  37 (36) 27  (32)                        10 (53) 
Clinical stage (C-stage) 
Stage I and II   37 (36) 29 (35)                         07 (37) 
Stage III and IV  67 (64) 55  (65)                        12 (63) 
Hormonal receptor status  
ER                
Positive 
Negative 
 
33 (32) 
45 (43) 
 
22 (26)                         11 (58) 
37 (44)                         08 (42) 
PR                
Positive 
Negative 
 
38 (37) 
42 (40) 
 
25 (30)                         13 (68) 
36  (43)                        06 (32) 
HER-2/neu 
Positive 
Negative  
 
41 (39) 
49 (47) 
 
32 (38)                         09 (47) 
44  (52)                        05 (26) 
Clinical outcome (survival) 
Free of relapse 61 (60) 57 (67)                         04 (21) 
With local recurrence 06 (06) 01 (01)                         05 (26) 
With metastasis 10 (09) 08 (10)                         02 (11) 
Died 
Died of breast cancer 13 (12) 09 (11)                         04 (21) 
Died of related disease 09 (09) 08 (10)                         01 (05) 
Unknown 05 (04) 01 (01)                         03 (16) 
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3.11 Immunohistochemistry of XRCC1 genes 
Immunohistochemical analysis of third selected BER pathway gene, XRCC1 was 
observed in 104 breast tumor samples. XRCC1 protein expression was down-
regulated in breast cancer tumor samples compared to positive control tissue samples. 
This down-regulation was observed more prevalent in undifferentiated breast tumor 
compared to moderately differentiated tumor samples as shown in Figure 3.27. 
Figure 3.27 Expression profiling of XRCC1 gene in breast tumor samples at 
translation level by immunohistochemistry. XRCC1 expression in (A) negative 
control, (B) positive control, (C) moderately differentiated primary tumors, (D) poorly 
differentiated or undifferentiated breast tumors. 
The XRCC1 immunoreactive intensity was measured in 104 breast tumor samples and 
observed that 61% cases showed weak immunoreactive intensity, 29% cases showed 
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moderate and 10% cases showed strong immunoreactive intensity. The weak 
immunoreactive intensity was observed in significantly higher (p<0.05) number of 
breast tumors when compared to moderate and strong immunoreactive intensities as 
shown in Figure 3.28A. Among these 104 breast tumor samples observed in present 
study, 73% patients showed down-regulation, 24% showed up-regulation and 3% 
showed no change as shown in Figure 3.28B 
 
Figure 3.28 (A) Immunoreactive intensity of XRCC1 gene in breast tumor samples 
(B) 73% patients showed down-regulation and 24% cases showed up-regulation 
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3.11.1 Correlation between XRCC1 expression and clinico-pathological 
characteristics 
Expression deregulation of XRCC1 gene at protein level was measured by IHC in 
association with different clinico-pathological categories (Age, age at menarche, 
family history, histological tumor type, tumor grade, C-stage and survival status) of 
breast cancer patients are shown in Table 3.41. The impact of these clinical factors 
and other genes under study (APEX1, OGG1 and Ki-67) on XRCC1 expression level 
was evaluated using Spearman correlation as explained in Table 3.43. 
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Table 3.41  Protein expression of XRCC1 gene in breast cancer patients 
Clinico-pathological 
Information 
Total 
patients 
(n=104) 
 
XRCC1 protein expression 
n (%) 
Down regulation      Up-regulation 
(n=76)                         (n=25) 
 n (%)                           n (%) 
Age  
≤40 41  (39) 31 (41)                     10 (40) 
>40 63  (61) 45 (59)                     15 (60) 
Age at menarche 
≤12 58 (56) 44 (58)                     14 (56) 
>12 46 (44) 32 (42)                     11  (44) 
Family History of cancer 
Yes 10 (10) 07 (09)                     03 (12) 
No 94 (90) 69  (91)                    22  (88) 
Site of breast tumor 
Unilateral Left 65 (62) 56 (73)                     08 (32) 
Unilateral Right 36 (35) 19 (25)                     15 (60) 
Bilateral 03  (03) 01 (02)                     02 (08) 
Histological tumor type 
Ductal carcinoma in-situ  24 (23) 18 (24)                     06 (24) 
Invasive ductal carcinoma 55 (53) 41  (54)                    14 (56) 
Invasive lobular carcinoma 25 (24) 17  (22)                    05(20) 
Histological grade 
Grade 1  27 (26) 20 (26)                     07 (28) 
Grade 2 40 (38) 30  (40)                    09 (36) 
Grade 3  37 (36) 26  (34)                    09 (36) 
Clinical stage (C-stage) 
Stage I and II   37 (36) 25 (33)                     11 (44) 
Stage III and IV  67 (64) 51 (67)                     14  (56) 
Hormonal receptor status  
ER                
Positive 
Negative 
 
33 (32) 
45 (43) 
 
24 (32)                     09 (36) 
33 (43)                     12 (48) 
PR                
Positive 
Negative 
 
38 (37) 
42 (40) 
 
28  (37)                    10 (40) 
33  (43)                    09 (36) 
HER-2/neu 
Positive 
Negative  
 
41 (39) 
49 (47) 
 
30  (39)                    11 (44) 
35  (46)                    14 (56) 
Clinical outcome (survival) 
Free of relapse 61 (60) 45 (59)                     15 (60) 
With local recurrence 06 (06) 04 (05)                     01  (04) 
With metastasis 10 (09) 07 (09)                     03  (12) 
Died 
Died of breast cancer 13 (12) 09 (12)                     03  (12) 
Died of related disease 09 (09) 07 (09)                     02  (08) 
Unknown 05 (04) 04 (05)                      01  (04) 
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3.12 Immunohistochemistry of Proliferation marker, Ki-67 
In addition to expression profiling of selected BER pathway genes (APEX1, OGG1 
and XRCC1), expression level of proliferation marker, Ki-67 was also evaluated in 
104 breast cancer tumor samples. Ki-67 protein expression was up-regulated in breast 
tumor samples compared to positive control tissue samples. This up-regulation was 
observed more prevalent in undifferentiated breast tumor compared to moderately 
differentiated tumor samples as shown in Figure 3.29. 
 
Figure 3.29 Expression profiling of proliferation marker Ki-67 in breast tumor 
samples at translation level by immunohistochemistry. Ki-67 expression in (A) 
negative control, (B) positive control, (C) moderately differentiated primary tumors, 
(D) poorly differentiated or undifferentiated breast tumors 
The Ki-67 immunoreactive intensity was measured in 104 breast tumor samples and 
observed that 8% cases showed weak immunoreactive intensity, 34% cases showed 
  Results 
225 
 
moderate and 58% cases showed strong immunoreactive intensity. The strong 
immunoreactive intensity was observed in significantly higher (p<0.05) number of 
breast tumors when compared to weak and moderate immunoreactive intensities as 
shown in Figure 3.30A. Among these 104 breast tumor samples observed in present 
study, 84% patients showed up-regulation, 10% showed down-regulation and 6% 
showed no change as shown in Figure 3.30B 
 
Figure 3.30 (A) Immunoreactive intensity of proliferation marker, Ki-67 in breast 
cancer tumor samples. (B) 84% patients showed up-regulation and 10% cases showed 
down-regulation. 
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3.12.1 Correlation between Ki-67 expression and clinico-pathological 
characteristics 
Expression deregulation of Ki-67 gene at protein level was measured using IHC in 
association with different clinico-pathological categories (Age, age at menarche, 
family history, histological tumor type, tumor grade, C-stage and survival status) of 
breast cancer patients are shown in Table 3.42. The relationship of these clinical 
factors and other genes under study (APEX1, OGG1 and XRCC1) with Ki-67 
expression level was evaluated using Spearman correlation as explained in Table 
3.43. 
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Table 3.42 Protein expression of proliferation marker Ki-67 in breast cancer patients 
Clinico-pathological 
Information 
Patients 
(n=104) 
Ki-67 protein expression 
n (%) 
Down regulation            Up-regulation 
(n=10)                          (n=88) 
n(%)                            n(%) 
Age  
≤40 41  (39) 07 (70)                             32 (36) 
>40 63  (61) 03 (30)                             56 (64) 
Age at menarche 
≤12 58 (56) 05 (50)                             49 (56) 
>12 46 (44) 05 (50)                             39 (44) 
Family History of cancer 
Yes 10 (10) 03 (30)                             07 (08) 
No 94 (90) 07 (70)                             81 (92) 
Site of breast tumor 
Unilateral Left 65 (62) 06 (60)                            58 (66) 
Unilateral Right 36 (35) 02 (20)                            29 (33) 
Bilateral 03 (03) 02 (20)                            01 (01) 
Histological tumor type 
Ductal carcinoma in-situ  24 (23) 05 (50)                            18 (20) 
Invasive ductal carcinoma 55 (53) 02 (20)                            50 (57) 
Invasive lobular carcinoma 25 (24) 03 (30)                            20 (23) 
Histological grade
 
 
Grade 1  27 (26) 02 (20)                            25 (28) 
Grade 2 40 (38) 06 (60)                            28 (32) 
Grade 3  37 (36) 02 (20)                            35 (40) 
Clinical stage (C-stage) 
Stage I and II   37 (36) 01 (10)                             30 (34) 
Stage III and IV  67 (64) 09 (90)                             58 (66) 
Hormonal receptor status  
ER                
Positive 
Negative 
 
33 (32) 
45 (43) 
 
07 (70)                              26 (30) 
03 (30)                              42 (48) 
PR                
Positive 
Negative 
 
38 (37) 
42 (40) 
 
08 (80)                             30 (34) 
02 (20)                             40 (45) 
HER-2/neu 
Positive 
Negative  
 
41 (39) 
49 (47) 
 
06 (60)                             35 (40) 
04 (40)                             45 (51) 
Clinical outcome (survival) 
Free of relapse 61 (60) 02 (20)                             56 (64) 
With local recurrence 06 (06) 01 (10)                             05 (05) 
With metastasis 10 (09) 02 (20)                             05 (05) 
Died Died of breast cancer 13 (12) 02 (20)                             11 (13) 
Died of related disease 09 (09) 02 (20)                             07 (08) 
Unknown 05 (04) 01 (10)                             04 (05) 
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3.13 Correlations between BER pathway genes, proliferation marker Ki-67 
and clinico-pathological parameters of study cohort at translational 
level 
Additionally, to explore gene versus gene relationship, we observed a positive 
Spearmen correlation between XRCC1 versus OGG1 (r = 0.308**, p<0.004) and a 
negative correlation between XRCC1 versus APEX1 (r = -0.344**, p<0.002) and 
XRCC1 versus Ki-67 (r= -0.230*, p<0.03) in breast cancer cases. (* indicates the level 
of significance of Spearmen correlations as calculated by SPSS). In addition to this, a 
negative Spearman correlation was observed between OGG1 versus APEX1 (r= -
0.219*, p<0.02) and OGG1 versus Ki-67 (r= -0.629***, p<0.0002). However, a 
positive non-significant correlation was observed between APEX1 versus Ki-67 (r= 
0.185, p<0.06) in breast cancer patients as shown in Table 3.43. 
 
In case of clinico-pathological versus clinico-pathological parameters and gene versus 
clinicopathological characteristic relationship, a positive correlation was observed 
between ER versus HER-2/neu (r= 0.213*, p<0.03), ER versus N-stage (r= 0.209*, 
p<0.05), C-stage versus grade (r = 0.598**, p<0.001), C-stage versus T-stage (r = 
0.219*, p<0.04), C-stage versus N-stage (r = 0.451**, p<0.004), C-stage versus M-
stage (r = 0.521**, p<0.002), grade versus T-stage (r = 0.368**, p<0.005), grade 
versus N-stage (r=0.373**, p<0.005), and grade versus M-stage (r=0.686**, 
p<0.001). Furthermore, positive correlation was also observed between T-stage versus 
M-stage (r=0.375**, p<0.005), N-stage versus M-stage (r=0.337**, p<0.005) and N-
stage versus APEX1 (r=0.046, p<0.64) in breast cancer patients as presented in Table 
3.43. 
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Table 3.43 Correlations between BER pathway genes (OGG1, APEX1and XRCC1), proliferation marker (Ki-67) expression and 
clinico-pathological characteristics of breast cancer patients
†
 
Type     ER       PR     HER-2/neu    C-stage    Grade   T-stage     N-stage     M-stage      XRCC1      OGG1      APEX1       Ki-67                         
Type     0.01     0.03      0.06          -0.104      0.05        0.118        0.107        0.025           -0.003          0.078        -0.14         -0.046    
ER                    -0.09     0.213*     -0.009      -0.007     -0.101      0.209*      -0.062          -0.026          -0.141       0.141       -0.024           
PR                                 -0.006       0.184       0.034      0.172        0.063        0.07             0.170           -0.02          0.025       -0.201* 
HER-2/neu                                    0.082       0.112      0.03          -0.001       0.168           -0.009          -0.07          0.014       0.056 
C-stage                                                           0.598*    0.219*     0.451**   0.521**       0.108           0.058         -0.063      0.003 
Grade                                                                             0.368**  0.373**    0.686**      0.003           0.037         -0.072      0.057 
T-stage                                                                                           0.109        0.375**       -0.053         0.105         -0.09        -0.120 
 N-stage                                                                                                           0.337**       0.016           0.138         0.046       0.153 
 M-stage                                                                                                                              -0.006          -0.014        0.036       0.104                                     
 XRCC1                                                                                                                                                   0.308**    -0.344**  -0.230* 
OGG1                                                                                                                                                                        -0.219*    -0.629*** 
APEX1                                                                                                                                                                                        0.185                                                                                                                                                                        
Ki-67                                                                                                                                                                                                  
† Spearman Correlation Coefficients. The expression levels of OGG1, APEX1, XRCC1 and Ki-67 for patient cohort were based on the relative protein level;  
The p values were computed using one way ANOVA and χ2-test; * p<0.05; **p<0.01; *** p<0.001 
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3.14 In-vitro analysis of BER pathway genes in breast carcinogenesis 
This study intends to explore the role of BER pathway genes (APEX1, OGG1 and 
XRCC1) in cellular behaviour during tumorigenesis. For this purpose, different breast 
cancer cell lines were used for multiple cell function assays such as growth, adhesion, 
invasion and cellular attachment and migration. 
3.14.1 Expression patterns of APEX1, OGG1 and XRCC1 in cancer 
cell lines 
Initially expression levels of selected BER genes (APEX1, OGG1 and XRCC1) were 
explored in human breast cancer cell lines (wild type). Normal expression of BER 
genes was observed using conventional PCR techniques in three breast cancer cell 
lines; MCF-7 (ECACC, Salibury, England), MDA-MB-231 (ATCC, Rockvillie, 
Maryland, USA) and ZR-75-1 (ECACC, Salibury, England). Expression was 
observed by performing three repeats of experiment and GAPDH was used as an 
internal control to compare and confirm the findings. Strong expression of all three 
genes; APEX1, OGG1 and XRCC1 was observed in all three cell lines, as shown in 
Figure 3.31. Since, knockdown was not successful in ZR-75-1 breast cancer cell line, 
so only two cell lines (MDA-MB-231 and MCF-7) were employed for further 
experiments. 
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Figure 3.31 mRNA expression in three breast cancer cell lines  
mRNA expression of APEX1, OGG1, XRCC1 and GAPDH (internal control) was 
determined using conventional PCR techniques. Strong expression (almost similar to 
GAPDH) of all three genes APEX1 (A), OGG1 (B) and XRCC1 (C) was observed in 
all three selected breast cancer cell lines 
3.14.2 Generation and amplification of gene specific ribozymes 
Gene specific ribozymes were amplified using touchdown PCR as mentioned in 
materials and methods section 2.18.2. Two different pairs of primers (Rib1F - Rib1R 
and Rib2F – Rib2R) were used to amplify two different types of ribozymes specific 
for respective gene (APEX1-Rib1 and APEX1-Rib2 specific for APEX gene, OGG1-
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Rib1 and OGG1-Rib2 specific for OGG1 gene and XRCC1-Rib1 and XRCC1-Rib2 
specific for XRCC1). Amplified ribozymes were run on an agarose gel along with 
ladder (1Kb) to confirm the exact size of amplified ribozyme product (Expected band 
size 50bp) as shown in Figure 3.32. 
 
Figure 3.32 Gene specific ribozymes amplified using touchdown PCR 
3.14.3 Successful transformation of APEX1, OGG1 and XRCC1 ribozyme 
molecules into competent cells 
Amplified PCR products of gene specific ribozymes were competently ligated into 
pEF6/V5-Hio-TOPO cloning vector and introduced to competent bacterial (E. coli) 
cells. After an overnight incubation (at 37°C) on ampicillin (10g/ml) containing LB 
agar medium at high and low seeding densities, ten colonies of competent bacterial 
cells for each ribozyme (Rib1 and Rib2) specific to each gene under study (APEX1, 
OGG1 and XRCC1) were randomly selected and picked from the petri dishes as 
shown in the Figure 3.33.  Following the transformation of competent E.coli cells, 
colonies were checked to confirm the presence and correct orientation of transgenic 
insert into the plasmid using direction specific PCR.  Two separate PCR reactions 
were performed for each colony using two different primer pairs (T7F primer vs 
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RbTOP primer for first PCR and T7F primer vs RbBMR primer for second PCR) 
were used as mentioned in table 2.8 and 2.19. Colonies showing positive and strong 
PCR results with correct product size in first PCR reaction (using T7F vs RbBMR 
primers) and negative PCR results in second PCR reaction (using T7F vs RbTOP 
primers) were considered with right (Rt) orientation of plasmid insert. Whereas 
colonies showing negative or week PCR results with first PCR reaction (using T7F vs 
RbBMR primers) and  positive PCR results with second PCR reaction (using T7F vs 
RbTOP primers) were considered with wrong (Wr) orientation (Table 3.44). 
Confirmation of correct PCR product sizes was done by electrophoresis (Figure 3.34).  
Table 3.44 Orientation verification of transgene insert using RbTOP and RbBMR 
primer pairs vs T7F primer 
PCR Primer pair Correct Incorrect 
Reaction-1 T7F vs RbBMR 150bp 90bp 
Reaction-2 T7F vs RbTOP 90bp 140bp 
 
 
 
Figure 3.33 White colonies of competent E. coli cells. Transformation in competent 
E. coli cells was observed after an overnight incubation at 37˚C through PCR 
reactions followed by gel electrophoresis. 
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Figure 3.34 Verification of presence and correct orientation of transgene 
ribozyme insert. Successful and correct orientation of RNA based transgene 
ribozyme transformation into competent E.coli cells (expected band size 150bp with 
T7F vs RbBMR primer pair) was verified using PCR and gel electrophoresis. The 
colonies 1, 4, 5, 6 and 10 show right orientation (Rt) whereas colonies 2, 3, 7, 8 and 9 
show wrong orientation (Wr) of transgenes insert into plasmid vector.  
3.14.4 Extraction of transgenic Plasmid 
After careful selection of colonies with right orientation (Rt) of transgenes insert, 
transgenic plasmid DNA was isolated from selected colonies as described in materials 
and methods (section 2.18.5). Extracted transgenic plasmids were then further 
subjected to verification of size and correct orientation through gel electrophoresis. 
Products were compared with 1kb ladder (101R plasmid DNA marker) on 1% agarose 
gel. Multiple bands were observed on gel, which indicate different conformations of 
plasmid DNA such as nicked, circular, partially or super-coiled and linier as shown in 
Figure 3.35. Closed, circular and supercoiled transgene plasmid vectors have product 
size (5840 bp) and move faster than linear nicked and partially coiled DNA 
molecules. Multiple conformational types of plasmid appeared in gel are induced by 
topoisomerase as cells were presence at different stages of cell cycle.  
 
  Results 
235 
 
 
Figure 3.35 Gel electrophoresis confirming the presence and correct size of isolated 
plasmid from competent E. coli cells. Plasmid vector pEF6/V5-His TOPO (5840bp) 
isolated from from E. coli showed different bands.  
 
3.14.5 TOPO cloning and cancer cell transfection; summery of the 
process and results 
Summarized process of TOPO cloning and mammalian cancer cell transfection by 
electroporation process is presented in Figure 3.36. 
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Figure 3.36 Process of TOPO cloning and cancer cell transfection 
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3.15 Generation of transfected breast cancer cell lines 
Breast cancer cell lines (MCF-7 and MDA-MB-231) were transfected with gene 
specific transgenic plasmid DNA using electroporation technique as mentioned in 
materials and methods section 2.18.7. Both cell lines were transfected for all three 
genes selected in present study i.e. APEX1, OGG1 and XRCC1. Transfection of MCF-
7 and MDA-MB-231 breast cancer cell lines with APEX1, OGG1 and XRCC1 
ribozyme transgenes successfully knocked down the mRNA and protein expression of 
these molecules in cancer cells.  
3.16 Confirmation of APEX1 Knockdown at mRNA Level 
Verification of successful knockdown in both cell lines (MCF-7 and MDA-MB-231) 
was carried out by RT-PCR and real time PCR at mRNA level and by western blot 
analysis and immuno-cyto-staining at protein level. Reduced mRNA expression of 
APEX1 was observed in MCF-7
APEX1-KnD
 and MDA-MB-231
APEX1-KnD
 compared to 
wild type (MCF-7
WT
 and MDA-MB-231
WT
) and plasmid vector control (MCF-7-
pEF6
 
and MDA-MB-23-
pEF6
) cells using RT-PCR followed by gel electrophoresis (Figure 
3.37A). Results were further confirmed using real time PCR as shown in Figure 
3.37B. GAPDH was used as internal control in both experiments. 
 
Figure 3.37A Confirmation of APEX1 knockdown at mRNA level and successful 
generation of transgenic breast cancer cell lines using RT-PCR. Electropherograms 
showing relatively lower mRNA expression of APEX1 in both transfected cell lines 
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(MCF-7
-APEX1-KnD
 and MDA-MB-231-APEX1
-KnD)
 using RT-PCR when compared 
with their wild type (MCF-7-WT-Ct) and pEF control (MCF-7-pEF-Ct) cell lines.  
GAPDH molecule was used as internal control for both these cell lines. 
 
Figure 3.37B Confirmation of APEX1 knockdown at mRNA level using qPCR and 
successful generation of transgenic breast cancer cell lines. Lower APEX1 transcript 
levels in both knockdown cells of both cell lines (MCF-7-
APEX1-KnD
 and MDA-MB-
231
-APEX1-knD
) compared with wild type control (APEX1-
WT
) and vector inserted 
control (APEX1-
pEF
) of respective cell lines 
3.16.1 Confirmation of APEX1 knockdown at translation level by western 
blotting  
Western blot analysis as mentioned in materials and methods section 2.20 was used 
for the confirmation of APEX1 gene knockdown at protein level of molecule in both 
selected breast cancer cell lines. Decreased APEX1 protein expression was observed 
in both knockdown cell lines (MCF-7
-APEX1-KnD
 and MDA-MB-231-
APEX1-KnD)
 
compared to their respective wild type control (MCF-7-
WT
 and MDA-MB-231-
WT
) 
and plasmid control (MCF-7-
pEF
 and MDA-MB-231-
pEF
). GAPDH was used as 
internal control to verify that the amount of protein was homogenous in the well. 
Protein assay was also performed and standard curve was measured to evaluate the 
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uniformity of protein samples before western blot experiment. Protein profiling detail 
is mentioned in Figure 3.37C. 
 
 
Figure 3.37C Protein expression of APEX1 gene through western blot analysis. 
Decreased APEX1 protein levels were observed in both knocked down breast cancer 
cell lines MCF-7-
APEX1-KnD
 and MDA-MB-231
-APEX1-KnD
 compared to the respective 
wild types (MCF-7-
WT
 and MDA-MB-231-
WT
) and plasmid inserted control (MCF-7-
pEF6
 and MDA-MB-231-
pEF6
). GAPDH was used as internal control. 
3.16.2 Confirmation of APEX1 knockdown at translational level using 
immuno-cytochemistry staining  
Further confirmation of knockdown of APEX1 gene expression at protein level, was 
performed by immuno-cytochemical staining of breast cancer cell lines with APEX1 
antibody. Cells were stained as per recommended protocol described in materials and 
methods section 2.21.1. Decreased and less dense APEX1 staining (brown colour) was 
observed in transfected MCF-7 and MDA-MB-231 cell lines (MCF-7-APEX1-KnD  
and and MDA-MB-231-APEX1-KnD) compared to respective control and wild type 
cell lines which narrate the knockdown of APEX1 molecule in MCF-7-
APEX1-KnD
 and 
MDA-MB-231-APEX1-KnD cells. Deregulated and low level of APEX1 protein 
expression is shown in Figure 3.37D. Images were captured using 40X lens.  
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Figure 3.37D Immuno-cytostaining of APEX1 protein in cancer cell lines.  Reduced 
cytoplasmic staining of transgenes ribozymes transfected (APEX1 knockdown) cells 
of both breast cancer cell lines (MCF-7 and MDA-MB-231) compared to pEF control 
cell lines. Reduction in APEX1 antibody staining in ribozyme transfected cells 
confirmed the knockdown of APEX1gene at protein level  
3.17 In-vitro characterization of APEX1 in Breast Cancer Cell Lines 
After confirmation of successful knockdown of APEX1 molecule in both cell lines, 
various cellular functional assays were performed to evaluate and compare the 
cellular behaviour in APEX1 knockdown cells of both breast cancer cell lines (MCF-
7-
APEX1-KnD
  and and MDA-MB-231-
APEX1-KnD
) with respective wild type control cells 
(MCF-7-WT-CT and MDA-MB-23-
WT-CT
) and pEF6 control cells (MCF-7-
pEF6
 and 
MDA-MB-231-
pEF
). 
3.17.1 Effect of APEX1 knockdown on proliferation of breast cancer cells 
Effect of APEX1 knockdown on proliferation of breast cancer cells was observed by 
performing growth assay as mentioned in materials and methods (section 2.22.1). On 
day-1 (after 24 hours) of growth assay, significantly decreased growth (p<0.01) was 
observed in APEX1 knockdown cells of both cell lines (MCF-7-
APEX1-KnD
 and MDA-
MB-231-
APEX1-KnD
) compared to respective plasmid control cells (MCF-7-pEF-Ct and 
MDA-MB-231-
pEF-Ct
). From day-1 to day-3 significantly decreased growth rate 
(p<0.001) was observed in both APEX1 knockdown cell lines (MCF-7-
APEX1-KnD
 and 
MDA-MB-231-
APEX1-KnD
). When pEF controls were normalised to 100, growth 
observed in APEX1 knockdown cells of both cell lines (MCF-7-
APEX1-KnD
  and MDA-
MB-231-
APEX1-KnD
) from day-1 to day-3 was almost 70% of the growth shown by 
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respective control cells (MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). Similarly, from day-
1 to day-5 significantly decreased growth rate (p<0.001) was observed in both APEX1 
knockdown cell lines (MCF-7-
APEX1-KnD
 and MDA-MB-231-
APEX1-KnD
) compared to 
pEF control cells. When pEF control was normalised to 100, growth in MCF-7-
APEX1-
KnD
 cells was observed 53% and in MDA-MB-231-
APEX1-KnD
 cells was about 72% of 
the growth shown by respective control cells (MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). 
Findings of growth assay are presented in Figure 3.37E, 3.37F, 3.37G, 3.37H, 3.37I 
and 3.37J.  
 
Figure.3.37E Growth assay for APEX1 Knockdown and control cells  
A) Relative growth of APEX1 Knockdown cell of MCF-7 breast cancer cell line 
(MCF-7-
APEX1-KnD
) compared with wild type control (MCF-7-
WT-Ct
) and plasmid 
transfected control (MCF-7-
pEF-Ct
) on day-5. B). Relative growth of APEX1 
Knockdown cells of MDA-MB-231 breast cancer cell line (MDA-MB-231
APEX1-KnD
) 
compared with wild type control (MDA-MB-231-
WT-Ct
) and plasmid transfected 
control (MDA-MB-231-
pEF-Ct
) on day 5 
  
  Results 
242 
 
 
Figure 3.37F Day-1 of growth assay for APEX1 knockdown and control cells of 
MCF-7 and MDA-MB-231 cancer cell lines  
* p <0.05; ** p <0.01; *** p <0.001 
 
 
 
Figure 3.37G Percentage growth increase from day-1 to day-3 in APEX1 knockdown 
and control cells of MCF-7 and MDA-MB-231 breast cancer cell lines 
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.37H Percentage growth in APEX1 knockdown cells of MCF-7 and MDA-
MB-231 cell lines from day-1 to day-3 when pEF control is normalised to 100. 
Growth observed in APEX1 knockdown cells was ~70% of the growth shown by 
control cells    
* p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.37I Percentage growth increase from day-1 to day-5 in APEX1 knockdown 
and control cells of MCF-7 and MDA-MB-231 cancer cell lines 
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.37J Percentage growth in APEX1 knockdown cells of MCF-7 and MDA-
MB-231 cell lines from day-1 to day-5 when pEF control is normalised to 100. 
Growth observed in APEX1 knockdown cells of MCF-7 and MDA-MB-231 cell line 
was ~53% and ~72% of their relative control respectively  
* p <0.05; ** p <0.01; *** p <0.001 
3.17.2 Effect of APEX1 knockdown on adhesion of breast cancer cells  
Role of APEX1 molecule was explored in cellular adhesion to the matrigel by 
performing three replicates of adhesion assay experiments according to the protocol 
cited in materials and methods section 2.22.2. Significantly increased (p<0.05) 
cellular adhesion was observed in APEX1 knockdown cells of both selected breast 
cancer cell lines (MCF-7-
APEX1-KnD
 and MDA-MB-231
APEX1-KnD
) when compared with 
wild type and pEF transfected controls of respective breast cancer cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). Increase in cellular 
adhesion with the membrane consequently has a direct influence on the cellular 
motility (invasion and migration). When pEF control is normalised to 100, adhesion 
ability observed in knockdown cells (APEX1-KnD) was ~109% of the adhesion 
shown by control cells (pEF-CT). p-values were computed using student’s t-test. 
Adhesiveness of knockdown and control cancer cells is presented in Figure 3.37K, 
3.37L and 3.37M.  
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Figure 3.37K Adhesion assay for APEX1 knockdown and control cells 
 A) Relative adhesion of APEX1 Knockdown MCF-7 cells (MCF-7-
APEX1-KnD
) 
compared with wild type control (MCF-7-
WT-Ct
) and plasmid transfected control 
(MCF-7-
pEF-Ct
) B). Relative adhesion of APEX1 Knockdown MDA-MB-231 cells 
(MDA-MB-231
APEX1-KnD
) compared with wild type control (MDA-MB-231-
WT-Ct
) and 
plasmid transfected control (MDA-MB-231-
pEF-Ct
)   
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Figure 3.37L Adhesion assay for APEX1 knockdown and control cells of MCF-7 and 
MDA-MB-231 cell lines 
* p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.37M Percentage adhesion in MCF-7 and MDA-MB-231 knockdown cell 
lines when pEF control is normalised to 100. Adhesion observed in APEX1 
knockdown cells was ~109% of the adhesion observed in pEF control cells 
* p <0.05; ** p <0.01; *** p <0.001 
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3.17.3 Effect of APEX1 knockdown on invasion of breast cancer cells  
Cell invasion assay was performed to evaluate the impact of APEX1 on one of the 
devastating features in carcinogenesis such as metastasis. Migration and proliferation 
of cancer cells from the site of its primary origin to distant organs requires a 
preliminary step of invasion and crossing of basal membrane. APEX1 knockdown 
cells of both breast cancer cell lines  showed a significant decrease (p<0.05) in 
invasion ability (in crossing matrigel membrane) of APEX1 knockdown cells of both 
lines (MCF-7-
APEX1-KnD 
and
 
MDA-MB-231
APEX1-KnD
) when compared with both wild 
type and plasmid inserted control cells of respective cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). When pEF control was 
normalised to 100, invasion ability observed in APEX1 knockdown cells was ~93% of 
the invasion observed in control cells (pEF-CT). Cancer cells invasiveness is shown 
in Figure 3.34 and Figure 3.35.   
 
 
Figure 3.37N Cell invasion assay of APEX1 knockdown and control cells of MCF-7 
and MDA-MB-231 cell lines 
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.37O Percentage of invasion ability in APEX1 knockdown cells of MCF-7 
and MDA-MB-231 cell lines when pEF control is normalised to 100. Invasion ability 
observed in APEX1 knockdown cells was ~93% of the invasion observed in pEF 
control cells. * p <0.05; ** p <0.01; *** p <0.001 
3.17.4 Analysis of APEX1 knockdown in breast cancer cells using 
electric cell substrate impedance sensing (ECIS) system  
3.17.4.1 Effect of APEX1 knockdown on breast cancer cell attachment analysed 
through ECIS system 
Results obtained from adhesion assay were further confirmed by analysis of 
attachment ability of cancer cells using electric cell substrate impedance sensing 
(ECIS) system. Ability of attachment of APEX1 knockdown and control breast cancer 
cell using ECIS system was recorded twice, after one hour of seeding and after two 
hours of seeding in ECIS 96 well plate. After one hour of seeding, there was an 
increased attachment ability of APEX1 knockdown cells of both cell lines (MCF-7-
APEX1-KnD 
and
 
MDA-MB-231
APEX1-KnD
) when compared with both wild type and 
plasmid inserted control cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-
CT
, MDA-MB-231-
pEF-CT
). Increased attachment ability after one hour of seeding into 
ECIS plate was not significant (p=0.078) in case of APEX1 knockdown cell of MCF-7 
breast cancer cell line (MCF-7-
APEX1-KnD
), whereas this enhanced attachment ability of 
APEX1 knockdown cells of MDA-MB-231 cell line (MDA-MB-231
APEX1-KnD
 ) was 
statistically significant (p=0.02). Significantly increased (p<0.05) attachment ability 
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of APEX1 knockdown cells of both breast cancer cell lines (MCF-7-
APEX1-KnD 
and
 
MDA-MB-231
APEX1-KnD
) was observed when compared with both types of control cell 
lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
) after 
two hours of seeding in ECIS plate. Cancer cell attachment ability of APEX1 
knockdown and control cells is shown in Figure 3.37P and 3.37Q. 
 
Figure 3.37P Effect of APEX1 knockdown on attachment ability of breast cancer 
cells after 1hour of seeding into 96 well ECIS plate 
* p <0.05; ** p <0.01; *** p <0.001 
 
Figure 3.37Q Effect of APEX1 knockdown on attachment ability of breast cancer 
cells compared with controls after two hours of seeding in ECIS plate 
* p <0.05; ** p <0.01; *** p <0.001 
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3.17.4.2 Effect of APEX1 knockdown on breast cancer cell migration analysed by 
using ECIS system 
Increased adhesive and decreased invasive abilities of APEX1 knockdown cells 
provided a clear evidence for exploring APEX1 role in relation to cell migration. After 
first electric wound, a decrease in resistance (ohms) was recorded by ECIS system in 
case of APEX1 knockdown cells of MCF-7 breast cancer cell line (p=0.08)
 
and
 
MDA-
MB-231 breast cancer cell line (p=0.21), compared to their respective wild type and 
plasmid inserted control cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-
CT
, MDA-MB-231-
pEF-CT
) but this decrease in migration rates of APEX1 knockdown 
cells was observed non-significant. Again after induction of second electric wound 
decreased migration rate was observed in APEX1 knockdown cells of MCF-7 breast 
cancer cell lines (p=0.08) and
 
MDA-MB-231 breast cancer cell line (p<0.01) when 
compared with their respective wild type and plasmid inserted control cells (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
 and MDA-MB-231-
pEF-CT
).  This decrease 
in migration rate of APEX1 knockdown cells was observed significant in case of 
MDA-MB-231
APEX1-KnD
 (p<0.01) but non-significant in case of MCF-7-
APEX1-KnD
 cells 
(p=0.08) compared to their respective controls. A brief graphical description of 
cellular migration by APEX1 knockdown and control cells of both cancer cell lines 
(MCF-7 and MDA-MB-231) after first and second wound induction is shown in 
Figures 3.37R, 3.37S, 3.37T and 3.37U. 
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Figure 3.37R Effect of APEX1 knockdown on migration ability of MCF-7 breast 
cancer cells as recorded by ECIS system after first wound. MCF-7-
APEX1-KnD
 cells 
showed decreased cellular migration (p=0.08) compared to control cells (MCF-7-
WT-
CT
 and MCF-7-
pEF-CT
); * p <0.05; ** p <0.01; *** p <0.001 
 
Figure 3.37S Effect of APEX1 knockdown on migration ability of MDA-MB-231 
breast cancer cells as recorded by ECIS system after first wound. MDA-MB-231-
APEX1-KnD
 cells showed decreased cellular migration (p=0.21) compared to control cells 
(MCF-7-
WT-CT
 and MCF-7-
pEF-CT
); * p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.37T Effect of APEX1 knockdown on migration ability of MCF-7 breast 
cancer cells as recorded by ECIS system after second electrical wound. MCF-7-
APEX1-
KnD
 cells showed decreased cellular migration (p=0.08) compared to control cells 
(MCF-7-
WT-CT
 and MCF-7-
pEF-CT
); * p <0.05; ** p <0.01; *** p <0.001 
 
Figure 3.37U Effect of APEX1 knockdown on migration ability of MDA-MB-231 
breast cancer cells as recorded by ECIS system after second electrical wound. MDA-
MB-231-
APEX1-KnD
 cells showed significant decrease in cellular migration (p<0.01) 
compared to control cells (MCF-7-
WT-CT
 and MCF-7-
pEF-CT
 
 * p <0.05; ** p <0.01; *** p <0.001 
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3.18 Confirmation of OGG1 knockdown at mRNA level 
Reduced mRNA expression of OGG1 was observed in MCF-7-
OGG1-KnD
 and MDA-
MB-231-
OGG1-KnD
 compared to wild type (MCF-7-
WT
 and MDA-MB-23-
WT
) and 
plasmid inserted control cells (MCF-7-
pEF6
 and MDA-MB-23-
pEF6
) using RT-PCR 
followed by gel electrophoresis (Figure 3.38A) and  real time PCR as shown in Figure 
3.38B. GAPDH was used as internal control in both experiments. 
 
Figure 3.38A Confirmation of OGG1 knockdown at mRNA level and successful 
generation of transgenic breast cancer cell lines using RT-PCR. Gel electrophoresis 
showed relatively lower mRNA expression of OGG1 in both transfected cell lines 
(MCF-7
-OGG1-KnD
 and MDA-MB-231-
OGG1-KnD
) using RT-PCR when compared with 
their wild type (MCF-7-WT-Ct) and pEF control (MCF-7-pEF-Ct) cell lines. GAPDH 
molecule was used as internal control for both cell lines 
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Figure 3.38B Confirmation of OGG1 knockdown at mRNA level using qPCR  and 
successful generation of transgenic breast cancer cell lines. Lower OGG1 transcript 
levels were observed in knockdown cells of both cell lines (MCF-7-
OGG1-KnD
 and 
MDA-MB-231
-OGG1-knD
) compared with wild type control (OGG1-
WT
) and vector 
inserted control cells (OGG1-
pEF
) of respective cell lines 
3.18.1 Confirmation of OGG1 knockdown at translation level by western 
blotting  
Western blot analysis as mentioned in materials and methods section 2.20 was used 
for the confirmation of OGG1 gene knockdown at protein in both breast cancer cell 
lines. Decreased OGG1 protein expression was observed in both knockdown cell lines 
(MCF-7
-OGG1-KnD
 and MDA-MB-231-
OGG1-KnD
) compared to their respective wild type 
control (MCF-7 
WT
 and MDA-MB-231
WT
) and plasmid control (MCF-7-
pEF
 and 
MDA-MB-23-
pEF
). GAPDH was used as internal control for normalization and 
homogeneous distribution of protein in each well. Protein assay was performed and 
standard curve was drawn to evaluate the uniformity of protein samples before 
western blotting experiment. Protein profiling detail is mentioned in Figure 3.38C. 
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Figure 3.38C Protein expression of OGG1 gene through western blot analysis. 
Decreased OGG1 protein levels was observed in both knockdown breast cancer cell 
lines MCF-7-
OGG1-KnD
 and MDA-MB-231
-OGG1-KnD
 compared to respective wild type 
(MCF-7-
WT
 and MDA-MB-231-
WT
) and plasmid inserted control (MCF-7-
pEF6
 and 
MDA-MB-231-
pEF6
). GAPDH was used as internal control. 
 
3.18.2 Confirmation of OGG1 knockdown at translational level using 
immuno-cytochemistry staining 
Further confirmation of knockdown of OGG1 gene expression at protein level was 
performed by immuno-cytochemical staining of breast cancer cell lines with OGG1 
antibody.  Sixteen well chambered slides were used to visualize the expression of 
OGG1 protein molecule in MDA-MB-231 and MCF-7 cell lines. Approximately 
equal number of cells transfected with OGG1 transgene ribozyme and control cells of 
both breast cancer cell lines (MCF-7-
OGG1-KnD
, MCF-7-
WT
 and MCF-7-
pEF-CT
 and 
MDA-MB-231-
OGG1-KnD
, MDA-MB-231-
WT
 and MDA-MB-231-
pEF-Ct
) were seeded 
separately in individual well of the slide. Cells were stained as per recommended 
protocol described in section 2.21.1. Decreased and less dense OGG1 staining (brown 
colour) was observed in transfected MCF-7 and MDA-MB-231 cell lines (MCF-7-
OGG1-KnD
 and MDA-MB-231-
OGG1-KnD
) as compared to respective control and wild 
type cell lines which narrate the knockdown of OGG1 molecule in MCF-7-
OGG1-KnD
 
and MDA-MB-231-
OGG1-KnD
 cells. Deregulated and low level of OGG1 expression is 
shown in Figure 3.38D. Images are taken at 40x magnification. 
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Figure 3.38D Immuno-cytostaining of OGG1 protein in cancer cell lines.  
Reduced cytoplasmic staining of transgenes ribozymes transfected (OGG1 
knockdown) cells of both breast cancer cell lines (MCF-7 and MDA-MB-231) 
compared to pEF control cell lines. Reduction in OGG1 antibody staining in ribozyme 
transfected cells confirm the knockdown of OGG1 gene at protein level. 
3.19 In-vitro characterization of OGG1 in breast cancer cell lines 
After confirmation of successful knockdown of OGG1 molecule in both cell lines, 
various cellular functional assays were performed to evaluate and compare the 
cellular behaviour in OGG1 knockdown cells of both breast cancer cell lines (MCF-7-
OGG1-KnD
 and MDA-MB-231-
OGG1-KnD
) with respective wild type control cells (MCF-
7-
WT-CT
 and MDA-MB-23-
WT-CT
) and pEF6 control cells (MCF-7- 
pEF6
and MDA-MB-
231-
pEF
). 
3.19.1 Effect of OGG1 knockdown on the proliferation of breast cancer 
cells 
Effect of OGG1 knockdown on proliferation of breast cancer cells was observed by 
performing growth assay as mentioned in materials and methods section 2.22.1. On 
day-1 (after 24 hours) of growth assay, increased growth was observed in OGG1 
knockdown cells of both breast cancer cell lines. Difference observed in growth was 
statistically significant in case of MDA-MB-231-
OGG1-KnD
 (p=0.037) cells but non-
significant in case of MCF-7-
OGG1-KnD
 (p=0.71) cells when compared with pEF 
controls of respective cell lines (MCF-7
-pEF-Ct
 and MDA-MB-231-
pEF-Ct
). From day-1 
to day-3 significantly increased growth rate was observed in OGG1 knockdown cells, 
MCF-7-
OGG1-KnD
 (p=0.002) and MDA-MB-231-
OGG1-KnD
 (p=0.016) when compared to 
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plasmid pEF controls of respective cell lines (MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). 
When pEF controls were normalized to 100, growth observed in MCF-7-
OGG1-KnD
 
cells from day-1 to day-3 was 132% (SEM ±31.1) and 105% (SEM ±3.84) in MDA-
MB-231
-OGG1-KnD
 cells. Similarly from day-1 to day-5, significantly increased growth 
rate was observed in MCF-7-
OGG1-KnD
 cells (p<0.001) and MDA-MB-231-
OGG1-KnD
 
cells (p=0.037) when compared to plasmid pEF controls of respective cell lines 
(MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). When pEF control was normalised to 100, 
growth rate observed from day-1 to day-5 in OGG1 knockdown cells of MCF-7 cell 
line (MCF-7-
OGG1-KnD
) was 125% (SEM ±12.96) and MDA-MB-231 cell line  (MDA-
MB-231-
OGG1-KnD
) was 105% (SEM ±4.57). Findings of growth assay with OGG1 
knockdown cells are presented in Figures 3.38E, 3.38F, 3.38G, 3.38H, 3.38I and 
3.38J.  
 
Figure.3.38E Growth assay for OGG1 Knockdown and control cells 
 A) Relative growth of OGG1 Knockdown cells of MCF-7 breast cancer cell line 
(MCF-7-
OGG1-KnD
) compared with wild type control (MCF-7-
WT-Ct
) and plasmid 
transfected control (MCF-7-
pEF-Ct
) on day-5. B). Relative growth of OGG1 
Knockdown cells of MDA-MB-231 breast cancer cell line (MDA-MB-231
OGG1-KnD
) 
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compared with wild type control (MDA-MB-231-
WT-Ct
) and plasmid transfected 
control (MDA-MB-231-
pEF-Ct
) on day-5  
 
Figure 3.38F Day-1 growth assay for OGG1 knockdown and control cells of MCF-7 
and MDA-MB-231 breast cancer cell lines; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.38G Percentage growth increase from day-1 to day-3 in OGG1 knockdown 
and control cells of MCF-7 and MDA-MB-231 breast cancer cell lines 
 * p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.38H Percentage growth in OGG1 knockdown cells of MCF-7 and MDA-
MB-231 breast cancer cell lines from day-1 to day-3 when pEF control was 
normalised to 100; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.38I Percentage growth increase from day-1 to day-5 in OGG1 knockdown 
and control cells of MCF-7 and MDA-MB-231 breast cancer cell lines  
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.38J Percentage growth in OGG1 knockdown cells of MCF-7 and MDA-
MB-231 breast cancer cell lines from day-1 to day-5 when pEF control was 
normalised to 100. Growth in MCF-7-
OGG1-KnD
 and MDA-MB-231-
pEF-Ct
 cells was 
observed 125% (SEM ±12.96) and 105% (SEM ±4.57) respectively, of relative pEF 
controls; * p <0.05; ** p <0.01; *** p <0.001 
3.19.2 Effect of OGG1 Knockdown on Adhesion of Breast Cancer 
Cells  
Role of OGG1 molecule was also explored in cellular adhesion to matrigel by 
performing three replicates of adhesion assay experiments according to the protocol 
cited in materials and methods section 2.22.2. Significant decrease in adhesion ability 
to matrigel membrane was observed in case of MDA-MB-231
OGG1-KnD
 (P=0.045) but 
non-significant decreases in adhesion was observed in case of MCF-7-
OGG1-KnD
 
(p=0.45) when compared with their respective controls (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, 
MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). When pEF controls were normalised to 
100, adhesion ability was observed 92% in MDA-MB-231
OGG1-KnD 
cells and 96% in 
MCF-7-
OGG1-KnD 
cells. Adhesiveness of OGG1 knockdown and control cancer cells is 
presented in Figures 3.38K, 3.38L and 3.38M. 
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Figure 3.38K Adhesion assay for OGG1 Knockdown and control cells 
 A) Relative adhesion of OGG1 Knockdown cells of MCF-7 cell line (MCF-7-
OGG1-
KnD
) compared with wild type control (MCF-7-
WT-Ct
) and plasmid transfected control 
(MCF-7-
pEF-Ct
) B). Relative adhesion of OGG1 Knockdown cells of MDA-MB-231 
cell line (MDA-MB-231
OGG1-KnD
) compared with wild type control (MDA-MB-231-
WT-Ct
) and plasmid transfected control (MDA-MB-231-
pEF-Ct
) 
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Figure 3.38L Adhesion assay for OGG1 knockdown and control cells of MCF-7 and 
MDA-MB-231 cell lines; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.38M Percentage of control cell’s adhesion in OGG1 knockdown cells of 
MCF-7 and MDA-MB-231 cell lines. Adhesion was observed 92% in MDA-MB-
231
OGG1-KnD
 and 96% in MCF-7-
OGG1-KnD
,
 
of the adhesion observed in respective pEF-
CT control cells (MDA-MB-231-pEF-CT and MCF-7-pEF-CT). p-values were 
computed using student’s t-test; * p <0.05; ** p <0.01; *** p <0.001 
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3.19.3 Effect of OGG1 knockdown on invasion of breast cancer cells  
Cell invasion assay was performed to evaluate the impact of OGG1 knockdown on 
invasion ability of cancer cells and role in carcinogenesis. Migration and proliferation 
of cancer cells from the site of its primary origin to distant organs requires a 
preliminary step of invasion and crossing of basal membrane. OGG1 knockdown 
breast cancer cells MCF-7-
OGG1-KnD
 (p=0.026) and
 
MDA-MB-231
OGG1-KnD
 (p=0.023
 
) 
were significantly more invasive with greater ability in crossing matrigel membrane 
when compared with both wild type and plasmid inserted control cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). When pEF control 
was normalised to 100, invasion ability in OGG1 knockdown cells (MCF-7-
OGG1-KnD
 
and MDA-MB-231
OGG1-KnD)
 was 106% of the invasion observed in pEF control cells. 
Invasiveness observed in OGG1 knockdown and control breast cancer cells is 
presented in Figure 3.38N and 3.38O.  
 
Figure 3.38N Cell invasion assay for OGG1 knockdown and control cells of MCF-7 
and MDA-MB-231 cell lines; * p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.38O Percentage of invasion in OGG1 knockdown cells of MCF-7 and 
MDA-MB-231 cell lines when pEF control was normalised to 100. Invasion ability in 
OGG1 knockdown cells (MCF-7-
OGG1-KnD
 and MDA-MB-231
OGG1-KnD)
 was observed 
106% of the invasion observed in pEF control cells 
* p <0.05; ** p <0.01; *** p <0.001 
3.19.4 Analysis of OGG1 knockdown in breast cancer cells using 
electric cell substrate impedance sensing (ECIS) system  
3.19.4.1 Effect of OGG1 knockdown on breast cancer cell attachment analysed 
using ECIS system 
Results obtained from adhesion assay were further confirmed by analysis of 
attachment ability of cancer cells using electric cell substrate impedance sensing 
(ECIS) system. Ability of attachment of breast cancer cells using ECIS system was 
recorded twice, after one hour and two hours of seeding in ECIS 96 well plate. After 
one hour of seeding, significant (p<0.001) decrease in attachment ability was 
observed in OGG1 knockdown cells of both cell lines (MCF-7-
OGG1-KnD 
and
 
MDA-
MB-231
OGG1-KnD
) when compared with both wild type and plasmid inserted control 
cells of respective breast cancer cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-
231-
WT-CT
, MDA-MB-231-
pEF-CT
). Attachment ability of OGG1 knockdown cells was 
also recorded after two hours of seeding in ECIS plate. Significantly decreased 
(p>0.001) attachment ability was again observed in OGG1 knockdown cells of both 
of breast cancer cell lines (MCF-7-
OGG1-KnD 
and
 
MDA-MB-231
OGG1-KnD
) compared to 
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wild type and plasmid inserted control cells of related breast cancer lines (MCF-7-
WT-
CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). Cancer cell 
attachment ability of OGG1 knockdown and control cells is shown in Figures 3.38P 
and 3.38Q. 
 
Figure 3.38P Effect of OGG1 Knockdown on attachment ability of breast cancer 
cells after 1 hour of seeding into ECIS plate; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.38Q Effect of OGG1 Knockdown on attachment ability of breast cancer 
cells after 2 hours of seeding into ECIS plate; * p <0.05; ** p <0.01; *** p <0.001  
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3.19.4.2 Effect of OGG1 Knockdown on breast cancer cell migration analysed 
using ECIS system 
Decreased adhesive and increased invasive abilities of OGG1 knockdown cells 
provided a clear evidence for exploring the role of OGG1 in relation to cell migration. 
It was observed that knockdown of OGG1 gene caused increased cellular migration in 
breast cancer cells. After first electric wound, significant increase in resistance (ohms) 
was recorded by the ECIS system in case of OGG1 knockdown cells of breast cancer 
cell lines (MCF-7-
OGG1-KnD
; p=0.0002 and
 
MDA-MB-231
OGG1-KnD
; p<0.0001) when 
compared with wild type and plasmid inserted control cells of their respective lines 
(MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). This 
increased rate of change in resistance narrates the rapid migration of OGG1 
knockdown cells of both breast cancer cell lines compared to their respective controls. 
Similarly after  induction of second electric wound, significantly increased migration 
rate was observed in OGG1 knockdown cells of MCF-7 breast cancer cell lines 
(p=0.04) and
 
MDA-MB-231 breast cancer cell line (p<0.0001) when compared with 
respective control cells (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-
MB-231-
pEF-CT
). Graphical description of cellular migration by OGG1 knockdown 
and control cells of both cancer cell lines (MCF-7 and MDA-MB-231) after first and 
second wound induction is shown in Figure 3.38R, 3.38S, 3.38T and 3.38U. 
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Figure 3.38R Effect of OGG1 Knockdown on migration ability of MCF-7 breast 
cancer cells after first wound as recorded by ECIS system. Significantly increased 
cellular migration (p=0.0002) of OGG1 knockdown cells of MCF-7 (MCF-7-
OGG1-
KnD
) was observed compared to control cells (MCF-7-
WT-CT
 and MCF-7-
pEF-CT
)  
 
Figure 3.38S Effect of OGG1 Knockdown on migration ability of MDA-MB-231 
breast cancer cells after first wound as recorded by ECIS system. Significantly 
increased cellular migration (p<0.0001) of OGG1 knockdown cells of MDA-MB-231 
cells (MDA-MB-231-
OGG1-KnD
) was observed compared to control cells (MDA-MB-
231-
WT-CT
 and MDA-MB-231-
pEF-CT
)  
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Figure 3.38T Effect of OGG1 Knockdown on migration ability of MCF-7 breast 
cancer cells after second wound as recorded by ECIS system. Significantly increased 
cellular migration (p=0.044) of OGG1 knockdown cells of MCF-7 breast cancer cell 
line (MCF-7-
OGG1-KnD
) was observed compared to control cells (MCF-7-
WT-CT
 and 
MCF-7-
pEF-CT
)  
 
Figure 3.38U Effect of OGG1 Knockdown on migration ability of MDA-MB-231 
breast cancer cells after second wound as recorded by ECIS system. Significantly 
increased cellular migration (p<0.0001) of OGG1 knockdown cells of MDA-MB-231 
breast cancer cell line (MDA-MB-231-
OGG1-KnD
) was observed compared to control 
cells (MDA-MB-231-
WT-CT
 and MDA-MB-231-
pEF-CT
)  
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3.20 Confirmation of XRCC1 Knockdown at mRNA Level 
Reduced mRNA expression of XRCC1 was observed in MCF-7-
XRCC1-KnD
 and MDA-
MB-231-
XRCC1-KnD
 compared to wild type (MCF-7-
WT
 and MDA-MB-231-
WT
) and 
plasmid inserted control (MCF-7-
pEF6
 and MDA-MB-231-
pEF6
) cells using RT-PCR 
followed by gel electrophoresis (Figure 3.39A) and real time PCR (Figure. 3.39B). 
GAPDH was used as internal control in both experiments. 
 
Figure 3.39A Successful generation of transgenic breast cancer cell lines with 
XRCC1 gene knockdown. Gel electrophoresis showing relatively lower mRNA 
expression of XRCC1 in both transfected cell lines (MCF-7
-
 
XRCC 1-KnD
 and MDA-MB-
231-
 XRCC 1-KnD)
 using RT-PCR when compared with respective wild type cells (MCF-
7-
WT-CT
) and pEF control cells (MCF-7-
pEF-CT
) cell lines.  GAPDH was used as 
internal control for both cell lines 
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Figure 3.39B Confirmation of XRCC1 knockdown in MCF-7 and MDA-MB-231 
cells using qPCR and successful generation of transgenic breast cancer cell lines. 
Lower XRCC1 transcript levels were observed in both knockdown cell lines (MCF-7-
XRCC1-KnD
 and MDA-MB-231
-XRCC1-knD
 cells when compared with their wild type 
control (XRCC1-
WT
) and vector inserted control (XRCC1-
pEF
) of respective breast 
cancer cell lines 
3.20.1 Confirmation of XRCC1 knockdown at translation level by western 
blotting  
Western blot analysis was used for confirmation of XRCC1 gene knockdown at 
protein level in both breast cancer cell lines used in this study. Decreased XRCC1 
protein expression was observed in both knockdown cell lines (MCF-7
-XRCC1-KnD
 and 
MDA-MB-231-
XRCC1-KnD)
 compared to respective wild type control (MCF-7 
WT
 and 
MDA-MB-231
WT
) and plasmid control (MCF-7-
pEF
 and MDA-MB-23-
pEF
). GAPDH 
was used as internal control to verify that the amount of protein was homogenous in 
the well. Protein assay was also performed and standard curve was plotted to evaluate 
the uniformity of protein samples before western blot experiment. Protein profiling 
detail is mentioned in Figure 3.39C. 
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Figure 3.39C Protein expression of XRCC1 gene confirmed by western blot analysis. 
Decreased XRCC1 protein levels were observed in both knockout breast cancer cell 
lines MCF-7-
XRCC1-KnD
 and MDA-MB-231
-OXRCC1-KnD
 compared to the respective wild 
type (MCF-7-
WT
 and MDA-MB-231-
WT
) and plasmid inserted control (MCF-7-
pEF6
 
and MDA-MB-231-
pEF6
). GAPDH was used as internal control. 
3.20.2 Confirmation of XRCC1 knockdown at translational level using 
immunocytochemistry staining 
Further confirmation of knockdown of XRCC1 gene expression at protein level was 
performed by immunocytochemical staining of breast cancer cell lines with XRCC1 
antibody.  Sixteen well chambered slides were used to visualize the expression of 
XRCC1 protein in MDA-MB-231 and MCF-7 cell lines. Approximately equal number 
of cells transfected with XRCC1 transgene ribozyme and control cells of both breast 
cancer cell lines (MCF-7- 
XRCC1-KnD
, MCF-7-
WT
 and MCF-7-
pEF-CT
 and MDA-MB-
231-
XRCC1-KnD
, MDA-MB-231-
WT
 and MDA-MB-231-
pEF-CT
) were seeded separately 
in individual wells of the slide. Cells were stained as per recommended protocol 
described in section 2.21.1. Decreased and less dense XRCC1 antibody staining 
(brown colour) was observed in transfected MCF-7 and MDA-MB-231 cell lines 
(MCF-7-XRCC1-KnD and MDA-MB-231- XRCC1-KnD) compared to respective 
control and wild type cell lines which shows the knockdown of XRCC1 molecule in 
MCF-7-
XRCC1-KnD
 and MDA-MB-231-
XRCC1-KnD
 cells. Deregulated and low level of 
XRCC1 expression is shown in Figure 3.39D. Images are taken at 40x magnification. 
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Figure 3.39D Immunocytostaining of XRCC1 molecule in cancer cell lines.  Reduced 
cytoplasmic staining of transgene ribozymes transfected (XRCC1 knockdown) cells of 
both breast cancer cell lines (MCF-7 and MDA-MB-231) compared to pEF control 
cell lines. Reduction in XRCC1 antibody staining in ribozyme transfected cells 
confirmed the knockdown of XRCC1 gene at protein level. 
3.21 In-vitro characterization of XRCC1 in breast cancer cell lines 
After confirmation of successful knockdown of XRCC1 molecule in both cell lines, 
various cellular functional assays were performed to evaluate and compare the 
cellular behaviour in XRCC1 knockdown cells of both breast cancer cell lines (MCF-
7-
XRCC1-KnD
 and MDA-MB-231-
XRCC1-KnD
) with respective wild type control cells 
(MCF-7-
WT-CT
 and MDA-MB-23-
WT-CT
) and pEF6 control cells (MCF-7-
pEF6
 and 
MDA-MB-231-
pEF
). 
3.21.1 Effect of XRCC1 Knockdown on the proliferation of Breast Cancer 
Cells 
Effect of XRCC1 knockdown on proliferation of breast cancer cells was observed by 
performing growth assay as mentioned in materials and methods section 2.22.1. On 
day-1 (after 24 hours) of growth assay, significant decrease in growth was observed in 
MCF-7-
XRCC1-KnD
 cells (p=0.045) but significant increase in growth was observed in 
MDA-MB-231-
XRCC1-KnD
 cells (p=0.05) when compared with pEF controls of 
respective cell lines. From day-1 to day-3, non-significant difference in growth rate 
was observed in MCF-7-
XRCC1-KnD
 (p=0.69) and and MDA-MB-231-
XRCC1-KnD
 (p=0.31) 
when compared to plasmid pEF control cells of respective cell lines (MCF-7-
pEF-Ct
 
and MDA-MB-231-
pEF-Ct
). When pEF controls were normalized to 100, growth from 
day-1 to day-3 in MCF-7-
XRCC1-KnD
 cells was 98% (SEM ±10.42) and 106% (SEM 
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±20.74) in MDA-MB-231-
XRCC1-KnD
 cells of the growth shown by respective control 
cells (MCF-7-
pEF-Ct 
and MDA-MB-231-
pEF-Ct
). Whereas from day-1 to day-5, 
significantly increased growth rate was observed in MCF-7-
XRCC1-KnD
 cells (p<0.05) 
and MDA-MB-231-
XRCC1-KnD 
cells (p<0.05) when compared to plasmid pEF controls 
of respective cell lines (MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). When pEF control 
was normalised to 100, growth rate observed from day-1 to day-5 in XRCC1 
knockdown cells of MCF-7 cell line (MCF-7-
XRCC1-KnD
) was 111% (SEM ±6.22) and 
106% (SEM ±10.14) in MDA-MB-231 cell line  (MDA-MB-231-
XRCC1-KnD
) of the 
growth shown by respective control cells (MCF-7-
pEF-Ct
 and MDA-MB-231-
pEF-Ct
). 
Findings of growth assay with XRCC1 knockdown cells are presented in Figures 
3.39E, 3.39F, 3.39G, 3.39H, 3.39I and 3.39J.  
 
Figure.3.39E Growth assay for XRCC1 Knockdown and control cells 
A) Relative growth of XRCC1 Knockdown cells of MCF-7 breast cancer cell line 
(MCF-7-
XRCC1-KnD
) compared with wild type control (MCF-7-
WT-Ct
) and plasmid 
transfected control (MCF-7-
pEF-Ct
) on day-5. B) Relative growth of OGG1 
Knockdown cells of MDA-MB-231 breast cancer cell line (MDA-MB-231
XRCC1-KnD
) 
compared with wild type control (MDA-MB-231-
WT-Ct
) and plasmid transfected 
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control (MDA-MB-231-
pEF-Ct
) on day-5. Increased growth was observed in 
knockdown cells of both breast cancer cell lines compared to control cells. 
 
Figure 3.39F Day-1 growth in XRCC1 knockdown and control cells of MCF-7 and 
MDA-MB-231 breast cancer cell lines; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.39G Mean percentage growth increase from day-1 to day-3 in XRCC1 
knockdown and control cells of MCF-7 and MDA-MB-231 breast cancer cell lines 
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.39H Mean percentage of control cell’s growth in XRCC1 knockdown cells 
of MCF-7 and MDA-MB-231 breast cancer cell lines from day-1 to day-3. pEF 
control was normalised to 100; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.39I Mean percentage growth increase from day-1 to day-5 in XRCC1 
knockdown and control cells of MCF-7 and MDA-MB-231 breast cancer cell lines  
* p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.39J Percentage of control cell’s growth in XRCC1 knockdown cells of 
MCF-7 and MDA-MB-231 breast cancer cell lines from day-1 to day-5.When pEF 
control was normalised to 100 growth in OGG1 knockdown cells, MCF-7-
OGG1-KnD
 
and MDA-MB-231-
pEF-Ct
 cells was observed 111% (SEM ± 6.22) and 106% (SEM ± 
10.14) respectively of their relative pEF controls 
* p <0.05; ** p <0.01; *** p <0.001 
3.21.2 Effect of XRCC1 knockdown on adhesion of breast cancer cells  
Role of XRCC1 was explored in cellular adhesion to the matrigel by performing three 
replicates of adhesion assay experiments according to the protocol cited in materials 
and methods section 2.22.2. Significant decrease in adhesion ability to matrigel 
membrane was observed in case of MCF-7-
XRCC1-KnD
 (P=0.042) but non-significant 
decrease in adhesion was observed in case of MDA-MB-231
XRCC1-KnD
 (p=0.08) when 
compared with respective controls (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-
CT
, MDA-MB-231-
pEF-CT
). When pEF controls were normalised to 100, adhesion 
ability in MCF-7-
XRCC1-KnD
 cells
 
was observed 88% and in MDA-MB-231
XRCC1-KnD 
cells was observed 90% of the adhesion shown by respective pEF-CT control cells 
(MDA-MB-231-
pEF-CT
 and MCF-7-
pEF-CT
). Adhesiveness of XRCC1 knockdown and 
control cancer cells is presented in Figure 3.39K, 3.39L and 3.39M. 
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Figure 3.39K Adhesion assay for XRCC1 Knockdown and control cells 
 A) Relative adhesion of XRCC1 Knockdown cells of MCF-7 cell line (MCF-7-
XRCC1-
KnD
) compared with wild type control (MCF-7-
WT-Ct
) and plasmid transfected control 
(MCF-7-
pEF-Ct
) B) Relative adhesion of XRCC1 Knockdown cells of MDA-MB-231 
cell line (MDA-MB-231
XRCC1-KnD
) compared with wild type control (MDA-MB-231-
WT-Ct
) and plasmid transfected control (MDA-MB-231-
pEF-Ct
)  
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Figure 3.939L Adhesion assay for XRCC1 knockdown and control cells of MCF-7 
and MDA-MB-231 cell lines; * p <0.05; ** p <0.01; *** p <0.001 
 
 
Figure 3.39M Percentage of control cell’s adhesion in XRCC1 knockdown cells of 
MCF-7 and MDA-MB-231 cell lines. pEF control was normalised to 100. Adhesion 
observed in MCF-7-
XRCC1-KnD
 cells was 88% and 90% in MDA-MB-231
XRCC1-KnD 
cells 
of the adhesion observed in respective pEF-
CT
 control cells (MDA-MB-231-
pEF-CT
 and 
MCF-7-
pEF-CT
).  p-values were computed using student’s t-test. 
* p <0.05; ** p <0.01; *** p <0.001 
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3.21.3 Effect of XRCC1 knockdown on invasion of breast cancer cells  
Cell invasion assay was performed to evaluate the impact of XRCC1 on invasion 
ability of cancer cells and role in carcinogenesis. Migration and proliferation of 
cancer cells from the site of its primary origin to distant organs requires a preliminary 
step of invasion and crossing of basal membrane. XRCC1 knockdown cells of both 
breast cancer cell lines were more invasive with significantly greater ability in 
crossing matrigel membrane as observed in MCF-7-
XRCC1-KnD
 (p=0.042)
 
and
 
MDA-
MB-231
XRCC1-KnD
 p=0.05) when compared with pEF control cells of respective cell 
lines. When pEF control was normalised to 100, invasion ability in XRCC1 
knockdown cells was observed 108% in MCF-7-
XRCC1-KnD
 and 103% in MDA-MB-
231
XRCC1-KnD 
cells, of the invasion observed in related pEF control cells. Results are 
suggestive of correlation of XRCC1 deregulation with cancer cell invasiveness ability.  
Cancer cells invasiveness is shown in Figure 3.39N and 3.39O. 
 
 
Figure 3.39N Cell invasion assay for XRCC1 knockdown and control cells of MCF-7 
and MDA-MB-231 cell lines; * p <0.05; ** p <0.01; *** p <0.001 
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Figure 3.39O Percentage of control cells’s invasion in XRCC1 knockdown cells of 
MCF-7 and MDA-MB-231 cell lines. When pEF control was normalised to 100, the 
invasion ability in XRCC1 knockdown cells, MCF-7-
OXRCC1-KnD
 was observed 108% 
and 103% in MDA-MB-231
XRCC1-KnD 
cells of the invasion observed in pEF control 
cells; * p <0.05; ** p <0.01; *** p <0.001 
3.21.4 Analysis of XRCC1 knockdown in breast cancer cells using electric 
cell substrate impedance sensing (ECIS) system 
3.21.4.1 Effect of XRCC1 Knockdown on breast cancer cell attachment analysed 
by ECIS system 
Results obtained from adhesion assay were further confirmed by analysis of 
attachment ability of cancer cells using electric cell substrate impedance sensing 
(ECIS) system. Ability of attachment of breast cancer cells using ECIS system was 
recorded twice, after one and then after two hours of seeding into ECIS 96 well plate. 
After one hour of seeding, significant decrease in attachment ability was observed in 
MCF-7-
XRCC1-KnD
 cells (p=0.012)
 
 and in
 
MDA-MB-231
XRCC1-KnD 
cells (p=0.021) when 
compared with both wild type and plasmid inserted control cells of respective breast 
cancer cell lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). Attachment ability of XRCC1 knockdown cells was also recorded after two 
hours of seeding in ECIS plate in which again significantly decreased attachment 
ability was observed in XRCC1 knockdown cells,
 
MCF-7-
XRCC1-KnD
  (p=0.022)
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MDA-MB-231
XRCC1-KnD
 (p=0.018) compared to wild type and plasmid inserted 
control cells of related breast cancer lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-
231-
WT-CT
, MDA-MB-231-
pEF-CT
). Cancer cell attachment ability of OGG1 
knockdown and control cells is shown in Figures 3.39P and 3.39Q. 
 
Figure 3.39P Effect of XRCC1 Knockdown on attachment ability of breast cancer 
cells after 1hour of seeding into 96 well ECIS plate 
 * p <0.05; ** p <0.01; *** p <0.001  
 
Figure 3.39Q Effect of XRCC1 Knockdown on attachment ability of breast cancer 
cells after 2hours of seeding into 96 well ECIS plate 
 * p <0.05; ** p <0.01; *** p <0.001 
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3.21.4.2 Effect of XRCC1 Knockdown on breast cancer cell migration analysed 
through ECIS system 
Decreased adhesive and increased invasive abilities of XRCC1 knockdown cells 
provided a clear evidence for exploring the role of XRCC1 gene in relation to cell 
migration. After first electric wound, significant increase in resistance (ohms) was 
recorded by the ECIS system in case of XRCC1 knockdown  breast cancer cells MCF-
7-
XRCC1-KnD 
(p=0.02) and
 
MDA-MB-231
XRCC1-KnD
 (p=0.01) when compared with 
control cells of respective lines (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, 
MDA-MB-231-
pEF-CT
). This increased rate in resistance shows the rapid migration of 
XRCC1 knockdown cells of both breast cancer cell lines as compared to their 
respective controls. Similarly, even after the induction of second electric wound, 
significantly increased migration rate was observed in XRCC1 knockdown cells of 
MCF-7 breast cancer cell line (p=0.04) and
 
MDA-MB-231 breast cancer cell line 
(p<0.0001) when compared with respective wild type and plasmid inserted control 
cells (MCF-7-
WT-CT
, MCF-7-
pEF-CT
, MDA-MB-231-
WT-CT
, MDA-MB-231-
pEF-CT
). This 
clearly shows that suppression of XRCC1 gene leads to increased cellular migration in 
breast cancer cells. Graphical description of cellular migration by XRCC1 knockdown 
and control cells of both cancer cell lines (MCF-7 and MDA-MB-231) after first and 
second wound induction is shown in Figure 3.39R, 3.39S, 3.39T and 3.39U. 
 
 
  Results 
283 
 
 
Figure 3.39R Effect of XRCC1 Knockdown on migrational ability of MCF-7 breast 
cancer cells after first wound as recorded by ECIS system  
 
 
Figure 3.39S Effect of XRCC1 Knockdown on migrational ability of MDA-MB-231 
breast cancer cells after first wound as recorded by ECIS system 
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Figure 3.39T.Effect of XRCC1 Knockdown on migrational ability of MCF-7 breast 
cancer cells after second wound as recorded by ECIS system  
 
 
 
Figure 3.39U Effect of XRCC1 Knockdown on migrational ability of MDA-MB-231 
breast cancer cells after second wound as recorded by ECIS system  
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4. Discussion  
Breast cancer is the most prevalent cancer (25.2% of all cancers) in women with 
highest incidence rate (43.3 per 100 000) than any other cancer worldwide (Bernard et 
al., 2014). Women of all geographic areas, races and ethnicities are reported to be 
affected from breast cancer. However, its incidence, clinical presentation and survival 
rates vary in different geographical areas and among different races and ethnicities 
within the same geographic region (Bhikoo et al., 2011). Approximately half of the 
global occurrence of this disease is observed in Asia, with 22% in China and 7-8% in 
India and Pakistan (Bernard et al., 2014). In Pakistan, it is the most commonly 
diagnosed cancer with an incidence rate of 33.1% of all cancer types, which is highest 
in all Asian populations except Israeli Jews (Bhurgri et al., 2006).  Globally, breast 
cancer accounts for ~14% of all cancer mortalities (Jemal et al., 2011) with ~5 fold 
variation in different regions (Khokher, 2012). In developed countries elevated breast 
cancer incidence but lower mortality rates are observed. Whereas, in developing and 
under developed countries late stage presentation of biologically aggressive disease in 
relatively younger population is characteristic feature. Genetic, economic, cultural and 
life style differences might be the main attributing factors (Jemal et al., 2011; 
Khokher, 2012; Bernard et al., 2014).  
For this, we characterized germ line mutations in base excision repair (BER) pathway 
genes for a possible association with breast cancer and analysed expression of these 
genes at mRNA and protein level in breast cancer patients along with healthy 
controls. For Mutational analysis, blood samples along with personal and disease 
related information of 530 breast cancer patients and 395 controls were collected. The 
data collected from patients revealed a higher incidence of breast cancer diagnosis at 
age 40 years or above. Mean age at onset of breast cancer in patients was calculated 
as 46.4 (±11.6) years. Similar findings have earlier been reported previously in many 
studies from different areas of Pakistan, where mean age of breast cancer cases in 
Pakistan was reported as 46 years (Imtiaz et al., 2012), <45 years (Afsar et al., 2010), 
between 30-50 years (Fatima et al., 2010), 47±12 years (Bhikoo et al.,  2011; 
Khokher, 2012), 47.6±12, (Badar et al., 2011) and 48 years (Siddiqui et al., 2000; 
Malik, 2002; Bhurgri et al., 2007; Sharif et al., 2009). In Pakistan, breast cancer has 
been reported as disease of younger age compared to developed western world 
(Bageman et al., 2007). The clear difference between developing and the developed 
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countries regarding breast cancer is younger age at presentation in developing 
countries (40 to 50 years) compared to developed countries (60 to 70 years) (Leong et 
al., 2010). Younger age at presentation is a feature of breast cancer patients in most of 
the developing countries like India (Saxena et al., 2005; Agarwal et al., 2007), Sri 
Lanka (Lokuhetty et al., 2009) and Cameroon (Ngowa et al., 2011). Younger age at 
presentation in developing countries may be due to lower life expectancy and greater 
environmental stress (Khokher, 2012). 
Association of important parameters with breast cancer pathogenesis is discussed here 
one by one. 
Menstrual and reproductive history of patients is one of the major risk factors 
which may be helpful in estimation of breast cancer risk using multiple risk prediction 
models including Gail Model breast cancer risk assessment tool 
(http://www.cancer.gov/bcrisktool/). Established reproductive risk factors for breast 
carcinogenesis include early menarche, delayed ﬁrst full-term pregnancy, nulliparity 
or lower parity and late menopausal age and use of oral contraceptives (Key et al., 
2001; Faheem et al., 2007; Yang et al., 2012). The role of reproductive factors in 
breast cancer etiology has been well-recognized but the relationship to specific 
underlying biological mechanisms has yet not been unveiled. Deregulations of 
endogenous hormonal profiles have generally been presumed to play a role in breast 
carcinogenesis but further investigations are necessary to elucidate their effects (Yang 
et al., 2012; Bernard et al., 2014).  In this study, association of multiple reproductive 
risk factors with breast cancer was analysed but the relationship of majority of these 
factors was observed non-significant which is in accordance with findings of many 
previous studies (Malik, 2002, Rusiecki et al., 2005; Gangat et al., 2007; Fatima et 
al., 2010, Baig et al., 2013).  
Early age at menarche may have important implications in the possibility of 
pregnancy and child-bearing and may lead to several pathologic conditions due to first 
menstruation at an earlier age (Gilani and Kamal, 2004). Exposure to estrogens for 
relatively prolonged duration in a female´s life, as a result of earlier age at menarche, 
is considered an important risk factor for breast carcinogenesis (Parsa and Parsa, 
2009). In this study, it was observed that only 25% patients had age at menarche 
<13years. There was no significant association observed between age at menarche and 
breast cancer in this study. Similar findings have also been reported in previous 
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studies involving Pakistani females where age at menarche was predominantly >13 
years (Gangat et al., 2007; Tariq et al., 2009). Older age of menstruation lowers the 
risk of breast cancer and this risk decreases by 5% with each 1 year delay in 
menarche. (Key et al., 2001, Bernard et al., 2014). This late age at menarche may play 
a protective effect due to exposure of the breast to endogenous hormones for lesser 
duration in life (Kruk, 2009). 
Menstrual characteristics have been considered an important factor in the 
prediction of breast cancer risk. Early age at menarche and late natural menopause, 
have been observed to be associated with the highest breast cancer risks, perhaps due 
to an impact of ovulatory activity (Parsa and Parsa, 2009; Phipps et al., 2010;  
CGHFBC, 2012;  Shamsi et al., 2013; Bernard et al., 2014). Late menopause presents 
a greater risk for breast cancer and with each year delay in menopause, risk increases 
by 3% (Key et al., 2001). In this study ~61 % female patients (among menopausal 
patients) had termination of menstrual cycle before 48 years of age. Mean age of post-
menopausal patients at menopause was 46.2 ±0.4 years. Similar results have earlier 
been published from different parts of Pakistan where average age of menopause was 
reported as 46.5 year (Shamsi et al., 2013), 44.5 years ±0.8 years in Karachi (Adhi et 
al., 2007) and 46±2 in a study from Khyber Pakhtunkhawa province, in female breast 
cancer patients (Lowe et al., 2011). All studies from Pakistan (including this study) 
show that mean menopausal age of breast cancer patients is lower (45–48 years) than 
that in the western world (50.3 years) (Singh et al., 2012).  
Another important risk factor for breast cancer documented in literature, is the 
parity status of females. It is well established that nulliparity in women may double 
the risk of breast cancer compared to the risk associated with the parous women and 
multiparity may be associated with decreased breast cancer risk. So women who have 
their first full term pregnancy at an early age are considered at lowest risk and this 
risk gradually increases with late ages at first birth (Bernstein, 2002). Decrease in 
breast cancer risk is mainly dependent on full-term pregnancy and no effect of short-
term pregnancies (miscarriages and abortions) is observed on breast cancer (Bernard 
et al., 2014). In present study we observed that most of the breast cancer patients were 
multiparous (61%), followed by 26% uniparous and only 13% patients were 
nulliparous. Statistically non-significant association was observed between parity 
alone and breast cancer risk but when later age of pregnancy, nulliparity and uni-
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parity were analyzed altogether, significant association was observed. Similar 
findings have earlier been reported (Bernstein, 2002; Faheem et al., 2007; Bernard et 
al., 2014), where early age at menarche, first pregnancy at late age, nulliparity and 
late menopause have been associated with a higher risk of breast cancer (Colditz et 
al., 2006).  
Family history of patients in this study was observed significantly associated 
(p<0.04) with breast cancer development when compared with controls.  Risk of 
developing breast cancer has been observed to increase almost two times in females 
with at least one first-degree relative with breast cancer compared to females with no 
first-degree relatives suffering from cancer. Breast cancer risk increases by three 
times or even higher if two or more first-degree relative are suffering from breast 
cancer. Moreover having a relative with bilateral breast cancer may increase the 
breast cancer risk as having two affected relatives (Pharoah et al., 1997; Mavaddat et 
al. 2010). Nevertheless, it has also been observed in many studies that more than 85% 
females with breast cancer in first-degree relative never develop breast cancer 
themselves and over 87% of female breast cancer patients have no first-degree 
relatives with cancer (Cuzick, 2008).   
In this study, association between smoking and breast cancer risk was 
observed significant (p<0.03) when breast cancer patients were compared with control 
individuals. Similar findings about significant association between smoking (active 
and passive) and breast cancer has earlier been explored in about 150 epidemiological 
studies and different consensus reviews where different conclusions have been made 
due to differences in interpretation (IARC, 2012; Bernard et al., 2014). Canadian 
expert panel on tobacco smoke and breast cancer risk, on the basis of bulk of 
evidences from epidemiological and toxicological studies along with understanding of 
underlying biological mechanisms, have concluded that there is an association 
between tobacco use (active or passive smoking) and breast cancer (both pre- and 
post-menopausal) which is also evident from consistent breast cancer related deaths in 
smokers (Collishaw et al., 2009). 
Deregulations in endogenous or exogenous female sex hormones have 
consistently been reported to influence the risk of breast cancer and cancers of female 
reproductive organs and breast. Mechanisms of involvement of female sex hormones 
in breast carcinogenesis include responses mediated by estrogen-receptors and direct 
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genotoxic effects of estrogenic hormones or their derivative products (IARC, 2012). 
Estrogen and progesterone receptors (ER, PR) and HER-2/neu greatly influence the 
management of this malignancy (Rampaul et al., 2001) and generally are found to be 
lower in Asian countries than Africa, western world, USA and Australia  (Ahmed et 
al., 2007; Hedayati-Moghadam 2008; Ahmed et al., 2011). 
Based on the results obtained from this study, it has been proposed that different 
genetic factors alone or in combination with other non-genetic factors might play a 
key role in breast carcinogenesis in Pakistani population (Faheem et al., 2007; Fatima 
et al., 2010; Khokher, 2012).  
4.1 Characterization of BER pathway genes in breast cancer patients 
Cancer susceptibility is a polygenic process and carcinogenesis involves a series of 
multiple genetic modifications and alterations in normal molecular and enzymatic 
machinery of cells which control cellular growth, differentiation, cell death or 
genomic instability. BER pathway is the most important in repair mechanisms and 
primary guardian against damage that results from cellular metabolism including 
reactive oxygen species, methylation, deamination and hydroxylation (Bunz, 2008). 
BER pathway detects and removes these various forms of base damage by number of 
coordinated sequential reactions (Dexheimer, 2013) and is a universal event in cells 
for preventing mutagenesis (Zhou et al. 2011a) Impaired base-excision repair (BER) 
function may give rise single nucleotide polymorphisms (SNPs) and accumulated 
DNA damage, leading to permanent mutations in the genome, which may ultimately 
contribute to carcinogenesis. Defective BER is associated with increased cancer risk 
of various organs including lung cancer (Speina et al., 2003), esophageal cancer (Hao 
et al., 2004) and bladder cancer (Huang et al., 2007). However, there is little data 
present for the association of these genes with breast cancer. BER pathway has been 
well studied in different populations with different cancers by focusing on three key 
genes: X-ray repair cross-complementing protein 1 (XRCC1), 8-oxoguanine DNA 
glycosylase (OGG1) and apurinic/apyrimidinic endonuclease 1(APEX1) (Hu et al., 
2001; Zhang et al., 2006; Lo et al., 2009; Lu et al., 2009; Li et al., 2011; Karahalil et 
al., 2012; Mahjabeen et al., 2013; Kim et al., 2013; Popanda et al., 2013; Ali et al., 
2014).  
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In this study we screened APEX1, OGG1 and XRCC1 genes for germ line variations 
involving 530 breast cancer patients and 395 controls from Pakistani population. We 
screened all exons and exon/intron junctions of three BER genes (APEX1, OGG1 and 
XRCC1) using PCR-SSCP followed by DNA sequencing. Additionally, association of 
germline variations with important clinico- histopathological parameters of breast 
cancer patients was also explored. 
 
4.1.1 Mutational analysis of APEX1 gene 
APEX1 is a multifunctional protein which plays an important role in DNA repair 
process through AP-endonucleolytic 3´ phosphodiesterase, 3´-5´ exonuclease and 3´ 
phosphatase activities. It is also involved in numerous critical cellular responses 
including tumor initiation and development, oxidative stress, cell cycle regulation and 
apoptosis (Zhang and Wang, 2010). It is the only known repair enzyme with self-
regulation system (Dyrkheeva et al., 2007). In this study, mutational screening of 
APEX1 gene for germline variations in breast cancer cases and controls individuals 
revealed a total of fourteen mutations. Seven mutations were found in 5´UTR region, 
one in 3´UTR region, two intronic and four missense mutations. Observed mutations 
include 11 novel and three known mutations (rs41561214, rs17112002 and 
Ser129Arg by Mahjabeen et al., 2013). Most of the mutations in 5´UTR, 3´UTR and 
intronic region were significantly higher in breast cancer patients compared with 
healthy control individuals. Promoter region and 5′UTR is important for the 
translation regulation of transcripts (Lodish and Havery, 2004), so mutations in these 
regions may be crucial for cellular functioning. Genetic alterations in 3′UTR region of 
repair genes have previously been found associated with higher susceptibility to 
various tumours (Vogelstein and Kinzler, 2002).  3′UTR mutations may result in 
either exon skipping or cryptic splice site activity and may deregulate protein levels 
and affect half-life of protein (Campbell and Farrell, 2009; Lheureux et al., 2011). 
Variants outside DNA repair domain such as 5´UTR or promoter regions of APEX1 
are informative and may be used as markers for the disease-causing SNPs (Avery, 
2007). Various SNPs have been reported in 5´UTR, 3´UTR and promoter regions of 
APEX1 gene and found to influence the susceptibility and progression of different 
cancers including lung cancer (Lo et al., 2009; Lu et al., 2009), bladder cancer (Wang 
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et al., 2010), glioblastoma (Zhou et al., 2011a), breast cancer (Kang et al., 2013a) and 
cervical cancer (Wang et al., 2013) risk in Asian populations.  
In addition to these mutations, four missense mutations (Glu101Lys, Ala121Pro, 
Ser123Trp and Ser129Arg) were also observed in exon 4 which covers both redox 
domain and DNA-repairing domain of APEX1. Glu101Lys at residue 101 is in the 
redox domain while Ala121Pro, Ser123Trp, Ser129Arg are found in DNA-repairing 
domain of APEX1. APEX1 protein has a spatial configuration and is 
mainly constituted by two overlapping functional domains at N- and C-terminals. The 
N-terminal domain is considered to be responsible for redox functioning and modify 
the DNA-binding capacity of multiple transcriptional factors and is involved in 
regulating the gene expression (Wong et al., 2003; Dyrkheeva et al., 2007; Zhang and 
Wang, 2010). C-terminal performs DNA repair functions and protects cells from the 
cytotoxicity caused by the continuously accumulating exogenous and endogenous AP 
site mutation (Zhang and Wang, 2010). Structural prediction of Ser129Arg variant in 
APEX1 by Mahjabeen et al (2013) has shown no major change in protein structure 
compared with wild-type protein nevertheless APEX1-compromised cells may be 
more susceptible to oxidative stress due to reduced redox and 3′phosphodiestrase 
activity impacting cell survival, pushing it towards apoptosis (Fishel et al., 2007). 
Presence of identified missense mutations in both Redox and Repair domains signify 
that how repair process of DNA might be affected due to inhibition of Redox and 
repair activity of APEX protein. Missense mutations observed in this study were 
analysed via Alamut biosoftware to check the conservation level of mutated 
nucleotides and encoded amino acids. It is predicted that observed missense 
mutations, especially of highly conserved nucleotides and amino acids, may show 
some deleterious, potentially disease causing effects resulting physiochemical 
alterations in the structure of amino acids.  
When analysed, APEX1 mutations observed in this study were found significantly 
correlated with different clinico-pathological parameters. Frequency of mutations was 
found higher in patients with invasive ductal carcinoma, tumors grade II, family 
history of cancer, early menopause and negative ER, PR, HER-2/neu status. These 
factors have already been reported to contribute in breast cancer development in 
Pakistani populations (Naeem et al., 2008; Azizun-Nisa et al., 2008; Sharif et al., 
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2010; Ahmed et al., 2011) and worldwide (Dumitrescu et al., 2005; Ahmed et al., 
2011; Popanda et al., 2013).  
4.1.2 Mutational analysis of OGG1 gene  
OGG1 is an important gene of BER pathway which encodes the enzyme responsible 
for the excision of 8-oxoguanine (8-oxoG), a mutagenic base byproduct, which arises 
as a result of exposure to reactive oxygen species (ROS). OGG1 is a bi-functional 
glycosylase, as it is able to cleave the glycosidic bond of the mutagenic lesion and 
causes a strand break in the DNA backbone (Duan et al., 2012). Literature survey of 
studies regarding germline OGG1 mutations shows that most of the studies (from 
2006-2014) have focused only one OGG1 mutation (Ser326Cys in 8-oxoguanine 
glycosylase domain) for its role in carcinogenesis. Majority of the studies (~60%) 
concluded a positive association of this mutation with different cancers. Mutations 
other than Ser326Cys, in the same domain or other domains of OGG1, singly or in 
combination, may also be important in initiation and development of cancer 
(Mahjabeen et al., 2011). Moreover, studies involving relatively larger population for 
exploration of different OGG1 mutations in relation to other clinico-histopathological 
parameters may also be important for their role in cancer development.  
In this study all exons and intron-exon margins of OGG1 gene were screened for 
possible germline variations at structural and functional level 530 breast cancer 
patients and 395 controls. A total of fifteen mutations were identified in patients and 
in control individuals. Eleven mutations were observed in different noncoding regions 
of OGG1 gene including five mutations in intronic regions, four in donor splice site 
and two mutations in 3´UTR regions. This includes, 12 novel mutations and three 
known mutation (rs55846930, TMP_ESP_3_9796483 and rs1052133). Frequencies of 
observed mutations were found significantly higher in patients compared to control 
individuals suggesting their possible association with breast carcinogenesis.  
Promoter region and 3′ UTR is important for the regulation of translation of specific 
mRNA (Lodish and Havery, 2004), whereas mutations in promoter region can 
influence interactions between transcriptional factors and affect their ability to 
recognize DNA sequences in a promoter region resultantly gene expression may be 
affected (Luo et al., 2014). So mutations observed in this study as discussed earlier 
are likely to be very crucial for cellular functioning. All mutations were also analyzed 
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by Alamut biosoftware (version 2.4-5) which predicted the skipping of exon 1, 5, 6 
and 7 as mutations were observed in donor splice site areas of respective exons. 
Splice sites in a gene are involved in the processing of precursor mRNA into mature 
mRNA. The deletion, insertion or any substitution in the splice site results in mature 
mRNA having one or more introns leading to the production of aberrant proteins. 
Splice site mutations may produce mRNA transcript which retain some information 
from introns along with the expression of exons. Splice site mutations may lead to 
several genetic disorders including cancer.  It has been estimated that 15% of all point 
mutations occurring within a splice site may lead to human genetic diseases (Carvalho 
et al., 1998). It has been demonstrated that splice site variant in the base excision 
repair genes are associated with the production of an aberrant mRNA transcript 
encoding a truncated BER protein (Tao et al., 2004). Nucleotide substitution causes 
abnormal splicing of the hOGG1 gene leading to partial inactivation of the splice site 
of intron1 and encoding a truncated hOGG1 protein in cancer cells (Kohno et al., 
1998). Since splice site regions in a gene are involved in the processing of precursor 
mRNA into mature mRNA. So deletion, insertion or any substitution in the splice 
sites may result in mature mRNA which may have one or more introns in it, leading 
to the production of aberrant proteins. 
Missense mutations result in change of amino acid in protein structure. At least 
twenty five validated sequence variants of OGG1 gene have previously been reported 
to change amino acid in OGG1 protein but Ser326Cys (rs1052133) has extensively 
been investigated and found associated with different types of cancers (Gerhard et al. 
2004; Vodicka et al. 2007) such as esophageal (Xing et al., 2001), gastric (Tsukino et 
al., 2004), gall bladder  (Srivastav et al., 2009) lung (Hung et al., 2005; Guan et al., 
2011; Duan et al., 2012), thyroid (García-Quispes et al., 2011), laryngeal (Mahjabeen 
et al., 2012) and pancreatic cancer (Yan et al., 2014). In this study, Ser326Cys is 
observed in breast cancer patients with significantly higher frequency (p=0.004) 
compared to controls. Ser326Cys variant is observed in 8-oxoguanine DNA-
glycosylase domain, which is involved in DNA glycosylase activity of OGG1 protein 
(Hashiguchi et al., 2004). Cells with Ser326Cys mutation in homozygous condition 
are deficient in the repair of oxidative DNA damage especially under excessive 
oxidative stress (Lee et al., 2008). OGG1 protein with hOGG1-Cys326 amino acid 
(mutated) in 8-hydroxyguanine DNA-glycosylase domain is associated with 
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significantly reduced DNA repair activity (Hung et al., 2005; Weiss et al., 2005; Lee 
et al., 2008; Guo et al., 2012), reduced enzyme activity and increased cancer risk (Lee 
et al., 2008; Guo et al., 2012) compared to normal hOGG1-Ser326 protein.  
In addition to Ser326Cys, two missense mutations (Val159Gly in Exon 3 and 
Gly221Arg in Exon 4) are also observed in C-terminus of OGG1 gene. Missense 
mutations, Val159Gly and Gly221Arg are found in HhH-GPD and 8-oxoguanine 
DNA-glycosylase domains of OGG1 protein. HhH-GPD domain of OGG1 protein 
contains a highly conserved motif that resembles to the helix–hairpin–helix (HhH) 
motif which is characteristic of active site of endonuclease III family of DNA 
glycosylases/AP lyases (Labahn et al., 1996; Lingaraju et al., 2005). Regions 
conserved among species are supposed to comprise of functionally important domains 
involved in the maintenance of normal protein function (Lamerdin et al., 1995). HhH-
GPD domain of OGG1 is very important since it performs the catalytic as well as 
DNA-binding functions of DNA glycosylase, so mutations in this domain can be 
pathogenic (Bruner et al., 2000; Norman et al., 2003).   
In this study, nonsense mutation Trp375STOP is observed in breast cancer patients 
with significantly high frequency (p=0.01) compared to controls. This mutation 
results in truncation of C-terminus of OGG1 protein (β isoform). Function of C-
terminus of β isoform of OGG1 is still not clear as it has been least investigated. αO-
helix domain in C-terminal of human OGG1 is essential for 8-oxoguanine DNA 
glycosylase activity. Mitochondrial β-OGG1 lacks this domain so does not have 
glycosylase activity. β isoform of OGG1 protein also retains HhH-GPD motif (which 
is highly conserved in EndoIII DNA glycosylase family) which suggests its possible 
role in some other step of base excision repair. C-terminus of β isoform of OGG1 
protein also has a long coiled tail spanning a trans-membrane domain which may be 
involved in anchoring of protein in membranous structures (Hashiguchi et al., 2004). 
In view if above cited facts, truncation of C-terminus of β isoform, may compromise 
the proper functioning of OGG1 protein in DNA repair process. Moreover, missense 
mutations (Val159Gly, Gly221Arg and Ser326Cys) and non-sense mutation 
(Trp375STOP) observed in this study with significantly high frequency in breast 
cancer patients compared to control individuals suggest their association with breast 
carcinogenesis. 
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Missense and non-sense mutations observed in this study were analysed via Alamut 
biosoftware (version 2.4-5) to check the conservation level of mutated nucleotides and 
encoded amino acids. As presented in Table 3.11, it was observed that missense 
mutations, especially of highly conserved nucleotides (g.9793544T>G) and conserved 
amino acids (Val159Gly; Gly221Arg and Trp375STOP) have shown some deleterious, 
potentially disease causing effects resulting in physiochemical alterations in structure 
of amino acids.  OGG1 mutation frequencies were also correlated with different 
clinico-pathological parameters and significant associations were observed. Higher 
mutation frequencies were found associated with invasive ductal carcinoma, family 
history of cancer, early menopause, smoking history and negative ER, PR, HER-2/neu 
status which have already been reported to contribute to breast cancer development in 
Pakistani populations (Naeem et al., 2008; Azizun-Nisa et al., 2008; Sharif et al., 
2010; Ahmed et al., 2011) and worldwide (Dumitrescu et al., 2005; Ahmed et al., 
2011; Popanda et al., 2013). Of these associations ER, PR status and smoking appears 
to play a strong role in breast carcinogenesis as shown in many earlier studies 
(Rampaul et al., 2001).  
In present study a significant interaction of OGG1 mutations was observed with 
smoking status of breast cancer patients and higher frequency of OGG1 mutations 
was observed in smokers when compared with non-smokers. International Agency for 
Research on Cancer has classified cigarette smoking as carcinogenic to the human 
breast (Collishaw et al., 2009; IARC, 2012; Bernard et al., 2014) and recent studies 
strongly support a role of smoking in breast cancer aetiology (Catsburg et al., 2014). 
Reactive oxygen species (ROS) and aromatic amines present in tobacco smoke 
produce 8-hydroxyguanine (8OH-G) (Kumar et al., 2012b), which may further induce 
aberrant modifications in adjacent DNA of smokers and play a significant role in the 
genomic instability and may lead to unregulated cell growth causing tumor (Vassallo 
et al., 2008) and enhanced metastatic potential of tumor cells (Kumar et al., 2012b). 
The OGG1 protein is front line cellular defense against oxidative DNA damage acting 
as key enzyme involved in the repair of 8oxoG DNA adducts (Crowe, 2002; Vineis et 
al., 2009). Repair activity for removal of 8-hydroxyguanine adducts has been 
observed decreased in homozygous mutant hOGG1 (Cys326Ser) protein (Guan et al., 
2011). Our findings are in agreement with results obtained from many earlier studies 
(De Stefani et al., 2005;  Faheem et al.,2007; Werbrouck et al., 2008; Masood et al., 
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2011, Mahjabeen et al., 2012a). Results of this study may be consistent with the fact 
that the genetic role in carcinogenesis may be overwhelmed or exaggerated by the 
environmental effects (Schroer et al., 2008) 
4.1.3 Mutational analysis of XRCC1 gene 
XRCC1 protein has a key role in coordination of base excision repair (BER) and 
single strand break repair (SSBR) (Caldecott, 2003; Fan et al., 2004; Vierhapper et 
al., 2004; Sterpone and Cozzi, 2010; Sandoval-Carrillo et al., 2014). XRCC1 acts as a 
central scaffolding protein by binding to DNA ligase III, DNA polymerase β, and 
poly (ADP-ribose) polymerase and provide a platform for other repair proteins in 
BER at the site of damaged DNA (Cappelli et al., 1997; Masson et al., 1998; 
Campalans et al., 2005; Mortusewicz and Leonhardt, 2007; Wu et al., 2011). In this 
study, sequence analysis of amplified samples for XRCC1 gene revealed different 
novel and already reported mutations in coding and non-coding regions of XRCC1 
gene. Mutations in noncoding region of XRCC1 include two 5´UTR, one 3´UTR, 
seven intronic and six splice site mutations (Table 3.17).  
Frequency of 5' UTR mutations was found higher in breast cancer patients when 
compared with controls. 5´UTR mutations in XRCC1 have previously been found 
associated with different cancers in different populations (Hao et al., 2004; Brem et 
al., 2006; Sterpone et al., 2010; Sterpone and Cozzi, 2010). Promoter region and 3′ 
UTR is important for the regulation of translation of specific mRNA (Lodish and 
Havery, 2004), whereas mutations in promoter region can influence interactions 
between transcriptional factors and affect their ability to recognize DNA sequences in 
a promoter region resultantly affecting the gene (Luo et al., 2014). So mutations, in 
such regions of gene are very crucial for normal protein synthesis and normal cellular 
functioning. Moreover, presence of these mutations in breast cancer patients at 
significantly higher frequency suggests their role in breast carcinogenesis. Alamut bio 
software (version 2.4-5) predicted the alteration of promoter region of XRCC1 due to 
5´UTR mutation (g.44079611G>A).  
Association of intronic mutations (g.44065030C>G, g.44057512C>T, 
g.44057108A>C, g.44050178delT) with breast cancer risk was observed significant. 
Functional significance of intronic SNPs may be less important but intronic mutations 
  Discussion 
298 
 
have been  significantly correlated with different types of cancers and chronic 
diseases (Freedman et al., 2004;  Chappell et al., 2004; Liu  et al., 2004; Shimazaki et 
al., 2005; Sano et al., 2005; Mototani et al., 2005; Lehman et al., 2005; Bu et al., 
2006). Regulatory sequences for transcription are found within intronic regions (5′ 
UTR and 3′ UTR), thus intronic mutations may have a biological role, if expression of 
gene is affected (Bu et al., 2006). Furthermore, immune-precipitation and gene 
expressional experiments have shown that about 30-40% of binding sites for 
transcriptional factor are found within introns (Martone et al., 2003; Euskirchen et al., 
2004).  
In this study, five novel mutations and one known mutation in splice site regions of 
XRCC1 gene were also observed. Splice site mutations were observed many folds 
higher in breast cancer patients as compared to controls and found associated with 
increased risk of breast cancer. All splice site mutations were observed at 2-5 bp 
upstream or downstream in donor or acceptor splice sites, causing frameshift and 
altered gene expression. Alamut bio software (version 2.4-5) also predicted skipping 
of exon 3, 5, 12, 15 and 16 due to these splice mutations. Mutations in splice site 
region may result in either skipping of respective exon or cryptic splice site 
functioning causing deregulation of protein expression or affected half-life (Campbell 
and Farrell, 2009; Lheureux et al., 2011). 
Mutational screening of all seventeen exons of XRCC1 gene revealed eight 
synonymous, thirteen missense, three frameshift and one non-sense mutations (Table 
3.19 and 3.21). Exonic variations may alter protein structure and ultimately affect 
gene’s role in the body (Bunz, 2008). Among synonymous mutations observed in this 
study, three mutations (Pro206Pro, rs915927; Glu521Glu, rs377436010 and 
Gln632Gln, rs3547) are known mutations and have extensively been studied in 
various cancers involving different populations worldwide 
 
(Yin et al.,2003; Hung et 
al., 2008; Hsieh et al., 2009; Yin et al., 2009; Vaezi et al., 2011, Mahjabeen et al., 
2012a).  
Synonymous substitutions have silent effect on protein structure but a higher 
frequency in patients compared to controls suggests their importance in context of 
consequences due to possible defects in functionality of this gene.  Frequency of 
synonymous mutation, Pro206Pro (rs915927) was found significantly higher 
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(p=0.003) in breast cancer patients when compared with controls and ~20-fold 
increased breast cancer risk was found associated with this mutation. These findings 
are in accordance with previously reported data where higher frequency of Pro206Pro, 
Glu521Glu and Gln632Gln was observed in different cancers in different populations 
(Jbic-allele, 2014; Yin et al., 2007; Hung et al., 2008; Heish et al., 2009; Mahjabeen 
et al., 2012a). Our findings strongly advocate that XRCC1 mutations Pro206Pro, 
Glu521Glu and Gln632Gln may significantly contribute to genetic susceptibility of 
breast cancer in Pakistani population. These results are in contradiction to some of 
earlier studies in other populations (Yin et al., 2003; Han et al., 2004; Sak et al., 
2007). Location of mutation in the gene and its effect on gene’s functions are 
important aspects to consider (Bunz, 2008). 
Among silent mutations observed in this study, three were known (Pro206Pro, 
Glu521Glu and Gln632Gln) and five mutations were novel (Glu122Glu, Gln331Gln, 
Gln430Gln, Gln449Gln and Arg608Arg). Protein’s structural prediction for XRCC1 
showed that silent polymorphisms, (Pro206Pro in exon 7, Glu521Glu in exon 14 and 
Gln632Gln in exon 17) are located in highly conserved and functionally important 
domains of human genome (Lamerdin et al., 1995). Novel missense mutations 
(g.44058846C>T, Glu122Glu; g.44056258C>T, Gln331Gln; g.44051039C>T, 
Gln430Gln; g.44050826C>T, Gln449Gln and g.44047622A>G, Arg608Arg) were 
also found in highly conserved and crucial domains of XRCC1 protein. Analysis of 
these mutations through Alamut biosoftware (version 2.2-5) predicted their presence 
in nuclear localization (NLS) domain, BRCA1 carboxy terminal-I (BRCT-I) domain 
and BRCA1 carboxy terminal-II (BRCT-II) domain. Variations in these domains 
might reduce the ability of XRCC1 protein to communicate with other BER proteins 
in repairing pathway (Yin et al., 2007) and thus inhibiting its critical role as scaffold 
protein. Presence of these mutations in important and conserved domains suggests 
their possible role in breast cancer. Although, the exact role of silent mutations is yet 
to be properly explored, but these mutations may necessarily affect the timing of co-
translational folding and consequently function of protein (Vogel et al., 2001, Yin et 
al., 2003; Yin et al., 2007, Mahjabeen et al., 2012a).  
Missense mutations were observed in different functionally important domains of 
XRCC1 protein. Three missense mutations (Gly61Ala, Val72Gly and Asn183Ser) 
were detected in N-terminal domain (NTD), three missense mutations, (Arg194Trp, 
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Arg280His and Ala283Asp), in nuclear localization signal (NLS) domain, two 
missense mutations (Asp356Asn and Asn510Ser) in BRCA1 carboxy terminal-I 
(BRCT-I) domain and five missense mutations (Arg559Gly, Arg560Gly, Tyr576Asn, 
Val629Gly and Val630Gly) in BRCA1 carboxy- terminal-II (BRCT-II) domain. 
Missense mutations in evolutionary conserved regions of XRCC1 have earlier been 
found associated with breast cancer (Shen et al., 1998; Sterpone and Cozzi, 2010). 
Existence of polymorphic alleles in BER or nucleotide-excision repair (NER) genes 
may compromise their repair capacity and hence may modify the actual biological 
responses towards exogenous and endogenous DNA damages, both at cellular and 
histological level. This may finally lead to mutant individual susceptible to cancer 
development and progression of different organs or sites (Sterpone and Cozzi, 2010).  
In this study, three frameshift mutations (Gly143fs*1, Ala182Argfs*29 and 
Ala587Serfs*9) and one non-sense mutation (g.44058837C>T, Trp125*) were also 
observed in functionally important domains of XRCC1 protein (Table 3.21). 
Frameshift mutation may alter whole coding sequence of gene thus damaging the 
functional ability of domains downstream of truncation. Two frameshift mutations 
were detected in nuclear localization signal (NLS) domain and one frameshift 
mutation in BRCA1 carboxy- terminal-II (BRCT-II) domain. Observed frameshift 
mutations severely affected the downstream reading frame which ended at STOP 
codon at 1, 28 and 8 position downstream, respectively.  Non-sense mutation 
observed in this study was detected in nuclear localization signal (NLS) domain of 
XRCC1 protein. This non-sense mutation severely interrupted the downstream reading 
frame and resulted into truncation of protein prematurely at amino acid 125.  Alamut 
bio software (version 2.4-5) predicted that mRNA produced as a result of frameshift 
and non-sense mutations might be targeted for nonsense mediated decay (NMD). 
In this part of the study, we observed significant association of 5´UTR, 3´UTR, splice 
site, missense, frameshift and nonsense mutations in APEX1, OGG1 and XRCC1 gene 
with breast carcinogenesis. These genetic variations in highly conserved and 
functionally important domains of APEX1, OGG1 and XRCC1 protein alone or in 
combination with other gene in vicinity, can conceivably play a role in the breast 
carcinogenesis; each adding a small effect to the overall risk of breast cancer. 
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4.2 Expressional analysis of BER pathway genes (APEX1, OGG1and 
XRCC1) and Ki-67 
Gene expression is the basic process by which genetically programmed information is 
used by the cell in the appearance of functional phenotypes (Storey et al., 2007).  The 
role of genes in cancer research can be confirmed through studies involving mRNA 
expression analysis and in turn many new insights are explored in cancer biology. It 
has proved to be a very useful and effective tool for characterization of different 
cancers, diagnosis and prognosis of the disease (de Wit, 2006). Evaluation of the 
genetic mutations affecting genetic pathways can also be made using direct mRNA 
from tumor tissues. Expression analysis has opened a new door for understanding the 
process of carcinogenesis at molecular level. Precise diagnosis, prognosis and 
prediction of treatment response may be better performed through gene expression 
data. Expressional analysis may also differentiate histologically identical diseases and 
may lead to develop some new prognostic methodologies (Huang et al., 2012).  
For confirmation of findings from germ line mutational analysis, expression analysis 
of BER pathway genes was carried out in two study cohorts (Pakistani and British 
Populations). mRNA expressional profile of BER pathway genes (APEX1, OGG1 and 
XRCC1) was analysed and found almost parallel in both study cohorts. mRNA 
expressional profiles of BER pathway genes (APEX1, OGG1 and XRCC1) were then 
correlated with each other and also with the expression profile of proliferation marker 
Ki-67. We observed a significantly decreased expression of OGG1 and XRCC1 at 
mRNA level is in breast cancer patients when compared to normal control 
background tissues. The differences observed in expression pattern of these genes in 
controls and cancer patients suggest heterogeneity of gene functioning, which might 
be due to different genetic variations, epigenetic characteristics or also environmental 
factors. The decreased expression of these BER genes has earlier been reported in 
various studies on different cancers (Shi et al., 2004; Wei et al., 2009; Kumar et al., 
2012, Mahjabeen et al., 2013). Nevertheless, increased mRNA expression of BER 
genes has also been reported in colorectal adenomas and in lung carcinoma (Hatt et 
al., 2008).   
In this study, APEX1 transcript levels were observed higher in tumor tissues when 
compared with normal tissues but the difference was statistically non-significant 
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(p<0.05) in both study cohorts. Up-regulation of APEX1 transcript level in breast 
tumour tissues compared with control tissues is in line with previous findings and 
irregular mRNA expression of APEX1 has been observed in numerous human solid 
tumors and has been positively correlated with cancer onset and progression, but the 
role of APEX1 in tumor progression is still not clearly defined (Kim et al., 2013). 
Similar results have also been observed in many earlier studies in osteosarcoma (Yang 
et al., 2010), pancreatic carcinoma (Jiang et al., 2010), lung carcinoma (Wu et al., 
2010), ovarian, gastro-oesophageal, pancreatico-biliary carcinomas (Al-Attar et al., 
2010) and colon carcinoma (Kim et al., 2013).  
In this study, positive correlation of APEX1 mRNA level was observed with pT-stage, 
C-stage, tumor grades and metastasis. Increased APEX1 mRNA expression was found 
associated with advanced stage, higher grade and aggressive tumor. Similar trend in 
APEX1 expression has also been observed in case of lung cancer (Puglisi et al., 2001), 
ovarian (Moore et al., 2000), thyroid (Tell et al., 2000; Russo et al., 2001), 
osteosarcoma (Yang et al., 2010), breast cancer (Puglisi et al., 2002), head and Neck 
cancer (Jenkins et al., 2013; Mahjabeen et al., 2013) and colon carcinoma (Kim et al., 
2013). Earlier studies have demonstrated that different oxidative agents promote an 
increase of APEX1 mRNA and protein expression (Ramana et al., 1998; Grosch et al., 
1999; Kelley et al., 2001). In yeast and animal model mechanistic studies, it has been 
observed that over-expression of APEX1 is related with different mutations and 
microsatellite instability. Impairment in APEX1 activities seems to be a mechanism 
which can contributes to genetic hypermutability and thus genomic instability. 
Genomic instability reinforces the development of dysplasia, malignancy, invasion, 
and metastasis in a variety of cancers (Jenkins et al., 2013).  
Accumulating evidence indicates that APEX1 compromised cells are more prone to 
oxidative stress mainly due to impairment in redox and enzymatic activity impacting 
cell survival and pushing it towards apoptosis. This finding is therapeutically 
important because APEX1 mRNA over-expression in tumor cells is suggestive of 
resistance to chemotherapeutic drugs perhaps by decreased apoptosis (Fishel and 
Kelley, 2007). In conclusion, we observed up-regulation of APEX1 transcript levels in 
breast cancer patients of both cohorts (ethnically different) when compared to normal 
background tissues. The APEX1 level gradually increased with advancement in stage, 
grade and differentiation of tumor when compared with primary or initial stage/ grade 
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tumours. Inhibition of DNA repair or redox or both activities of APEX1, as a result of 
mutations or any other factor may potentially sensitize the tumor cells to therapeutic 
agents, thus presenting APEX1, an attractive and good molecular target in cancer 
treatment diagnosis or staging. 
In case of OGG1, reduced expression at mRNA level in tumor samples was observed 
compared to controls in both study cohorts. These observations are in accordance with 
previous studies reporting down-regulation of OGG1 mRNA expression in multiple 
tumors compared to control tissues (Habib, 2009, Mahjabeen et al., 2013). The 
reported down regulation of OGG1 mRNA expression may lead to reduced BER 
activity which is associated with leading to accumulation of many fold increased 
levels of 8-OHdG adducts in tumor tissue samples (Kondo et al., 2000; Paz-Elizur et 
al., 2003; Mambo et al., 2005; Habib, 2009). Whereas, in some studies, there was no 
difference observed, in OGG1 mRNA expression of in lung cancer (Chevillard et al., 
1998).  
In present study, statistically significant down regulation of XRCC1 mRNA 
expression was also observed in breast tumor samples compared to controls in both 
studied cohorts. Lower expression of XRCC1 has earlier been observed in gastric 
cancer which was associated with unfavorable TNM stage and reduced survival of 
patients (Engin, 2013). Higher proliferative activity is reflected as high grade 
malignancy of breast cancer. We observed a decrease in XRCC1 expression with 
increase in tumor grade. Similar observation have been made previously in breast 
tumor (Rybarova et al., 2011), lung carcinoma, (Liu et al., 2011), gastric carcinoma 
(Wang et al., 2010), medulloblastoma, (Chetty et al., 2012) and in head and neck 
cancer (Kumar et al., 2012; Mahjabeen et al., 2012) whereas, conflicting results have 
been reported in some of other studies showing significantly enhanced XRCC1 
mRNA expression levels in tumor samples of all clinical and histopathological types 
(Santos et al., 2014). These observations imply that down regulation of XRCC1 
mRNA, may lead to impaired BER and single strand break (SSB) repair with reduced 
activity as a scaffold protein, greater mutational load and therefore an increased 
cancer risk (Vineis et al., 2009; Vaezi et al., 2011; Kumar et al., 2012; Wang et al., 
2012, Mahjabeen et al., 2012).  
In this study, Ki-67 was used as a proliferative marker and its mRNA expression was 
also observed significantly up-regulated in breast tumours when compared with 
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background control tissue sample. A gradual increase in expression of Ki-67 in 
successively advanced tumor stages/grades provides clear evidence of a multi-step 
deregulation of breast tumor proliferation in patients.  
For gene to gene interaction Spearman’s correlation was performed and results are 
shown in Table 3.30. A significantly positive correlation was observed between 
APEX1 and Ki-67 mRNA expression and similar positive correlation was also 
observed between OGG1 and XRCC1 mRNA expression. When mRNA expression of 
both APEX1 and Ki-67 was independently correlated with mRNA expression of 
XRCC1 and OGG1, a significantly negative correlation was observed in both cases. 
Up-regulation of proliferation marker Ki-67 along with deregulation of DNA repair 
genes (OGG1, APEX1 and XRCC1) in breast cancer patients may be involved in rapid 
proliferation of breast tumor which suggests aggressiveness of tumors and 
development of cancer in both study cohorts. A high proliferation rate has been 
associated with aggressive behavior of tumors from various sites (Zoeller et al.1994; 
Van et al., 1998; Saito et al., 1999; Petrini et al., 2006). Ki-67 expression has 
previously been correlated with classical histopathological parameters, grading and 
staging (Liu et al., 2001; Spyratos et al., 2002; Trihia et al., 2003; Inwald et al., 2013) 
and results of this study are in accordance to previous studies. Ki-67 expression has 
also been correlated previously with Cyclin-B1, Cyclin-D1, Cyclin-dependent kinase 
inhibitors, with caspases, p53, VEGF, Carbonic Anhydrase IX and CDC25 in 
different cancers (Grabenbauer et al., 2003; Harada et al., 2006; Wang et al., 2006; 
Andressakis et al., 2006; Petrini et al., 2006; Kim et al., 2007; Gregory et al., 2009).  
In conclusion, deregulation of mRNA expression of BER genes (down regulation of 
OGG1 and XRCC1 and up regulation of APEX1) along with up regulated expression 
of proliferation marker Ki-67, in tumor tissues compared to controls may be 
associated with initiation and development of breast cancer in Pakistani and British 
populations.  
4.3 Immunohistochemical analysis of BER pathway genes and Ki-67 
For further confirmation of our findings at mutational and mRNA expressional level 
and illumination of the role played by BER pathway genes (APEX1, OGG1and 
XRCC1) and tumor proliferation marker (Ki-67) in breast cancer, the expression of  
these genes was observed by immunohistochemistry in 104 breast cancer patients.  
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Protein expression profiling of APEX1, by IHC analysis demonstrated up-regulation 
of APEX1 in breast cancer tissues. A significant increase in protein level was 
observed in undifferentiated tumors compared to poorly or moderately differentiated 
tumors. This up-regulation of APEX1 has consistently been observed in different type 
of cancers (Moore et al., 2000; Bobola et al., 2001; Wang et al., 2004; Sak et al., 
2005; Bobola et al., 2005; Yang et al., 2005; Raffoul et al., 2007; Jiang et al., 2010; 
Fishel et al., 2011; Lee et al., 2012, Mahjabeen et al., 2013). In this study, staining of 
both nuclear and cytoplasmic nature was observed in breast tumor tissue and staining 
ranged from strong to week. The finding for APEX1 protein expression are generally 
in agreement with findings of many of the previous studies on different cancers such 
as cervical cancer (Schindl et al., 2001), epithelial ovarian cancer (Freitas et al., 
2003), breast cancer (Kakolyris et al., 1998) and sino-nasal small cell carcinoma (Lee 
et al., 2012). It has been reported in many of the previous studies that nuclear and 
cytoplasmic expression of APEX1 may be related to tumor invasiveness, prognosis 
and malignant behaviour of different cancers (Moore et al., 2000; Lee et al., 2012). 
Although, the change in APEX1 protein levels is considered to be affecting APEX1 
DNA repair capabilities but exact cause of significantly higher APEX1 protein level in 
breast tumor is not clear (Moore et al., 2000; Freitas et al., 2003).  
Down-regulation in OGG1 protein level was observed in breast tumor samples 
compared to background control tissues. Similar findings have earlier been reported in 
many studies while analysing different cancers (Fan et al., 2001; Mambo et al., 2005; 
Kunisada et al., 2005; Huang et al., 2012; Karihtala et al., 2012; Mahjabeen et al,., 
2013). Contradictory to the findings of this study regarding OGG1 expression have 
also been reported in different cancers (Salim et al., 2008; Preston et al., 2009; 
Karihtala et al., 2012). In this study, localization of OGG1 protein is both cytoplasmic 
and nuclear, which is different than other reported studies, where OGG1 
immunohistochemical expression was assessed (Salim et al., 2008; Ku et al., 2009; 
Karihtala et al., 2012). Exact reason of significantly reduced expression of OGG1 in 
breast tumors is not clear. However, accumulation of higher levels of 8-oxoG adducts 
as a result of associated OGG1 mutations (Paz-Elizur et al., 2003; Mambo et al., 
2005; Habib, 2009) and reduced OGG1 mRNA expression level may be associated 
with impaired BER activity, ultimately leading to breast cancer (Huang et al., 2012). 
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In this study, down-regulation of XRCC1 protein level was observed in breast tumor 
tissues compared to controls. This down-regulation was higher in undifferentiated 
tumors compared to poor or moderately differentiated tumors. Similar observations 
have been made in lung carcinoma (Liu et al., 2011), in gastric carcinoma (Wang et 
al., 2010; Wang et al., 2012), medulloblastoma (Chetty et al., 2012) HNC 
(Mahjabeen et al., 2013). XRCC1 down-regulation has also been observed in HeLa 
cells and resultantly decreased LIG3 protein levels were observed, but the levels of 
DNA polymerase beta (POLb) were not affected. Conflicting results for XRCC1 
protein level have been reported in some of other studies (Sak et al., 2005; Cheng et 
al., 2009; Kang et al., 2010; Ang et al., 2011; Rybarova et al., 2011). In this study, 
localization of XRCC1 protein was cytoplasmic as well as nuclear, similar to staining 
localization observed in lung cancer (Liu et al., 2011) which is contradictory to 
several previous studies in which XRCC1 immunohistochemical expression has been 
assessed specifically nuclear (Fujimura et al., 2000; Kang et al., 2010; Ang et al., 
2011; Chetty et al., 2012). It appears that combination of splice site, missense, 
nonsense and frameshift mutations, down regulation of XRCC1 mRNA level and 
decreased XRCC1 protein level may affect breast cancer susceptibility in Pakistani 
population, but exact mechanism still remains unknown. Nevertheless, many studies 
have reported that nuclear and cytoplasmic expression of BER genes may be related 
to tumor invasiveness, prognosis and malignant behaviour of different cancers (Moore 
et al., 2000; Lee et al., 2012). 
Molecular markers have been extensively explored for earlier and accurate 
diagnosis of breast cancer, also for long-term outcome and prediction of response 
about specific therapy. Proliferation is a significant aspect in tumor progression and 
has been widely evaluated by immunohistochemical assessment of nuclear antigen 
Ki-67.  Level of Ki-67 expression has been positively correlated with the progression 
of S-phase in cell and hence proliferation of breast tumor (Inwald et al., 2013). Ki-67 
is an important prognostic factor both for disease-free survival (DFS) as well as for 
overall survival (OS) and may be considered independently of common clinical and 
histopathological parameters in breast cancer patients (Inwald et al., 2013).  
In this study we also examined the expression profile of Ki-67 (tumor proliferation 
marker), in 104 breast tumor samples by IHC and then correlated with expression 
levels of BER pathway genes. We observed a significant up-regulation of Ki-67 in 
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breast tumor samples compared to positive controls. Up-regulation was even higher in 
undifferentiated tumor samples compared to poorly or moderately differentiated 
tumor samples. Higher expression of Ki-67 has been considered an indication of 
poorer prognosis (Dowsett et al., 2011; Luftner et al., 2012; Kolberg et al., 2012) and 
is related to excessive proliferation, recurrence, metastasis and more aggressiveness of 
tumors in different cancers (Jiang et al., 2012; Mahjabeen et al., 2012b).  
For gene to gene interaction, in present study OGG1 indicated significantly negative 
correlation with APEX1 and Ki-67 and significantly positive correlation with XRCC1 
protein level. Further analysis showed that APEX1 also exhibited significantly 
negative correlation with XRCC1 and significantly positive correlation with Ki-67 
protein level. In addition to this, XRCC1 is negatively correlated with Ki-67 and 
correlation was again significant. Similar trends in correlation between BER pathway 
genes and Ki-67 at mRNA level has earlier been reported in HNC (Mahjabeen et al., 
2012b). Our data suggests that down-regulation of BER pathway genes, such as 
OGG1 and XRCC1, and over-expression of APEX1 combined with up-regulation of 
Ki-67 may contribute to the initiation, progression and aggressive proliferation of 
breast cancer in Pakistani population. 
4.4 In-vitro characterization of BER Pathway genes (APEX1, OGG1 and 
XRCC1) 
In this part of the study, BER pathway genes were extensively explored for their role 
in tumor onset and progression by performing different cellular function assays. Two 
breast cancer cell lines, MCF-7 and MDA-MB-231 with normal expression of BER 
genes were successfully knocked down to down regulate their mRNA and protein 
expression by transfecting gene specific ribozyme transgenes (APEX1-Rib, OGG1-
Rib and XRCC1-Rib). Knockdown expression of BER molecules in ribozyme 
transfected cancer cell lines was confirmed at both transcriptional and translational 
levels and cell functional assay related to carcinogenic behaviour of cells were 
performed for each of the three genes. 
4.4.1 In-vitro characterization of APEX1 
APEX1 is involved in multiple anticancer properties at various functional levels such 
as inhibition of cancer cell migration, cell invasion, inhibition of tumor growth tumor 
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in xenografts  and inhibition of colony formation in soft agar and angiogenesis (Yang 
et al., 2007; Zou and Mitra, 2008; Zou et al., 2009; Kim et al., 2009; Fishel et al., 
2011). When cells respond to oxidative stress, APEX1 performs two different types of 
functions; it acts as an AP-endonuclease in DNA repair and secondly as a 
transcriptional regulator for multiple transcription factors leading to cell survival or 
cell-cycle arrest (Tell et al., 2009). This part of study was designed to investigate 
possible role of APEX1 molecule in breast tumorigenesis and to verify possible 
involvement of APEX1 in oncogenic mechanism using two breast cancer cell lines i.e. 
MCF-7 and MDA-MB-231. Significant decrease in growth (p<0.0001) was observed 
in APEX1 knockdown cells of MCF-7 and MDA-MB-231 cell line compared to 
plasmid pEF controls of respective cell lines. Relative growth observed in APEX1 
knockdown cells of MCF-7 and MDA-MB-231 cell lines was 53% and 72% 
compared to control cells. When APEX1 knockdown cells were compared with 
respective controls for their growth abilities, results of this study were found 
consistent with the findings of previous studies (Fung and Demple, 2005; Fishel et al., 
2008). APEX1 protein has been implicated with cancer cell proliferation and 
tumorigenic behavior in colon and breast cancer cells (Fung and Demple, 2005).  
Recent in-vitro studies using APEX1 knockdown colon cancer cell lines and 
xenografts, showed a significantly decreased cancer cell growth in cell lines and in 
development and growth of tumors in xenografted mouse (Kim et al., 2013). APEX1 
knockdown showed a significantly decreased cell proliferation in in-vitro cellular 
assays and significantly decreased tumor growth in xenograft mouse models using 
ovarian cancer cells (Fishel et al., 2008) and pancreatic cancer cells (Fishel et al., 
2011). Contradictory results have been reported by Hausmann (2011), where 
significant decrease in cell growth was observed in APEX1 knockdown MCF-7 cells 
and no difference in cancer cell growth was observed in APEX1 knockdown HMEpC 
cells. Possible explanation for this contradiction may be difference in knockdown 
level of target genes at protein level. APEX1 protein is expressed in cells abundantly 
so insufficient knockdown may show no or even contrast differences in cellular 
functions as residual activity of APEX1 under week knockdown condition might be 
enough for the cells growth (Hausmann, 2011). It is difficult to absolutely estimate 
the effects of APEX1 knockdown expression on growth and apoptotic abilities of 
cancer cells because APEX1 is essential redox activator. It usually induces DNA 
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binding action of multiple transcription factors including NF-Y, p53, AP-1, NF-kB, 
Egr-1 and HIF1a ( Xanthoudakis et al., 1992;Huang et al., 1993; Nakshatri et al., 
1996; Gaiddon et al., 1999; Lando et al., 2000; Nishi et al., 2002) and some other 
target genes.  
Decreased adhesion ability of cancer cells is involved directly in carcinogenic 
behavior of tissues. APEX1 protein has consistently been observed over expressed 
indifferent tumor tissues including breast tumor (Raffoul et al., 2007; Jiang et al., 
2010; Fishel et al., 2011; Lee et al., 2012, Mahjabeen et al., 2013). In this study when 
APEX1 was knocked down in breast cancer cell lines to evaluate its role in cellular 
adhesion. A significant increase in adhesion to matrigel membrane (p<0.05) was 
observed in knockdown cells (APEX1-
KnD
) of both breast cancer cell lines (MCF-7 
and MDA-MB-231) compared to plasmid pEF controls of respective cell lines. 
Adhesion observed in APEX1-
KnD
 cells was ~109% of the adhesion observed in 
control cells (pEF-
CT
). After two hours of seeding into ECIS plate, attachment ability 
of APEX1 knockdown cells of both breast cancer cell lines (MCF-7-
APEX1-KnD 
and
 
MDA-MB-231
APEX1-KnD
) was observed significantly higher (p<0.05) when compared 
with respective wild type and plasmid inserted control cell lines.  Similar findings 
have earlier been reported in different studies in the past involving different cancer 
cell lines of multiple cancers (Kelley et al., 2001; Croce and Beltrami, 2007; Kim et 
al., 2013). 
Proliferation and then migration of cancer cells from the site of its primary origin to 
distant organs requires a preliminary step of invasion and crossing of basal 
membrane. In this study, knockdown of APEX1 caused a significant decrease in 
invasion ability (p<0.05) in APEX1-
KnD
 cells of both breast cancer cell lines (MCF-7 
and MDA-MB-231) compared to plasmid pEF controls of respective cell lines. 
Invasion observed in knockdown cells (APEX1-KnD) was ~93% of the invasion 
observed in control cells (pEF-
CT
). These results are suggestive of correlation of 
APEX1 deregulation with cancer cell invasiveness ability. APEX1 knockdown has 
been implicated in reduced invasion in pancreatic and colon cancer cell lines 
(Kakolyris et al., 1997; Noike et al., 2008; Zou and Mitra, 2008; Kim et al., 2009). 
Similarly, significantly decreased cancer cell invasion was observed in recent 
experiments using two APEX1 knockdown colon cancer cell lines and reduced tumor 
progression in xenograft mouse (Kim et al., 2013).   
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Increased adhesive and decreased invasive abilities of APEX1 knockdown cells 
provide a clear evidence for exploring the role of APEX1 in relation to cell migration. 
Effect of APEX1 knockdown on breast cancer cell migration was analysed using ECIS 
system, after first and second electrical wounds. Decreased migration ability was 
observed in APEX1 knock down cells of MCF-7 (non-significant) and MDA-MB-231 
(significant) cell lines compared to their respective controls. This clearly narrates that 
suppression of APEX1 in cancer cell lines leads to decrease in cellular migration and 
its over expression in breast tumor tissues may play a role in metastasis, which is an 
important step in carcinogenesis. APEX1 knockdown has been observed to be 
associated with inhibition of cellular migration and reduced invasion in pancreatic and 
colon cancer cells (Kakolyris et al., 1997; Noike et al., 2008; Zou and Mitra, 2008; 
Kim et al., 2009). APEX1 knockdown boosted invasive and migratory characteristics 
of cancer cells which the metastasized to lungs in xenografted mouse (Kim et al., 
2013). Decreased migratory ability was observed in APEX1 knockdown colon cancer 
compared to cancer cells with normal expression of APEX1. Down regulation or 
knockdown of APEX1 molecule also affects other cancer related properties of cells. 
Down regulation or knockdown of APEX1 have also been observed to significantly 
suppress colony formation by mouse epithelial cells in soft agar (Yang et al., 2007) 
and significant inhibition of angiogenesis in APEX1 redox domain suppressed tumor-
associated endothelial cells (Zou et al., 2009). 
It has been observed in many studies, that APEX1 overexpression observed in 
expression studies and behavior of APEX1 molecule in knockdown cancer cell lines 
of different cancers is directly correlated with cancer initiation and progression which 
suggests using APEX1 as an intriguing potential target for anticancer strategies and 
therapies. Nevertheless, the role of APEX1 for its selection as a therapeutic target still 
needs to be further explored. 
4.4.2 In-vitro characterization of OGG1 
OGG1 is an important gene of BER pathway which encodes the enzyme responsible 
for the excision of 8-oxoguanine (8-oxoG), a mutagenic base byproduct which occurs 
as a result of exposure to reactive oxygen species (ROS). OGG1 is a bi-functional 
glycosylase, as it is able to cleave the glycosidic bond of the mutagenic lesion and 
causes a strand break in the DNA backbone. Thus deficiency of OGG1 protein in cells 
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may cause defective DNA repair, accumulation of DNA lesion and instability of 
genome, especially under oxidative stress and may lead to increased cancerous 
characteristics (Duan et al., 2012; De Summa et al., 2014). Deregulation in OGG1 
expression is associated with different types of breast cancer (Vogelstein et al., 2004).  
In this study, significant differences in breast cancer cell proliferation, adhesion, 
invasion and migration was observed in OGG1 knockdown breast cancer cells 
compared to pEF control cells. OGG1 knockdown in breast cancer cell lines has 
previously been found associated with defective DNA repair capacity in the cancer 
cells and hence play a role in breast tumorigenesis. Defective DNA repair ability of 
OGG1 knockdown multiple breast cancer cell lines results in accumulation of 8-OH-
Gua adduct under oxidative stress which may be correlated with initiation, invasion 
and progression of breast cancers (Nyaga et al., 2006). OGG1 knock-down cell lines 
are more sensitive to oxidative stress compared to control cell lines. OGG1 knock-
down may result in accumulation of 8-OHGua adduct especially under oxidative 
stress and DNA repair capacity is compromised with a change in behavior of cells 
(shOGG1A, shOGG1B) (Alli et al., 2009). These adducts are removed by repair 
genes especially BER pathway. OGG1 knock-down results in significantly decreased 
ability to remove remove 8-oxoG adduct in different breast cancer cell lines (MCF-7, 
MDA-MB-468 and HCC1937) (Mambo et al., 2002; Nyaga et al., 2006) whereas, 
breast cancer cell lines with upregulated OGG1 expression showed significantly 
enhanced capacity to remove 8-OHGua adduct (Nyaga et al., 2006).  
Significant increase in growth was observed from day-1 to day-3 and similarly from 
day-1 to day-5 in OGG1 knockdown cells of both breast cancer cell lines compared to 
pEF controls of respective cell lines.  In the absence of any relevant studies in 
previous literature regarding breast cancer cell proliferation with OGG1 knockdown, 
results cannot be confirmed. Nevertheless, one study on neural stem cells (NSC) 
proliferation has reported that knockdown of OGG1 significantly decreases NSC 
proliferation as compared to control cells (Reis et al., 2012). Although it is 
contradictory to the results of this study but it may be suggested that suppression of 
OGG1 affects smooth progression of cell cycle.   
In this study, significantly decreased adhesion was observed in MDA-MB-231
OGG1-
KnD
 cells (P=0.045) but decrease was observed non-significant in MCF-7-
OGG1-KnD
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cells (p=0.45) compared to their respective pEF control cells. Adhesion observed in 
OGG1 knockdown MDA-MB-231
OGG1-KnD 
cells was ~92% and ~96% in MCF-7-
OGG1-
KnD 
cells of the adhesion observed in respective pEF-CT control cells. Decreased 
adhesion ability of cancer cells is involved directly in carcinogenic behavior of tissues 
(De Summa et al., 2014). Decrease in adhesion ability observed in OGG1 knockdown 
cells through adhesion assay was further confirmed by analysing attachment ability of 
cancer cells using ECIS system. Two hours after seeding into the ECIS plate, 
significantly decreased (p<0.0001) attaching ability was observed in MCF-7-
OGG1-KnD 
and
 
MDA-MB-231
OGG1-KnD
 cells compared with respective wild type and pEF control 
cells.   
Results from this study show that, OGG1 knockdown cells were observed more 
invasive with significantly greater ability in crossing matrigel membrane compared to 
pEF controls of respective cell lines. Invasion ability observed in OGG1 knockdown 
cells of MCF-7 and MDA-MB-231cell lines was ~106%, of the invasion observed in 
related pEF control cells (pEF-CT) which shows compromised DNA repair capacity. 
Similar defective DNA repair has been observed in OGG1 knockdown colorectal 
cancer cell lines, lung cancer cell lines, isogenic cell lines (HCT116 p53+/+ and 
HCT116 p53-/-) after oxidative stress, which resulted in deregulation in proliferative 
and invasive properties of breast cancer cells (Mambo et al., 2002; Nyaga et al., 
2006). This decreased adhesive and increased invasive ability of OGG1 knockdown 
cells provide a clear evidence for exploring the role of OGG1 in relation to cell 
migration, which is an important feature of aggressive tumors.  
Alterations in migration tendency of OGG1 knock down cells compared to controls 
after electrical wounding were calculated using ECIS system. After first and second 
electrical wound, a significant increase in migration rates was observed in OGG1 
knock down cells of MCF-7 and MDA-MB-231cell lines compared with their 
respective pEF controls. This clearly shows that suppression of OGG1 leads to 
increased cellular migration in breast cancer cells, possibly playing a role in 
metastasis. Differentiation of tumours provides a clue for its stage, progression, 
apoptosis or necrosis and knockdown of OGG1 at mRNA level resulted into 
decreased differentiation and proliferation with no difference in cell survival (Reis et 
al., 2012). Alli et al (2009), has also suggested that knockdown of OGG1 molecule in 
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breast cancer cell lines confers its sensitivity to PARP inhibitors suggesting OGG1 
gene as an important possible prognostic factor and therapeutic agent.  
In summary, OGG1 being first line of defense against oxidative stress, expressional 
deregulations and its role in tumorigenesis needs to be explored in detail through in-
vitro studies involving cancer cell lines. Knockdown of OGG1 compromises the DNA 
repair capacity of breast cancer cells and results in accumulation of 8-OH-Gua adduct 
especially under conditions with oxidative stress. Accumulation of 8-OH-Gua adduct 
is associated with breast tumorigenesis. These results clearly suggest that knockdown 
or down regulation of OGG1 expression may conceivably induce carcinogenic 
behavior in the mammary cells and make OGG1, a possible target for selection as 
diagnostic molecule in breast cancer studies. Nevertheless role of OGG1 as a 
diagnostic marker need to be further explored. 
 
4.4.3 In-vitro characterization of XRCC1 
XRCC1 has been observed to interact with various proteins involved in cell cycle 
checkpoints through its BRCT-I and BRCT-II domains. It might be involved in 
regulation of cell cycle and thus might affect growth of cancer cells. Variations in the 
expression levels of XRCC1 in cancerous tissue (as observed in mRNA and protein 
expression studies) is considered an important clue to explicate the effects of the 
XRCC1 knockdown by analyzing multiple cellular functional assays. Previous studies 
have reported contradictory findings, regarding effects of XRCC1 knockdown, on 
growth capacity of cancer cells. These differences in effect of  knockdown on growth 
capacity has been observed even within the same cell line or in different cell lines 
(Kwok et al., 2010; Hausmann, 2011). Knockdown of XRCC1 caused no effect on 
cellular growth in HMEpC cell line (Hausmann, 2011) and MCF7 cell line (Kwok et 
al., 2010) when compared with controls. Nevertheless, knockdown of XRCC1 gene in 
cells of MCF-7 breast cancer cell line resulted highly decreased growth capacity when 
compared with control cells (Hausmann, 2011).  
In present study, XRCC1 knockdown affected the growth rate in both breast cancer 
cell lines (MCF-7 and MDA-MB-231). Growth rate was observed lower in MCF-7-
XRCC1-KnD
 cells (p=0.69) and higher in MDA-MB-231-
XRCC11-KnD
 cells (p=0.31) 
compared with pEF control cells but the difference in growth was observed 
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statistically non-significant (p>0.05) from day 1 to 3. However, significantly 
increased growth (p<0.05) was observed in XRCC1 knockdown cells of both cell lines 
(MCF-7 and MDA-MB-231) from day-1 to day-5. When pEF control was normalised 
to 100, growth rate in MCF-7-
XRCC1-KnD
 was observed 111% (SEM ±6.22) and 106% 
(SEM ±10.14) in MDA-MB-231-
XRCC1-KnD
. Variable growth behavior observed in two 
different XRCC1 knockdown cell lines may be attributed to the difference in their 
origin and response to knockdown stress in first three days. Interestingly, both cell 
lines showed significantly increased growth compared with pEF control cells, five 
days after knockdown. Contrasting findings of other studies may also be due to 
differences in knockdown level of target genes in different cell lines. BER proteins 
are expressed in cells abundantly, so insufficient knockdown may produce same or 
different results at functional level. Under week knockdown condition, residual 
activity of BER might be enough for the cell to grow (Hausmann, 2011). 
XRCC1 is a scaffold protein which has been observed to interact with several other 
proteins involved in single-strand break repair BER pathways (DNA glycosylases, 
APEX1/REF1, PARP1, PNK, and ligIII) and possibly handles and coordinates the 
various steps of the damaged DNA repair processes (Ladiges et al., 2006; Hegde et 
al., 2008). Moreover, XRCC1 protein has also been found to be involved in non-
homologous end-joining repair pathway (De Summa et al., 2014). On knockdown of 
XRCC1 protein, BER pathway may not operate, as smoothly as required, for effective 
damage repair due to lack or irregularity of coordination among various BER 
proteins. In such circumstances increased growth rate in XRCC1 knockdown cells is 
justifiable since mutations in genes controlling cell cycle and growth may not have 
been repaired efficiently.   
Adhesive character of cancer cells may be influenced by a range of different 
molecules and alterations in cellular adhesion has a direct influence on the cellular 
motility (invasion and migration) and carcinogenic behavior of cells (De Summa et 
al., 2014).  In this study, decreased adhesion ability to matrigel membrane was 
observed in XRCC1 knockdown cells of both breast cancer cell lines when compared 
with pEF control cells. Decrease in adhesion was observed significant in case of 
MCF-7-
XRCC1-KnD
 (P=0.042) but non-significant in MDA-MB-231
XRCC1-KnD
 (p=0.08) 
when compared to their respective controls. When pEF control was normalised to 
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100, adhesion observed in MCF-7-
XRCC1-KnD
 cells was 88% and 90% in MDA-MB-
231
XRCC1-KnD
 cells. 
XRCC1 is involved in stimulation of activity of glycosylases (Nazarkina et al., 2007) 
and down regulation of XRCC1, as observed in various breast cancer cell lines, may 
lead to hypo stimulated BER protein especially glycosylases (OGG1) and NTHL1 and 
defective DNA repair (De Summa et al., 2014). Knockdown of XRCC1 causes 
decrease in adhesion ability of breast cancer cells and this decreased adhesion of 
cancer cells is directly involved in carcinogenic behavior of tissues (De Summa et al., 
2014). This fact may also be supported by the down regulation of XRCC1 protein and 
its association with multiple cancers including breast cancer. This has been observed 
in present expressional study as well as in many previous studies on different cancers 
such as lung carcinoma (Liu et al., 2011), gastric carcinoma (Wang et al., 2010; 
Wang et al., 2012), and medulloblastoma (Chetty et al., 2012), HNC (Mahjabeen et 
al., 2013).  
Migration and proliferation of cancer cells from the site of its primary origin to distant 
organs requires a preliminary step of invasion and crossing of basal membrane. In 
present study, XRCC1 knockdown cells of both breast cancer cell lines (MCF-7-
XRCC1-
KnD 
and
 
MDA-MB-231
XRCC1-KnD)
 were more invasive with significantly increased 
ability in crossing matrigel membrane when compared with pEF controls of 
respective cell lines. When pEF control was normalised to 100, invasion ability 
observed in MCF-7-
XRCC1-KnD
 cells was 108% and 103% in MDA-MB-231
XRCC1-KnD
 
cells. Important role of XRCC1 in repair of DNA damage, invasion migration and 
apoptosis in wild type and knock down cells of various cancer cell lines has 
previously been demonstrated in multiple studies (Zhang et al., 2010; Kudo et al., 
2012; Abdel-Fatah et al., 2013;   Xu et al., 2014). Significantly enhanced invasion 
ability of XRCC1 knockdown cells of both breast cancer cell lines observed in in-vitro 
experiments together with significantly down regulated XRCC1 expression (at 
transcriptional and translational levels) associated with tumor metastasis in breast 
cancer patients clearly demonstrate the  role of XRCC1 in breast tumorigenesis. Loss 
or down regulation of XRCC1 has also been reported in invasive breast cancer as an 
independent prognostic indicator of poor clinical outcome and metastasis (Sultana et 
al., 2013).  
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Decreased adhesive and increased invasive abilities of XRCC1 knockdown cells 
provide a clear evidence for the role of XRCC1 in relation to cell migration. In this 
study, significantly increased migratory ability was observed in XRCC1 knockdown 
cells of both breast cancer cell lines (MCF-7-
XRCC1-KnD 
and
 
MDA-MB-231
XRCC1-KnD
) 
when compared with pEF control cells. These findings are in agreement with previous 
studies on different cancer cells reporting the effect of XRCC1 knockdown in 
metastasis and other cancer related properties of cells (Peasland et al., 2011; Sultana 
et al., 2013; Abdel-Fatah et al., 2014). Many preclinical studies have also linked 
XRCC1 deficiency or knockdown to enhancement in effects of DNA-damaging 
agents. Knockdown of XRCC1 protein appears to block double-strand break repair 
pathways which may result in aggressive metastatic behavior of cancer cells (Sultana 
et al., 2013; De Summa et al., 2014). Effects of XRCC1 knockdown on other 
associated proteins and behavior of cancer cells, suggest that XRCC1 protein levels 
can be considered as a molecular target for multistage tumorigenesis. 
4.5 Conclusions and future studies 
In this study, various novel and reported mutations have been observed in three BER 
pathway genes at germline level in breast cancer patients. Eleven novel (six 5´UTR, 
two intronic and three missense) and three already reported mutations (one 5´UTR, 
one 3´UTR and one missense mutation) were observed in APEX1 gene. Sequence 
analysis of OGG1 revealed 15 mutations including twelve novel and three already 
reported mutations. Eleven OGG1 mutations were observed in noncoding regions 
(five intronic, four splice site and two 3´ UTR mutations) and four mutations were 
observed in coding region (three missense and one non-sense mutations).  In case of 
XRCC1 gene, twenty five mutations were observed in different coding regions 
including thirteen missense, eight synonymous and one nonsense mutation. 
Significant association of some the of these BER gene mutations with family history, 
menopausal age and smoking history of breast cancer patients suggest familial, 
reproductive and environmental role in genomic instability. Presence of these frequent 
germline mutations in BER pathway genes and their association with some important 
risk factors on a population scale suggests their possible involvement in the process of 
breast carcinogenesis.  
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These BER genes were further investigated at expressional level involving two 
different study cohorts, one from Pakistani population and the other from British 
population. Expressional analysis of APEX1, OGG1 and XRCC1 and proliferation 
marker Ki-67 at mRNA and protein levels revealed significant deregulations (down 
and up-regulation) in expressional profile of BER genes, which were found 
significantly correlated (negatively and positively) with up-regulated expression of 
tumor proliferation marker Ki-67. Keeping in view, the above cited observations 
regarding defective repair of DNA damage beside abnormal expression at 
transcriptional and translational level, it may be suggested that deregulated expression 
of BER pathway genes is correlated with breast tumorigenesis and aggressive 
proliferative behaviour of breast cancer. 
 Effects of alterations observed in expressional profile of BER genes were further 
explored using two breast cancer cell lines (MCF-7 and MDA-MB-MDA-231), 
knockdown for selected BER pathway genes. APEX1 knocked down cells of both cell 
lines showed decreased growth, invasion and migration abilities and increased 
adhesion ability. Knockdown of OGG1 and XRCC1 caused significant increase in 
cancerous characteristics of both cell lines by showing decreased adhesion and 
enhanced proliferation, invasion and rapid migration of knockdown cells. It may be 
concluded that multiple mutations of highly conserved nucleotides especially in 
functionally important domains and deregulations in transcriptional and translational 
expression of BER genes may contribute in the process of breast carcinogenesis 
independently or in combination with other genes of associated pathways may 
contribute in the process of breast carcinogenesis; each adding a small effect on the 
overall breast cancer risk in Pakistani population. These findings are further supported 
by in-vitro studies, where carcinogenic irregularities are observed in cellular 
behaviour of two different breast cancer cell lines, knocked down for BER genes. 
For a better understanding of the role of these genes in breast carcinogenesis, further 
research is warranted. Followings are few interesting domains which needs to be 
explored for meaningful conclusion. 
1). Epigenetic analysis of BER pathway genes including methylation of OGG1, 
APEX1 and XRCC1 promoter region is an interesting domain which needs to be 
explored.  
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2). Moreover, evaluation of effects of deregulated BER pathway genes on tumor 
initiation and progression in vivo using mouse xenograft models is also an important 
and relevant field.  
3). Identification of gene specific microRNA for breast cancer is another important 
domain which may provide rational for developing potential microRNA-based 
therapy for breast cancer. Deep insight into these gene functions may be helpful to 
design better diagnostic and treatment strategies for breast cancer. 
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